# Perrigo Company (PRGO) 10-Q SEC filing - Q2 FY2026

- Filed: Aug 5, 2026, 1:44 PM EDT
- Fiscal quarter: Q2 FY2026
- Calendar quarter: Q2 2026
- Accession: 0001585364-26-000145
- OpenCapital page: https://www.opencapital.sh/filings/0001585364-26-000145
- Markdown URL: https://www.opencapital.sh/filings/0001585364-26-000145.md
- Official SEC filing index: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/0001585364-26-000145-index.htm

## Filing documents

- [10-Q (prgo-20260627.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/prgo-20260627.htm)
- [EX-10.3 (perrigocompanyexecutivec.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/perrigocompanyexecutivec.htm)
- [EX-10.5 (restrictedstockunitaward.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/restrictedstockunitaward.htm)
- [EX-10.6 (performancebasedrestrict.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/performancebasedrestrict.htm)
- [EX-22 (cy26q210qex22.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex22.htm)
- [EX-31.1 (cy26q210qex311.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex311.htm)
- [EX-31.2 (cy26q210qex312.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex312.htm)
- [EX-32 (cy26q210qex32.htm)](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex32.htm)

---

## 10-Q

SEC source: [prgo-20260627.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/prgo-20260627.htm)

### UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: June 27, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             

Commission file number 001-36353

Perrigo Company plc

(Exact name of registrant as specified in its charter)

Ireland Not Applicable

(State or other jurisdiction of   incorporation or organization) (I.R.S. Employer   Identification No.)

The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74

+353 1 7094000

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class / Ordinary shares, €0.001 par value | Trading Symbol(s) / PRGO | Name of each exchange on which registered / New York Stock Exchange |
| --- | --- | --- |
| 5.150% Notes due 2030 | PRGO30 | New York Stock Exchange |
| 6.125% Notes due 2032 | PRGO32A | New York Stock Exchange |
| 5.375% Notes due 2032 | PRGO32B | New York Stock Exchange |
| 5.300% Notes due 2043 | PRGO43 | New York Stock Exchange |
| 4.900% Notes due 2044 | PRGO44 | New York Stock Exchange |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of July 31, 2026, there were 138,769,245 ordinary shares outstanding.

PERRIGO COMPANY PLC

FORM 10-Q

INDEX

- PAGENUMBER
- [Cautionary Note Regarding Forward-Looking Statements](#i227bcb81299846b0903b4c75e8c40a6b_10) [3](#i227bcb81299846b0903b4c75e8c40a6b_10)
- PART I. FINANCIAL INFORMATION
- [Item 1. Financial Statements (Unaudited)](#i227bcb81299846b0903b4c75e8c40a6b_13)
- [Condensed Consolidated Statements of Operations](#i227bcb81299846b0903b4c75e8c40a6b_16) [4](#i227bcb81299846b0903b4c75e8c40a6b_16)
- [Condensed Consolidated Statements of Comprehensive Income](#i227bcb81299846b0903b4c75e8c40a6b_19) [5](#i227bcb81299846b0903b4c75e8c40a6b_19)
- [Condensed Consolidated Balance Sheets](#i227bcb81299846b0903b4c75e8c40a6b_22) [6](#i227bcb81299846b0903b4c75e8c40a6b_22)
- [Condensed Consolidated Statements of Shareholders' Equity](#i227bcb81299846b0903b4c75e8c40a6b_28) [7](#i227bcb81299846b0903b4c75e8c40a6b_28)
- [Condensed Consolidated Statements of Cash Flows](#i227bcb81299846b0903b4c75e8c40a6b_34) [8](#i227bcb81299846b0903b4c75e8c40a6b_34)
- [Notes to the Condensed Consolidated Financial Statements](#i227bcb81299846b0903b4c75e8c40a6b_37)
- 1 [Summary of Significant Accounting Policies](#i227bcb81299846b0903b4c75e8c40a6b_40) [9](#i227bcb81299846b0903b4c75e8c40a6b_40)
- 2 [Revenue Recognition](#i227bcb81299846b0903b4c75e8c40a6b_43) [10](#i227bcb81299846b0903b4c75e8c40a6b_43)
- 3 [Divestitures](#i227bcb81299846b0903b4c75e8c40a6b_46) [11](#i227bcb81299846b0903b4c75e8c40a6b_46)
- 4 [Discontinued Operations](#i227bcb81299846b0903b4c75e8c40a6b_55) [12](#i227bcb81299846b0903b4c75e8c40a6b_55)
- 5 [Inventories](#i227bcb81299846b0903b4c75e8c40a6b_58) [12](#i227bcb81299846b0903b4c75e8c40a6b_58)
- 6 [Investments](#i227bcb81299846b0903b4c75e8c40a6b_61) [12](#i227bcb81299846b0903b4c75e8c40a6b_61)
- 7 [Leases](#i227bcb81299846b0903b4c75e8c40a6b_64) [13](#i227bcb81299846b0903b4c75e8c40a6b_64)
- 8 [Goodwill and Intangible Assets](#i227bcb81299846b0903b4c75e8c40a6b_67) [14](#i227bcb81299846b0903b4c75e8c40a6b_67)
- 9 [Fair Value Measurements](#i227bcb81299846b0903b4c75e8c40a6b_70) [15](#i227bcb81299846b0903b4c75e8c40a6b_70)
- 10 [Derivative Instruments and Hedging Activities](#i227bcb81299846b0903b4c75e8c40a6b_73) [17](#i227bcb81299846b0903b4c75e8c40a6b_73)
- 11 [Indebtedness](#i227bcb81299846b0903b4c75e8c40a6b_79) [22](#i227bcb81299846b0903b4c75e8c40a6b_79)
- 12 [Earnings per Share and Shareholders' Equity](#i227bcb81299846b0903b4c75e8c40a6b_82) [24](#i227bcb81299846b0903b4c75e8c40a6b_82)
- 13 [Accumulated Other Comprehensive Income (Loss)](#i227bcb81299846b0903b4c75e8c40a6b_85) [24](#i227bcb81299846b0903b4c75e8c40a6b_85)
- 14 [Restructuring Charges](#i227bcb81299846b0903b4c75e8c40a6b_88) [24](#i227bcb81299846b0903b4c75e8c40a6b_4398046512733)
- 15 [Income Taxes](#i227bcb81299846b0903b4c75e8c40a6b_91) [26](#i227bcb81299846b0903b4c75e8c40a6b_91)
- 16 [Commitments and Contingencies](#i227bcb81299846b0903b4c75e8c40a6b_94) [28](#i227bcb81299846b0903b4c75e8c40a6b_94)
- 17 [Segment and Geographic Information](#i227bcb81299846b0903b4c75e8c40a6b_97) [33](#i227bcb81299846b0903b4c75e8c40a6b_97)
- [Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i227bcb81299846b0903b4c75e8c40a6b_103) [36](#i227bcb81299846b0903b4c75e8c40a6b_103)
- [Item 3. Quantitative and Qualitative Disclosures About Market Risk](#i227bcb81299846b0903b4c75e8c40a6b_163) [51](#i227bcb81299846b0903b4c75e8c40a6b_163)
- [Item 4. Controls and Procedures](#i227bcb81299846b0903b4c75e8c40a6b_166) [51](#i227bcb81299846b0903b4c75e8c40a6b_166)
- PART II. OTHER INFORMATION
- [Item 1. Legal Proceedings](#i227bcb81299846b0903b4c75e8c40a6b_172) [51](#i227bcb81299846b0903b4c75e8c40a6b_172)
- [Item 1A. Risk Factors](#i227bcb81299846b0903b4c75e8c40a6b_175) [52](#i227bcb81299846b0903b4c75e8c40a6b_175)
- [Item 5. Other Information](#i227bcb81299846b0903b4c75e8c40a6b_178) [52](#i227bcb81299846b0903b4c75e8c40a6b_178)
- [Item 6. Exhibits](#i227bcb81299846b0903b4c75e8c40a6b_184) [52](#i227bcb81299846b0903b4c75e8c40a6b_184)
- [Signatures](#i227bcb81299846b0903b4c75e8c40a6b_187) [53](#i227bcb81299846b0903b4c75e8c40a6b_187)

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this report, including certain statements contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “forecast,” “predict,” “potential” or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including: supply chain impacts on our business, including those caused or exacerbated by armed conflict, trade and other economic sanctions and/or disease; general economic, credit, and market conditions; increased or new tariffs by the U.S. or foreign governments (and any retaliatory or reciprocal tariffs) and changes in global trade relations; the impact of the war in Ukraine and any escalation thereof, including the effects of economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries related thereto; the outbreak or escalation of conflict in other regions where we do business, including the ongoing conflict and social, political and economic environment in Israel and the broader Middle East; current and future impairment charges, if we determine that the carrying amount of specific assets may not be recoverable from the expected future cash flows of such assets; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than we do; pricing pressures from customers and consumers; resolution of uncertain tax positions and any litigation relating thereto, ongoing or future government investigations and regulatory initiatives; uncertainty regarding our ability to obtain and maintain our regulatory approvals; potential costs and reputational impact of product recalls or sales halts; potential adverse changes to U.S. and foreign tax, healthcare and other government policy; the effect of epidemic or pandemic disease; the timing, amount and cost of any share repurchases (or the absence thereof) and/or any refinancing of outstanding debt at or prior to maturity; fluctuations in currency exchange rates and interest rates; receipt of potential earnout payments in connection with the sale of the HRA Rare Diseases Business and the risk that potential costs or liabilities incurred or retained in connection with this transaction may exceed our estimates or adversely affect our business or operations; the satisfaction of certain deferred payment milestones associated with the Dermacosmetics Business divestment; the risk that potential costs or liabilities incurred or retained in connection with the sale of our Rx business may exceed our estimates or adversely affect our business or operations; the consummation and success of other announced and unannounced acquisitions or dispositions, and our ability to realize the desired benefits thereof; and our ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives and investments, including our ability to achieve the expected benefits from our ongoing restructuring programs and strategic review processes described herein. Adverse results with respect to pending litigation could have a material adverse impact on our operating results, cash flows and liquidity, and could ultimately require the use of corporate assets to pay damages, reducing assets that would otherwise be available for other corporate purposes. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025, in this report under “Risk Factors” and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this report are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

TRADEMARKS, TRADE NAMES AND SERVICE MARKS

This report contains trademarks, trade names and service marks that are the property of Perrigo Company plc, as well as, for informational purposes, trademarks, trade names, and service marks that are the property of other organizations. Solely for convenience, certain trademarks, trade names, and service marks referred to in this report appear without the ®, ™ and SM symbols, but those references are not intended to indicate that we or the applicable owner, as the case may be, will not assert, to the fullest extent under applicable law, our or their rights to such trademarks, trade names, and service marks.

Perrigo Company plc - Item 1

PART I. FINANCIAL INFORMATION

## ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

**PERRIGO COMPANY PLC**

### CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

_(in millions, except per share amounts) · (unaudited)_

| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Net sales | $1,022.8 | $1,056.3 | $1,992.0 | $2,100.2 |
| Cost of sales | 708.9 | 693.4 | 1,352.6 | 1,345.0 |
| Gross profit | 313.9 | 362.9 | 639.4 | 755.2 |
| Operating expenses |  |  |  |  |
| Distribution | 21.7 | 23.6 | 44.3 | 46.4 |
| Research and development | 23.7 | 22.0 | 48.4 | 48.7 |
| Selling | 129.5 | 136.5 | 259.2 | 282.7 |
| Administration | 100.0 | 113.0 | 215.0 | 225.2 |
| Impairment charges | 1.0 | 1.5 | 331.8 | 4.6 |
| Restructuring | 14.4 | 8.7 | 89.5 | 38.1 |
| Other operating expense, net | — | 12.2 | — | 17.2 |
| Total operating expenses | 290.5 | 317.5 | 988.3 | 662.9 |
| Operating income (loss) | 23.5 | 45.4 | (348.9) | 92.3 |
| Interest expense, net | 38.4 | 39.6 | 79.3 | 78.6 |
| Other (income) expense, net | (120.5) | 2.6 | (126.5) | 2.2 |
| Loss on extinguishment of debt | 0.1 | — | 1.4 | — |
| Income (loss) from continuing operations before income taxes | 105.4 | 3.2 | (303.1) | 11.5 |
| Income tax expense (benefit) | 16.9 | 3.7 | (1.8) | 11.9 |
| Income (loss) from continuing operations | 88.5 | (0.5) | (301.3) | (0.4) |
| Loss from discontinued operations, net of tax | (14.1) | (7.9) | (22.8) | (14.4) |
| Net income (loss) | $74.5 | $(8.4) | $(324.1) | $(14.8) |
| Earnings (loss) per share |  |  |  |  |
| Basic |  |  |  |  |
| Continuing operations | $0.64 | $(0.00) | $(2.17) | — |
| Discontinued operations | (0.10) | (0.06) | (0.16) | (0.10) |
| Basic earnings (loss) per share | $0.54 | $(0.06) | $(2.33) | $(0.10) |
| Diluted |  |  |  |  |
| Continuing operations | $0.63 | $(0.00) | $(2.17) | — |
| Discontinued operations | (0.10) | (0.06) | (0.16) | (0.10) |
| Diluted earnings (loss) per share | $0.53 | $(0.06) | $(2.33) | $(0.10) |
| Weighted-average shares outstanding |  |  |  |  |
| Basic | 139.1 | 138.2 | 138.9 | 138.0 |
| Diluted | 139.6 | 138.2 | 138.9 | 138.0 |

See accompanying Notes to the Condensed Consolidated Financial Statements.

Perrigo Company plc - Item 1

**PERRIGO COMPANY PLC**

### CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

_(in millions) · (unaudited)_

| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Net income (loss) | $74.5 | $(8.4) | $(324.1) | $(14.8) |
| Other comprehensive income (loss): |  |  |  |  |
| Foreign currency translation adjustments, net of tax | (20.9) | 150.4 | (36.1) | 263.9 |
| Change in fair value of derivative financial instruments, net of tax | 1.2 | (4.8) | 9.0 | (26.0) |
| Change in post-retirement and pension liability, net of tax | (0.1) | (0.2) | (0.6) | (0.5) |
| Other comprehensive income (loss), net of tax | (19.8) | 145.4 | (27.6) | 237.4 |
| Comprehensive income (loss) | $54.7 | $137.0 | $(351.7) | $222.6 |

See accompanying Notes to the Condensed Consolidated Financial Statements.

Perrigo Company plc - Item 1

**PERRIGO COMPANY PLC**

### CONDENSED CONSOLIDATED BALANCE SHEETS

_(in millions, except per share amounts) · (unaudited)_

| Line item | June 27, 2026 | December 31, 2025 |
| --- | --- | --- |
| Assets |  |  |
| Cash and cash equivalents | $399.7 | $531.6 |
| Accounts receivable, net of allowance for credit losses of $3.9 and $6.5, respectively | 709.9 | 612.8 |
| Inventories | 1,064.5 | 1,149.0 |
| Prepaid expenses and other current assets | 277.7 | 231.4 |
| Current assets held for sale | — | 272.6 |
| Total current assets | 2,451.7 | 2,797.4 |
| Property, plant and equipment, net | 849.0 | 898.7 |
| Operating lease assets | 156.0 | 167.8 |
| Goodwill and indefinite-lived intangible assets | 1,697.6 | 2,054.7 |
| Definite-lived intangible assets, net | 2,190.2 | 2,351.5 |
| Deferred income taxes | 6.3 | 3.3 |
| Other non-current assets | 258.6 | 261.8 |
| Total non-current assets | 5,157.7 | 5,737.8 |
| Total assets | $7,609.5 | $8,535.2 |
| Liabilities and Shareholders’ Equity |  |  |
| Liabilities |  |  |
| Accounts payable | $400.4 | $474.5 |
| Payroll and related taxes | 153.2 | 112.2 |
| Accrued customer programs | 109.4 | 111.4 |
| Other accrued liabilities | 265.4 | 216.1 |
| Accrued derivative liabilities | 86.2 | 14.5 |
| Accrued income taxes | 28.8 | 20.8 |
| Current indebtedness | 11.4 | 36.6 |
| Current liabilities held for sale | — | 26.8 |
| Total current liabilities | 1,054.8 | 1,012.9 |
| Non-current liabilities |  |  |
| Long-term debt, less current portion | 3,283.4 | 3,603.6 |
| Deferred income taxes | 146.7 | 168.9 |
| Other non-current liabilities | 608.8 | 814.3 |
| Total non-current liabilities | 4,038.9 | 4,586.8 |
| Total liabilities | 5,093.7 | 5,599.7 |
| Contingencies - Refer to Note 16 |  |  |
| Shareholders’ equity |  |  |
| Controlling interests: |  |  |
| Preferred shares, $0.0001 par value per share, 10 shares authorized | — | — |
| Ordinary shares, €0.001 par value per share, 10,000 shares authorized | 6,540.5 | 6,608.2 |
| Accumulated other comprehensive income (loss) | (22.8) | 4.8 |
| Retained earnings (accumulated deficit) | (4,001.9) | (3,677.5) |
| Total shareholders’ equity | 2,515.8 | 2,935.5 |
| Total liabilities and shareholders' equity | $7,609.5 | $8,535.2 |
| Supplemental Disclosures of Balance Sheet Information |  |  |
| Preferred shares, issued and outstanding | — | — |
| Ordinary shares, issued and outstanding | 138.7 | 137.6 |

See accompanying Notes to the Condensed Consolidated Financial Statements.

Perrigo Company plc - Item 1

**PERRIGO COMPANY PLC**

### CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

_(in millions, except per share amounts) · (unaudited)_

| Line item | Ordinary Shares Issued / Shares | Ordinary Shares Issued / Amount | Accumulated Other Comprehensive Income (Loss) | Retained Earnings(Accumulated Deficit) | Total |
| --- | --- | --- | --- | --- | --- |
| Balance at December 31, 2024 | 136.5 | $6,733.9 | $(162.4) | $(2,252.1) | $4,319.4 |
| Net loss | — | — | — | (6.4) | (6.4) |
| Other comprehensive income | — | — | 92.0 | — | 92.0 |
| Restricted stock plan | 1.2 | — | — | — | — |
| Compensation for restricted stock | — | 11.6 | — | — | 11.6 |
| Cash dividends, $0.29 per share | — | (40.6) | — | — | (40.6) |
| Shares withheld for payment of employees' withholding tax liability | (0.5) | (12.0) | — | — | (12.0) |
| Balance at March 29, 2025 | 137.2 | $6,692.9 | $(70.4) | $(2,258.5) | $4,364.0 |
| Net loss | — | — | — | (8.4) | (8.4) |
| Other comprehensive income | — | — | 145.4 | — | 145.4 |
| Restricted stock plan | 0.6 | — | — | — | — |
| Compensation for restricted stock | — | 16.8 | — | — | 16.8 |
| Cash dividends, $0.29 per share | — | (39.8) | — | — | (39.8) |
| Shares withheld for payment of employees' withholding tax liability | (0.2) | (5.7) | — | — | (5.7) |
| Balance at June 28, 2025 | 137.6 | $6,664.2 | $75.0 | $(2,266.9) | $4,472.3 |

| Line item | Ordinary Shares Issued / Shares | Ordinary Shares Issued / Amount | Accumulated Other Comprehensive Income (Loss) | Retained Earnings(Accumulated Deficit) | Total |
| --- | --- | --- | --- | --- | --- |
| Balance at December 31, 2025 | 137.6 | $6,608.2 | $4.8 | $(3,677.5) | $2,935.5 |
| Net loss | — | — | — | (398.6) | (398.6) |
| Other comprehensive income | — | — | (7.8) | — | (7.8) |
| Restricted stock plan | 0.8 | — | — | — | — |
| Compensation for restricted stock | — | 14.4 | — | — | 14.4 |
| Cash dividends, $0.29 per share | — | (41.7) | — | — | (41.7) |
| Shares withheld for payment of employees' withholding tax liability | (0.3) | (2.8) | — | — | (2.8) |
| Balance at March 28, 2026 | 138.1 | $6,578.1 | $(3.0) | $(4,076.3) | $2,498.8 |
| Net income | — | — | — | 74.5 | 74.5 |
| Other comprehensive income | — | — | (19.8) | — | (19.8) |
| Restricted stock plan | 1.0 | — | — | — | — |
| Compensation for restricted stock | — | 6.8 | — | — | 6.8 |
| Cash dividends, $0.29 per share | — | (40.1) | — | — | (40.1) |
| Shares withheld for payment of employees' withholding tax liability | (0.4) | (4.2) | — | — | (4.2) |
| Balance at June 27, 2026 | 138.7 | $6,540.5 | $(22.8) | $(4,001.9) | $2,515.8 |

See accompanying Notes to the Condensed Consolidated Financial Statements.

Perrigo Company plc - Item 1

**PERRIGO COMPANY PLC**

### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

_(in millions) · (unaudited)_

| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- |
| Cash Flows From (For) Operating Activities |  |  |
| Net income (loss) | $(324.1) | $(14.8) |
| Adjustments to derive cash flows: |  |  |
| Depreciation and amortization | 179.1 | 166.2 |
| Restructuring charges | 84.9 | 35.0 |
| Share-based compensation | 21.2 | 28.4 |
| Impairment charges | 331.8 | 4.6 |
| Amortization of debt discount | 4.1 | 4.4 |
| Deferred income taxes | (19.3) | 9.6 |
| (Gain) loss on sale of business | (129.5) | 1.6 |
| Amortization on hedging instruments | (10.3) | (12.6) |
| Other non-cash adjustments, net | (8.7) | 1.2 |
| Subtotal | 129.3 | 223.6 |
| Increase (decrease) in cash due to: |  |  |
| Inventories | 74.2 | (97.4) |
| Accrued income taxes | (13.4) | (54.5) |
| Payroll and related taxes | (45.0) | (23.6) |
| Accounts payable | (66.8) | (19.9) |
| Accrued customer programs | 0.5 | (0.6) |
| Other accrued liabilities | 44.4 | (29.3) |
| Accounts receivable | (102.3) | (5.9) |
| Other long term liabilities | 2.6 | 2.4 |
| Prepaid expenses and other current assets | (54.6) | 16.6 |
| Subtotal | (160.3) | (212.2) |
| Net cash (for) from operating activities | (31.0) | 11.4 |
| Cash Flows From (For) Investing Activities |  |  |
| Net proceeds from sale of businesses | 362.9 | 14.4 |
| Asset acquisitions, net | — | (1.5) |
| Additions to property, plant and equipment | (28.1) | (44.7) |
| Other investing, net | 2.2 | 2.3 |
| Net cash from (for) investing activities | 337.0 | (29.5) |
| Cash Flows From (For) Financing Activities |  |  |
| Payments on long-term debt | (759.3) | (17.6) |
| Cash dividends | (80.1) | (79.5) |
| Borrowings of revolving credit agreements and other financing, net | 427.6 | — |
| Payments for debt issuance costs | (5.5) | — |
| Shares used to settle taxes | (7.0) | (17.7) |
| Other financing, net | (9.9) | (1.0) |
| Net cash for financing activities | (434.2) | (115.8) |
| Effect of exchange rate changes on cash and cash equivalents | (6.1) | 29.3 |
| Net decrease in cash and cash equivalents | (134.2) | (104.6) |
| Cash and cash equivalents of continuing operations, beginning of period | 531.6 | 558.8 |
| Cash and cash equivalents held for sale, beginning of period | 2.3 | — |
| Less cash and cash equivalents held for sale, end of period | — | — |
| Cash and cash equivalents of continuing operations, end of period | $399.7 | $454.2 |

See accompanying Notes to the Condensed Consolidated Financial Statements.

Perrigo Company plc - Item 1

### Note 1

### NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

General Information

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc (“Elan”). Unless the context requires otherwise, the terms Perrigo, the “Company,” “we,” “our,” “us,” and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter (“OTC”) self-care market, Perrigo is led by its vision “To Provide The Best Self-Care For Everyone” and its purpose to “Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All”.

Basis of Presentation

Our unaudited Condensed Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2025 (“2025 Form 10-K”). In the opinion of management, all adjustments considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Some amounts in this report may not add due to rounding.

Segment Reporting

Our segments reflect the way in which our chief operating decision maker (“CODM”), who is our Chief Executive Officer (“CEO”), makes operating decisions, allocates resources and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in [Note 2](#i227bcb81299846b0903b4c75e8c40a6b_43) and [Note 17](#i227bcb81299846b0903b4c75e8c40a6b_97).

In the first quarter of 2026, we completed the implementation of a new operating model intended to further enhance the execution of our strategy and prior period segment disclosures have been revised to reflect the new segments.

We now report results in the following three reporting segments:

- Self Care is comprised of our Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally.
- Specialty Care is comprised of our Women's Health and Skin Health product categories globally.
- Infant Formula is comprised of the Infant Formula product category, which includes nutrition products designed to meet the dietary needs of infants.

Our Oral Care product category and Other product category, which includes our Dermacosmetics Business (refer to [Note 3](#i227bcb81299846b0903b4c75e8c40a6b_46)), are together disclosed as “All Other.”

We previously had an Rx segment which was comprised of our generic prescription pharmaceuticals business in the U.S., and other pharmaceuticals and diagnostic business in Israel, which have been divested. Following the divestiture, there were no substantial assets or operations left in this segment. The Rx segment was reported as Discontinued Operations in 2021, and is presented as such for all periods in this report (refer to [Note 4](#i227bcb81299846b0903b4c75e8c40a6b_55)).

Perrigo Company plc - Item 1

### Note 1

Foreign Currency Translation and Transactions

We translate our non-U.S. dollar-denominated operations’ assets and liabilities into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of Accumulated other comprehensive income (loss) (“AOCI”). Gains or losses from foreign currency transactions are included in Other (income) expense, net.

#### Allowance for Credit Losses

Expected credit losses on trade receivables and contract assets are measured collectively by geographic location. Historical credit loss experience provides the primary basis for estimation of expected credit losses and is adjusted for current conditions and for reasonable and supportable forecasts. Receivables that do not share risk characteristics are evaluated on an individual basis and are not included in the collective evaluation. The following table presents the allowance for credit losses activity (in millions):

| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Balance at beginning of period | $4.3 | $5.4 | $6.5 | $6.0 |
| Provision for credit losses, net | 0.3 | 2.3 | 0.5 | 2.1 |
| Receivables written-off | (0.7) | (1.7) | (3.0) | (2.3) |
| Recoveries collected | — | 0.1 | 0.1 | 0.1 |
| Currency translation adjustment | — | 0.4 | (0.1) | 0.6 |
| Balance at end of period | $3.9 | $6.5 | $3.9 | $6.5 |

### NOTE 2 - REVENUE RECOGNITION

The following is a summary of our net sales by category (in millions):

| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Self Care |  |  |  |  |
| Upper Respiratory | $178.4 | $181.3 | $375.7 | $396.0 |
| Digestive Health | 115.7 | 119.8 | 212.4 | 232.6 |
| Healthy Lifestyle | 157.8 | 154.7 | 300.6 | 311.7 |
| Pain & Sleep | 124.6 | 142.8 | 231.2 | 272.5 |
| Total Self Care | $576.6 | $598.6 | $1,119.9 | $1,212.8 |
| Specialty Care |  |  |  |  |
| Skin Health | $161.8 | $170.3 | $313.7 | $319.9 |
| Women's Health | 64.8 | 62.7 | 119.9 | 112.3 |
| Total Specialty Care | $226.6 | $233.1 | $433.6 | $432.2 |
| Infant Formula | $100.9 | $82.0 | $190.6 | $169.8 |
| All Other(1) | $118.6 | $142.7 | $247.8 | $285.4 |
| Total net sales | $1,022.8 | $1,056.3 | $1,992.0 | $2,100.2 |

(1) Consists primarily of Oral Care, Dermacosmetics Business prior to sale (refer to[Note 3](#i227bcb81299846b0903b4c75e8c40a6b_46) for details) and other miscellaneous or otherwise uncategorized product lines, none of which is greater than 10% of the segment net sales.

Perrigo Company plc - Item 1

### Note 2

The following table provides information about contract assets from contracts with customers (in millions):

| Line item | Balance Sheet Location | June 27, 2026 | December 31, 2025 |
| --- | --- | --- | --- |
| Short-term contract assets | Prepaid expenses and other current assets | $40.1 | $37.3 |

We generated net sales in the following geographic locations(1) (in millions):

| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| U.S. | $626.4 | $610.9 | $1,180.8 | $1,220.2 |
| Europe(2) | 371.7 | 421.7 | 763.1 | 833.9 |
| All other countries(3) | 24.7 | 23.7 | 48.1 | 46.1 |
| Total net sales | $1,022.8 | $1,056.3 | $1,992.0 | $2,100.2 |

(1) The net sales by geography are derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $7.7 million and $11.8 million for the three and six months ended June 27, 2026, respectively, and $9.8 million and $20.8 million for the three and six months ended June 28, 2025, respectively. Refer to[Note 3](#i227bcb81299846b0903b4c75e8c40a6b_46) for details regarding the divestment of the Dermacosmetics Business impacting net sales in Europe.

(3) Includes net sales generated primarily in Australia and Canada.

### NOTE 3 - DIVESTITURES

Divestitures During the Three Months Ended June 27, 2026

Dermacosmetics Business

On April 30, 2026, the sale of the Dermacosmetics Business was completed for total consideration of $362.9 million, net of cash delivered. The transaction consists of €305.6 million, or $358.5 million, in upfront cash, $6.2 million of proceeds received for inventory on hand, less $1.8 million of cash delivered. The transaction also stipulates up to an additional €27.0 million contingent on the achievement of net sales milestones, of which €18.0 million is remaining through 2027. The sale resulted in a pre-tax gain of $129.5 million recorded in Other (income) expense, net on the Consolidated Statements of Operations. Brands sold in the transaction include ACO, Biodermal, and Iwostin.

The assets associated with this business were not included in any of our reporting segments and therefore were reported in All Other. The estimated fair value less costs to sell of the Dermacosmetics Business exceeded its carrying value. As such, no impairment charge was recorded during the year ended December 31, 2025 or the six months ended June 27, 2026.

Divestitures During the Three Months Ended June 28, 2025

Richard Bittner Business

On April 11, 2025, we completed the sale of the Richard Bittner Business AG, an Austrian contract manufacturing entity (the "Richard Bittner Business") to HBI Health & Beauty Innovations Limited for total consideration of $14.4 million, net of cash delivered. The sale resulted in a pre-tax loss of $1.6 million, net of professional fees, recorded in Other (income) expense, net on the Condensed Consolidated Statements of Operations within our Self Care segment.

The assets associated with this business were reported within our Self Care segment. We determined the carrying value of the net assets held for sale of this business exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million during the six months ended June 28, 2025, inclusive of a goodwill impairment charge of $1.2 million.

Perrigo Company plc - Item 1

### Note 4

### NOTE 4 - DISCONTINUED OPERATIONS

Our discontinued operations primarily consist of our former Rx segment, which held our prescription pharmaceuticals business in the U.S. and our pharmaceuticals and diagnostic businesses in Israel (collectively, the “Rx business”).

In connection with the sale of the Rx business, Perrigo retained certain pre-closing liabilities arising out of antitrust (refer to [Note 16](#i227bcb81299846b0903b4c75e8c40a6b_94) under the header “Price-Fixing Lawsuits”) and opioid matters and the Company’s Albuterol recall, subject to, in each case, Altaris Capital Partners, LLC (“Altaris”) obligation to indemnify the Company for fifty percent of these liabilities up to an aggregate cap on Altaris' obligation of $50.0 million. As of June 27, 2026, the loss accrual for litigation contingencies reflected on the Condensed Consolidated Balance Sheets in Other accrued liabilities included $67.0 million related to price-fixing lawsuits. A recovery receivable was recorded for fifty percent of this liability as of June 27, 2026 reflected on the Condensed Consolidated Balance Sheets in Prepaid expenses and other current assets.

Current and prior period reported net loss from discontinued operations primarily relates to the provision for litigation contingencies.

### NOTE 5 - INVENTORIES

Major components of inventory were as follows (in millions):

| Line item | June 27, 2026 | December 31, 2025 |
| --- | --- | --- |
| Finished goods | $655.2 | $685.6 |
| Work in process | 206.7 | 259.4 |
| Raw materials | 202.6 | 204.0 |
| Total inventories | $1,064.5 | $1,149.0 |

### NOTE 6 - INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):

| Measurement Category | Balance Sheet Location | June 27, 2026 | December 31, 2025 |
| --- | --- | --- | --- |
| Fair value method(1) | Other non-current assets | $0.9 | $0.9 |
| Equity method | Other non-current assets | $23.2 | $23.4 |

(1) Measured using the Net Asset Value practical expedient.

The following table summarizes the (income) loss recognized in earnings of our equity securities (in millions):

| Measurement Category | Income Statement Location | Three Months Ended / June 27,2026 | Three Months Ended / June 28,2025 | Six Months Ended / June 27,2026 | Six Months Ended / June 28,2025 |
| --- | --- | --- | --- | --- | --- |
| Fair value method | Other operating expense, net | — | $(0.1) | — | $(0.1) |
| Equity method | Other operating expense, net | $0.3 | $0.4 | $0.2 | $0.5 |

Perrigo Company plc - Item 1

### Note 7

### NOTE 7 - LEASES

The balance sheet locations of our lease assets and liabilities were as follows (in millions):

| Assets | Balance Sheet Location | June 27, 2026 | December 31, 2025 |
| --- | --- | --- | --- |
| Operating | Operating lease assets | $156.0 | $167.8 |
| Finance | Other non-current assets | 10.1 | 11.5 |
| Total |  | $166.2 | $179.3 |

| Liabilities | Balance Sheet Location | June 27, 2026 | December 31, 2025 |
| --- | --- | --- | --- |
| Current |  |  |  |
| Operating | Other accrued liabilities | $25.4 | $25.7 |
| Finance | Current indebtedness | 1.5 | 1.8 |
| Non-Current |  |  |  |
| Operating | Other non-current liabilities | 138.5 | 151.5 |
| Finance | Long-term debt, less current portion | 10.5 | 11.5 |
| Total |  | $176.0 | $190.5 |

Expenses related to leases were as follows (in millions):

| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Operating leases(1) | $13.0 | $12.2 | $23.2 | $23.9 |
| Finance leases |  |  |  |  |
| Amortization | $0.5 | $0.6 | $1.0 | $1.2 |
| Interest | 0.1 | 0.1 | 0.2 | 0.2 |
| Total finance leases | $0.6 | $0.7 | $1.2 | $1.4 |

(1) Includes short-term leases and variable lease costs, which are immaterial.

The annual future maturities of our leases as of June 27, 2026 are as follows (in millions):

| Line item | Operating Leases | Finance Leases | Total |
| --- | --- | --- | --- |
| 2026 | $15.9 | $1.0 | $16.9 |
| 2027 | 30.6 | 1.8 | 32.4 |
| 2028 | 24.9 | 1.8 | 26.7 |
| 2029 | 21.0 | 1.7 | 22.7 |
| 2030 | 15.8 | 1.6 | 17.4 |
| After 2030 | 83.4 | 5.8 | 89.2 |
| Total lease payments | $191.6 | $13.8 | $205.4 |
| Less: Interest | 27.7 | 1.7 | 29.4 |
| Present value of lease liabilities | $163.9 | $12.1 | $176.0 |

Perrigo Company plc - Item 1

### Note 7

Our weighted average lease terms and discount rates are as follows:

| Weighted-average remaining lease term (in years) | June 27, 2026 | June 28, 2025 |
| --- | --- | --- |
| Operating leases | 8.81 | 9.01 |
| Finance leases | 7.59 | 8.52 |
| Weighted-average discount rate |  |  |
| Operating leases | 4.0% | 4.0% |
| Finance leases | 3.5% | 3.5% |

Our lease cash flow classifications are as follows (in millions):

| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- |
| Cash paid for amounts included in the measurement of lease liabilities |  |  |
| Operating cash flows for operating leases | $17.0 | $18.6 |
| Operating cash flows for finance leases | $0.2 | $0.2 |
| Financing cash flows for finance leases | $0.9 | $1.2 |
| Leased assets used in exchange for new finance lease liabilities | $(0.3) | — |
| Leased assets obtained in exchange for new operating lease liabilities | $4.2 | $1.3 |

### NOTE 8 - GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reporting segment, were as follows (in millions):

| Line item | December 31, 2025 | Impairments | Currency translation adjustments | June 27, 2026 |
| --- | --- | --- | --- | --- |
| Self Care | $1,113.9 | — | $(13.6) | $1,100.3 |
| Specialty Care | 682.8 | (77.4) | (11.6) | 593.8 |
| Infant Formula | 66.3 | (66.3) | — | — |
| All Other | 187.2 | (187.2) | — | — |
| Total goodwill | $2,050.1 | $(330.8) | $(25.3) | $1,694.1 |

Reporting Unit Goodwill

Women’s Health, Infant Formula, and Oral Care Reporting Units

During the three months ended March 28, 2026, we changed our reporting segments to align with organizational structure changes intended to further enhance the execution of our strategic priorities. As a result of the change, we prepared a quantitative goodwill impairment test under the previous and newly established reporting units. We determined the carrying value of the Women’s Health, Infant Formula, and Oral Care reporting units exceeded their respective fair values. We recorded goodwill impairment charges of $77.4 million, $66.3 million, and $187.2 million in Women’s Health, Infant Formula, and Oral Care reporting units, respectively. This resulted in $107.1 million remaining goodwill in the Women’s Health reporting unit as of March 28, 2026, which is reported within the Specialty Care segment. The goodwill related to Infant Formula and Oral Care reporting units are fully impaired, and the respective goodwill balances for these reporting units have been reduced to zero.

Perrigo Company plc - Item 1

### Note 8

Intangible Assets

Intangible assets and related accumulated amortization consisted of the following(1) (in millions):

| Line item | June 27, 2026 / Gross | June 27, 2026 / Accumulated Amortization | December 31, 2025 / Gross | December 31, 2025 / Accumulated Amortization |
| --- | --- | --- | --- | --- |
| Indefinite-lived intangibles: |  |  |  |  |
| Trademarks, trade names, and brands | $3.5 | — | $3.5 | — |
| In-process research and development | 0.1 | — | 1.1 | — |
| Total indefinite-lived intangibles | $3.5 | — | $4.6 | — |
| Definite-lived intangibles: |  |  |  |  |
| Distribution and license agreements and supply agreements | $99.3 | $64.1 | $109.5 | $70.1 |
| Developed product technology, formulations, and product rights | 345.4 | 251.0 | 351.9 | 247.9 |
| Customer relationships and distribution networks | 1,753.2 | 1,213.0 | 1,845.5 | 1,257.2 |
| Trademarks, trade names, and brands | 2,344.6 | 824.1 | 2,446.3 | 826.5 |
| Non-compete agreements | — | — | 2.1 | 2.1 |
| Total definite-lived intangibles | $4,542.5 | $2,352.3 | $4,755.3 | $2,403.8 |
| Total intangible assets | $4,546.0 | $2,352.3 | $4,759.9 | $2,403.8 |

(1) Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.

We recorded amortization expense of $54.5 million and $109.0 million for the three and six months ended June 27, 2026, respectively, and $56.6 million and $111.4 million for the three and six months ended June 28, 2025, respectively.

### NOTE 9 - FAIR VALUE MEASUREMENTS

The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):

| Measured at fair value on a recurring basis: | June 27, 2026 / Level 1 | June 27, 2026 / Level 2 | June 27, 2026 / Level 3 | December 31, 2025 / Level 1 | December 31, 2025 / Level 2 | December 31, 2025 / Level 3 |
| --- | --- | --- | --- | --- | --- | --- |
| Assets: |  |  |  |  |  |  |
| Foreign currency forward contracts | — | $2.9 | — | — | $2.4 | — |
| Interest rate swap agreements | — | — | — | — | 1.1 | — |
| Total assets | — | $2.9 | — | — | $3.5 | — |
| Liabilities: |  |  |  |  |  |  |
| Foreign currency forward contracts | — | $16.1 | — | — | $14.5 | — |
| Cross-currency swaps | — | 192.8 | — | — | 265.6 | — |
| Interest rate swap agreements | — | 17.7 | — | — | 32.8 | — |
| Total liabilities | — | $226.6 | — | — | $312.9 | — |
| Measured at fair value on a non-recurring basis: |  |  |  |  |  |  |
| Assets: |  |  |  |  |  |  |
| Goodwill(1) | — | — | $107.1 | — | — | $2,050.1 |
| Definite-lived intangible assets | — | — | — | — | — | 5.5 |
| Equity method investments | — | — | — | — | — | 3.5 |
| Total assets | — | — | $107.1 | — | — | $2,059.1 |

(1) During the three months ended March 28, 2026, we assessed the fair value of our Women’s Health, Infant Formula, and Oral Care reporting units, resulting in residual goodwill of $107.1 million, $0, and $0, respectively. During the three months ended December 31, 2025, we assessed the fair value of our prior reporting units resulting in residual goodwill of $1,168.8 million and $881.3 million related to Consumer Self Care Americas and Consumer Self Care International, respectively.

Perrigo Company plc - Item 1

### Note 9

There were no transfers within Level 3 fair value measurements during the three and six months ended June 27, 2026 or the year ended December 31, 2025 (refer to [Note 10](#i227bcb81299846b0903b4c75e8c40a6b_73) for a discussion of derivatives).

Non-recurring Fair Value Measurements

The non-recurring fair values represent only those assets whose carrying values were adjusted to fair value during the reporting period presented.

Women’s Health, Infant Formula, and Oral Care Reporting Units

As a result of changes in the operating model, goodwill was reallocated to the Company’s new reporting units based on their estimated relative fair values. Although the aggregate estimated fair value and carrying value of the Company’s reporting units did not change as of the testing date, January 1, 2026, the reallocation of goodwill and fair value on a relative basis resulted in reporting units where the carrying value exceeded their estimated fair value. Goodwill impairments were identified for the Women’s Health, Infant Formula, and Oral Care reporting units.

We performed a quantitative goodwill impairment test utilizing a combination of discounted cash flow techniques and comparable market approach for each reporting unit. Our cash flow projections included revenue growth rates and projected margins based on the reporting unit’s growth plans (Level 3 inputs). Discount rates and long‑term growth rates were developed for each reporting unit to reflect the rates of return and growth assumptions that market participants would apply, considering the relative risk profiles of the respective businesses.

Where appropriate, we also applied valuation multiples derived under the market approach based on a peer group of comparable companies, utilizing both observable and unobservable market data (Level 2 and Level 3 inputs, respectively). The market approach was applied to the Women’s Health and Oral Care reporting units but was not considered appropriate for Infant Formula. The key assumptions used in both the income and market approaches are summarized in the table below.

.

| Reporting Unit | Discount Rate | Long-Term Growth Rate | GPCM Multiple |
| --- | --- | --- | --- |
| Women’s Health | 14.0% | 2.5% | 7.6x |
| Infant Formula | 10.0% | 2.5% | n/a* |
| Oral Care | 10.0% | 2.5% | 8.0x |

*The market approach was not considered applicable for the Infant Formula reporting unit.

Consumer Self Care Americas (“CSCA”) and Consumer Self Care International (“CSCI”) Prior Reporting Units

During the year ended December 31, 2025, we prepared a goodwill impairment test utilizing a combination of discounted cash flow techniques and comparable company market approach for each of our prior reporting units. Our cash flow projections included revenue growth rates and projected margins based on the reporting unit’s growth plans (Level 3 inputs). In our discounted cash flow analysis, we used a long-term growth rate of 2.5% for CSCA and 2.5% for CSCI. We used a discount rate of 11.5% for CSCA and 11.0% for CSCI in the analysis, which correlates with the required investment return and risk that we believe market participants would apply to the projected growth rate. In our comparable company market approach, we considered observable and unobservable market information (Level 2 and 3 inputs, respectively) which resulted in selected current and forward multiples averaging 7.0x of comparable adjusted earnings for CSCA. For CSCI, the current and forward multiples averaged 8.1x of comparable adjusted earnings.

Prevacid® Branded Product

During the year ended December 31, 2025, we measured the impairment of our Prevacid® branded product, a definite-lived intangible asset. We utilized a discounted cash flow technique to estimate the fair value of the asset. Significant valuation inputs and assumptions relate to our projected future contribution margin, which include our estimated market share at planned investment levels and the expected selling price. We concluded the fair value was $5.5 million as of December 31, 2025.

Perrigo Company plc - Item 1

### Note 9

Kazmira LLC

During the three months ended December 31, 2025, we identified potential indicators of impairment of our equity method investment in Kazmira LLC. We utilized an income approach, specifically a liquidation value method, to estimate the fair value based on the realizable value of Kazmira’s tangible assets. We concluded the fair value of our investment in Kazmira LLC was $3.5 million as of December 31, 2025 (refer to [Note 6](#i227bcb81299846b0903b4c75e8c40a6b_61)).

Fixed Rate Long-term Debt    

Our fixed rate long-term debt consisted of the following (in millions):

| Public Bonds | June 27, 2026 / Level 1 | December 31, 2025 / Level 1 |
| --- | --- | --- |
| Carrying value (excluding discount) | $2,257.8 | $2,270.5 |
| Fair value | $2,074.3 | $2,149.8 |

The fair values of our public bonds for all periods were based on quoted market prices.

The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt, revolving credit agreements, and variable rate long-term debt, approximate their fair value.

### NOTE 10 - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

Interest Rate Swaps

We have $712.5 million notional amount of variable-to-fixed interest rate swaps used to economically hedge interest rate risk on a substantial portion of our Senior Secured Credit Facilities (as defined in [Note 11](#i227bcb81299846b0903b4c75e8c40a6b_79)). The interest rate swaps were designated as cash flow hedges to fix the variable interest rate. As a designated cash flow hedge, changes in fair value will be deferred in AOCI and recognized within Interest expense, net when interest is paid on the Senior Secured Credit Facilities.

As of June 27, 2026, the designated instruments used to hedge the exposure to variable interest on the Senior Secured Credit Facilities totaled $712.5 million notional amount which is effective through April 2029.

As of June 27, 2026, the undesignated economically offsetting interest rate swaps totaling $600.0 million are effective through April 2029.

Cross-currency Swaps

We have $2.3 billion notional amount fixed-for-fixed cross-currency interest rate swaps designated as net investment hedges to hedge the European Euro (“EUR”) currency exposure of our investment in European operations. As designated net investment hedges, gains and losses related to the EUR spot exchange rate will be deferred within the Cumulative Translation Adjustment, a component of AOCI, and recognized in the Condensed Consolidated Statements of Operations when the hedged EUR net investment is substantially liquidated. Gains and losses on excluded components (e.g., interest differentials) will be recorded in Interest expense, net on a systematic and rational basis.

As of June 27, 2026, of the total $2.3 billion notional amount, $1.0 billion, $300.0 million, $450.0 million, $380.0 million, and $200.0 million notional amounts are effective through April 2027, September 2028, November 2030, December 2030, and March 2033, respectively.

Other Hedging Instruments

The €350.0 million 2032 Notes (as defined in [Note 11](#i227bcb81299846b0903b4c75e8c40a6b_79)) are designated as a net investment hedge on our investment in European operations.

Perrigo Company plc - Item 1

### Note 10

As a designated net investment hedge, gains and losses related to the EUR spot exchange rate will be deferred within the Cumulative Translation Adjustment, a component of AOCI, and recognized in the Condensed Consolidated Statements of Operations when the hedged EUR net investment is substantially liquidated.

Foreign Currency Forwards

Notional amounts of foreign currency forward contracts were as follows (in millions):

| Line item | June 27, 2026 | December 31, 2025 |
| --- | --- | --- |
| European Euro (EUR) | $397.9 | $50.1 |
| United States Dollar (USD) | 111.3 | 160.6 |
| British Pound (GBP) | 106.1 | 148.1 |
| Polish Zloty (PLZ) | 58.3 | 43.3 |
| Danish Krone (DKK) | 39.4 | 56.8 |
| Canadian Dollar (CAD) | 15.1 | 21.2 |
| Swedish Krona (SEK) | 11.2 | 48.6 |
| Hungarian Forint (HUF) | 11.2 | 11.0 |
| Chinese Yuan (CNH) | 11.0 | 16.3 |
| Norwegian Krone (NOK) | — | 4.6 |
| Other(1) | 8.5 | 18.1 |
| Total | $769.8 | $578.7 |

(1) Number consists of notional amounts of various currencies, none of which individually exceed $10.0 million in either year presented.

The maximum term of our forward currency exchange contracts is 60 months.

On August 1, 2025, we entered into a deal-contingent EUR/USD forward contract of €300 million to hedge foreign exchange risk related to the proceeds expected for the planned divestiture of our Dermacosmetics Business (refer to [Note 3](#i227bcb81299846b0903b4c75e8c40a6b_46) for additional details). The contract was contingent on the successful closing of the transaction, which occurred on April 30, 2026. Gains or losses on the derivatives due to changes in the EUR/USD exchange rate prior to the close of the divestiture were economically offset at closing in the final settlement of the euro-denominated Dermacosmetics Business purchase price. The total settlement loss was $5.6 million of which we recorded a loss of $4.8 million and a gain of $3.2 million during the three and six months ended June 27, 2026, respectively, and a loss of $8.8 million during the twelve months ended December 31, 2025 in Other (income) expense, net on the Condensed Consolidated Statements of Operations.

Perrigo Company plc - Item 1

### Note 10

Effects of Derivatives on the Financial Statements

The below tables indicate the effects of all derivative instruments on the Condensed Consolidated Financial Statements. All amounts exclude income tax effects.

The balance sheet location and gross fair value of our derivative instruments were as follows (in millions):

| Line item | Balance Sheet Location | June 27, 2026 | December 31, 2025 |
| --- | --- | --- | --- |
| Designated derivative assets: |  |  |  |
| Foreign currency forward contracts | Prepaid expenses and other current assets | $0.9 | $0.3 |
| Interest rate swap agreements | Other non-current assets | — | 1.1 |
| Total designated derivative assets |  | $0.9 | $1.4 |
| Non-designated derivative assets: |  |  |  |
| Foreign currency forward contracts | Prepaid expenses and other current assets | $2.0 | $2.1 |
| Total non-designated derivatives |  | $2.0 | $2.1 |
| Designated derivative liabilities: |  |  |  |
| Foreign currency forward contracts | Accrued derivative liabilities | $2.2 | $1.1 |
| Cross-currency swaps | Accrued derivative liabilities | 70.1 | — |
| Cross-currency swaps | Other non-current liabilities | 122.7 | 265.6 |
| Interest rate swap agreements | Other non-current liabilities | 8.7 | 22.0 |
| Total designated derivative liabilities |  | $203.7 | $288.7 |
| Non-designated derivative liabilities: |  |  |  |
| Foreign currency forward contracts | Accrued derivative liabilities | $13.9 | $13.4 |
| Interest rate swap agreements | Other non-current liabilities | 9.0 | 10.8 |
| Total non-designated derivative liabilities |  | $22.9 | $24.2 |

The amounts of (income)/expense recognized in earnings related to our non-designated derivatives on the Condensed Consolidated Statements of Operations were as follows (in millions):

| Non-Designated Derivatives | Income Statement Location | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- | --- |
| Foreign currency forward contracts | Other (income) expense, net | $19.2 | $0.3 | $21.4 | $(0.8) |
| Interest rate swap agreements | Interest expense, net | — | $0.2 | — | $0.4 |

The following tables summarize the effect of derivative instruments designated as hedging instruments in AOCI (in millions):

Perrigo Company plc - Item 1

### Note 10

| Three Months Ended June 27, 2026 | Amount of Gain or (Loss) Recognized in OCI(1) / Three Months Ended June 27, 2026 | Gain or (Loss) Reclassified from AOCI into Earnings / Related to Amounts Included in Effectiveness Testing / Location of Gain or (Loss) | Gain or (Loss) Reclassified from AOCI into Earnings / Related to Amounts Included in Effectiveness Testing / Amount Reclassified(2) | Gain or (Loss) Reclassified from AOCI into Earnings / Related to Amounts Excluded from Effectiveness Testing / Location of Gain or (Loss) | Gain or (Loss) Reclassified from AOCI into Earnings / Related to Amounts Excluded from Effectiveness Testing / Amount Reclassified(2) |
| --- | --- | --- | --- | --- | --- |
| Cash flow hedges |  |  |  |  |  |
| Interest rate swap agreements | $1.7 | Interest expense, net | $0.2 | Interest expense, net | — |
| Foreign currency forward contracts | (0.3) | Net sales | 0.2 | Net sales | — |
|  |  | Cost of sales | (0.4) | Cost of sales | — |
|  |  |  |  | Other (income) expense, net | — |
| Total Cash flow hedges | $1.4 |  | — |  | — |
| Net investment hedges |  |  |  |  |  |
| Cross-currency swaps | $19.1 |  |  | Interest expense, net | $8.6 |
| Euro Notes Due 2032 | 4.3 |  |  |  |  |
| Total Net investment hedges | $23.4 |  |  |  | $8.6 |
| Six Months Ended June 27, 2026 |  |  |  |  |  |
| Cash flow hedges |  |  |  |  |  |
| Interest rate swap agreements | $11.5 | Interest expense, net | $1.4 | Interest expense, net | — |
| Foreign currency forward contracts | (1.2) | Net sales | 0.1 | Net sales | 0.1 |
|  |  | Cost of sales | (1.1) | Cost of sales | — |
|  |  |  |  | Other (income) expense, net | — |
| Total Cash flow hedges | $10.3 |  | $0.5 |  | $0.1 |
| Net investment hedges |  |  |  |  |  |
| Cross-currency swaps | $74.3 |  |  | Interest expense, net | $16.8 |
| Euro Notes Due 2032 | 12.5 |  |  |  |  |
| Total Net investment hedges | $86.8 |  |  |  | $16.8 |
| Three Months Ended June 28, 2025 |  |  |  |  |  |
| Cash flow hedges |  |  |  |  |  |
| Interest rate swap agreements | $(5.0) | Interest expense, net | $4.4 | Interest expense, net | — |
| Foreign currency forward contracts | 2.8 | Net sales | 0.1 | Net sales | (0.1) |
|  |  | Cost of sales | 0.1 | Cost of sales | — |
|  |  |  |  | Other (income) expense, net | (0.1) |
| Total Cash flow hedges | $(2.2) |  | $4.6 |  | $(0.2) |
| Net investment hedges |  |  |  |  |  |
| Cross-currency swaps | $(169.0) |  |  | Interest expense, net | $9.5 |
| Euro Notes Due 2032 | (31.0) |  |  |  |  |
| Total Net investment hedges | $(200.0) |  |  |  | $9.5 |
| Six Months Ended June 28, 2025 |  |  |  |  |  |
| Cash flow hedges |  |  |  |  |  |
| Interest rate swap agreements | $(16.1) | Interest expense, net | $9.1 | Interest expense, net | — |
| Foreign currency forward contracts | 3.3 | Net sales | 0.1 | Net sales | (0.1) |
|  |  | Cost of sales | 0.4 | Cost of sales | 0.1 |
|  |  |  |  | Other (income) expense, net | (0.1) |
| Total Cash flow hedges | $(12.8) |  | $9.6 |  | $(0.1) |
| Net investment hedges |  |  |  |  |  |
| Cross-currency swaps | $(228.9) |  |  | Interest expense, net | $18.9 |
| Euro Notes Due 2032 | (47.4) |  |  |  |  |
| Total Net investment hedges | $(276.3) |  |  |  | $18.9 |

(1) Net income of $35.1 million is expected to be reclassified out of AOCI into earnings during the next 12 months.

(2) For additional details about the effect of the amounts reclassified from AOCI refer to [Note 13](#i227bcb81299846b0903b4c75e8c40a6b_85).

Perrigo Company plc - Item 1

### Note 10

The classification and amount of gain/(loss) recognized in earnings related to fair value and hedging relationships on the Condensed Consolidated Statement of Operations were as follows (in millions):

| Three Months Ended June 27, 2026 | Net Sales | Cost of Sales | Interest Expense, net | Other (Income) Expense, net |
| --- | --- | --- | --- | --- |
| Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded | $1,022.8 | $708.9 | $38.4 | $(120.5) |
| Gain (loss) on cash flow hedging relationships |  |  |  |  |
| Foreign currency forward contracts |  |  |  |  |
| Amount of gain reclassified from AOCI into earnings | $0.2 | $(0.4) | — | — |
| Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach | — | — | — | — |
| Interest rate swap agreements |  |  |  |  |
| Amount of gain reclassified from AOCI into earnings | — | — | $0.2 | — |
| Six Months Ended June 27, 2026 |  |  |  |  |
| Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded | $1,992.0 | $1,352.6 | $79.3 | $(126.5) |
| Gain (loss) on cash flow hedging relationships |  |  |  |  |
| Foreign currency forward contracts |  |  |  |  |
| Amount of gain reclassified from AOCI into earnings | $0.1 | $(1.1) | — | — |
| Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach | $0.1 | — | — | — |
| Interest rate swap agreements |  |  |  |  |
| Amount of gain reclassified from AOCI into earnings | — | — | $1.4 | — |
| Three Months Ended June 28, 2025 |  |  |  |  |
| Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded | $1,056.3 | $693.4 | $39.6 | $2.6 |
| Gain (loss) on cash flow hedging relationships |  |  |  |  |
| Foreign currency forward contracts |  |  |  |  |
| Amount of gain reclassified from AOCI into earnings | $0.1 | $0.1 | — | — |
| Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach | $(0.1) | — | — | $(0.1) |
| Interest rate swap agreements |  |  |  |  |
| Amount of gain reclassified from AOCI into earnings | — | — | $4.4 | — |
| Six Months Ended June 28, 2025 |  |  |  |  |
| Total amounts of income and expense line items presented on the Condensed Consolidated Statements of Operations in which the effects of fair value or cash flow hedges are recorded | $2,100.2 | $1,345.0 | $78.6 | $2.2 |
| Gain (loss) on cash flow hedging relationships |  |  |  |  |
| Foreign currency forward contracts |  |  |  |  |
| Amount of gain (loss) reclassified from AOCI into earnings | $0.1 | $0.4 | — | — |
| Amount excluded from effectiveness testing recognized using a systematic and rational amortization approach | $(0.1) | $0.1 | — | $(0.1) |
| Interest rate swap agreements |  |  |  |  |
| Amount of gain reclassified from AOCI into earnings | — | — | $9.1 | — |

Perrigo Company plc - Item 1

### Note 11

### NOTE 11 - INDEBTEDNESS

Total borrowings are summarized as follows (in millions):

| Line item | June 27, 2026 | December 31, 2025 |
| --- | --- | --- |
| Revolvers |  |  |
| 2026 Revolver due March 20, 2031(1) | $92.6 | — |
| Total revolvers | $92.6 | — |
| Term loans |  |  |
| Term A Loans due April 20, 2027(1) | — | $421.9 |
| Term B Loans due April 20, 2029(1) | 970.0 | 972.4 |
| Total term loans | $970.0 | $1,394.3 |
| Notes and Bonds |  |  |
| Due |  |  |
| June 15, 2030 | $750.0 | $750.0 |
| September 30, 2032(2) | 398.4 | 411.1 |
| September 30, 2032(2) | 715.0 | 715.0 |
| November 15, 2043 | 90.5 | 90.5 |
| December 15, 2044 | 303.9 | 303.9 |
| Total notes and bonds | $2,257.8 | $2,270.5 |
| Other financing | 11.8 | 12.9 |
| Unamortized discount | (17.7) | (19.7) |
| Deferred financing fees | (19.7) | (17.8) |
| Total borrowings outstanding | $3,294.8 | $3,640.2 |
| Current indebtedness | (11.4) | (36.6) |
| Total long-term debt less current portion | $3,283.4 | $3,603.6 |

(1) Discussed collectively herein as the "Senior Secured Credit Facilities".

(2) Discussed below collectively as the “2032 Notes”.

* Debt denominated in euros subject to fluctuations in the euro-to-U.S. dollar exchange rate.

Credit Agreements

On April 20, 2022, we and our indirect wholly owned subsidiary, Perrigo Investments, LLC (the “Borrower”) entered into the senior secured credit facilities, which consisted of (i) a $1.0 billion five-year revolving credit facility (the “Revolver”), (ii) a $500.0 million five-year Term Loan A facility (the “Term Loan A Facility” and the Term A Loans thereunder, the “Term A Loans”), and (iii) a $1.1 billion seven-year Term Loan B facility (the “Term Loan B Facility” and the Term B Loans thereunder borrowed on April 20, 2022, the “2022 Term B Loans”, pursuant to a Credit Agreement (the “Credit Agreement”).

On December 15, 2023, we and the Borrower entered into Amendment No. 1 and Incremental Assumption Agreement (the “Amendment”) to the Credit Agreement. The Amendment provided for a fungible add on to the 2022 Term B Loans in an aggregate principal amount of $300.0 million (the “2023 Incremental Term B Loans”). The terms of the 2023 Incremental Term B Loans, including pricing and maturity, are identical to the 2022 Term B Loans. The net proceeds from the 2023 Incremental Term B Loans were used to settle the cash tender offer by Perrigo Finance Unlimited Company (“Perrigo Finance”), a public unlimited company incorporated under the laws of Ireland and an indirect wholly-owned finance subsidiary of Perrigo for $300.0 million in aggregate principal amount of 3.900% Senior Notes due 2024 (“2024 Notes”). The tender offer was settled on December 15, 2023, and Perrigo Finance accepted for purchase $300.0 million of the 2024 Notes and paid approximately $295.1 million in aggregate cash consideration (excluding accrued interest). On December 15, 2024, we and the Borrower entered into Amendment No. 2 to the Credit Agreement, which established a new tranche of loans under the Term B Facility (the “Term B Loans”) and which refinanced all of the 2023 Incremental Term B Loans and the 2022 Term B Loans outstanding under the Credit Agreement in the aggregate amount of $984.7 million, which resulted in a repricing to lower interest rate and increased the discount by $1.5 million. The Term B Loans will mature on April 20, 2029.

Perrigo Company plc - Item 1

### Note 11

On March 20, 2026, we entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) with Perrigo Investments, the other subsidiaries of the Company named therein, JPMorgan Chase Bank, N.A. and J. P. Morgan SE, as administrative agent, JPMorgan Chase Bank, N.A., as collateral agent and the other lenders party thereto. The Amended and Restated Credit Agreement amends and restates the Credit Agreement to, among other things, (i) extend the maturity of the Revolving Facility (defined below), (ii) eliminate the credit spread adjustment applicable to loans under the Revolving Facility and (iii) amend such other provisions of the Credit Agreement for the benefit of the Company. The Amended and Restated Credit Agreement provides for a $1.0 billion revolving credit facility maturing on March 20, 2031 (the “Revolving Facility”) and a $972.4 million term loan B facility maturing on April 20, 2029 (the “Term Loan B Facility” and together with the Revolving Facility, the “Senior Secured Credit Facilities”). The outstanding balance and maturity date of the Term Loan B Facility remain unchanged under the Amended and Restated Credit Agreement. The Company used the proceeds from a drawdown on the Revolving Facility to prepay the Term A Loans (as defined in the Credit Agreement) in their entirety, together with any accrued and unpaid interest and fees thereon and pay any associated transaction costs.

The Senior Secured Credit Facilities are being incurred by Perrigo Investments and will continue to be guaranteed, along with any hedging or cash management obligations entered into with a lender, by the Company and certain other wholly-owned subsidiaries of the Company (the “Guarantor Subsidiaries”). Additionally, the Borrower and the Guarantor Subsidiaries provide full and unconditional guarantees, jointly and severally, on a senior unsecured basis, of the 5.300% Notes due 2043 issued by the Company, and the Guarantor Subsidiaries, the Company and the Borrower provide full and unconditional guarantees, jointly and severally, on a senior unsecured basis, of the 5.150% Notes due 2030, the 6.125% USD Notes due 2032, the 5.375% Euro Notes due 2032 and the 4.900% Notes due 2044 issued by Perrigo Finance.

We are subject to financial covenants in the Senior Secured Credit Facilities. The agreements contain financial covenants that require the Borrower and its restricted subsidiaries to (a) not exceed a maximum first lien secured net leverage ratio of 3.00 to 1.00 at the end of each fiscal quarter and (b) not fall below a minimum interest coverage ratio of 3.00 to 1.00 at the end of each fiscal quarter, provided that such covenants apply only to the Revolving Facility and the Term Loan B Facility. If we consummate certain qualifying acquisitions during the term of the loan, we can elect to increase the maximum first lien secured net leverage ratio covenant to 3.25 to 1.00 for the quarter in which the acquisition occurs and the three following fiscal quarters thereafter.

Due to timing, no principal repayments were made on the Term Loan A Facility or Term Loan B Facility during the three months ended June 27, 2026. During the six months ended June 27, 2026, principal repayments of $424.3 million were made on the Term Loan A Facility and Term Loan B Facility.

Using proceeds received as a result of the Dermacosmetics Business divestment, a repayment was made in the amount of $335.0 million on the Revolving Facility during the three months ended June 27, 2026. As of June 27, 2026, borrowings outstanding under the Revolving Facility totaled $92.6 million. There were no borrowings outstanding under the Revolver as of December 31, 2025.

We were in compliance with all the covenants under our debt agreements as of June 27, 2026.

Other Financing

We have overdraft facilities available that we use to support our cash management operations. We report any balances outstanding in the above table under “Other financing”. There were no material borrowings outstanding under the overdraft facilities as of June 27, 2026 or December 31, 2025.

We have financing leases that are reported in the above table under “Other financing” (refer to [Note 7](#i227bcb81299846b0903b4c75e8c40a6b_64)).

Perrigo Company plc - Item 1

### Note 12

### NOTE 12 - EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY

Earnings per Share

A reconciliation of the numerators and denominators used in our basic and diluted earnings per share (“EPS”) calculation is as follows (in millions):

| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Numerator: |  |  |  |  |
| Income (loss) from continuing operations | $88.5 | $(0.5) | $(301.3) | $(0.4) |
| Loss from discontinued operations, net of tax | (14.1) | (7.9) | (22.8) | (14.4) |
| Net income (loss) | $74.5 | $(8.4) | $(324.1) | $(14.8) |
| Denominator: |  |  |  |  |
| Weighted average shares outstanding for basic EPS | 139.1 | 138.2 | 138.9 | 138.0 |
| Dilutive effect of share-based awards(1) | 0.6 | — | — | — |
| Weighted average shares outstanding for diluted EPS | 139.6 | 138.2 | 138.9 | 138.0 |

(1) In the period of a net loss, diluted shares equal basic shares.

#### Shareholders' Equity

Our common stock consists of ordinary shares of Perrigo Company plc, a public limited company incorporated under the laws of Ireland.

Our common equity has traded on the New York Stock Exchange under the symbol PRGO since June 6, 2013. Prior to that, our common equity traded on the Nasdaq Global Select Market under the same symbol. Our common equity was also traded on the Tel Aviv Stock Exchange (“TASE”) under the same symbol between March 16, 2005 and February 23, 2022, when we voluntarily delisted from trading in connection with the Rx business divestiture.

### NOTE 13 - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Changes in our AOCI balances, net of tax were as follows (in millions):

| Line item | Fair Value of Derivative Financial Instruments, net of tax | Foreign Currency Translation Adjustments, net of tax | Post-Employment Plan Adjustments, net of tax | Total AOCI |
| --- | --- | --- | --- | --- |
| Balance at December 31, 2025 | $(1.2) | $9.3 | $(3.3) | $4.8 |
| OCI before reclassifications | 9.6 | (19.3) | (0.6) | (10.2) |
| Amounts reclassified from AOCI | (0.6) | (16.8) | — | (17.4) |
| Other comprehensive income (loss) | $9.0 | $(36.1) | $(0.6) | $(27.6) |
| Balance at June 27, 2026 | $7.8 | $(26.8) | $(3.9) | $(22.8) |

For additional details about the effect of the amounts reclassified from AOCI refer to [Note 10](#i227bcb81299846b0903b4c75e8c40a6b_73).

The tax effects on the net activity related to each component of other comprehensive income (loss), were as follows (in millions):

| Tax (benefit) expense | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Fair value of derivative financial instruments | — | $(2.4) | — | $(6.2) |
| Foreign currency translation adjustments | 1.0 | (53.5) | 1.0 | (72.3) |
| (Benefit) expense for income taxes related to other comprehensive income (loss) | $1.0 | $(55.9) | $1.0 | $(78.5) |

Perrigo Company plc - Item 1

### Note 13

Except for the tax effects of foreign currency translation adjustments related to our foreign-denominated notes and cross-currency interest rate swaps designated as net investment hedges (refer to [Note 10](#i227bcb81299846b0903b4c75e8c40a6b_73)), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in the Condensed Consolidated Statements of Shareholders' Equity rather than in the Condensed Consolidated Statements of Operations.

### NOTE 14 - RESTRUCTURING CHARGES

We periodically take action to reduce redundant expenses and improve operating efficiencies. Restructuring activity includes severance, lease exit costs, asset impairments, and related consulting fees. The following reflects our restructuring activity (in millions):

| Line item | Three Months Ended / June 27, 2026 / Supply Chain Reinvention | Three Months Ended / June 27, 2026 / Project Energize | Three Months Ended / June 27, 2026 / Nutrition Network Optimization | Three Months Ended / June 27, 2026 / Operational Enhancement Program | Total |
| --- | --- | --- | --- | --- | --- |
| Beginning balance | — | $14.2 | $20.5 | $64.0 | $98.7 |
| Additional charges | 1.1 | 2.6 | 14.8 | (4.1) | 14.4 |
| Payments | (1.1) | (10.9) | (5.5) | (17.3) | (34.8) |
| Non-cash adjustments | — | (0.1) | — | (0.1) | (0.2) |
| Foreign currency effect | — | 0.3 | — | (1.7) | (1.4) |
| Ending balance | — | $6.1 | $29.8 | $40.8 | $76.7 |

| Line item | Six Months Ended / June 27, 2026 / Supply Chain Reinvention | Six Months Ended / June 27, 2026 / Project Energize | Six Months Ended / June 27, 2026 / Nutrition Network Optimization | Six Months Ended / June 27, 2026 / Operational Enhancement Program | Total |
| --- | --- | --- | --- | --- | --- |
| Beginning balance | — | $24.3 | $18.3 | $2.6 | $45.2 |
| Additional charges | 1.2 | 2.3 | 17.0 | 69.0 | 89.5 |
| Payments | (1.2) | (15.5) | (5.5) | (27.9) | (50.1) |
| Non-cash adjustments | — | (3.3) | — | (1.3) | (4.6) |
| Foreign currency effect | — | (1.7) | — | (1.6) | (3.3) |
| Ending balance | — | $6.1 | $29.8 | $40.8 | $76.7 |

_June 28, 2025_

| Line item | Three Months Ended / Supply Chain Reinvention | Three Months Ended / HRA Pharma Integration | Three Months Ended / Project Energize | Three Months Ended / Nutrition Network Optimization | Three Months Ended / Other Initiatives | Three Months Ended / Total |
| --- | --- | --- | --- | --- | --- | --- |
| Beginning balance | $0.8 | $1.6 | 26.7 | $16.5 | — | $45.6 |
| Additional charges | 2.2 | (1.5) | 6.8 | 1.2 | — | 8.7 |
| Payments | (1.7) | — | (8.5) | — | — | (10.2) |
| Non-cash adjustments | — | — | (2.8) | — | — | (2.8) |
| Foreign currency effect | (0.2) | (0.1) | — | — | $0.3 | — |
| Ending balance | $1.1 | — | $22.2 | $17.7 | — | $41.0 |

Perrigo Company plc - Item 1

Note14

_June 28, 2025_

| Line item | Six Months Ended / Supply Chain Reinvention | Six Months Ended / HRA Pharma Integration | Six Months Ended / Project Energize | Six Months Ended / Nutrition Network Optimization | Six Months Ended / Other Initiatives | Six Months Ended / Total |
| --- | --- | --- | --- | --- | --- | --- |
| Beginning balance | $2.3 | $1.6 | $27.9 | — | $1.0 | $32.8 |
| Additional charges | 6.8 | (1.5) | 15.1 | 17.7 | — | 38.1 |
| Payments | (8.6) | — | (22.9) | — | (1.0) | (32.5) |
| Non-cash adjustments | — | — | (2.8) | — | — | (2.8) |
| Foreign currency effect | 0.6 | (0.1) | 4.9 | — | — | 5.4 |
| Ending balance | $1.1 | — | $22.2 | $17.7 | — | $41.0 |

The charges incurred during the three months ended June 27, 2026 were primarily associated with employee separation costs as a result of actions taken on Nutrition Network Optimization. The charges incurred during the six months ended June 27, 2026 were primarily associated with employee separation costs as a result of the Operational Enhancement Program. The charges incurred during the three months ended June 28, 2025 were primarily associated with employee separation costs as a result of actions taken on Project Energize. The charges incurred during the six months ended June 28, 2025 were primarily associated with employee separation costs as a result of actions taken on Nutrition Network Optimization and Project Energize.

Of the amount recorded during three months ended June 27, 2026, our Self Care and Specialty Care segments reversed charges in the amounts of $0.8 million and $3.8 million, respectively, due primarily to adjustments to employee separation costs related to the Operational Enhancement Program. Of the amount recorded during the six months ended June 27, 2026, our Self Care and Specialty Care segments incurred charges in the amounts of $35.8 million and $8.4 million, respectively, due primarily to employee separation costs related to the Operational Enhancement Program. Of the amount recorded during the three and six months ended June 27, 2026, $14.8 million and $22.5 million, respectively, related to our Infant Formula segment, due primarily to Nutrition Network Optimization. Charges totaling $5.0 million and $18.5 million during the three and six months ended June 27, 2026, respectively, primarily for separation costs associated with the Operational Enhancement Program were corporate costs not allocated to a reporting segment.

Of the amount recorded during the three and six months ended June 28, 2025, $3.8 million and $9.1 million, respectively, were related to our Self Care segment, due primarily to Project Energize, and $1.2 million and $3.0 million, respectively, related to our Specialty Care segment, due primarily to Project Energize, and $1.2 million and $17.7 million, respectively, related to our Infant Formula segment, due to Nutrition Network Optimization. Charges totaling $2.5 million and $8.0 million during the three and six months ended June 28, 2025, respectively, primarily for separation costs associated with Project Energize were corporate costs not allocated to a reporting segment.

There were no other material restructuring programs for the periods presented. All charges are recorded in Restructuring expense on the Condensed Consolidated Statements of Operations. The remaining $76.7 million liability for employee severance benefits and consulting fees is expected to be mostly paid within the next year, with the exception of approximately $14 million of charges recorded for Nutrition Network Optimization, which are recorded as a long-term liability on the Condensed Consolidated Balance Sheets as they are not currently expected to be paid out until 2028.

### NOTE 15 - INCOME TAXES

The effective tax rates were as follows:

| Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- |
| 16.0% | 115.7% | 0.6% | 103.6% |

The effective tax rate on pre-tax income for the three months ended June 27, 2026, decreased when compared to the effective tax rate on pre-tax income for the three months ended June 28, 2025, primarily due to increases in our

Perrigo Company plc - Item 1

### Note 15

reserves for uncertain tax positions in 2025 and changes in jurisdictional mix of earnings, offset by impacts related to the Dermacosmetics Business divestiture in 2026.

The effective tax rate on pre-tax loss for the six months ended June 27, 2026, decreased when compared to the effective tax rate on pre-tax income for the six months ended June 28, 2025, primarily due to a reduction in our reserves for uncertain tax positions in 2026, the impact of goodwill impairments in 2026, offset by impacts related to the Dermacosmetics Business divestiture in 2026 and increases in our reserves for uncertain tax positions in 2025.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law. The OBBBA includes significant changes to federal tax law and permanently extends or modifies various provisions from the 2017 Tax Cuts and Jobs Act, including, but not limited to, deductions for federal bonus depreciation, domestic research and development expenditures, and certain changes, some taxpayer-favorable and others not, for determining the limitation on business interest expense. We evaluated the OBBBA provisions enacted and determined they resulted in a tax benefit of $21.7 million for 2025, primarily due to the increased realizability of deferred tax assets associated with interest expense carryforwards following the restoration of depreciation and amortization in the Section 163(j) business interest expense limitation calculation. The remaining provisions of the OBBBA have multiple effective dates, with certain provisions effective in 2025 and others implemented over subsequent years. We are not anticipating the remaining provisions of the OBBBA to have a material effect on our consolidated financial statements.

The Organization for Economic Co-operation and Development (“OECD”), which represents a coalition of member countries, has recommended changes to numerous long-standing tax principles. In particular, the OECD's Pillar Two initiative introduces a global per-country minimum tax of 15%. Pillar Two legislation has been enacted or substantively enacted in many of the jurisdictions in which we operate. We are in compliance with the OECD’s Pillar Two framework. After a comprehensive assessment, we have determined that there is no material impact on our financial results as a result of the implementation of the Pillar Two framework to date.

We believe that our existing global tax strategies will adequately address any necessary adjustments to comply with Pillar Two without significantly affecting our effective tax rate or overall financial position. We will continue to monitor regulatory developments to ensure ongoing compliance, but we do not anticipate any adverse effects on our operations or profitability due to the implementation of the Pillar Two framework.

Internal Revenue Service Audits of Perrigo Company, a U.S. Subsidiary

Perrigo Company, our U.S. subsidiary (“Perrigo U.S.”), is engaged in a series of tax disputes in the U.S. relating primarily to transfer pricing adjustments including income in connection with the purchase, distribution, and sale of store-brand OTC pharmaceutical products in the United States, including the heartburn medication omeprazole. On August 27, 2014, we received a statutory notice of deficiency from the Internal Revenue Service (“IRS”) relating to our fiscal tax years ended June 27, 2009, and June 26, 2010 (the “2009 tax year” and “2010 tax year”, respectively). On April 20, 2017, we received a statutory notice of deficiency from the IRS for the years ended June 25, 2011 and June 30, 2012 (the “2011 tax year” and “2012 tax year”, respectively). Specifically, both statutory notices proposed adjustments related to the offshore reporting of profits on sales of omeprazole in the United States resulting from the assignment of an omeprazole distribution contract to an Israeli affiliate. In addition to the transfer pricing adjustments, which applied to all four tax years, the statutory notice of deficiency for the 2011 and 2012 tax years included adjustments requiring the capitalization and amortization of certain legal expenses that were deducted when paid or incurred in defending against certain patent infringement lawsuits related to Abbreviated New Drug Applications (“ANDAs”) filed with a Paragraph IV Certification.

We do not agree with the audit adjustments proposed by the IRS in either of the notices of deficiency. We paid the assessed amounts of tax, interest, and penalties set forth in the statutory notices and timely filed claims for refund on June 11, 2015 for the 2009 and 2010 tax years, and on June 7, 2017, for the 2011 and 2012 tax years. On August 15, 2017, following disallowance of such refund claims, we timely filed a complaint in the United States District Court for the Western District of Michigan seeking refunds of tax, interest, and penalties of $27.5 million for the 2009 tax year, $41.8 million for the 2010 tax year, $40.1 million for the 2011 tax year, and $24.7 million for the 2012 tax year, for a total of $134.1 million, plus statutory overpayment interest thereon from the dates of payment. The amounts sought in the complaint for the 2009 and 2010 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended March 28, 2015, and the amounts sought in the complaint for the 2011 and 2012 tax years were recorded as deferred charges in Other non-current assets on our balance sheet during the three months ended July 1, 2017.

Perrigo Company plc - Item 1

### Note 15

A bench trial was held during the period May 25, 2021 to June 7, 2021 for the refund case in the United States District Court for the Western District of Michigan. The total amount of cumulative deferred charge that we are seeking to receive in this litigation is approximately $113.3 million, which reflects the impact of conceding that Perrigo U.S. should have received a 5.24% royalty on all omeprazole sales. That concession was previously paid and is the subject of the above refund claims. The issues outlined in the statutory notices of deficiency described above are continuing in nature, and the IRS will likely carry forward the adjustments set forth therein as long as the OTC medication is sold, in the case of the omeprazole issue, and for all post-2012 Paragraph IV filings that trigger patent infringement suits, in the case of the ANDA issue. On September 25, 2025, the court issued an opinion in the case that predominantly sided with Perrigo U.S. on both the omeprazole and the ANDA issues. The court ordered the parties to submit computations implementing the opinion and to submit a proposed final judgment by January 23, 2026, as extended. The court, thereafter, issued a final, appealable judgment on January 27, 2026. On March 26, 2026, the opinion of the District Court was appealed by the Department of Justice. Perrigo followed by filing a cross appeal on April 6, 2026.

On January 13, 2021, the IRS issued a 30-day letter and Revenue Agent's Report (“RAR”) with respect to its audit of our fiscal tax years ended June 29, 2013, June 28, 2014, and June 27, 2015. The 30-day letter proposed, among other modifications, transfer pricing adjustments in connection with the distribution of omeprazole consistent with the IRS position in the prior years in the aggregate amount of $141.6 million and ANDA-related adjustments in the aggregate amount of $21.9 million. We timely filed a protest to the 30-day letter for those additional adjustments but noted that, due to the pending refund litigation described above, IRS Appeals would not consider the merits of the omeprazole or ANDA matters. We believe that we should prevail on the merits on both carryforward issues and have reserved for taxes and interest payable on the 5.24% deemed royalty on omeprazole through the tax year ended December 31, 2018. Beginning with the tax year ended December 31, 2019, we began reporting income commensurate with the 5.24% deemed royalty. We have not reserved for the ANDA-related issue described above. While we believe we should prevail on the merits of this case, the outcome remains uncertain. If our litigation position on the omeprazole issue is not ultimately sustained as part of any appeal, the outcome for the 2009–2012 tax years could range from a reduction in the refund amount to denial of any refund. In addition, we expect that the outcome of the refund litigation could effectively bind future tax years. In that event, a final adverse ruling on the omeprazole issue could have a material impact on subsequent periods (i.e., 2013 to date), with additional tax liability in the range of $25.0 million to $128.0 million, not including interest and any applicable penalties.

On December 2, 2021, the IRS commenced an audit of our federal income tax returns for the tax years ended December 31, 2015, through December 31, 2019, which remains ongoing. On March 12, 2025, the IRS issued a NOPA to reduce Perrigo U.S.’s deductible interest expense for the 2015 through 2018 tax years by $348.2 million, using the same interest rates that we agreed with IRS Appeals for the 2014 and 2015 tax years, and a Closing Agreement has been since executed that resolves this issue with finality. We previously adjusted our reserves using such interest rates and, as a result, we are fully reserved for the adjustment specified in the NOPA.

On February 27, 2026, the IRS issued a NOPA proposing to reallocate income via transfer pricing adjustments arising from the activities of Perrigo Ireland for the 2016 through 2019 tax years. Although we strongly disagree with the IRS’s position and intend to pursue administrative and/or judicial remedies, the ultimate resolution is uncertain.

### NOTE 16 - COMMITMENTS AND CONTINGENCIES

In view of the inherent difficulties of predicting the outcome of various types of legal proceedings, we cannot determine the ultimate resolution of the matters described below. We establish reserves for litigation and regulatory matters when losses associated with the claims become probable and the amounts can be reasonably estimated. The actual costs of resolving legal matters may be substantially higher or lower than the amounts reserved for those matters. For matters where the likelihood or extent of a loss is not probable or cannot be reasonably estimated as of June 27, 2026, we have not recorded a loss reserve. If certain of these matters are determined against us, there could be a material adverse effect on our financial condition, results of operations, or cash flows. We currently believe we have valid defenses to the claims in these lawsuits and intend to defend these lawsuits vigorously regardless of whether or not we have a loss reserve. Other than what is disclosed below, we do not expect the outcome of the litigation matters to which we are currently subject to have, individually or in the aggregate, a material adverse effect on our financial condition, results of operations, or cash flows.

Price-Fixing Lawsuits Related to the Company's Former Rx Business

Beginning in 2016, the Company, along with other manufacturers, was named as a defendant in lawsuits in the United States and Canada generally alleging anticompetitive conduct with respect to the sale of generic drugs by the Company’s former Rx business. The complaints have been filed by putative classes of direct purchasers, end

Perrigo Company plc - Item 1

### Note 16

payors, and indirect resellers, as well as individual direct and indirect purchasers that have opted out of the putative classes, including pharmacies, health insurers, hospitals, self-insured employers, retail customers and certain cities and counties. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. There are 50 complaints naming Perrigo entities as defendants that are currently pending in the MDL court and several other state and federal courts. Five additional complaints naming Perrigo entities as defendants were filed in 2025 by certain pharmacy chains, health insurers and self-insured employers. Perrigo was dismissed with prejudice from the case in Canada in February 2026.

While most of the class complaints involve alleged single-drug conspiracies, the three putative classes and many of the opt-out plaintiffs have each filed over-arching conspiracy complaints alleging that Perrigo and other manufacturers (and some individuals) entered into an “overarching conspiracy” that involved allocating customers, rigging bids, and raising, maintaining, and fixing prices for various products. The vast majority of the lawsuits described in this section have been consolidated in the In re Generic Pharmaceuticals Pricing Antitrust Litigation multidistrict litigation (“MDL”) MDL No. 2724 (United States District Court for the Eastern District of Pennsylvania).

The MDL Court initially designated three sets of cases to proceed as the first phase of “bellwethers,” meaning that they will proceed on a more expedited basis than the other cases in the MDL. Those cases are (a) class actions alleging “single drug” conspiracies, one set involving Clobetasol and one set involving Clomipramine; and (b) the third Complaint filed by the State Attorneys General alleging an overarching conspiracy concerning various topical products (described below). Perrigo was initially named as a defendant in the Clobetasol class bellwether cases, but the classes voluntarily dismissed their claims against Perrigo relating to “single drug” conspiracies involving Clobetasol in May 2023. The court certified classes of direct and “end-user” customers of the products at issue in the bellwether class cases on March 7, 2025. The Third Circuit accepted an appeal of the class certification decisions in the class bellwether cases on June 17, 2025. That appeal remains pending. All district court proceedings in those cases are stayed pending resolution of that appeal. Summary judgment motions in the State bellwether case were initially filed in September 2024, and briefing on those motions is complete. The district court denied motions for summary judgment concerning claim splitting, the alleged overarching conspiracy and statutes of limitations and granted in part and denied in part a motion for summary judgment concerning the damages, civil penalties, and other remedies that the states may seek. Several additional summary judgment motions, including Perrigo's company-specific summary judgment motion, remain to be decided. The case is set for trial beginning on February 3, 2027.

On October 15, 2024, the MDL Court selected the first multi-drug complaint brought by direct action plaintiff Humana, Inc., which names Perrigo as a defendant, to proceed in the second phase of bellwether cases in the MDL. In June 2026, Perrigo reached an agreement to settle the claims asserted by Humana in that bellwether case and two other cases filed by Humana.

On September 26, 2025, the MDL Court selected three additional multi-drug complaints brought by direct action plaintiffs Kroger Co., Cigna Corp., and CVS Pharmacy, Inc., each of which names Perrigo as a defendant, to proceed in the third phase of bellwether cases in the MDL. The Court in February 2026 issued orders designating portions of the complaints in the Kroger and Cigna cases as bellwethers with the trials in those bellwethers set to start in August 2027 and January 2028, respectively, and setting schedules for the remaining pretrial deadlines in those cases. No trial date has been set for the CVS bellwether case.

As of June 27, 2026, we reported a liability for the claims listed in the “Price-Fixing Lawsuits Related to the Company's Former Rx Business” section above for the reasonable estimates of probable loss (refer to [Note 4](#i227bcb81299846b0903b4c75e8c40a6b_55)). We intend to defend each of these lawsuits vigorously.

Securities Litigation

In the United States (cases related to events in 2023-2025)

On November 17, 2025, a purported securities class action complaint was filed against the Company and our current CFO, Eduardo Bezerra, former CEO, Patrick Lockwood-Taylor, and former CEO, Murray Kessler, in the U.S. District Court for the Southern District of New York (Tanner French v. Perrigo Company plc, et al., filed 11/17/2025). The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 based on statements made by the Company and its current and former executives related to our infant formula business and the strategic review of the business announced in November 2025 on behalf of a purported class of shareholders for the period from November 1, 2022 through November 5, 2025, inclusive.

Perrigo Company plc - Item 1

### Note 16

Pursuant to the Private Securities Litigation Reform Act of 1995, on February 13, 2026, the Court appointed the International Brotherhood of Teamsters Local No. 710 Pension Fund as Lead Plaintiff and approved Cohen Milstein to serve as lead counsel for the proposed class. On May 1, 2026, Lead Plaintiff filed an Amended Complaint. We intend to defend the lawsuit vigorously.

Other Matters

Talcum Powder

The Company has been named, together with other manufacturers, in product liability lawsuits in a variety of state courts alleging that the use of body powder products containing talcum powder causes mesothelioma and lung cancer due to alleged asbestos contamination of the raw material talc. The majority of these cases involve legacy talcum powder products that have not been manufactured by the Company since 1999. As of the date of these financial statements, the Company is currently named in approximately 220 pending lawsuits seeking compensatory and punitive damages. This number reflects recent group resolutions. Nationwide the number of new cases against manufacturers and retailers of talc-containing products alleging injury related to asbestos-contaminated talc continues to grow. The rate of filings against the Company is consistent with this trend and has increased as well; approximately 115 new complaints were filed against the Company in the first half of 2026. The Company has several defenses and continues to both vigorously defend these lawsuits and explore various means of expeditiously resolving these claims before trial, including through dismissals and settlements of certain plaintiffs' claims. Trials for these lawsuits are currently scheduled throughout 2026 and 2027. There are currently over 30 trials set for these cases through the end of 2026. The Company continues to evaluate these cases and vigorously defend itself against such claims while pursuing resolution of certain of the claims, including through dismissals and settlement. The Company’s retailer customers that are also named in the litigation are seeking indemnity from the Company, including for their defense costs and liability relating to these cases.

Ranitidine

After regulatory bodies announced worldwide that ranitidine may potentially contain N-nitrosodimethylamine (“NDMA”), the Company promptly began testing its externally-sourced ranitidine Active Pharmaceutical Ingredients (“API”) and ranitidine-based products. On October 8, 2019, the Company halted shipments of those products based upon preliminary results and on October 23, 2019, the Company made the decision to conduct a voluntary retail market withdrawal.

In February 2020, the resulting actions involving Zantac® and other ranitidine products were transferred for coordinated pretrial proceedings to an MDL (In re Zantac®/Ranitidine Products Liability Litigation, MDL No. 2924) in the U.S. District Court for the Southern District of Florida. The Company successfully moved to dismiss the first set of Master Complaints in the MDL based on federal preemption, which the Court granted without prejudice.

After the filing of Amended Complaints, on June 30, 2021, the Court again dismissed all claims against the retail and distributor defendants with prejudice and on July 8, 2021, the Court again dismissed all claims against the Company, this time with prejudice. Appeals of these dismissal orders to the U.S. Court of Appeals for the 11th Circuit have been filed. In December 2022, the Court granted in full the brand defendants' Daubert motions, finding that Plaintiffs' causation experts' opinions were unreliable and thus inadmissible. The Court later ruled that it was appropriate to apply the same expert causation standards to the retail and distributor defendants as well as the generic defendants, and the Court thereby ruled that its Daubert decision barring Plaintiffs' expert opinions applied equally to these defendants as well. Thus, the Court's rulings on both federal preemption and scientific causation grounds dismissed all claims against the Company on two independent grounds and are also binding on all claims remaining in the MDL Census Registry. Appeals of these orders have been filed to the 11th Circuit and oral arguments were held on October 10, 2025. The Company continues to vigorously defend itself against such claims at the appellate level.

As noted above, the Company has won multiple motions to dismiss in the MDL. The Company has also won motions to dismiss at the state-court level, most recently in Illinois where the Circuit Court granted in full the Company's motions to dismiss based on federal preemption. The Company has also been dismissed from additional state court actions in California, Pennsylvania, Illinois, Ohio, New York, New Jersey, North Carolina, and Maryland. Plaintiffs elected not to appeal any of those state-court dismissals, with the exception of Illinois (where the Company prevailed on appeal). In April 2025, the Company reached a settlement in principle in the Illinois state court lawsuits, including in the sole case on appeal. The pending settlement is for an immaterial amount and is expected to be fully funded by insurance.

Perrigo Company plc - Item 1

### Note 16

Other than the MDL and state court matters that have been dismissed at the trial court level, as of the date of these financial statements, the Company was also named in approximately 190 personal injury lawsuits in the state of California. In November 2024, the Company reached a settlement in principle in each of the remaining Ranitidine California state court lawsuits. The pending settlement is for an immaterial amount and is expected to be fully funded by insurance.

In March 2025, a New Mexico state court granted in full Perrigo’s Motion to Dismiss a ranitidine action against the Company by the New Mexico Attorney General based on nuisance and negligence theories for lack of personal jurisdiction. The New Mexico Attorney General did not appeal that decision, which ended the case against the Company. With the dismissal of the New Mexico action, there are no active lawsuits against the Company with respect to ranitidine at the trial court level, in state or federal court.

Some of the Company’s retailer customers are seeking indemnity from the Company for a portion of their defense costs and liability relating to these cases.

Acetaminophen

In October 2022, the Judicial Panel on Multidistrict Litigation consolidated a number of pending actions filed in various federal courts alleging that prenatal exposure to acetaminophen is purportedly associated with the development of autism spectrum disorder (“ASD”) and attention-deficit/hyperactivity disorder (“ADHD”). The acetaminophen MDL is styled In re: Acetaminophen – ASD/ADHD Products Liability Litigation (MDL No. 3043) and is pending before the U.S. District Court for the Southern District of New York. Plaintiffs in the MDL asserted claims against Johnson & Johnson Consumer, Inc. (“JJCI”) (now known as Kenvue Brands LLC) and various retailer chains alleging that plaintiff-mothers took acetaminophen products while pregnant and that plaintiff-children developed ASD and/or ADHD as a result of prenatal exposure to these acetaminophen products. As of the date of these financial statements, the Company has not been named as a defendant in any Complaints filed in the MDL. Certain of the Company’s customers have made requests regarding indemnity from the Company for a portion of their defense costs and potential liability. The Company has agreed to defense cost-sharing arrangements with certain retailer customers.

On December 18, 2023, the MDL court granted in full defendants' motions to exclude testimony of Plaintiffs' general causation expert witnesses, finding Plaintiffs presented no reliable evidence of scientific causation between prenatal ingestion of acetaminophen and ASD or ADHD in children. Final judgment has been entered as to the majority of pending cases with an appeal proceeding in the Second Circuit. A small minority of cases were exempted from the Court’s dismissal to enable Plaintiffs to present an additional expert to be evaluated through a similar process as the larger majority to determine if they can withstand scientific causation through this new expert. However, on July 10, 2024, the Court granted in full defendants' motion to exclude testimony of Plaintiffs' new general causation expert witness in this subset of carve out cases for similar reasons as the Court's December 2023 Order. Final judgment was entered against the Plaintiffs in those carve out cases, which have now been appealed to the Second Circuit.

The appeals before the Second Circuit were fully briefed and argument was held on November 17, 2025. On July 13, 2026, the Second Circuit issued an Order vacating the MDL Court’s Orders excluding each of Plaintiffs’ general causation expert witnesses pursuant to Rule 702. The Second Circuit held that the MDL Court exceeded its discretion as gatekeeper in excluding three of Plaintiffs’ original five experts including their primary epidemiology expert, but found that the MDL Court was within its discretion in excluding the remaining two experts in pharmacology and teratology. The Second Circuit also concluded that the MDL Court correctly declined to dismiss the cases on the grounds that the Plaintiffs’ failure to warn claims were preempted, based on warnings requirements. If no appellate relief is sought by a party or is denied, the cases will be remanded to the MDL Court for further proceedings consistent with the Second Circuit opinion. Currently, it is not possible to assess reliably the outcome of these cases or reasonably estimate any potential future financial impact on the Company.

There are state court actions pending in California, Illinois and Florida against the manufacturers of Tylenol, and against certain retailer defendants for the sale of store brand acetaminophen. At this time, the Company is not named in any state court action, and no state court case has proceeded to trial.

Phenylephrine

In September 2023, the Food and Drug Administration’s (“FDA”) Advisory Committee on Nonprescription Drugs issued an advisory opinion calling into question the efficacy of orally administered phenylephrine (“PE”) containing products as a nasal decongestant. While the FDA itself has thus far taken no action in response to the Advisory Committee opinion, several putative class action lawsuits were filed asserting various economic injury claims to consumers. These actions were consolidated into an MDL (In re: Oral Phenylephrine Marketing and Sales Practices

Perrigo Company plc - Item 1

### Note 16

Litigation, MDL No. 3089), pending in the U.S. District Court for the Eastern District of New York. The Court permitted Plaintiffs to file a streamlined and consolidated bellwether complaint for purposes of testing the Plaintiffs’ case and enabling briefing on threshold issues. Defendants filed a consolidated motion to dismiss, and the Court heard oral argument in September 2024. In October 2024, the Court dismissed in its entirety Plaintiffs’ Streamlined and Consolidated Bellwether Complaint, finding that all of Plaintiffs’ claims regarding PE were preempted by federal law, and separately dismissing Plaintiffs’ RICO claims for lack of standing. Final judgment was entered and Plaintiff filed a Notice of Appeal to the Second Circuit. Appellate briefing is complete, and oral argument was held on March 4, 2026. The Second Circuit issued its decision on July 30, 2026. The Court affirmed dismissal of the majority of Plaintiffs’ state law claims on preemption grounds and dismissed the RICO claims entirely. The Court vacated dismissal of the “Maximum Strength” labeling claims and any claims relating to NDA-approved PE products, remanding both for further proceedings.

Individual arbitrations involving similar efficacy allegations have also been threatened or initiated against certain retailers in various arbitral forums. Some of the Company's retail customers sought indemnity and defense costs from the Company relating to these cases. Agreements are in place to resolve these matters.

PLD & Conry Litigation

Perrigo Company plc, L. Perrigo Company, and PBM Nutritionals, LLC (collectively, the “Perrigo Defendants”) are defendants in two pending litigations, P&L Development, LLC v. Gerber Products Company, et al. (the “PLD Action”), and Conry, et al. v. Gerber Products Company, et al. (the “Conry Action” and together with the PLD Action, the “Actions”), both of which are pending in the U.S. District Court for the Eastern District of New York. The PLD Action was brought by P&L Development, LLC (“PLD”), and the Conry Action was brought by a proposed class of Store Brand infant formula purchasers (the “Conry Plaintiffs”). Gerber Products Company (“Gerber”) is a co-defendant in both Actions. The Actions involve allegations that PLD entered into a memorandum of understanding with Gerber for Gerber to supply PLD with infant formula with which to compete with Perrigo, and that Gerber allegedly repudiated that commitment because of an agreement with the Perrigo Defendants, which unreasonably restrained trade in violation of Section 1 of the Sherman Act. The Actions also involve allegations that the Perrigo Defendants’ acquisition of the Gateway infant formula manufacturing facility from Gerber was anticompetitive. Perrigo has reached an agreement in principle with both PLD and the Conry Plaintiffs to settle all claims against Perrigo in both the PLD Action and the Conry Action. Perrigo, PLD, and the Conry Plaintiffs are preparing final settlement agreements and the court has stayed the PLD Action and the Conry Action against Perrigo in the interim. The PLD Action and the Conry Action are proceeding with respect to Gerber. Fact discovery is closed, expert discovery is ongoing, and class certification and summary judgment have yet to be briefed.

Contingencies Accruals

As a result of the matters discussed in this Note, the Company has established a loss accrual for litigation contingencies where we believe a loss to be probable and for which an amount of loss can be reasonably estimated. Except as otherwise discussed for specific matters above, we cannot determine a reasonable estimate of the maximum possible loss or range of loss for these matters given that they are at various stages of the litigation process and each case is subject to inherent uncertainties of litigation. As of June 27, 2026, the loss accrual for litigation contingencies reflected on the Condensed Consolidated Balance Sheet in Other accrued liabilities was $91.9 million, inclusive of the accrual related to Discontinued Operations. The Company also recorded a recovery receivable reflected on the Condensed Consolidated Balance Sheets in Prepaid expenses and other current assets of $48.4 million, inclusive of the recovery receivable related to Discontinued Operations, as of June 27, 2026. The Company’s management believes these accruals for contingencies are reasonable and sufficient based upon information currently available to management; however, there can be no assurance that final costs related to these contingencies will not exceed current estimates, nor any assurance as to the amount of such final costs that may be covered by insurance. In addition, we have other litigation matters pending for which we have not recorded any accruals because our potential liability for those matters is not probable or cannot be reasonably estimated based on currently available information. For those matters where we have not recorded an accrual but a loss is reasonably possible, we cannot determine a reasonable estimate of the maximum possible loss or range of loss for these matters given that they are at various stages of the litigation process and each case is subject to the inherent uncertainties of litigation.

Perrigo Company plc - Item 1

### Note 17

### NOTE 17 - SEGMENT AND GEOGRAPHIC INFORMATION

During the first quarter of 2026, we implemented changes to our organizational structure and internal management reporting to better align with how the CODM evaluates segment performance and allocates resources going forward.

Our reporting segments are as follows:

Reporting Segment Product Categories

Self Care Includes over-the-counter health and wellness products intended for consumer self-treatment of common conditions, such as pain & sleep, upper respiratory, digestive health and healthy lifestyle products including vitamins, minerals, and supplements and oral electrolyte beverages

Specialty Care Includes branded and specialty consumer health products that address more targeted or complex self-care needs, including women's health and skin health offerings, such as skin healing and insect repellant

Infant Formula Comprised of the infant formula product category, which includes nutrition products designed to meet the dietary needs of infants

Our Oral Care product category and Other product category, which includes our Dermacosmetics business (through its April 30, 2026 divestment), are together disclosed as “All Other.” We have reflected this segment change in all historical periods presented.

In the first quarter of 2026, following changes to our segments, our CODM reevaluated and changed the primary measure utilized to evaluate segment profitability from segment operating income to segment adjusted operating income. We have reflected this change from segment operating income to segment adjusted operating income in all historical periods presented.

For each segment, the CODM uses this information to assist in evaluating underlying trends, to monitor budget and forecast versus actual results, to make investment decisions to allocate resources both in total, and between the segments, and to make key segment personnel decisions. Segment adjusted operating income is based on Operating income, excluding amortization expense, acquisition and integration-related charges and contingent consideration, impairment charges, Infant Formula remediation, (gain) loss on divestitures and brand sales, loss on debt extinguishment, unusual litigation, and restructuring charges and other termination benefits (referred to herein as “Segment operating income (loss)”), as the CODM excludes these items in assessing segment financial performance. General corporate/unallocated expenses, which include expenses related to treasury, legal operations, and certain other expenses are not allocated to the segments. In assessing segment performance and managing operations, the CODM reviews total inventory by segment but does not review segment assets in total, accordingly certain asset related disclosures are omitted.

The tables below show select financial measures by reporting segment(1) (in millions):

| Net Sales | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Self Care | $576.6 | $598.6 | $1,119.9 | $1,212.8 |
| Specialty Care | 226.6 | 233.1 | 433.6 | 432.2 |
| Infant Formula | 100.9 | 82.0 | 190.6 | 169.8 |
| Reporting segment net sales | 904.1 | 913.6 | 1,744.2 | 1,814.8 |
| All Other | 118.6 | 142.7 | 247.8 | 285.4 |
| Total Consolidated net sales | $1,022.8 | $1,056.3 | $1,992.0 | $2,100.2 |

Perrigo Company plc - Item 1

### Note 17

| Line item | Three Months Ended June 27, 2026 / Self Care | Three Months Ended June 27, 2026 / Specialty Care |  | Reporting Segments Total |
| --- | --- | --- | --- | --- |
| Reporting segment net sales(2) | 576.6 | $226.6 |  | $904.1 |
| Adjusted cost of sales | 402.3 | 106.1 |  |  |
| Adjusted other expense items(3) | 95.6 | 72.7 |  |  |
| Segment operating income | $78.7 | $47.8 |  | $130.5 |
| Reconciliation to Income from continuing operations before income taxes: |  |  |  |  |
| All Other adjusted operating income |  |  | 25.8 |  |
| Unallocated expense |  |  | (31.8) |  |
| Amortization expense related primarily to acquired intangible assets |  |  | (54.5) |  |
| Impairment charges(4) |  |  | (1.0) |  |
| Restructuring charges and other termination benefits |  |  | (14.4) |  |
| Unusual litigation |  |  | (12.4) |  |
| Other(5) |  |  | (18.8) |  |
| Operating income |  |  | $23.5 |  |

| Line item | Six Months Ended June 27, 2026 / Self Care | Six Months Ended June 27, 2026 / Specialty Care |  | Reporting Segments Total |
| --- | --- | --- | --- | --- |
| Reporting segment net sales(2) | $1,119.9 | $433.6 |  | $1,744.2 |
| Adjusted cost of sales | 763.5 | 198.9 |  |  |
| Adjusted other expense items(3) | 209.2 | 131.6 |  |  |
| Segment operating income (loss) | $147.3 | $103.2 |  | $247.0 |
| Reconciliation to Income from continuing operations before income taxes: |  |  |  |  |
| All Other adjusted operating income |  |  | 57.6 |  |
| Unallocated expense |  |  | (67.2) |  |
| Amortization expense related primarily to acquired intangible assets |  |  | (109.0) |  |
| Impairment charges(4) |  |  | (331.8) |  |
| Restructuring charges and other termination benefits |  |  | (89.5) |  |
| Unusual litigation |  |  | (28.9) |  |
| Other(5) |  |  | (27.0) |  |
| Operating loss |  |  | $(348.9) |  |

| Line item | Three Months Ended June 28, 2025 / Self Care | Three Months Ended June 28, 2025 / Specialty Care | Three Months Ended June 28, 2025 / Infant Formula | Reporting Segments Total |
| --- | --- | --- | --- | --- |
| Reporting segment net sales(2) | 598.6 | $233.1 | $82.0 | $913.6 |
| Adjusted cost of sales | 397.1 | 98.1 | 71.2 |  |
| Adjusted other expense items(3) | 107.6 | 68.7 | 23.0 |  |
| Segment operating income (loss) | $93.9 | $66.3 | $(12.2) | $148.0 |
| Reconciliation to Income from continuing operations before income taxes: |  |  |  |  |
| All Other adjusted operating income |  |  |  | 25.7 |
| Unallocated expense |  |  |  | (38.5) |
| Amortization expense related primarily to acquired intangible assets |  |  | (56.8) |  |
| Impairment charges(4) |  |  | (1.5) |  |
| Restructuring charges and other termination benefits |  |  | (8.7) |  |
| Unusual litigation |  |  | (15.4) |  |
| Other(5) |  |  | (7.4) |  |
| Operating income |  |  | $45.4 |  |

Perrigo Company plc - Item 1

### Note 17

| Line item | Six Months Ended June 28, 2025 / Self Care | Six Months Ended June 28, 2025 / Specialty Care | Six Months Ended June 28, 2025 / Infant Formula | Reporting Segments Total |
| --- | --- | --- | --- | --- |
| Reporting segment net sales(2) | $1,212.8 | $432.2 | $169.8 | $1,814.8 |
| Adjusted cost of sales | 785.4 | 180.2 | 126.4 |  |
| Adjusted other expense items(3) | 220.7 | 143.6 | 45.0 |  |
| Segment operating income (loss) | $206.7 | $108.4 | $(1.6) | $313.5 |
| Reconciliation to Income from continuing operations before income taxes: |  |  |  |  |
| All Other adjusted operating income |  |  |  | 46.6 |
| Unallocated expense |  |  |  | (78.3) |
| Amortization expense related primarily to acquired intangible assets |  |  | (111.8) |  |
| Impairment charges(4) |  |  | (4.6) |  |
| Infant formula remediation |  |  | (0.9) |  |
| Restructuring charges and other termination benefits |  |  | (38.1) |  |
| Unusual litigation |  |  | (24.3) |  |
| Other(5) |  |  | (9.8) |  |
| Operating income |  |  | $92.3 |  |

(1) Amounts may not add or recalculate due to rounding.

(2) See table above for reconciliation to Consolidated net sales.

(3) Adjusted other expense items include distribution, research and development, and selling and administrative expenses.

(4) During the three months ended June 27, 2026, we determined the carrying value of an in-process R&D asset was impaired by $1.0 million. During the six months ended June 27, 2026, we also determined the carrying value of our reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $330.8 million. During the three months ended June 28, 2025, we determined the carrying value of our Prevacid® branded product was impaired by $1.5 million. During the six months ended June 28, 2025, we also determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million, inclusive of a goodwill impairment charge of $1.2 million.

(5) Other pre-tax adjustments impacting operating income for the three months ended June 27, 2026 includes $3.4 million of professional consulting fees for potential divestiture activity and other legal matters and $15.4 million of accelerated depreciation as a result of a partial plant shut-down to rationalize capacity as part of Nutrition Network Optimization. Other pre-tax adjustments impacting operating income for the six months ended June 27, 2026 includes $11.2 million of professional consulting fees for potential and actual divestiture activity, partially offset by $3.1 million of favorable hedging activity related to the Dermacosmetics Business divestiture, and $18.9 million of accelerated depreciation as part of Nutrition Network Optimization Program. Other pre-tax adjustments for the three months ended June 28, 2025 are related to $4.5 million of accelerated depreciation as a result of Nutrition Network Optimization and $2.8 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the six months ended June 28, 2025 include expenses of $5.3 million related to professional consulting fees for divestiture activity and $4.5 million related to accelerated depreciation as a result of Nutrition Network Optimization.

The tables below show select financial measures by reporting segment(1) (in millions):

| Inventory | June 27, 2026 | December 31, 2025 |
| --- | --- | --- |
| Self Care | $668.8 | $695.9 |
| Specialty Care | 133.4 | 146.1 |
| Infant Formula | 170.4 | 188.4 |
| All Other | 91.7 | 118.6 |
| Total inventory | $1,064.5 | $1,149.0 |

| Depreciation | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Self Care | $13.5 | $15.4 | $27.0 | $30.7 |
| Specialty Care | 4.3 | 3.9 | 7.4 | 7.8 |
| Infant Formula | 19.5 | 8.4 | 27.2 | 12.4 |
| All Other | 4.2 | 1.6 | 8.4 | 3.9 |
| Total depreciation | $41.4 | $29.3 | $70.1 | $54.8 |

(1) Amounts may not add or recalculate due to rounding.

## Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Perrigo Company plc - Item 2

Executive Overview

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis (“MD&A”) is intended to provide readers with an understanding of our financial condition, results of operations, and cash flows by focusing on changes in certain key measures from year to year. This MD&A is provided as a supplement to, and should be read in conjunction with our Condensed Consolidated Financial Statements and accompanying Notes found in [Item 1](#i227bcb81299846b0903b4c75e8c40a6b_13) included in this Form 10-Q, and our Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”). These historical financial statements may not be indicative of our future performance. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under “Risk Factors” in Item 1A of our 2025 Form 10-K and [Part II. Item 1A](#i227bcb81299846b0903b4c75e8c40a6b_175) of this Form 10-Q.

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc (“Elan”). Unless the context requires otherwise, the terms Perrigo, the “Company,” “we,” “our,” “us,” and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

EXECUTIVE OVERVIEW

Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter (“OTC”) self-care market, Perrigo is led by its vision “To Provide The Best Self-Care For Everyone” and its purpose to “Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All”.

Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for:

- Access: Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness.
- Value: Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions.
- Reliability: Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers.

Perrigo provides access to trusted self-care solutions that can be used without the need to visit a health practitioner for a prescription. Guided by our vision and purpose, our strategic goal is to create sustainable and value accretive growth by 1) delivering consumer preferred brands and innovation, 2) driving category growth with our customers, 3) powering our business with our world-class, quality assured supply chain, including a focus on sustainability with meaningful goals to reduce greenhouse gas emissions, water, and waste, in addition to increasing the recyclability of our packaging, and 4) evolving our global organization to one cohesive operating model. Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.

Perrigo's broad offerings are well diversified across several major product categories as well as across geographies, primarily in North America and Europe, with no one product representing more than 5% of total revenue. In North America, Perrigo is the leading store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, in addition to offering brands including Opill® and Mederma®. In Europe, our portfolio consists primarily of brands, including Compeed®, ellaOne®, Solpadeine®, and Jungle Formula®.

Perrigo’s unique portfolio of businesses complement each other, where 1) store brands generate cash for investments into the Company’s key higher margin, higher growth brands, 2) branding and innovation capabilities are leveraged for both brand and store brand demand generation designed to generate stronger customer partnerships, 3) consumer-led innovation is scaled across brands, store brands and geographies, and 4) leveraging the scale of our global supply chain with more molecules at more price points to more consumers to drive increased household penetration.

Perrigo Company plc - Item 2

Executive Overview

The Company’s plan to drive increased cash flow and total shareholder return is anchored in its ‘Three-S’ plan – ‘Stabilizing,’ ‘Streamlining,’ and ‘Strengthening’ our business. This process centers on restoring consistency in our core business, streamlining our cost structure and building capabilities that support scalable long-term growth.

Our fiscal year begins on January 1 and ends on December 31. We end our quarterly accounting periods on the Saturday closest to the end of the calendar quarter, with the fourth quarter ending on December 31 of each year.

Our Segments

Our reporting and operating segments reflect the way our chief operating decision maker, who is our Interim Chief Executive Officer (“CEO”), makes operating decisions, allocates resources and manages the growth and profitability of the Company. Our reporting segments are:

- Self Care includes over-the-counter health and wellness products intended for consumer self-treatment of common conditions, such as pain & sleep, upper respiratory, digestive health and healthy lifestyle products including vitamins, minerals and supplements ("VMS") and oral electrolyte beverages.
- Specialty Care includes branded and specialty consumer health products that address more targeted or complex self-care needs, including women's health and skin health offerings, such as skin healing and insect repellant.
- Infant Formula is comprised of the infant formula product category, which includes nutrition products designed to meet the dietary needs of infants.

The Company's Oral Care product category and Other product category, which includes the Dermacosmetics business (through its April 30, 2026 divestment), are together disclosed as “All Other.”

We previously operated an Rx segment consisting of our U.S. generic prescription pharmaceuticals business and other pharmaceuticals and diagnostic businesses in Israel, which have been divested. The Rx segment was reported as Discontinued Operations in 2021, and is presented as such for all periods in this report. See [Item 1. Note 4](#i227bcb81299846b0903b4c75e8c40a6b_55) for more information.

Products

We offer products in the following categories:

- Reporting Segment Product Category Description
- Self Care Upper Respiratory Products that relieve upper respiratory symptoms, including cough suppressants, expectorants, sinus and allergy relief.
- Digestive Health Products such as antacids, anti-diarrheal, and anti-heartburn that relieve symptoms associated with digestive issues.
- Healthy Lifestyle Products that help consumers live a healthy lifestyle such as smoking cessation, weight management, heart health, VMS, nutraceutical and electrolytes.
- Pain and Sleep-Aids Products comprised of pain relievers, fever reducers and sleep-aids.
- Specialty Care Skin Health Products for the face and body such as scar management, lice treatment, insect repellant and other products for various skin conditions.
- Women's Health Women's health products, including feminine hygiene and contraceptives.
- Infant Formula Infant Formula Infant nutrition products designed to meet dietary needs.
- All Other Oral Care Products used for oral care, including toothbrushes, toothbrush replacement heads, floss, flossers, whitening products and toothbrush covers.
- Other(1) Other miscellaneous self-care products, including the Dermacosmetics business.

(1) The Dermacosmetics business was historically reported in the Skin Care category and is now included within Other through its April 30, 2026 divestment.

Perrigo Company plc - Item 2

Executive Overview

Recent Developments

- On April 30, 2026, the sale of the Dermacosmetics Business was completed for total consideration of $362.9 million, net of cash delivered. The transaction consists of €305.6 million or $358.5 million in upfront cash, $6.2 million of proceeds received for inventory on hand, less $1.8 million of cash delivered. The transaction also stipulates up to an additional €27.0 million contingent on the achievement of net sales milestones, of which €18.0 million is remaining through 2027. The sale resulted in a pre-tax gain of $129.5 million during the quarter. Brands sold in the transaction include ACO, Biodermal, and Iwostin.
- On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors of the Company. Concurrently, the Board appointed Albert A. Manzone, Director and member of the Audit Committee of the Board, as the Company’s Interim President and Chief Executive Officer.
- On June 30, 2026, the Board of Directors of the Company appointed Salman Amin and Omer Gajial to serve as members of the Board effective as of June 30, 2026. In connection with the appointments, the Board increased the size of the Board from 8 to 10.

Restructuring

Supply Chain Reinvention Program

In 2022, we initiated a Supply Chain Reinvention Program to reduce structural costs, improve profitability and our service levels to our retail partners, and strengthen our resiliency by streamlining and simplifying our global supply chain. Through this initiative, we have reduced portfolio complexity, invested in advanced planning capabilities, diversified sourcing, and optimized our manufacturing assets and distribution models. The program objectives are now realized with approximately $157 million of annualized benefits (not including related depreciation expense on capital investments) achieved by the end of fiscal year 2025. Total costs incurred over the same period including capital investments, restructuring expenses and implementation costs totaled approximately $286 million. For the remaining project wind-down activities, we anticipate less than $10 million of additional costs to be incurred through fiscal year 2026. Refer to [Item 1. Note 14](#i227bcb81299846b0903b4c75e8c40a6b_4398046512733) for further details on restructuring charges.

Project Energize

As part of our sustainable, value accretive growth strategy, we launched Project Energize in the first quarter of 2024 - a global investment and efficiency program to drive the next evolution of capabilities and organizational agility. This three-year program was expected to produce significant benefits in our long-term business performance by enabling our One Perrigo growth strategy, increasing organizational agility and mitigating impacts from stabilizing and strengthening the infant formula business. As of December 31, 2025, Project Energize had achieved these objectives and has substantively completed.

Project Energize delivered approximately $167 million of annualized pre-tax savings as of the end of the fiscal year 2025, within the range of $140 million to $170 million expected by the end of 2026. Reinvestment savings were $35 million over the same period. Restructuring and related charges associated with these actions were approximately $138 million over the same period compared to an original estimated range of $140 million to $160 million. For the remaining project wind-down activities, we anticipate less than $10 million of additional costs to be incurred through fiscal year 2026. Refer to [Item 1. Note 14](#i227bcb81299846b0903b4c75e8c40a6b_4398046512733) for further details on restructuring charges.

Nutrition Network Optimization; Strategic Review

In 2025, we initiated the Nutrition Network Optimization project to optimize our infant formula manufacturing footprint, upgrade packaging capabilities, harmonize quality processes, and enhance our research and development capabilities. On November 5, 2025, we announced a strategic review of our infant formula business. The review will assess a full range of alternatives and is aligned with our ‘Three‑S’ plan and reflects our commitment to disciplined capital allocation and supporting improved return on invested capital and total shareholder return. It will focus on a combination of accelerating cash flows and reassessing the previously announced investment in this business of $240 million, while optimizing portfolio impact and management focus. During the three months ended June 27, 2026, we executed a partial plant shut-down of our Vermont facility to rationalize capacity as part of this program. For further details on our restructuring charges related to the strategic review, refer to [Item 1. Note 14](#i227bcb81299846b0903b4c75e8c40a6b_4398046512733).

Perrigo Company plc - Item 2

Executive Overview

Operational Enhancement Program

Building on the ‘Streamlining’ actions within our 'Three-S' Plan, in the fourth quarter of 2025 we launched a two-year, enterprise-wide operational enhancement program to create a more agile, more resilient platform positioned for growth in our core business. The program is designed to streamline operations in response to near-term industry pressures, including soft consumer consumption leading to lower volumes, while freeing up capital to further invest behind our key brands and store brands.

We expect the program to enhance organizational effectiveness by evolving our structure to improve agility, accelerate decision‑making and better leverage technology. As part of this effort, we expect to reduce approximately 7% of our workforce as of December 31, 2025. The program will also target operational cost reductions mainly in our supply chain and distribution network.

We anticipate gross pre‑tax annual run rate cost savings of $80 million to $100 million from the program, the majority of which are expected to be achieved in 2026. Cash costs to achieve these savings are expected to range between $80 million and $90 million primarily in 2026.

For further details on our restructuring charges, refer to [Item 1. Note 14](#i227bcb81299846b0903b4c75e8c40a6b_4398046512733).

Market Factors and Trends

Macroeconomic Uncertainty

Current macroeconomic conditions remain dynamic, including impacts from inflation and interest rates, volatile changes in foreign currency exchange rates, tariffs and other trade restrictions, political unrest and uncertainty and legislative and regulatory changes. Any causes of market size contraction could reduce our sales or erode our operating margin and consequently reduce our net earnings and cash flows. As a result of these dynamic conditions and uncertainties, we have modified, and may further modify, our operations and strategic initiatives, including by adjusting our investment priorities, reallocating resources, or delaying specific initiatives, such as deferring capital expenditures on Nutrition Network Optimization, initiating an enterprise-wide operational enhancement program, and seeking further working capital improvements.

Current uncertainties arising from increased tariffs on imported products could have an adverse effect on our Company. In 2025, the U.S. government announced new or additional tariffs on products imported from many countries and individualized “reciprocal” tariffs on countries with which the U.S. has the largest trade deficits. While some tariffs have become effective, others have been temporarily suspended, increased then reduced or permanently repealed. The U.S. government has announced trade agreements with various governments and additional tariffs on countries due to geo-political issues. As a result, there continues to be significant volatility and uncertainty regarding the scope, timing, implementation and effective rates of tariffs.

During the first quarter of 2026, following the U.S. Supreme Court’s determination that tariffs imposed under the International Emergency Economic Powers Act were unlawful and subsequent orders of the U.S. Court of International Trade directing U.S. Customs and Border Protection to refund such duties, the Company concluded that recovery of a portion of previously paid tariffs is probable. Accordingly, the Company recorded a net receivable of approximately $21 million that benefited gross profit during the three months ended March 28, 2026, representing refunds expected to be received related to eligible import entries, based on information currently available, including shipment‑level data and applicable court guidance. During the three months ended June 27, 2026, we recorded a $9.6 million adjustment benefiting gross profit based on updated information, resulting in a net receivable of approximately $31 million. The timing of receipt of these refunds is subject to U.S. Customs and Border Protection’s administrative processes, and actual amounts received may differ from estimates as refund claims are validated.

In addition, our interest expense is impacted by the overall global economic and interest rate environment. We manage interest rate risk through our capital structure and the use of interest rate swaps to fix the interest rate on greater than 90% of our outstanding debt.

Inflationary Costs and Supply Chain

Supply chain disruptions continue in multiple commodity categories such as agricultural commodities due to climate impacts and impacts across the overall supply chain due to the conflicts between Russia and Ukraine, the Middle

Perrigo Company plc - Item 2

Executive Overview

East Conflict and overall geopolitical tensions. Inflationary pressures are still a significant cost factor in major economies globally across food, energy and labor and general materials. The ongoing conflict involving Iran has contributed to volatility in global oil markets, resulting in rising oil prices. This escalation in oil prices presents an inflation risk for the broader economy. We previously experienced employment vacancies and attrition in the labor market which negatively impacted productivity and drove wage rate increases and other retention benefits. We implemented a series of actions to substantially mitigate these and other inflationary cost pressures, such as strategic pricing and our Supply Chain Reinvention Program. Benefits from our actions have substantially offset the impacts of inflation to date. However, future supply chain disruptions and inflationary pressures from the continuation of the conflicts between Russia and Ukraine, escalating conflicts in the Middle East, the duration and extent of oil price increases and persistent geopolitical tensions along with the impact of tariff and trade policy continue to foster uncertainty.

Infant Formula

As part of its efforts to prevent supply interruptions and risk of Cronobacter spp. illnesses associated with powdered infant formula, in March 2023, the Food and Drug Administration ("FDA") released an “Immediate National Strategy to Increase the Resiliency of the U.S. Infant Formula Market” and issued a letter to the powdered infant formula industry to share information to assist the industry in improving the microbiologic safety of powdered infant formula. In response to those changes, we made considerable investments in all our infant formula manufacturing sites. These investments included, among other things, enhancing our cleaning and sanitation protocols, our environmental monitoring programs, and quality oversight, as well as additional quality and operations personnel. These changes have resulted in higher costs and lower manufacturing output and production yields across our infant formula network. In March 2025, the U.S. Department of Health and Human Services (HHS) launched

Operation Stork Speed, a regulatory initiative aimed at strengthening the safety, quality, transparency, and resilience

of the U.S. infant formula supply. This initiative intends to review the nutrients used in infant nutrition, expand testing

for contaminants, and enhance labelling expectations, and will evaluate potential future regulatory updates. In addition, Operation Stork Speed extends the FDA’s personal importation policy, which allows individuals to import certain infant formula products for personal use, thereby potentially increasing competitive pressures in the U.S. infant formula market. Together, these measures may introduce new compliance and regulatory obligations and may affect competitive dynamics in the U.S. market.

As previously disclosed, we received a warning letter from the FDA on August 30, 2023 relating to the Perrigo Wisconsin infant formula facility, which we acquired in November 2022. While we worked to resolve the issues raised in the August 30 letter, on November 29, 2023, we received notice from the FDA of additional inspection observations relating to Perrigo Wisconsin. Consistent with our commitment to quality, we temporarily paused all production at that facility and conducted an extended site-wide assessment and cleaning.

We also bolstered our internal resources and brought in additional outside expertise to help revise, enhance and strengthen comprehensive standards and processes across our infant formula network, including in some instances, pausing production for comprehensive cleaning and infrastructure improvements. All planned large-scale manufacturing plant resets have been completed, we have implemented quality enhancements, including further protocol, process and procedural improvements at the site level, and all sites are producing reliable, quality-assured product.

In October and November 2024, the FDA conducted its first inspection of the Perrigo Wisconsin infant formula facility since the November 2023 inspection. Following this 2024 inspection, the FDA did not issue written observations via Form FDA 483. In February 2026, the FDA conducted an additional inspection of the Perrigo Wisconsin infant formula facility and issued a Form 483. The matters raised in the February 2026 Form 483 do not relate to a production batch or an actual or potential recall of past production. We have initiated corrective actions and will continue to work collaboratively with the FDA.

We incurred certain extraordinary non-recurring costs associated with the remediation and enhancement actions described above and the evolving U.S. infant formula regulatory landscape, including consulting and legal fees relating to our responses to the FDA and the development and institution of new protocols across our infant formula manufacturing sites, as well as other costs relating to the extended cleaning and sanitization and the pausing and restarting of production. Cash costs to achieve this remediation plan were approximately $22.6 million with approximately 95% of such costs incurred during the year ended December 31, 2024.

We have been focusing on rebuilding market share, while managing the additional cost and production processes. Although we have gained market share in non-WIC infant formula powder, heightened competition from existing and

Perrigo Company plc - Item 2

Executive Overview

new entrants, particularly as a result of continued regulatory forbearance allowing imported infant formulas has led to increased supply of infant formula in the United States, and the previously disclosed lost distribution of the Good Start® brand have hindered our efforts to recover our previous market share. On November 5, 2025, we announced a strategic review of our infant formula business focused on a combination of accelerating cash flows and reassessing the previously announced investment in this business, while optimizing portfolio impact and management focus. See Nutrition Network Optimization; Strategic Review above.

War in Ukraine

The invasion of Ukraine by Russia and resulting economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries on Russia, Belarus, and occupied regions in Ukraine have negatively impacted our results from operations in the region. Future impacts are difficult to predict due to the high level of uncertainty related to the war's duration, evolution and resolution. If the conflict spreads or materially escalates, or economic conditions deteriorate, the impact on our business and results of operations could be material.

Middle East Conflicts

We continue to closely monitor the ongoing conflict and the social, political and economic environment in Israel and in the broader Middle East to evaluate the impacts on our operations and supply chain. Israel is a global technology research and development center that plays a critical role in the global Active Pharmaceutical Ingredients ("API") market, as a number of our key suppliers are located within Israel. The Company sources some raw materials and finished goods from suppliers in Israel for certain self-care products, including omeprazole. To date, Perrigo has confirmed that our suppliers in the region have active operations and continue to manufacture materials for us, and we have not received any reports of restrictions on imports or exports in Israel. However, there is potential for some disruption as it relates to in-country logistics, including freight. As a precaution, Perrigo has engaged alternate suppliers to help minimize a potential supply disruption. If the conflict spreads or materially escalates, or if the conflict leads to further volatility and uncertainty in financial markets or economic conditions, the impact on our business and results of operations could be material. For example, an escalation in military activity in the Strait of Hormuz and Red Sea region has the potential to disrupt supply chains and has lead to further inflationary pressures which we are also continuing to monitor.

Foreign Exchange

We have both translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate impacts of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1) the impact from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances denominated in currencies other than the functional currency. Significant exchange rate fluctuations, especially in the Euro or the British Pound Sterling, have had, and could continue to have, a significant impact on our net sales, net earnings and cash flows.

For additional information, refer to [Part II. Item 1A - Risk Factors](#i227bcb81299846b0903b4c75e8c40a6b_175).

RESULTS OF OPERATIONS

Currency Translation

Any currency translation effects described below represent estimates of the net differences between translation of foreign currency transactions into U.S. dollars for the three and six months ended June 27, 2026 at the average exchange rates for the reporting period and average exchange rates for the three and six months ended June 28, 2025.

Perrigo Company plc - Item 2

Consolidated

CONSOLIDATED FINANCIAL RESULTS

Three Month Comparison

| (in millions, except percentages) | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $1,022.8 | $1,056.3 |
| Gross profit | $313.9 | $362.9 |
| Gross profit % | 30.7% | 34.4% |
| Operating income | $23.5 | $45.4 |
| Operating income % | 2.3% | 4.3% |

Net sales decreased $33.5 million, or 3.2%, due primarily to:

- $13.7 million decrease, or 1.3%, due primarily to lower retailer inventory levels and soft consumption within the Self Care reporting segment. These factors were partially offset by continued market share gains in the Self Care and Infant Formula reporting segments, supported by innovation launches;
- $23.6 million decrease due primarily to the sale of the Dermacosmetics Business that completed in April 2026; partially offset by
- $3.7 million increase from favorable foreign currency translation.

Operating income decreased $22.0 million, or 48.4%, due primarily to:

- $49.0 million decrease in gross profit due to the impact of lower net sales volumes, primarily within our Self Care reporting segment, the carry over impacts of planned under-absorption stemming from lower prior-year sales volumes, and unfavorable mix, partially offset by the net recognition of a recovery of a portion of previously paid tariffs of approximately $9.6 million. Gross profit as a percentage of net sales decreased 370 basis points compared to the prior year due primarily to the same factors that drove gross profit. This was partially offset by
- $27.0 million decrease in operating expenses driven by reduced administration costs associated primarily with the Operational Enhancement Program, as well as decreased expenses for litigation compared to the prior year period.

Six Month Comparison

| (in millions, except percentages) | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $1,992.0 | $2,100.2 |
| Gross profit | $639.4 | $755.2 |
| Gross profit % | 32.1% | 36.0% |
| Operating income | $(348.9) | $92.3 |
| Operating income % | (17.5)% | 4.4% |

Net sales decreased $108.2 million, or 5.2%, due primarily to:

- $116.4 million decrease, or 5.6%, due primarily to soft consumption and lower retailer inventory levels within the Self Care segment. These were partially offset by continued market share gains in the Self Care reporting segment, supported by innovation launches;
- $25.5 million decrease due primarily to the sale of the Dermacosmetics Business that completed in April 2026; partially offset by
- $33.8 million increase from favorable foreign currency translation.

Operating income decreased $441.2 million, or 478.0%, due primarily to:

- $115.8 million decrease in gross profit due to the carry over impacts of planned under-absorption stemming from lower prior-year sales volumes, and the impact of lower net sales volumes, primarily within our Self Care reporting segment, partially offset by the net recognition of a recovery of a portion of previously paid tariffs of approximately $30.6 million. Gross profit as a percentage of net sales decreased 390 basis points compared to the prior year due primarily to the same factors that drove gross profit.

Perrigo Company plc - Item 2

Consolidated

- $325.4 million increase in operating expenses driven by the $331.8 million goodwill impairment charge.

SELF CARE FINANCIAL RESULTS

Three Month Comparison

| (in millions, except percentages) | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $576.6 | $598.6 |
| Segment operating income | $78.7 | $93.9 |
| Segment operating margin | 13.6% | 15.7% |

Net sales decreased $22.0 million, or 3.7%, due primarily to:

- $23.1 million decrease, or 3.9%, due primarily to unfavorable net pricing impacts and lower consumption across both the U.S. and Europe, driven in part by lower seasonal incidence of cough and cold versus the prior year, which also led to lower retailer inventory levels;
- $2.1 million decrease due primarily to previously announced divestitures; partially offset by
- $3.2 million increase from favorable foreign currency translation.

Segment operating income decreased $15.2 million, or 16.2%, due primarily to unfavorable gross profit flow through partially offset by a $12.0 million decrease in operating expenses driven by benefits from the Operational Enhancement Program.

Six Month Comparison

| (in millions, except percentages) | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $1,119.9 | $1,212.8 |
| Segment operating income | $147.3 | $206.7 |
| Segment operating margin | 13.1% | 17.0% |

Net sales decreased $92.9 million, or 7.7%, due primarily to:

- $108.9 million decrease, or 9.0%, due primarily to lower retailer inventory levels and continued soft consumption across both the U.S. and Europe, driven in part by lower seasonal incidence of cough and cold versus the prior year;
- $4.1 million decrease due primarily to previously announced divestitures; partially offset by
- $20.1 million increase from favorable foreign currency translation.

Segment operating income decreased $59.4 million, or 28.8%, due primarily to unfavorable gross profit flow through partially offset by a $11.6 million decrease in operating expenses driven by benefits from the Operational Enhancement Program.

SPECIALTY CARE FINANCIAL RESULTS

Three Month Comparison

| (in millions, except percentages) | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $226.6 | $233.1 |
| Segment operating income | $47.8 | $66.3 |
| Segment operating margin | 21.1% | 28.5% |

Net sales decreased $6.4 million, or 2.8%, due primarily to:

- $6.7 million decrease, or 2.9%, due primarily to lower net sales in Skin Health driven by lower store brand sales of Minoxidil and lower net sales of Mederma® due to prior year inventory restocking. The decline in

Perrigo Company plc - Item 2

Specialty Care

Skin Health was partially offset by the Women’s Health category, led by continued momentum from Opill® and ellaOne®.

Segment operating income decreased $18.5 million, or 27.9%, due primarily to unfavorable gross profit flow through as a result of the carry over impacts of prior year manufacturing volume headwinds and unfavorable mix, as well as a $4.0 million increase in operating expenses as higher advertising and promotional investments were made to support second half growth initiatives.

Six Month Comparison

| (in millions, except percentages) | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $433.6 | $432.2 |
| Segment operating income | $103.2 | $108.4 |
| Segment operating margin | 23.8% | 25.1% |

Net sales increased $1.4 million, or 0.3%, due primarily to:

- $9.8 million increase from favorable foreign currency translation; partially offset by
- $8.3 million decrease, or 1.9%, due primarily to lower net sales in Skin Health as lower store brand sales of Minoxidil and lower net sales of Mederma® were partially offset by share gains in Compeed® and Jungle Formula®. The net decline in Skin Health was partially offset by the Women’s Health category, led by continued momentum from Opill® and ellaOne®.

Segment operating income decreased $5.2 million, or 4.8%, due primarily to unfavorable gross profit flow through as a result of the carry over impacts of prior year manufacturing volume headwinds and unfavorable mix, partially offset by a $12.0 million decrease in operating expenses driven by lower advertising and promotional spend, including planned lower Opill® investment levels.

INFANT FORMULA FINANCIAL RESULTS

Three Month Comparison

| (in millions, except percentages) | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $100.9 | $82.0 |
| Segment operating income | $4.0 | $(12.2) |
| Segment operating margin | 3.9% | (14.9)% |

Net sales increased $18.9 million, or 23.1%, due primarily to:

- $18.9 million increase, or 23.1%, due primarily to timing of contract infant formula shipments, in addition to increased net sales of store brand formula.

Segment operating income increased $16.2 million, due primarily to favorable gross profit flow through from the lapping of isolated production variability in the prior-year period that resulted in higher product scrap, and higher net sales, as well as a $6.2 million decrease in operating expenses driven by lower selling costs as a result of actions taken as part of Nutrition Network Optimization.

Six Month Comparison

| (in millions, except percentages) | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $190.6 | $169.8 |
| Segment operating income | $(3.5) | $(1.6) |
| Segment operating margin | (1.8)% | (0.9)% |

Net sales increased $20.8 million, or 12.3%, due primarily to:

- $20.6 million increase, or 12.1%, due primarily to growth in contract infant formula, partially offset by lower net sales in store brand and branded infant formula as the prior year period was elevated due to customer inventory replenishment.

Perrigo Company plc - Item 2

Infant Formula

Segment operating income decreased $1.9 million, due primarily to unfavorable gross profit flow through driven by the carry over impacts of prior year manufacturing volume headwinds, partially offset by a $10.2 million decrease in operating expenses driven by lower selling costs as a result of actions taken as part of Nutrition Network Optimization.

ALL OTHER FINANCIAL RESULTS

Three Month Comparison

| (in millions, except percentages) | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $118.6 | $142.7 |
| Segment operating income | $25.8 | $25.7 |
| Segment operating margin | 21.7% | 18.0% |

Net sales decreased $24.1 million, or 16.9%, due primarily to:

- $21.5 million decrease due to the sale of the Dermacosmetics Business that completed in April 2026; as well as
- $2.9 million decrease, or 2.4%, due primarily to lower net sales of Oral Care products.

Segment operating income was comparable to the prior year period.

Six Month Comparison

| (in millions, except percentages) | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- |
| Net sales | $247.8 | $285.4 |
| Segment operating income | $57.6 | $46.6 |
| Segment operating margin | 23.2% | 16.3% |

Net sales decreased $37.6 million, or 13.2%, due primarily to:

- $21.5 million decrease due to the sale of the Dermacosmetics Business that completed in April 2026;
- $19.8 million decrease, or 7.5%, due primarily to lower net sales of Oral Care products; partially offset by
- $3.6 million increase from favorable foreign currency translation.

Segment operating income increased $11.0 million, or 23.6%, due primarily to a $12.5 million decrease in operating expenses driven by lower costs as a result of the Operational Enhancement Program, partially offset by lower net sales flow through.

Interest expense, net, Other (income) expense, net and Loss on extinguishment of debt

| (in millions) | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- | --- |
| Interest expense, net | $38.4 | $39.6 | $79.3 | $78.6 |
| Other (income) expense, net | $(120.5) | $2.6 | $(126.5) | $2.2 |
| Loss on extinguishment of debt | $0.1 | — | $1.4 | — |

Interest expense, net

Interest expense, net during the three and six months ended June 27, 2026 was comparable to the prior year periods.

Other (income) expense, net

The $123.0 million and $128.7 million increase in Other (income) expense, net during the three and six months ended June 27, 2026, respectively, compared to the prior year periods was due primarily to the gain on sale related to the divestiture of the Dermacosmetics Business (refer to [Item 1. Note 3](#i227bcb81299846b0903b4c75e8c40a6b_46)).

Perrigo Company plc - Item 2

Interest expense, net Other and Change in financial assets

Loss on extinguishment of debt

The loss on extinguishment of debt recognized during the six months ended June 27, 2026 is a result of the Amended and Restated Credit Agreement (refer to [Item 1. Note 11](#i227bcb81299846b0903b4c75e8c40a6b_79)).

Income Taxes (Consolidated)

The effective tax rates were as follows:

| Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
| --- | --- | --- | --- |
| 16.0% | 115.7% | 0.6% | 103.6% |

The effective tax rate on pre-tax income for the three months ended June 27, 2026, decreased when compared to the effective tax rate on pre-tax income for the three months ended June 28, 2025, primarily due to increases in our reserves for uncertain tax positions in 2025 and changes in jurisdictional mix of earnings, offset by impacts related to the Dermacosmetics Business divestiture in 2026.

The effective tax rate on pre-tax loss for the six months ended June 27, 2026, decreased when compared to the effective tax rate on pre-tax income for the six months ended June 28, 2025, primarily due to a reduction in our reserves for uncertain tax positions in 2026, the impact of goodwill impairments in 2026, offset by impacts related to the Dermacosmetics Business divestiture in 2026 and increases in our reserves for uncertain tax positions in 2025.

FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES

Overview

We finance our operations with internally generated funds, supplemented by credit arrangements with third parties and capital market financing. We routinely monitor current and expected operational requirements and financial market conditions to evaluate other available financing sources including term and revolving bank credit and securities offerings. In determining our future capital requirements, we regularly consider, among other factors, known trends and uncertainties, such as the geopolitical environment, inflation and interest rates, the status of material contingent liabilities, recent financial market volatility, tariffs and potential tariff and trade policies and other uncertainties. Subject to relevant restrictions under our debt agreements, our cash requirements for other purposes and other factors management deems relevant, we may from time to time use available funds to redeem, repurchase or refinance our debt in privately negotiated or open market transactions, by tender offer or otherwise, in compliance with applicable laws, rules and regulations, at prices and on terms we deem appropriate (which may be below par).

Based on the foregoing, management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements, as described below. However, an adverse result with respect to our appeal of any material outstanding tax assessments or litigation, including securities or drug pricing matters and product liability cases, damages resulting from third-party claims, and related interest and/or penalties, could ultimately require the use of corporate assets to pay such assessments and any such use of corporate assets would limit the assets available for other corporate purposes. As such, we continue to evaluate the impact of the above factors on liquidity and may determine that modifications to our capital structure are appropriate if market conditions deteriorate, favorable capital market opportunities become available, or any change in conditions relating to the war in Ukraine and conflicts in the Middle East, a government shutdown in the United States or elsewhere, inflation and interest rates, the status of material contingent liabilities, financial market volatility, tariffs, potential tariff and trade policies or other uncertainties have a material impact on our capital requirements.

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Cash and Cash Equivalents

| (in millions) | June 27, 2026 | December 31, 2025 |
| --- | --- | --- |
| Cash and cash equivalents | $399.7 | $531.6 |
| Working capital(1) | $1,008.7 | $1,043.7 |

(1) Working capital represents current assets less current liabilities, excluding cash and cash equivalents, assets and liabilities held for sale and current indebtedness.

Cash, cash equivalents, cash flows from operations, and borrowings available under our credit facilities are expected to be sufficient to finance our liquidity and capital expenditures in both the short and long term. Although our lenders have made commitments to make funds available to us in a timely fashion under our revolving credit agreements and overdraft facilities, if economic conditions worsen or new information becomes publicly available impacting the institutions’ credit rating or capital ratios, these lenders may be unable or unwilling to lend money pursuant to our existing credit facilities. Should our outlook on liquidity requirements change substantially from current projections, we may seek additional sources of liquidity in the future.

Cash Flows

The following table includes summarized cash flow activities:

| (in millions) | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 | $ Change |
| --- | --- | --- | --- |
| Net cash (for) from operating activities | $(31.0) | $11.4 | $(42.4) |
| Net cash from (for) investing activities | 337.0 | (29.5) | 366.5 |
| Net cash for financing activities | (434.2) | (115.8) | (318.4) |
| Effect of exchange rate changes on cash and cash equivalents | (6.1) | 29.3 | (35.4) |
| Net decrease in cash and cash equivalents | $(134.2) | $(104.6) | $(29.6) |

Net cash (for) from Operating Activities

The $42.4 million decrease in operating cash flow was primarily driven by a decrease in cash flow from the change in net earnings after adjustments for items including impairment, depreciation and amortization, gain (loss) on sale of business and restructuring, partially offset by a decrease in working capital.

Net cash from (for) Investing Activities

The $366.5 million increase in investing cash flow was due primarily to proceeds received associated with the sale of the Dermacosmetics Business (refer to [Item 1. Note 3](#i227bcb81299846b0903b4c75e8c40a6b_46)).

Net cash for Financing Activities

The $318.4 million decrease in financing cash flow was primarily driven by additional one-time payments made on our outstanding debt (refer to [Item 1. Note 11](#i227bcb81299846b0903b4c75e8c40a6b_79)).

Borrowings and Capital Resources

Credit Agreements

On April 20, 2022, we and our indirect wholly owned subsidiary, Perrigo Investments, LLC (the “Borrower”) entered into the senior secured credit facilities, which consisted of (i) a $1.0 billion five-year revolving credit facility (the “Revolver”), (ii) a $500.0 million five-year Term Loan A facility (the “Term Loan A Facility” and the Term A Loans thereunder, the “Term A Loans”), and (iii) a $1.1 billion seven-year Term Loan B facility (the “Term Loan B Facility” and the Term B Loans thereunder borrowed on April 20, 2022, the “2022 Term B Loans”, pursuant to a Credit Agreement (the “Credit Agreement”).

On December 15, 2023, we and the Borrower entered into Amendment No. 1 and Incremental Assumption

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Agreement (the “Amendment”) to the Credit Agreement. The Amendment provided for a fungible add on to the 2022 Term B Loans in an aggregate principal amount of $300.0 million (the “2023 Incremental Term B Loans”). The terms of the 2023 Incremental Term B Loans, including pricing and maturity, are identical to the 2022 Term B Loans. The net proceeds from the 2023 Incremental Term B Loans were used to settle the cash tender offer by Perrigo Finance Unlimited Company (“Perrigo Finance”), a public unlimited company incorporated under the laws of Ireland and an indirect wholly-owned finance subsidiary of Perrigo for $300.0 million in aggregate principal amount of 3.900% Senior Notes due 2024 (“2024 Notes”). The tender offer was settled on December 15, 2023, and Perrigo Finance accepted for purchase $300.0 million of the 2024 Notes and paid approximately $295.1 million in aggregate cash consideration (excluding accrued interest).

On December 15, 2024, we and the Borrower entered into Amendment No. 2 to the Credit Agreement, which established a new tranche of loans under the Term B Facility (the “Term B Loans”) and which refinanced all of the 2023 Incremental Term B Loans and the 2022 Term B Loans outstanding under the Credit Agreement in the aggregate amount of $984.7 million, which resulted in a repricing to lower interest rate and increased the discount by $1.5 million. The Term B Loans will mature on April 20, 2029.

On March 20, 2026, we entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) with Perrigo Investments, the other subsidiaries of the Company named therein, JPMorgan Chase Bank, N.A. and J. P. Morgan SE, as administrative agent, JPMorgan Chase Bank, N.A., as collateral agent and the other lenders party thereto. The Amended and Restated Credit Agreement amends and restates the Credit Agreement to, among other things, (i) extend the maturity of the Revolving Facility (defined below), (ii) eliminate the credit spread adjustment applicable to loans under the Revolving Facility and (iii) amend such other provisions of the Credit Agreement for the benefit of the Company. The Amended and Restated Credit Agreement provides for a $1.0 billion revolving credit facility maturing on March 20, 2031 (the “Revolving Facility”) and a $972.4 million term loan B facility maturing on April 20, 2029 (the “Term Loan B Facility” and together with the Revolving Facility, the “Senior Secured Credit Facilities”). The outstanding balance and maturity date of the Term Loan B Facility remain unchanged under the Amended and Restated Credit Agreement. The Company used the proceeds from a drawdown on the Revolving Facility to prepay the Term A Loans (as defined in the Credit Agreement) in their entirety, together with any accrued and unpaid interest and fees thereon and pay any associated transaction costs. Refer to [Item 1. Note 11](#i227bcb81299846b0903b4c75e8c40a6b_79).

As of June 27, 2026, we had $970.0 million outstanding under our Term Loan B Facility. As of December 31, 2025, we had $1,394.3 million outstanding under our Term Loan A Facility and Term Loan B Facility. Our short-term debt as of June 27, 2026 of $11.4 million is comprised of (i) amortization payments for the Term B Loans and (ii) lease payments.

Using proceeds received as a result of the Dermacosmetics Business sale, a payment was made in the amount of $335.0 million on the Revolving Facility during the three months ended June 27, 2026. As of June 27, 2026, borrowings outstanding under the Revolving Facility totaled $92.6 million. There were no borrowings outstanding under the Revolver as of December 31, 2025.

The interest rate net of derivatives results in a fixed rate on a substantial portion of our long-term debt, the earliest of which matures in April 2029.

We are in compliance with all the covenants under our debt agreements as of June 27, 2026.

Other Financing

We have overdraft facilities available that we may use to support our cash management operations. There were no material borrowings outstanding under the overdraft facilities as of June 27, 2026 or December 31, 2025.

Leases

We had $176.0 million and $190.5 million of lease liabilities and $166.2 million and $179.3 million of lease assets as of June 27, 2026 and December 31, 2025, respectively. For information on our operating and finance lease obligations and the amount and timing of future payments refer to [Item 1. Note 7](#i227bcb81299846b0903b4c75e8c40a6b_64).

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

Credit Ratings

Our credit ratings on June 27, 2026 were Ba3 (negative), B+ (stable), and BB (negative) by Moody's Investors Service ("Moody's"), S&P Global Ratings ("S&P"), and Fitch Ratings Inc. ("Fitch"), respectively.

The interest rate on the 3.150% Senior Notes due 2030 increased from 4.900% to 5.150% for payments made after December 15, 2025 as a result of previous credit rating adjustments. Interest rate adjustments for the 3.150% Senior Notes due 2030 are subject to a 2.0% cap above the original 3.150% interest rate, ensuring that the interest rate does not exceed 5.150%. This adjustment is contingent upon certain rating events, as outlined in the Note’s Supplemental Indenture No. 3, dated as of June 19, 2020, among Perrigo Finance Unlimited Company, Perrigo Company plc and Wells Fargo Bank, National Association, serving as trustee.

Credit rating agencies review their ratings periodically, and therefore, the credit rating assigned to us by each agency may be subject to revision at any time. Accordingly, there can be no assurance that our credit ratings will remain as disclosed above. Factors that can affect our credit ratings include, but are not limited to, changes in operating performance, the economic environment, our financial position, and changes in business strategy. If changes in our credit ratings were to occur, they could impact, among other things, future borrowing costs, access to capital markets, and vendor financing terms. A credit rating is not a recommendation to buy, sell or hold securities.

Guarantor Financial Information

As detailed in [Item 1. Note 11](#i227bcb81299846b0903b4c75e8c40a6b_79), the Guarantor Subsidiaries and the Borrower provide full and unconditional guarantees, jointly and severally, on a senior unsecured basis, of the 5.300% Notes due 2043 issued by the Company, and the Guarantor Subsidiaries, the Borrower and the Company provide full and unconditional guarantees, jointly and severally, on a senior unsecured basis, of the 5.150% Notes due 2030, the 5.375% Euro Notes due 2032, the 6.125% USD Notes due 2032, and the 4.900% Notes due 2044 issued by Perrigo Finance.

The guarantees of the Guarantor Subsidiaries, the Company and the Borrower are subject to release in limited circumstances only upon the occurrence of certain customary conditions. The guarantees of the Guarantor Subsidiaries, the Company and the Borrower rank senior in right of payment to any future subordinated indebtedness of the Company, equal in right of payment with all of the Company’s existing and future senior indebtedness and effectively subordinated to any of the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing such indebtedness.

Basis of Presentation

The following tables include summarized financial information of the obligor groups of debt issued by Perrigo Finance and the Company. The summarized financial information of each obligor group is presented on a combined basis with balances and transactions within the obligor group eliminated. Investments in and the equity in earnings of non-guarantor subsidiaries, which would otherwise be consolidated in accordance with U.S. GAAP, are excluded from the below summarized financial information pursuant to SEC Regulation S-X Rule 13-01.

The summarized balance sheet information for the consolidated obligor group of debt issued by Perrigo Finance and the Company is presented in the table below:

| Line item | June 27, 2026 | December 31, 2025 |
| --- | --- | --- |
| Current assets | $1,754.1 | $1,919.1 |
| Non-current assets | $2,693.8 | $3,959.8 |
| Current liabilities | $807.4 | $720.6 |
| Non-current liabilities | $9,911.3 | $10,216.1 |
| Due to non-guarantors | $6,257.9 | $6,020.6 |

Perrigo Company plc - Item 2

Financial Condition, Liquidity and Capital Resources

The summarized results of operations information for the consolidated obligor group of debt issued by Perrigo Finance and the Company is presented in the table below:

_June 27, 2026_

| Line item | Six Months Ended |
| --- | --- |
| Total revenues | $1,430.1 |
| Gross profit | $393.3 |
| Operating income (loss) | $(356.2) |
| Net income (loss) | $(373.4) |
| Revenue from non-guarantors | $183.2 |
| Operating expenses to non-guarantors | $0.2 |
| Other (income) expense to non-guarantors | $(55.6) |

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our financial condition, changes in financial condition, net sales or expenses, results of operations, liquidity, capital expenditures, or capital resources.

Contractual Obligations

There were no material changes in contractual obligations as of June 27, 2026 from those provided in our 2025 Form 10-K.

Significant Accounting Policies

There have been no material changes to the significant accounting policies as disclosed in our 2025 Form 10-K.

Critical Accounting Estimates

The determination of certain amounts in our financial statements requires the use of estimates. These estimates are based upon our historical experiences combined with management’s understanding of current facts and circumstances. Although the estimates are considered reasonable based on the currently available information, actual results could differ from the estimates we have used. There have been no material changes to the critical accounting estimates as disclosed in our 2025 Form 10-K other than those discussed below.

Goodwill

During the first quarter of 2026, we changed our reporting segments to align with changes in the organization structure. As we transitioned from a geographic segment reporting structure to one that is product category based, our reporting units changed from Consumer Self Care Americas and Consumer Self Care International to Self Care, Skin Health, Women’s Health, Infant Formula, Oral Care, and Other. In connection with the segment reorganization, we prepared a quantitative goodwill impairment test based on the new reporting units as of January 1, 2026. We determined that the carrying value of the Women’s Health, Infant Formula, and Oral Care reporting units exceeded their estimated fair values. As a result, we recognized a goodwill impairment charge of $77.4 million for the Women’s Health reporting unit, resulting in a remaining goodwill balance of $107.1 million as of March 28, 2026. We also fully impaired the Infant Formula and Oral Care reporting units, recording goodwill impairment charges of $66.3 million and $187.2 million, respectively. We continue to monitor the Self Care, Skin Health, and Women’s Health reporting units for indicators of impairment and will perform impairment assessments as required, including our annual impairment testing during the fourth quarter.

The cash flow forecasts used for our reporting units include assumptions about future activity levels in the near term and longer-term. If growth in our reporting units is lower than expected, we may experience deterioration in our cash flow forecasts that may indicate goodwill in one or more reporting units is impaired in future impairment tests. Certain macroeconomic factors which are not controlled by the reporting units, such as rising inflation or interest rates, could cause an increase in the discount rate to occur. An increase in the discount rate could negatively impact

Perrigo Company plc - Item 2

Critical Accounting Estimates

the estimated fair value of the reporting units and lead to future impairment. Furthermore, our estimates of fair value give consideration to the level of implied control premium, which is the amount a buyer is willing to pay over the current market price of a company (i.e. market capitalization) to acquire a controlling interest. We have experienced significant decreases in our market capitalization. We may experience further sustained decreases in our market capitalization which could imply an impairment of one or more of our reporting units. Each of the reporting unit fair value includes material benefits from our Corporate-led initiatives and, as a result, is sensitive to changes in estimates related to these initiatives. Reductions in the net projected benefits could represent a potential indicator of impairment requiring further impairment analysis.

We performed sensitivity analyses on the discounted cash flow valuations that were prepared to estimate the fair value of each reporting unit with goodwill remaining. The Self Care reporting unit continued to have passing margin with a 100 basis point increase in discount rate or a 100 basis point decrease in perpetual revenue growth rates. The Skin Health reporting unit’s fair value indicated impairment with a 25 basis point increase in discount rate and a 75 basis point decrease in perpetual revenue growth rates. The Women’s Health fair value equals its carrying value and therefore is sensitive to any negative change in discount rates and perpetual revenue growth rates.

The Women’s Health and the Skin Health reporting units have passing margins of less than 10%. An increase in the discount rate over the next twelve months could negatively impact the estimated fair values of the reporting units and lead to a future impairment. Certain macroeconomic factors which are not controlled by the reporting units, such as rising inflation or interest rates, could cause an increase in the discount rate to occur. Deterioration in performance of our reporting units over the next twelve months, such as lower than expected revenue or profitability that has a sustained impact on future periods, could also represent potential indicators of impairment requiring further impairment analysis. We have experienced significant decreases in our market capitalization. Given the sensitivity of assumptions on control premium, further decreases in our market capitalization in the next twelve months, could represent a potential impairment indicator requiring further impairment analysis.

See [Item 1. Note 8](#i227bcb81299846b0903b4c75e8c40a6b_67) and [Note 9](#i227bcb81299846b0903b4c75e8c40a6b_70) for further information.

## ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our quantitative or qualitative disclosures found in Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," of our 2025 Form 10-K.

## ITEM 4. CONTROLS AND PROCEDURES

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Our management, with the participation of our Interim Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) of the Exchange Act) as of June 27, 2026. Based upon that evaluation, our Interim Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective in ensuring that all material information relating to us and our consolidated subsidiaries required to be included in our periodic SEC filings would be made known to them by others within those entities in a timely manner and that no changes are required at this time.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during the three months ended June 27, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

## ITEM 1. LEGAL PROCEEDINGS

Refer to [Item 1. Note 15](#i227bcb81299846b0903b4c75e8c40a6b_91) and [Item 1. Note 16](#i227bcb81299846b0903b4c75e8c40a6b_94) of the Notes to the Condensed Consolidated Financial Statements.

Perrigo Company plc - Item 1A

Risk Factors

## ITEM 1A. RISK FACTORS

Our 2025 Form 10-K includes a detailed discussion of our risk factors. At the time of this filing, there have been no material changes to the risk factors that were included in the Form 10-K.

## ITEM 5. OTHER INFORMATION

Rule 10b5-1 Trading Plans

During the three months ended June 27, 2026, no director or executive officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement", as each term is defined in Item 408(a) of Regulation S-K.

## ITEM 6. EXHIBITS

| Exhibit Number | Description |
| --- | --- |
| 3.1 | Certificate of Incorporation of Perrigo Company plc (formerly known as Perrigo Company Limited) (incorporated by reference from Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed on December 19, 2013). |
| 3.2 | Memorandum and Articles of Association of Perrigo Company plc, as amended and restated (incorporated by reference from Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on May 7, 2025) (File No. 001-36353). |
| 10.1 | Amended and Restated Credit Agreement, dated March 20, 2026, among Perrigo Company plc, as parent, Perrigo Investments, LLC, as initial borrower, the other subsidiaries of the Parent named therein, as Designated Borrowers, each of the lenders, issuing banks and swing line lenders identified therein, JPMorgan Chase Bank, N.A. and J.P. MORGAN SE, as administrative agent, and JPMorgan Chase Bank, N.A., as collateral agent (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 23, 2026). |
| 10.2* | Employment Agreement, effective July 3, 2026, by and between Perrigo Pharma International D.A.C. and Albert Manzone (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K/A filed on July 6, 2026). |
| 10.3* | Perrigo Company plc Executive Committee Severance Policy, as amended and restated Effective June 29, 2026 (the “Executive Severance Policy”). |
| 10.4* | Perrigo Company plc 2026 Long-Term Incentive Plan (incorporated by reference from Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 5, 2026). |
| 10.5* | Form of Restricted Stock Unit Award Agreement (Service Based) under the Perrigo Company plc 2026 Long-Term Incentive Plan. |
| 10.6* | Form of Restricted Stock Unit Award Agreement (Performance Based) under the Perrigo Company plc 2026 Long-Term Incentive Plan. |
| 22 | List of Guarantor Subsidiaries (filed herewith). |
| 31.1 | Rule 13a-14(a) Certification by Albert Manzone, Interim Chief Executive Officer (filed herewith). |
| 31.2 | Rule 13a-14(a) Certification by Eduardo Bezerra, Chief Financial Officer (filed herewith). |
| 32 | Certification Pursuant to 18 United States Code 1350 and Rule 13a-14(b) of the Securities Exchange Act of 1934 (furnished herewith). |
| 101. INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL (contained in Exhibit 101). |

*Denotes management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PERRIGO COMPANY PLC

(Registrant)

Date: August 5, 2026 /s/ Albert A. Manzone

Albert A. Manzone

Interim Chief Executive Officer and President

(Principal Executive Officer)

Date: August 5, 2026 /s/ Eduardo Bezerra

Eduardo Bezerra

Chief Financial Officer

(Principal Accounting and Financial Officer)

---

## EX-10.3

SEC source: [perrigocompanyexecutivec.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/perrigocompanyexecutivec.htm)

![Slide 1](<perrigocompanyexecutivec001.jpg>)

> **Source slide transcript**
>
> 89126997.6 PERRIGO COMPANY PLC EXECUTIVE COMMITTEE SEVERANCE POLICY As Amended and Restated Effective June 29, 2026 ARTICLE I INTRODUCTION Perrigo Company plc (the “Company”) established the Perrigo Company plc Executive Committee Severance Policy (the “Policy”) effective June 14, 2017, for the benefit of certain “Eligible Employees” of the Company and its Affiliates, as amended on October 8, 2018, and February 13, 2019. The Policy was previously terminated effective January 15, 2020, and is hereby reinstated and amended and restated in its entirety effective June 29, 2026. Unless earlier terminated by the Company, the Policy will terminate at the end of the “CEO Transition Period.” The Policy is intended to be a top hat welfare plan maintained primarily for the purpose of providing benefits for a select group of management or highly compensated employees within the meaning of Sections 201(2), 301(a)(3), and 401(a)(1) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), with the intent that it be exempt from the relevant requirements of Title I of ERISA. The Policy shall be administered and interpreted in a manner that is consistent with such intent. The Policy shall be binding on any successor to all or substantially all of the Company’s assets or business. Except as otherwise provided herein, the Policy supersedes any prior formal or informal severance plans, programs or policies of the Company or its Affiliates covering Eligible Employees. ARTICLE II DEFINITIONS 2.1 “Act” means the Irish Companies Act 1963, as amended from time to time. References to any provision of the Act shall be deemed to include successor provisions thereto and regulations thereunder. 2.2 “Affiliate” means any member of the group of corporations, trades or businesses or other organizations comprising the “controlled group” with the Company under Code Section 414. 2.3 “Base Salary” means an Eligible Employee’s regular annual base salary compensation rate in effect on his/her Severance Date. If an Eligible Employee’s Triggering Event is a Separation for Good Reason related to a Significant Reduction in Scope or Base Compensation, “Base Salary” under the Policy will be determined without regard to such reduction. For purposes of Sections 2.21 and 5.2, to the extent approved by the Board of Directors of the Company or the Talent & Compensation Committee of the Company, as applicable, and communicated to an Eligible Employee in writing by the Chief Executive Officer (or Interim Chief Executive Officer) of the Company or the Chair of the Talent & Compensation Committee, “Base Salary” shall also include an Eligible Employee’s additional stipend.

---

![Slide 2](<perrigocompanyexecutivec002.jpg>)

> **Source slide transcript**
>
> 89126997.6 2 2.4 “Cause” means, except as otherwise approved by the Board of Directors of the Company or the Talent & Compensation Committee of the Company, as applicable, and communicated to an Eligible Employee in writing by the Interim Chief Executive Officer or the Chief Executive Officer of the Company or the Chair of the Talent & Compensation Committee: (a) The commission of an act which, if proven in a court of law, would constitute a felony violation under applicable criminal laws; (b) A breach of any material duty or obligation imposed upon the Employee by the Company or any Affiliate; (c) Divulging the Company’s or any Affiliate’s confidential information, or breaching or causing the breach of any confidentiality agreement to which the Employee, the Company, or any Affiliate is a party; (d) Engaging or assisting others to engage in business in competition with the Company or any Affiliate; (e) Refusal to follow a lawful order of the Employee’s superior or other conduct which the Administrator determines to represent insubordination on the part of the Participant; or (f) Other conduct by the Employee which the Administrator, in its discretion, deems to be sufficiently injurious to the interests of the Company or any Affiliate to constitute Cause. Notwithstanding the foregoing, following a Change in Control, “Cause” means (i) the Employee is convicted of a felony, (ii) the Employee’s breach of any material duty or obligation imposed upon the Employee by the Company or any Affiliate that results in material, demonstrable harm to the Company or any Affiliate, or (iii) the Employee divulges the Company’s or any Affiliate’s confidential information or breaches or causes the breach of any confidentiality agreement to which the Employee, the Company, or any Affiliate is a party. Any determination of whether Cause exists shall be made by the Administrator in its sole discretion. 2.5 “CEO Transition Period” means the period beginning on June 7, 2026 and ending on the one-year anniversary of the date on which a new Chief Executive Officer (as successor to the Interim Chief Executive Officer, Albert Manzone) commences employment with the Company. 2.6 “Change in Control” means: (a) The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if more than fifty percent (50%) of the combined voting power of the continuing or surviving entity’s issued shares or securities outstanding immediately after such merger, consolidation or other reorganization is owned by persons who were not shareholders of the Company immediately prior to such merger, consolidation or other reorganization;

---

![Slide 3](<perrigocompanyexecutivec003.jpg>)

> **Source slide transcript**
>
> 89126997.6 3 (b) The sale, transfer or other disposition of all or substantially all of the assets of the Company; (c) Individuals who as of the effective date of the Policy constitute the Board of Directors of the Company (the “Incumbent Directors”) cease for any reason, including, without limitation, as a result of a tender offer, proxy contest, merger or similar transaction, to constitute a majority of the Board of Directors of the Company; provided, however, that any individual who becomes a director of the Company subsequent to the above date shall be considered an Incumbent Director if such person’s election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors; but, provided further, that any such person whose initial assumption of office is in connection with an actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board of Directors of the Company (such actual or threatened solicitation, a “Proxy Solicitation”), including by reason of agreement intended to avoid or to settle any such actual or threatened contest or solicitation, shall not be considered an Incumbent Director until such time as such person has been (i) recommended by the Nominating & Governance Committee for election as a director of the Company and (ii) elected by the Company’s shareholders to serve on the Board of Directors of the Company at three successive annual general meetings; but provided further, if an Incumbent Director of the Company terminates other than in connection with a Proxy Solicitation, if within thirty (30) days of such termination a new director is appointed with the approval of the majority of the remaining Incumbent Directors, such new director shall be considered an Incumbent Director and a Change in Control under the Policy shall not be considered to have occurred as a result of the termination of such former Incumbent Director; (d) A transaction as a result of which a person or company obtains the ownership directly or indirectly of the ordinary shares in the Company carrying more than fifty percent (50%) of the total voting power represented by the Company’s issued share capital in pursuance of a compromise or arrangement sanctioned by the court under Section 201 of the Act or becomes bound or entitled to acquire ordinary shares in the Company under Section 204 of the Act; or (e) Any transaction as a result of which any person becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing at least fifty percent (50%) of the total voting power represented by the Company’s then outstanding voting securities (e.g., issued shares). For purposes of this subsection (e), the term “person” shall have the same meaning as when used in Sections 13(d) and 14(d) of the Exchange Act but shall exclude (i) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or of any subsidiary of the Company, and (ii) a company owned directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership of the ordinary shares of the Company. 2.7 “Code” means the Internal Revenue Code of 1986, as amended. 2.8 “Code Section 409A” means Section 409A of the Code, and the regulations promulgated thereunder.

---

![Slide 4](<perrigocompanyexecutivec004.jpg>)

> **Source slide transcript**
>
> 89126997.6 4 2.9 “Company” means Perrigo Company plc. 2.10 “Comparable Position” means a position either with the Company or any of its Affiliates or with a successor or transferee of all or a part of the business of the Company or Affiliate, on terms which do not give rise to condition(s) which would result in a Separation for Good Reason if the Eligible Employee timely provided written notice of such condition(s) to his/her Employer and the condition(s) were not timely remedied by the Employer (e.g., a Significant Reduction in Scope or Base Compensation or a Relocation). Prior to a Change in Control, such determination will be made by the Administrator in its sole discretion. 2.11 “Confidential Information” means confidential, trade secret, or proprietary information, or any other information, knowledge or data of the Company or any Affiliate that is not publicly available, or that of any third parties obtained by an Employee during his/her period of employment with the Company or any Affiliate. Such Confidential Information includes, but is not limited to, secret or confidential matters (i) of a technical nature, such as, but not limited to, methods, know-how, formulas, compositions, processes, discoveries, machines, inventions, computer programs and similar items or research projects, (ii) of a business nature, such as, but not limited to, information about costs, purchasing profits, marketing, sales or lists of customers, and (iii) pertaining to future developments, such as, but not limited to, research and development or future marketing or merchandising. If an Eligible Employee entered into a separate confidentiality or proprietary rights agreement with the Company or any Affiliate, the term “Confidential Information” for purposes of this Policy shall have the meaning ascribed to any such term or concept as it is defined under, or used in, the separate agreement. 2.12 “Eligible Employee” means each Employee who (i) is subject to the reporting requirements of Section 16(a) of the Exchange Act, and (ii) works primarily in an office located in the United States; provided, however, that neither the Interim Chief Executive Officer nor the Chief Executive Officer of the Company shall be considered an Eligible Employee. 2.13 “Employee” means any employee of an Employer. 2.14 “Employer” means the Company and each Affiliate of the Company. 2.15 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 2.16 “Involuntary Termination” means the involuntary termination of an Eligible Employee’s employment by his/her Employer without Cause, including, but not limited to, (i) a termination effective when the Eligible Employee exhausts a leave of absence during, or at the end of, a WARN Notice Period, and (ii) a situation where an Eligible Employee on an approved leave of absence during which the Employee’s position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), returns from such leave, and cannot be placed in employment with the Employer. 2.17 “Policy” means the Perrigo Company plc Executive Committee Severance Policy, as set forth herein and as it may be amended from time to time.

---

![Slide 5](<perrigocompanyexecutivec005.jpg>)

> **Source slide transcript**
>
> 89126997.6 5 2.18 “Relocation” means, except as otherwise approved by the Board of Directors of the Company or the Talent & Compensation Committee of the Company, as applicable, and communicated to an Eligible Employee in writing by the Interim Chief Executive Officer or Chief Executive Officer of the Company or the Chair of the Talent & Compensation Committee, a material change in the geographic location at which the Eligible Employee is required to perform services. Such change in an Eligible Employee’s primary job site will be considered material if the new location increases the Eligible Employee’s commute between home and primary job site by at least thirty (30) miles. 2.19 “Separation for Good Reason” means, except as otherwise approved by the Board of Directors of the Company or the Talent & Compensation Committee of the Company, as applicable, and communicated to an Eligible Employee in writing by the Interim Chief Executive Officer or Chief Executive Officer of the Company or the Chair of the Talent & Compensation Committee, an Eligible Employee’s voluntary resignation from the Employer and the existence of one or more of the following conditions that arose without the Eligible Employee’s consent: (i) a Relocation, or (ii) a Significant Reduction in Scope or Base Compensation; provided, however, that a voluntary resignation from the Employer shall not be considered a Separation for Good Reason unless the Eligible Employee provides his/her Employer notice, in writing, of the Eligible Employee’s voluntary resignation and the existence of the condition(s) giving rise to the separation within ninety (90) days of its initial existence. The Employer shall then have thirty (30) days to remedy the condition, in which case the Eligible Employee shall not be deemed to have incurred a Separation for Good Reason. In the event the Employer fails to cure the condition within the thirty (30) day period, the Eligible Employee’s Severance Date shall occur on the thirty-first (31st) day following his/her Employer’s receipt of such written notice. 2.20 “Severance Date” means the final day of employment with the Employer which date shall be communicated in writing by the Employer to the Employee (except as otherwise set forth in Section 2.19). 2.21 “Significant Reduction in Scope or Base Compensation” means a material diminution in the Eligible Employee’s authority, duties or responsibilities or a material diminution in the Eligible Employee’s Base Salary or incentive compensation opportunities. Prior to a Change in Control, the Administrator, in its sole discretion, will determine whether an Eligible Employee experiences a “Significant Reduction in Scope or Base Compensation.” 2.22 “Target Bonus” means the bonus payable to an Eligible Employee, if any, for the calendar year in which the Eligible Employee’s Triggering Event occurs and which is calculated based on his/her Base Salary and target percentage in effect on the Eligible Employee’s Severance Date. If an Eligible Employee’s Triggering Event is a Separation for Good Reason related to a Significant Reduction in Scope or Base Compensation, “Target Bonus” under the Policy will be determined without regard to such reduction. 2.23 “Triggering Event” means an Involuntary Termination or a Separation for Good Reason which occurs on or prior to the last day of the CEO Transition Period. 2.24 “WARN Act” means the Worker Adjustment and Retraining Notification Act.

---

![Slide 6](<perrigocompanyexecutivec006.jpg>)

> **Source slide transcript**
>
> 89126997.6 6 2.25 “WARN Notice Date” means the date the Employer is required to notify an Eligible Employee pursuant to the WARN Act or similar state law that he/she is to be terminated from employment with the Employer in conjunction with a “plant closing” or “mass layoff” as described in the WARN Act or similar state law. 2.26 “WARN Notice Period” means the sixty (60) consecutive calendar day period, or other applicable period under similar state law, commencing on an Eligible Employee’s WARN Notice Date. ARTICLE III ELIGIBILITY 3.1 Conditions of Eligibility. To be eligible for benefits as described in Article V, the Eligible Employee must (i) experience a Triggering Event, (ii) remain an Employee through the Severance Date, (iii) through the Severance Date, fulfill the normal responsibilities of his/her position, including meeting regular attendance, workload and other standards of the Employer, as applicable, and (iv) submit the signed Waiver and Release Agreement required by the Administrator on, or within forty-five (45) days after, his/her Severance Date or receipt of the Waiver and Release Agreement (whichever occurs later) and not revoke the signed Waiver and Release Agreement. 3.2 Conditions of Ineligibility. An otherwise Eligible Employee shall not receive severance pay or severance benefits under the Policy if: (a) the Employee ceases to be an Eligible Employee as defined by the Policy, other than as a result of a Triggering Event; (b) the Employee terminates employment with the Employer by reason of death; (c) the Employee terminates employment with the Employer for Cause as defined above; (d) the Employee terminates employment with the Employer through job abandonment; (e) other than as set forth in Section 2.15(ii), the individual is no longer an Employee and is receiving long-term disability benefits from his/her Employer (as determined under the applicable Employer long-term disability plan) as of the date the Triggering Event would have occurred had the individual been an Employee on such date; (f) the Employee is employed in an operation, division, department or facility, that is sold, leased or otherwise transferred, in whole or in part, from his/her Employer, and the Employee accepts any position with the new owner/operator, or the Employee is offered a Comparable Position by the new owner/operator;

---

![Slide 7](<perrigocompanyexecutivec007.jpg>)

> **Source slide transcript**
>
> 89126997.6 7 (g) the Employee gives notice of his/her voluntary termination (other than pursuant to Section 2.15 or Section 2.17) prior to his/her Severance Date or the effective date of a sale, lease or transfer of an operation, division, department or facility, as described in Section 3.2(f), regardless of the effective date of such termination; (h) the Employee terminates from employment with his/her Employer and is eligible to receive severance benefits under another group reorganization/restructuring benefit policy or severance program sponsored by the Company or any of its Affiliates, in which event the Employee will receive severance under this Policy or the other policy or program, whichever provides the greater benefit. (i) the Employee is offered a Comparable Position from the Company or any Affiliate, or accepts any position with the Company or any Affiliate, even if it is not a Comparable Position; (j) the Employee experiences a Triggering Event after the Policy terminates; (k) the Employee does not timely execute and return to the Administrator a valid Waiver and Release Agreement; (l) the Employee works primarily in an office located in a country other than the United States and is entitled to severance benefits under the laws of such country or the policies of the company at which he/she is based and such severance benefits may not be waived; or (m) the Employee is offered a Comparable Position by, or accepts any position with, an employer with which the Company or any of its Affiliates has reached an agreement or arrangement under which the employer agrees to offer employment to the otherwise Eligible Employee. The foregoing list of conditions is intended to be illustrative and may not be all inclusive; the Administrator will determine in the Administrator’s sole discretion whether an Eligible Employee is eligible for severance pay and severance benefits under the Policy. ARTICLE IV PAY AND BENEFITS IN LIEU OF WARN NOTICE 4.1 Wage Payments. The provisions of this Section 4.1 apply only to U.S. based Eligible Employees. If an Eligible Employee is entitled to advance notice of a “plant closing” or a “mass layoff” under the WARN Act or similar state law, but experiences a Triggering Event before the end of a WARN Notice Period, the Eligible Employee shall also be entitled to receive pay until the end of the WARN Notice Period as if he/she were still employed through such date. The pay under this Section 4.1 will be issued according to the normal payroll practices of the Employer and shall not be subject to the Waiver and Release Agreement. 4.2 Benefits. An Eligible Employee described in Section 4.1 shall be entitled to benefits under Employer-sponsored medical, dental and vision benefit plans, as amended from

---

![Slide 8](<perrigocompanyexecutivec008.jpg>)

> **Source slide transcript**
>
> 89126997.6 8 time to time, through the end of the WARN Notice Period on the same terms and under the same conditions as applied to the Eligible Employee immediately prior to the Triggering Event. The benefits under this Section 4.2 are not subject to the Waiver and Release Agreement. ARTICLE V SEVERANCE PAY AND SEVERANCE BENEFITS 5.1 Generally. In exchange for providing the Administrator with an enforceable Waiver and Release Agreement, in accordance with Article VI, an Eligible Employee who terminates employment on account of a Triggering Event shall be eligible to receive severance pay and severance benefits as described below, subject to the terms of the Policy. The consideration for the voluntary Waiver and Release Agreement shall be the severance pay and severance benefits the Eligible Employee would not otherwise be eligible to receive. 5.2 Severance Pay. Severance pay shall equal to the sum of (i) 150% of the Eligible Employee’s Base Salary, and (ii) 150% of the Eligible Employee’s Target Bonus. Severance may be paid over eighteen (18) months in equal installments at regularly scheduled payroll intervals, provided the Eligible Employee has executed and submitted a Waiver and Release Agreement and the period during which the Employee is entitled to revoke the Waiver and Release Agreement has expired, with any such severance payments to commence on the sixtieth (60th) day following the Severance Date. Any severance payable to the Eligible Employee for the period following his/her Severance Date and the date payments commence shall be paid in a lump sum at the time installment payments commence. In the sole discretion of the Administrator, but subject to compliance with Code Section 409A, severance may be paid in a lump sum within sixty (60) days following the Eligible Employee’s Severance Date, provided the Eligible Employee has executed and submitted a Waiver and Release Agreement and the period during which the Employee is entitled to revoke the Waiver and Release Agreement has expired. All legally required taxes and any sums owed the Employer shall be deducted from Policy severance pay. Severance paid in installments on regularly scheduled payroll dates will continue to be payable upon the death of a former Eligible Employee who was receiving severance payments at the time of death. The remaining payments will be made in a lump sum to the estate of the former Eligible Employee as soon as practicable following death, but in no event later than two (2) years following termination of employment. 5.3 Severance Benefits. (a) Medical, Dental and Vision Benefits Coverage Continuation. The provisions of this subsection (a) apply only to U.S. based Eligible Employees. Under the U.S. Consolidated Omnibus Budget Reconciliation Act (“COBRA”), an Eligible Employee who is receiving health care coverage under an Employer-sponsored plan is entitled to elect health care continuation coverage under the applicable Employer health plan if his/her employment terminates for certain reasons. Any of the Triggering Events would qualify

---

![Slide 9](<perrigocompanyexecutivec009.jpg>)

> **Source slide transcript**
>
> 89126997.6 9 the Eligible Employee to receive such continuation coverage, subject to the terms of the applicable health plan and governing law. If an Eligible Employee experiences a Triggering Event before his/her WARN Notice Period (if applicable) expires, his/her COBRA rights begin when the WARN Notice Period expires. If an Eligible Employee becomes eligible for severance pursuant to the Policy and elects health care continuation coverage under COBRA for the Eligible Employee and/or his/her eligible covered dependents equivalent to the coverage which they were receiving immediately prior to the Severance Date, for the Continuation Period (as defined below), the Eligible Employee shall be required to pay the applicable active employee rate for such coverage (the “Health Care Benefits”); provided, however, that the Eligible Employee may be required to pay his/her share of the cost of coverage on an after-tax basis to the extent reasonably determined by his/her Employer to be necessary to avoid the Health Care Benefits from being considered to have been provided under a discriminatory self-insured medical reimbursement plan pursuant to Code Section 105(h). For purposes of this Section 5.3(a), the term “Continuation Period” means the eighteen (18) month period beginning on an Eligible Employee’s Severance Date; provided, however, that the Continuation Period shall cease at such time that the Eligible Employee is eligible to receive health care benefits under another employer-provided plan (but no repayment of any previously-paid premium shall be required). All of the terms and conditions of Employer-sponsored medical, dental and vision benefit plans, as amended from time to time, shall be applicable to an Eligible Employee (and his/her eligible dependents, if applicable) participating in any form of continuation coverage under such Employer-sponsored medical, dental and vision benefit plans. This Policy is not to be interpreted to expand an Eligible Employee’s health care continuation rights under COBRA. That is, continuation coverage under this Policy will run concurrent with (and not consecutively to) COBRA continuation coverage. Continuation coverage under this Policy will not extend the maximum COBRA continuation coverage period applicable to an Eligible Employee or to his/her eligible covered dependents. (b) Severance Bonus. An Eligible Employee who, in the absence of an Involuntary Termination, would have been eligible to receive a bonus under any bonus plan or policy of the Company or any Affiliate for the year in which the Severance Date occurs, shall receive a severance bonus pro-rated for the actual bonus payout. Such pro- rated severance bonus shall be paid at the same time that annual bonuses are generally payable under any such bonus plan or policy of the Company or any Affiliate, but in no event later than March 15 of the year following the year in which the Severance Date occurs, and shall be calculated in the same manner as applicable to employees of the Company and its Affiliates generally. (c) Long-Term Incentives. Long-term incentive payments shall be payable in accordance with the terms of any long-term incentive plan or award agreement applicable to an Eligible Employee.

---

![Slide 10](<perrigocompanyexecutivec010.jpg>)

> **Source slide transcript**
>
> 89126997.6 10 (d) Career Transition Assistance. A career transition assistance firm selected by the Administrator and paid for the Eligible Employee’s Employer shall provide career transition assistance as determined by the Administrator. An Eligible Employee must begin the available career transition assistance services within sixty (60) days following his/her Severance Date. (e) Reemployment. If the Company or any Affiliate reemploys a former Eligible Employee who is receiving or who is eligible to receive severance benefits and severance pay under the Policy, then (i) the rehired Employee and his/her covered dependents shall become ineligible to receive such severance benefits effective as of the rehired Employee’s reemployment date, (ii) severance pay which is payable in installments shall cease effective as of the rehired Employee’s reemployment date, and (iii) in the case of severance pay paid in a lump sum, the rehired Employee must repay to the Company the portion of the lump sum severance pay attributable to the period that begins on the date of his/her reemployment. If the Administrator, in its sole discretion, determines that the former Eligible Employee’s services address a critical business need, then the Administrator may provide that no such repayment is required. ARTICLE VI WAIVER AND RELEASE AGREEMENT In order to receive the severance pay and severance benefits available under the Policy, an Eligible Employee must submit a signed Waiver and Release Agreement form to the Administrator on or within forty-five (45) days after his/her Severance Date or receipt of the Waiver and Release Agreement, whichever occurs later. The required Waiver and Release Agreement will, among other things, include a release of the Company and its Affiliates from any and all claims, debts, suits or causes of action, known or unknown, based upon any fact, circumstance, or event occurring or existing at or prior to the Eligible Employee’s execution of the Waiver and Release Agreement, and will be on a form determined by the Administrator. The required Waiver and Release Agreement may also include provisions relating to confidentiality, inventions, non-solicitation of employees and customers, and, prior to a Change in Control, non-competition and non- disparagement. In no event will the Waiver and Release Agreement require the Eligible Employee to release claims regarding employee benefits or rights to indemnification. An Eligible Employee may revoke his/her signed Waiver and Release Agreement within seven (7) days of signing the Waiver and Release Agreement by submitting his/her signed revocation to the Administrator within the seven (7) day period in accordance with the procedures set forth in the Waiver and Release Agreement. Notwithstanding any provision of this Policy to the contrary, in no event shall the timing of the Eligible Employee’s execution of the Waiver and Release Agreement, directly or indirectly, result in the Eligible Employee designating the calendar year of any severance payment, and if a payment that is subject to execution of the Waiver and Release Agreement could be made in more than one taxable year, payment shall be made in the later taxable year. An Eligible Employee who timely revokes his/her Waiver and Release Agreement shall not be eligible to receive any severance pay or severance benefits under the Policy. Eligible Employees shall be advised to contact their personal attorney at their own expense to review the Waiver and Release Agreement form if they desire.

---

![Slide 11](<perrigocompanyexecutivec011.jpg>)

> **Source slide transcript**
>
> 89126997.6 11 ARTICLE VII ADMINISTRATOR The Talent & Compensation Committee, or any committee or individual as may be designated by the Company, shall administer the Policy (the “Administrator”). The Administrator may delegate to other persons responsibilities for performing certain of the Administrator’s duties under the Policy. Except as otherwise provided in the Policy and subject to Article VIII, the Administrator shall have the authority to construe the terms of the Policy, including, but not limited to, the making of factual determinations, the determination of questions concerning benefits, the procedures for claim review, and establishing and enforcing such rules, regulations and procedures as it deems necessary or proper for the efficient administration of the Policy. In the event of a group termination, as determined in the sole discretion of the Administrator, the Administrator shall furnish affected Eligible Employees with such additional information as may be required by law. ARTICLE VIII CLAIMS FOR SEVERANCE BENEFITS 8.1 Claim for Benefits. It is not necessary that an Eligible Employee apply for severance pay and severance benefits under the Policy. However, if an Eligible Employee wishes to file a claim for severance pay and severance benefits, such claim must be in writing and filed with the Administrator. If the Eligible Employee does not provide all the necessary information for the Administrator to process the claim, the Administrator may request additional information and set deadlines for the Eligible Employee to provide that information. The Administrator will review a claim, and will make a determination of the claim and provide notice of that determination within ninety (90) days of the date the written claim is submitted to the Administrator. 8.2 Benefits Review. If the claim is completely or partially denied, the Administrator will furnish a written or electronic notice to the claimant that specifies the reasons for the denial, refers to the Policy provisions on which the denial is based, describes any additional information that must be provided by the claimant in order to support the claim, explains why the information is necessary, and explains the appeal procedures under the Policy. 8.3 Appeal Procedures. A claimant may appeal the denial of his/her claim and request the Administrator reconsider the decision. The claimant or the claimant’s authorized representative may: (a) appeal by written request to the Administrator not later than sixty (60) days after receipt of notice from the Administrator denying his/her claim; (b) review or receive copies or any documents, records or other information relevant to the claimant’s claim; and (c) submit written comments, documents, records and other information relating to his/her claim. In deciding a claimant’s appeal, the Administrator shall take into account all comments, documents, records and other information submitted by the claimant relating to the claim. If the claimant does not provide all the necessary information for the Administrator to decide the appeal, the Administrator may request additional information and set deadlines for the claimant to provide that information. The Administrator will make a decision with respect to such an appeal within sixty (60) days after receiving the written request for appeal. The claimant will be advised of the Administrator’s decision on the appeal in writing or electronically. The notice will include the

---

![Slide 12](<perrigocompanyexecutivec012.jpg>)

> **Source slide transcript**
>
> 89126997.6 12 reasons for the decision, references to Policy provisions upon which the decision on the appeal is based, and a statement that the claimant is entitled to receive, upon request, reasonable access to, and copies of, all documents, records or other information relevant to the claimant’s claim. In no event shall a claimant or any other person be entitled to challenge a decision of the Administrator in court or in any other administrative proceeding unless and until the claim and appeal procedures described above have been complied with and exhausted. No legal action may be brought more than six (6) months following the Administrator’s final determination. In addition, no action at law or in equity shall be brought in connection with the Policy except in the United States District Court for the Western District of Michigan. Following a Change in Control, all determinations of the Administrator will be subject to de novo review by a court of competent jurisdiction. ARTICLE IX AMENDMENT/TERMINATION/VESTING Unless earlier terminated by the Company, the Policy shall, without any further action by the Company, terminate effective as of 11:59 PM Eastern Time on the last day of the CEO Transition Period. The Company by written action of its Board of Directors or any duly authorized designee of the Board reserves the right to amend or to terminate the Policy at any time. Notwithstanding the foregoing, no such amendment or termination shall impact severance rights accrued prior to the amendment or termination, provided, further, that following a Change in Control, no amendment or termination of the Policy shall adversely impact the rights or protections of an Eligible Employee under the Policy as of immediately prior to the amendment or termination, including, but not limited to, an amendment that would reduce the amount of severance pay or severance benefits, or change the time of payment of severance pay or benefits, or narrow the conditions under which severance pay or severance benefits are payable or limit the individuals who are eligible for severance pay or severance benefits under the Policy. ARTICLE X CONFIDENTIAL INFORMATION 10.1 Confidential Information. An Eligible Employee shall not, during or at any time after his/her termination of employment with the Company and its Affiliates, use, divulge, or convey to others any Confidential Information. Upon termination of employment with the Company and its Affiliates, or at any time at the Company’s or an Affiliate’s request, an Eligible Employee shall deliver promptly to the Company or Affiliate all drawings, blueprints, manuals, letters, notes, notebooks, reports, sketches, formulae, computer programs and similar items, memoranda, customer lists and all other materials and all copies thereof relating in any way to the Company’s or any Affiliate’s sale, manufacture, distribution, or development of any Company or Affiliate’s product or store brand and value brand OTC drug and nutritional products and/or topical generic prescription pharmaceutical programs and in any way obtained by the Eligible Employee during the period of his/her employment with the Company and its Affiliates which are in his/her possession or under his/her control. An Eligible Employee shall not make or retain any copies of any of the foregoing and will so represent to the Company and its Affiliates upon termination of employment. An Eligible Employee shall not disclose or provide to the Company or its Affiliates any information or documents of a confidential nature which belong to his/her prior employer or any

---

![Slide 13](<perrigocompanyexecutivec013.jpg>)

> **Source slide transcript**
>
> 89126997.6 13 other third-party which he/she is prohibited from disclosing or providing to the Company or its Affiliates, whether by the terms of any agreement to which he/she is a party or otherwise. The Eligible Employee shall provide to the Company or its affiliates copies of any previous employment agreement, severance agreement, non-competition agreement, confidentiality agreement or other agreement, statement or policies to which the Eligible Employee is a party or otherwise bound which in any way restricts or would affect the performance of his/her duties for the Company and its Affiliates. Notwithstanding the foregoing, nothing in the Policy shall prohibit the Eligible Employee from reporting possible violations of law or regulation to any governmental agency or entity, including, but not limited to, the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General, or from filing a charge with or participating in an investigation by any such agency or entity, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. The Eligible Employee does not need the prior authorization of the Company or any Affiliate to make any such reports or disclosures and the Eligible Employee is not required to notify the Company or any Affiliate that the Eligible Employee has made such reports or disclosures. 10.2 Cessation of Severance Benefits. Recognizing that the failure to comply with Section 10.1 above will cause serious and irreparable injury to the Company and its Affiliates, Eligible Employees acknowledge that in addition to any other remedy permissible by law, payment of severance pay and severance benefits under the Policy shall cease if an Eligible Employee violates the terms of Section 10.1. Any Eligible Employee subject to an individual confidentiality agreement or proprietary rights agreement with the Company or any Affiliate will be deemed to violate the terms of Section 10.1 if he/she violates the terms of the individual confidentiality agreement or proprietary rights agreement. ARTICLE XI MISCELLANEOUS PROVISIONS 11.1 Return of Property. In order for an Eligible Employee to receive severance pay and severance benefits under the Policy, he/she shall be required to (i) return all Company and Affiliate property (including, but not limited to, Confidential Information, client lists, keys, credit cards, documents and records, identification cards, equipment, laptop computers, software, and pagers), and (ii) repay any outstanding bills, advances, debts, amounts due to the Company or any Affiliate, as of his/her Severance Date. To the extent the Eligible Employee has any Company or Affiliate property stored electronically (including, but not limited to, in the form of email) on his/her personal computer, in a personal email account, on a personal storage device, or otherwise, such Eligible Employee shall promptly provide copies of all such information to his/her Employer and thereafter permanently delete or otherwise destroy the Eligible Employee’s personal copy. All pay and other benefits (except Policy severance pay and severance benefits) payable to an Eligible Employee as of his/her Severance Date according to the established policies, plans, and procedures of his/her Employer shall be paid in accordance with the terms of those established policies, plans and procedures. In addition, any benefit continuation or conversion rights which an Eligible Employee has as of his/her Severance Date according to the established policies, plans, and procedures of his/her Employer shall be made available to him/her.

---

![Slide 14](<perrigocompanyexecutivec014.jpg>)

> **Source slide transcript**
>
> 89126997.6 14 11.2 No Assignment. Severance pay and severance benefits payable under the Policy shall not be subject to anticipation, alienation, pledge, sale, transfer, assignment, garnishment, attachment, execution, encumbrance, levy, lien, or charge, and any attempt to cause such severance pay and severance benefits to be so subjected shall not be recognized, except to the extent required by law. 11.3 Unemployment Benefits. In accordance with applicable state law, an Eligible Employee may apply for unemployment benefits after the period for which severance has been paid has been exhausted. 11.4 Code Section 409A Compliance. (a) General. It is intended that payments and benefits made or provided under this Policy shall not result in penalty taxes or accelerated taxation pursuant to Code Section 409A. Any payments that qualify for the “short-term deferral” exception, the separation pay exception or another exception under Code Section 409A shall be paid under the applicable exception. For purposes of the limitations on nonqualified deferred compensation under Code Section 409A, each payment of compensation under this Policy shall be treated as a separate payment of compensation for purposes of applying the exclusion under Code Section 409A for short-term deferral amounts, the separation pay exception or any other exception or exclusion under Code Section 409A. All payments to be made upon a termination of employment under this Policy may only be made upon a “separation from service” under Code Section 409A to the extent necessary in order to avoid the imposition of penalty taxes on an Eligible Employee pursuant to Code Section 409A. In no event may an Eligible Employee, directly or indirectly, designate the calendar year of any payment under this Policy. (b) Reimbursements and In-Kind Benefits. Notwithstanding anything to the contrary in this Policy, all reimbursements and in-kind benefits provided under this Policy that are subject to Code Section 409A shall be made in accordance with the requirements of Code Section 409A, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during an Eligible Employee’s lifetime (or during a shorter period of time specified in this Policy); (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided in any other calendar year; (iii) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. (c) Delay of Payments. Notwithstanding any other provision of this Policy to the contrary, if an Eligible Employee is considered a “specified employee” for purposes of Code Section 409A (as determined in accordance with the methodology established by the Company as in effect on the Termination Date), any payment that constitutes nonqualified deferred compensation within the meaning of Code Section 409A that is otherwise due to the Eligible Employee under this Policy during the six-month period immediately following the Eligible Employee’s separation from service (as determined in accordance

---

![Slide 15](<perrigocompanyexecutivec015.jpg>)

> **Source slide transcript**
>
> 89126997.6 15 with Code Section 409A) on account of the Eligible Employee’s separation from service shall be accumulated and paid to an Eligible Employee on the first business day of the seventh month following his separation from service (the “Delayed Payment Date”). If an Eligible Employee dies during the postponement period, the amounts and entitlements delayed on account of Code Section 409A shall be paid to the personal representative of his estate on the first to occur of the Delayed Payment Date or thirty (30) calendar days after the date of the Eligible Employee’s death. 11.5 Representations Contrary to the Policy. No employee, officer, or director of the Company or any Affiliate has the authority to alter, vary, or modify the terms of the Policy except by means of an authorized written amendment to the Policy. No verbal or written representations contrary to the terms of the Policy and its written amendments shall be binding upon the Policy, the Administrator, the Company, or any Affiliate. 11.6 No Employment Rights. This Policy shall not confer employment rights upon any person. No person shall be entitled, by virtue of the Policy, to remain in the employment of an Employer and nothing in the Policy shall restrict the right of an Employer to terminate the employment of any Eligible Employee or other person at any time. 11.7 Policy Funding. No Eligible Employee shall acquire by reason of the Policy any right in or title to any assets, funds, or property of the Company or any Affiliate. Any severance pay, which becomes payable under the Policy is an unfunded obligation and shall be paid from the general assets of the Employee’s Employer. No employee, officer, director or agent of the Company or any Affiliate personally guarantees in any manner the payment of Policy severance pay and severance benefits. 11.8 Applicable Law. This Policy shall be governed and construed in accordance with the laws of the State of Michigan without regard to its conflicts of law provisions and, to the extent that applicable foreign law differs from the Code and Michigan law, in accordance with applicable foreign law. 11.9 Indemnification. To the extent permitted by law and to the extent not covered by any applicable insurance policy, the Administrator, excluding any third-parties, will be indemnified by the Company against all liability, joint or several, for the Administrator’s acts and omissions and for the acts and omissions of the Administrator’s agents and other fiduciaries in the administration and operation of the Policy. This will include indemnification of the Administrator by the Company against all costs and expenses reasonably incurred by the Administrator, including reasonable legal fees, in connection with the defense of any action, suit or proceeding in which the Administrator may be made party defendant by reason of the Administrator being or having been the Administrator, whether or not then serving as such, including the cost of reasonable settlements (other than amounts paid to the Company) made to avoid costs of litigation and payment of any judgment or decree entered in such action, suit or proceeding. The Company will not, however, indemnify the Administrator, including any third parties, with respect to any act finally adjudicated to have been caused by the willful misconduct or bad faith of such Administrator; or with respect to the cost of any settlement unless the Company has approved the settlement. The right of indemnification will not be exclusive of any other right to which the Administrator may be legally entitled and it will inure to the benefit of any duly appointed legal representative of the

---

![Slide 16](<perrigocompanyexecutivec016.jpg>)

> **Source slide transcript**
>
> 89126997.6 16 Administrator. The terms of this indemnification will also extend to any employees of the Company or any of its Affiliates to whom any fiduciary responsibility has been assigned in connection with the administration of the Policy. 11.10 Severability. If any provision of the Policy is found, held or deemed by a court of competent jurisdiction to be void, unlawful or unenforceable under any applicable statute or other controlling law, the remainder of the Policy shall continue in full force and effect.

---

---

## EX-10.5

SEC source: [restrictedstockunitaward.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/restrictedstockunitaward.htm)

![Slide 1](<restrictedstockunitaward001.jpg>)

> **Source slide transcript**
>
> PERRIGO COMPANY PLC RESTRICTED STOCK UNIT AWARD AGREEMENT (SERVICE-BASED) (Under the Perrigo Company plc 2026 Long-Term Incentive Plan) TO: Participant Name RE: Notice of Restricted Stock Unit Award (Service-Based) This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2026 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of service-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan. SECTION 1 Restricted Stock Units – Service-Based Vesting 1.1 Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants you Number of Awards Granted (“Restricted Stock Units” or “RSUs”). Each RSU shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the applicable RSU Vesting Date, provided the vesting conditions described in Section 1.2 are satisfied. 1.2 Vesting. Except as provided in Section 1.3, the RSUs awarded in Section 1.1 shall vest as follows following the Grant Date (“RSU Vesting Date(s)”): Vesting Schedule (Dates & Quantities) provided, however, that you continue in the service of the Company from the Grant Date through the applicable RSU Vesting Date. Except as provided in Section 1.3, if your Termination Date occurs prior to the RSU Vesting Date, any RSUs awarded under Section 1.1 that have not previously vested as of such Termination Date shall be permanently forfeited on your Termination Date. 1.3 Special Vesting Rules. Notwithstanding Section 1.2 above or anything to the contrary in the Plan: (a) If your Termination Date occurs by reason of death, Disability or Retirement with the Company’s consent, any RSUs awarded under Section 1.1 that have not vested prior to such Termination Date shall become fully vested. (b) If your Termination Date occurs by reason of an Involuntary Termination for Economic Reasons, any RSUs awarded under Section 1.1 that would otherwise be scheduled to vest under Section 1.2 in the 24-month period following such Termination Date shall continue to vest during such 24-month period according to the vesting schedule in effect prior to such

---

![Slide 2](<restrictedstockunitaward002.jpg>)

> **Source slide transcript**
>
> 2 Termination Date; provided, however, that if your Termination Date occurs for a reason that is both described in this subsection (b) and in subsection (c) below, the special vesting rules described in subsection (c) shall apply in lieu of the vesting rules described in this subsection (b). Any RSUs that are not scheduled to vest during such 24-month period will be permanently forfeited on the Termination Date. (c) If your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all RSUs awarded under Section 1.1 that have not vested or been forfeited prior to such Termination Date shall become fully vested. (d) As used in this Section 1.3, the following terms shall have the meanings set forth below: (1) “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice. (2) “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company. 1.4 Settlement of RSUs. As soon as practicable after the RSU Vesting Date (or such earlier vesting date in accordance with Section 1.3), the Company shall transfer to you one Ordinary Share for each RSUs becoming vested on such date (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company may withhold shares otherwise transferable to you to the extent necessary to satisfy withholding taxes due by reason of the vesting of the RSUs, in accordance with Section 2.6. Notwithstanding the foregoing, the Committee, in its sole discretion, may elect to settle RSUs in cash based on the fair market value of the Ordinary Shares on the RSU Vesting Date.

---

![Slide 3](<restrictedstockunitaward003.jpg>)

> **Source slide transcript**
>
> 3 1.5 Dividend Equivalents. The RSUs awarded under Section 1.1 shall be eligible to receive dividend equivalents in accordance with the following: (a) An “Account” will be established in your name. Such Account shall be for recordkeeping purposes only, and no assets or other amounts shall be set aside from the Company’s general assets with respect to such Account. (b) On each date that a cash dividend is paid with respect to Ordinary Shares, the Company shall credit your Account with the dollar amount of dividends you would have received if each RSU held by you on the record date for such dividend payment had been an Ordinary Share. No interest or other earnings shall accrue on such Account. (c) As of each RSU Vesting Date, you shall receive a payment equal to the amount of dividends that would have been paid on the RSUs vesting on such date had they been Ordinary Shares during the period beginning on the Grant Date and ending on the RSU Vesting Date, and the Account shall be debited appropriately. If you forfeit RSUs, any amounts in the Account attributable to such RSUs shall also be forfeited. (d) If dividends are paid in the form of Ordinary Shares rather than cash, then you will be credited with one additional RSU for each Ordinary Share that would have been received as a dividend had your outstanding RSUs been Ordinary Shares. Such additional RSUs shall vest or be forfeited at the same time as the RSU to which they relate. SECTION 2 General Terms and Conditions 2.1 Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution. 2.2 No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the RSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares. 2.3 Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately. 2.4 Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by

---

![Slide 4](<restrictedstockunitaward004.jpg>)

> **Source slide transcript**
>
> 4 the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply. 2.5 Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you. 2.6 Acknowledgement. The Company and you agree that the RSUs are granted under and governed by the Notice of Grant, this Agreement (including the Appendix, if applicable) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant. 2.7 Taxes and Withholding. (a) Withholding (Only Applicable to Individuals Subject to U.S. Tax Laws). This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law. (b) Responsibility for Taxes (Only Applicable to Individuals Subject to Tax Laws Outside the U.S.) Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including, but not limited to, the grant, vesting or settlement of the RSUs, the subsequent sale of Ordinary Shares acquired pursuant to such settlement and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate your liability for Tax-Related Items or

---

![Slide 5](<restrictedstockunitaward005.jpg>)

> **Source slide transcript**
>
> 5 achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the RSU Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction. (1) Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (A) withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or (B) withholding from proceeds of the sale of Ordinary Shares acquired upon settlement of the RSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (C) withholding in Ordinary Shares to be issued upon settlement of the RSUs. (2) To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable statutory withholding amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been issued the full number of Ordinary Shares subject to the vested RSUs, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items. (3) Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Shares or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items. 2.8 Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to

---

![Slide 6](<restrictedstockunitaward006.jpg>)

> **Source slide transcript**
>
> 6 issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity. 2.9 Code Section 409A (Only Applicable to Individuals Subject to U.S. Federal Tax Laws) (a) RSUs other than RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons and dividend equivalents payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, RSUs (other than RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons) will be settled and dividend equivalents will be paid no later than the 15th day of the third month following the later of (i) the end of your taxable year in which the RSU Vesting Date occurs, or (ii) the end of the fiscal year of the Company in which the RSU Vesting Date occurs. (b) RSUs that continue to vest by reason of your Involuntary Termination for Economic Reasons are subject to the provisions of this subsection (b). Any distribution in settlement of such RSUs will occur provided your Involuntary Termination for Economic Reasons constitutes a “separation from service” as defined in Treasury Regulation §1.409A-1(h). If the Company determines that you are a “specified employee” as defined in Code Section 409A (i.e., an officer with annual compensation above $130,000 (as adjusted for inflation), a five- percent owner of the Company or a one-percent owner with annual compensation in excess of $150,000), distribution in settlement of any such RSUs that would be payable within six months of your separation from service shall be delayed to the first business day following the six-month anniversary of your separation from service. Any distribution in settlement of such RSUs that would be made more than six months after your separation from service (without application of the six-month delay) shall not be subject to the six-month delay described in this subsection. 2.10 Data Privacy. (a) U.S. Data Privacy Rules (Only Applicable if this Award is Subject to U.S. Data Privacy Laws). By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Personal Data”), (c) understand that Personal Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any data privacy rights you may have with respect to the data, and (e) authorize the Company, its Affiliates and its agents, to store and transmit such information in electronic form.

---

![Slide 7](<restrictedstockunitaward007.jpg>)

> **Source slide transcript**
>
> 7 (b) Non-U.S. Data Privacy Rules (Only Applicable if this Award is Subject to Data Privacy Laws Outside of the U.S.) (1) By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other RSU grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. (2) You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Ordinary Shares or directorships held in the Company, details of all RSUs or any other entitlement to Ordinary Shares awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). (3) You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country of residence. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative. 2.11 Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company. 2.12 Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the applicable Code provisions to the maximum extent possible and otherwise by the laws of the State of Michigan without regard to principals of conflict of laws, provided that if you are a foreign national or employed outside the United States, this Agreement

---

![Slide 8](<restrictedstockunitaward008.jpg>)

> **Source slide transcript**
>
> 8 shall be governed by and construed and enforced in accordance with applicable foreign law to the extent that such law differs from the Code and Michigan law. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof. 2.13 Forfeiture of RSUs. (a) For Section 16 Officers. If you are or were designated as an officer of the Company in accordance with Rule 16a-1(f) of the Exchange Act (“Section 16 Officer”), any RSUs and any gains or profits on the sale of such RSUs shall be subject to the Compensation Recovery Policy of the Company or any other “clawback” or recoupment policy now in effect or later adopted by the Company. (b) For All Other Employees. If you are not a Section 16 Officer, if the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, and the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment (including dividend equivalents) relating to any RSUs earned or accrued during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding RSUs (including related dividend equivalents) that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy now in effect or later adopted by the Company. 2.14 Special Rules for Non-U.S. Grantees (Only Applicable if You Reside Outside of the U.S.) (a) Nature of Grant. In accepting the grant, you acknowledge, understand and agree that: (1) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan; (2) the grant of the RSUs is voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted repeatedly in the past; (3) all decisions with respect to future RSU grants, if any, will be at the sole discretion of the Company; (4) you are voluntarily participating in the Plan;

---

![Slide 9](<restrictedstockunitaward009.jpg>)

> **Source slide transcript**
>
> 9 (5) the RSUs and the Ordinary Shares subject to the RSUs are an extraordinary item and which is outside the scope of your employment or service contract, if any; (6) the RSUs and the Ordinary Shares subject to the RSUs are not intended to replace any pension rights or compensation; (7) the RSUs and the Ordinary Shares subject to the RSUs are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate; (8) the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate; (9) the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty; (10) no claim or entitlement to compensation or damages shall arise from forfeiture of the RSUs resulting from your Termination Date (for any reason whatsoever, whether or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the RSUs to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and (11) you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between the currency of the country in which you reside and the United States Dollar that may affect the value of the RSUs or of any amounts due to you pursuant to the settlement of the RSUs or the subsequent sale of any Ordinary Shares acquired upon settlement. (b) Appendix. Notwithstanding any provisions in this Agreement, the RSU grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement for your country. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. If you relocate to the United States, the special terms and conditions in the Appendix will apply, or cease to apply, to you, to the extent the Company determines that the application or otherwise

---

![Slide 10](<restrictedstockunitaward010.jpg>)

> **Source slide transcript**
>
> 10 of such provisions is necessary or advisable in order to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement. (c) Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the RSUs and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. 2.15 Noncompetition and Nonsolicitation. (a) Noncompetition. During your employment with the Company and its Affiliates and for a twelve (12) month period following your Termination Date (the “Restricted Period”), you shall not (i) directly or indirectly, without the prior written consent of the Company, engage in or invest as an owner, partner, stockholder, licensor, director, officer, agent or consultant for any Person that conducts a business that is in competition with a business conducted by the Company or any of its Affiliates anywhere in the world; or (ii) accept employment or an engagement for the provision of services in any capacity, including as an employee, director, consultant or advisor, directly or indirectly, with any Person that conducts a business that is in competition with a business conducted by the Company or any of its Affiliates anywhere in the world except where prohibited by local law. For purposes hereof, conducting a business that is in competition with a business conducted by the Company or any of its Affiliates shall include the sale, manufacture, distribution or research and development of any product or service that is similar to a product or service sold, distributed, marketed or being researched or developed (including through a joint venture or investment in another entity) by the Company or any of its Affiliates, including store brand and value brand OTC drug or nutritional products, extended topical generic prescription pharmaceutical products, infant nutrition products, oral care products, and any other product or products that the Company or an Affiliate is marketing or actively planning to market during your employment with the Company and during the one­year period following your Termination Date. If there is a completed sale, transfer or other disposition of the Perrigo Prescription Pharmaceutical business during the Restricted Period, this Section 2.15(a) will not apply to the Perrigo Prescription Pharmaceutical business. Notwithstanding the foregoing, nothing in this provision shall prevent you from passively owning two percent (2%) or less of the outstanding securities of any class of any company listed on a national securities exchange or quoted on an automated quotation system. You may make a written request in writing to the CHRO of the Company for an exception to this Section 2.15(a) and such exception will not be unreasonably withheld. (b) Nonsolicitation of Service Providers. During your employment with the Company and its Affiliates and for the duration of the Restricted Period, you shall not, directly or indirectly, without the prior written consent of the Company, (i) actively solicit, recruit or hire any Person who is at such time, or who at any time during the 12­month period prior to such solicitation or hiring had been, an employee or consultant of the Company or any of its Affiliates, (ii) solicit or encourage any employee of the Company or any of its Affiliates to leave the employment of the Company or any of its Affiliates or (iii) interfere with the relationship of the Company or any of its Affiliates with any Person or entity who or that is employed by or

---

![Slide 11](<restrictedstockunitaward011.jpg>)

> **Source slide transcript**
>
> 11 otherwise engaged to perform services for the Company or any of its Affiliates except where prohibited by local law. (c) Nonsolicitation of Clients. During your employment with the Company and its Affiliates and for the duration of the Restricted Period, you shall not, directly or indirectly, alone or in association with any other Person, without the prior written consent of the Company, (i) induce or attempt to induce any client, customer (whether former or current), supplier, licensee, franchisee, joint venture partner or other business relation of the Company or any of its Affiliates (collectively, “Clients”) to cease doing business with the Company or any such Affiliate, (ii) divert all or any portion of a Client’s business with the Company to any competitor of the Company or any such Affiliate, or (iii) in any way interfere with the relationship between any Client, on the one hand, and the Company or any such Affiliate, on the other hand except where prohibited by local law. (d) Remedies and Injunctive Relief. You acknowledge that a violation by you of any of the covenants contained in this Section 2.15 would cause irreparable damage to the Company and its Affiliates in an amount that would be material but not readily ascertainable, and that any remedy at law (including the payment of damages) would be inadequate. Accordingly, you agree that, notwithstanding any provision of this Agreement to the contrary, in addition to any other damages it is able to show, the Company and its Affiliates shall be entitled (without the necessity of showing economic loss or other actual damage) to injunctive relief (including temporary restraining orders, preliminary injunctions and permanent injunctions), without posting a bond, in any court of competent jurisdiction for any actual or threatened breach of any of the covenants set forth in this Section 2.15 in addition to any other legal or equitable remedies it may have. In addition, in the event of your Willful Restrictive Covenant Breach (as defined in this Section 2.15), (i) all of your rights under this Agreement, whether or not vested, shall terminate immediately, and (ii) any Shares, cash or other property paid or delivered to you pursuant to this Agreement shall be forfeited and you shall be required to repay such Shares, cash or other property to the Company, no later than thirty (30) calendar days after the Company makes demand to you for repayment. For purposes of this Agreement, “Willful Restrictive Covenant Breach” means your material breach of any of the covenants set forth in this Section 2.15 which you knew, or with due inquiry, should have known, would constitute such a material breach. The preceding sentences of this Section 2.15 shall not be construed as a waiver of the rights that the Company and its Affiliates may have for damages under this Agreement or otherwise, and all such rights shall be unrestricted. The Restricted Period shall be tolled during (and shall be deemed automatically extended by) any period during which you are in violation of the provisions of Section 2.15(a), (b) or (c), as applicable. In the event that a court of competent jurisdiction determines that any provision of this Section 2.15 is invalid or more restrictive than permitted under the governing law of such jurisdiction, then, only as to enforcement of this Section 2.15 within the jurisdiction of such court, such provision shall be interpreted and enforced as if it provided for the maximum restriction permitted under such governing law. (e) Acknowledgments. (1) You acknowledge that the Company and its Affiliates have expended and will continue to expend substantial amounts of time, money and effort to develop business strategies, employee, customer and other relationships and goodwill to build an

---

![Slide 12](<restrictedstockunitaward012.jpg>)

> **Source slide transcript**
>
> 12 effective organization. You acknowledge that the Company and its Affiliates have a legitimate business interest in and right to protect its goodwill and employee, customer and other relationships, and that the Company and its Affiliates could be seriously damaged by the loss or deterioration of its employee, customer and other relationships. You further acknowledge that the Company and its Affiliates are entitled to protect and preserve the going concern value of the Company and its Affiliates to the extent permitted by law. (2) In light of the foregoing acknowledgments, you agree that the covenants contained in this Agreement are reasonable and properly required for the adequate protection of the businesses and goodwill of the Company and its Affiliates. You further acknowledge that, although your compliance with the covenants contained in this Agreement may prevent you from earning a livelihood in a business similar to the business of the Company and its Affiliates, your experience and capabilities are such that you have other opportunities to earn a livelihood and adequate means of support for you and your dependents. (3) In light of the acknowledgements contained in this Section 2.15, you agree not to challenge or contest the reasonableness, validity or enforceability of any limitations on, and obligations of, you contained in this Section 2.15. ****

---

![Slide 13](<restrictedstockunitaward013.jpg>)

> **Source slide transcript**
>
> 13 We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award. Very truly yours, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 14](<restrictedstockunitaward014.jpg>)

> **Source slide transcript**
>
> 14 PERRIGO COMPANY PLC ACCORD RELATIF À L’ATTRIBUTION D’UNITÉS D’ACTION AVEC RESTRICTIONS (RÉMUNÉRATION FONDÉE SUR LES SERVICES) (Dans le cadre du Plan d’incitation à long terme 2026 de Perrigo Company plc) À : Participant Name OBJET : Avis d’attribution d’unités d’action avec restrictions (rémunération fondée sur les services) Les présentes visent à vous informer que Perrigo Company plc (la « Société ») vous a octroyé une Prime dans le cadre du Plan d’incitation à long terme 2026 de Perrigo Company plc (le « Plan »), avec prise d’effet à la Grant Date (la « Date d’octroi »). Cette Prime est constituée d’unités d’action avec restrictions sur la base des services. Les conditions de cette incitation sont exposées dans le reste du présent accord, dénommé collectivement l’« Accord » (y compris toutes les conditions particulières stipulées dans les appendices applicables à votre pays [l’« Appendice »]). Les termes commençant par une lettre majuscule utilisés dans le présent Accord et qui n’y sont pas définis ont le sens qui leur est attribué en vertu du Plan. SECTION 1 Unités d’action avec restrictions — Dévolution sur la base des services 1.1 Octroi. À compter de la Date d’octroi et sous réserve des conditions du présent Accord et du Plan, la Société vous octroie Number of Awards Granted (« Unités d’action avec restrictions » ou « UAR »). Chaque UAR vous donne droit à une action ordinaire de la Société d’une valeur nominale de 0,001 € par action (« Action ordinaire ») à la Date de dévolution des UAR applicable pour autant qu’il soit satisfait aux conditions décrites à la section 1.2. 1.2 Dévolution. Sous réserve des cas prévus à la section 1.3, les UAR attribuées à la section 1.1 sont dévolues comme suit après la Date d’octroi (« Date(s) de dévolution des UAR ») : Vesting Schedule (Dates & Quantities); pour autant, toutefois, que vous restiez au service de la Société de la Date d’octroi jusqu’à la Date de dévolution applicable. Sauf dans les cas prévus à la section 1.3, si votre Date de cessation d’emploi survient avant la Date de dévolution des UAR, toutes les UAR attribuées en vertu de la section 1.1 n’ayant pas encore été dévolues à ladite Date de cessation d’emploi sont déchues définitivement à cette date. 1.3 Règles de dévolution particulières. Nonobstant les dispositions de la section 1.2 : (a) Si votre Date de cessation d’emploi survient à la suite d’un décès, d’un Handicap ou d’un Départ à la retraite avec l’accord de la Société, toutes les UAR attribuées en vertu de la section 1.1 n’ayant pas été dévolues avant la Date de cessation d’emploi le deviennent alors intégralement.

---

![Slide 15](<restrictedstockunitaward015.jpg>)

> **Source slide transcript**
>
> 15 (b) Si votre Date de cessation d’emploi survient à la suite d’un Licenciement involontaire pour motifs économiques, toutes les UAR attribuées en vertu de la section 1.1 qui auraient, en d’autres circonstances, été dévolues en vertu de la section 1.2 au cours de la période de 24 mois suivant ladite Date de cessation d’emploi continuent d’être dévolues durant cette période de 24 mois, conformément au programme de dévolution en vigueur avant cette date ; toutefois, si votre Date de cessation d’emploi survient pour un motif décrit aussi bien dans la présente sous-section (b) et dans la sous-section (c), les règles de dévolution particulières décrites dans la sous-section (c) s’appliquent au lieu de celles décrites dans la présente sous- section (b). Toutes les UAR dont la dévolution n’est pas planifiée durant la période de 24 mois en question sont déchues définitivement à la Date de cessation d’emploi. (c) Si votre Date de cessation d’emploi survient en raison d’un Licenciement sans motif valable ou d’un Départ pour motifs justifiés au moment ou à la suite d’un Changement de contrôle (défini dans le Plan, cette définition pouvant être modifiée par la suite) et avant le deuxième (2e) anniversaire du Changement de contrôle, toutes les UAR attribuées en vertu de la section 1.1 n’ayant pas été dévolues ou déchues avant la Date de cessation d’emploi sont dévolues intégralement. (d) Tels qu’ils sont utilisés dans la présente section 1.3, les termes suivants ont le sens qui leur est attribué ci-après : (1) Par « Départ pour motifs justifiés », on entend votre démission volontaire de la Société et l’existence d’une ou de plusieurs des conditions suivantes, survenues sans votre consentement : (i) une modification importante de l’emplacement géographique où vous êtes tenu de fournir les services, de sorte que le trajet entre votre domicile et votre lieu de travail principal est allongé de plus de 50 km ou (ii) une réduction importante de votre autorité, de vos fonctions ou de vos responsabilités ou une baisse considérable de votre rémunération de base ou de vos possibilités de rémunération incitatives, étant toutefois entendu qu’une démission volontaire de la Société n’est pas considérée comme un Départ pour motifs justifiés tant que vous ne signifiez pas à la Société, par écrit, ladite démission et l’existence de la ou des conditions donnant lieu à la cessation d’emploi dans un délai de 90 jours après le moment où elles surviennent pour la première fois. La Société dispose ensuite de 30 jours pour remédier à la situation, auquel cas il ne sera pas considéré que vous avez subi un Départ pour motifs justifiés. Si la Société n’est pas en mesure de remédier à la situation dans ce délai de 30 jours, votre Date de cessation d’emploi intervient le 31e jour suivant la réception de votre avis écrit par la Société. (2) Par « Licenciement sans motif valable », on entend la cessation involontaire et sans motif de votre emploi ou de la relation contractuelle qui vous lie à la Société, notamment, de manière non limitative, (i) un licenciement intervenant lorsque vous épuisez un congé durant ou au terme d’une période de préavis en vertu du Worker Adjustment and Retraining Notification Act (« WARN ») et (ii) une situation dans laquelle vous bénéficiez d’un congé autorisé durant lequel votre poste est protégé en vertu de la loi applicable (par exemple le Family Medical Leave Act) et, à votre retour de congé, vous ne pouvez pas être employé ou conclure une autre forme de relation contractuelle avec la Société. 1.4 Règlement des UAR. Le plus tôt possible après la Date de dévolution des UAR, la Société vous cède une Action ordinaire pour chaque UAR dévolue à cette date (la date

---

![Slide 16](<restrictedstockunitaward016.jpg>)

> **Source slide transcript**
>
> 16 de cession étant dénommée la « date de règlement » aux fins du présent Accord), étant toutefois entendu que la Société peut retenir des actions qui devraient vous être cédées pour satisfaire à des retenues d’impôt dues en conséquence de la dévolution des UAR, conformément à la section 2.6. Vous ne détenez aucun droit en tant qu’actionnaire relatif aux UAR attribuées en vertu des présentes avant la date d’émission, à votre bénéfice, d’un ou de plusieurs certificats concernant les actions en question. Nonobstant ce qui précède, le Comité peut, à sa seule discrétion, choisir de régler les UAR en espèces sur la base de la juste valeur de marché des Actions ordinaires à la Date de dévolution des UAR. 1.5 Équivalents de dividendes. Les UAR attribuées en vertu de la section 1.1 sont admissibles au versement d’équivalents de dividendes conformément à ce qui suit : (a) Un « Compte » est établi à votre nom. Ce Compte est uniquement utilisé à des fins de tenue des dossiers et aucun actif ou autre montant ne sera prélevé des actifs généraux de la Société pour y être déposé. (b) À chaque date à laquelle un dividende en espèces est versé relativement aux Actions ordinaires, la Société crédite votre Compte du montant, en dollars, des dividendes que vous auriez reçus si chaque UAR que vous détenez à la date d’enregistrement du paiement des dividendes avait été une Action ordinaire. Aucun intérêt ou autre revenu ne sera accumulé sur ce Compte. (c) À chaque Date de dévolution des UAR, vous recevez un paiement équivalant au montant des dividendes qui vous auraient été versés sur les UAR dévolues à cette date s’il s’était agi d’Actions ordinaires au cours de la période débutant à la Date d’octroi et se terminant à la Date de dévolution des UAR, et le compte est débité en conséquence. Si des UAR sont déchues, tous les montants du Compte imputables à ces UAR sont déchus également. (d) Si des dividendes sont versés sous la forme d’Actions ordinaires plutôt que d’espèces, vous êtes crédité d’une UAR supplémentaire pour chaque Action ordinaire qui aurait été perçue sous forme de dividende si vos UAR en suspend avaient été des Actions ordinaires. Ces UAR supplémentaires sont dévolues ou déchues au même moment que les UAR auxquelles elles se rapportent. SECTION 2 Conditions générales 2.1 Incessibilité. La Prime qui fait l’objet du présent Accord ne peut être cédée par d’autres voies que par testament ou en vertu du droit successoral. 2.2 Absence de droits d’actionnaire. Vous ne détenez aucun droit en tant qu’actionnaire relatif aux Actions ordinaires soumises aux UAR attribuées en vertu du présent Accord avant la date d’émission, à votre bénéfice, d’un ou de plusieurs certificats concernant les actions en question.

---

![Slide 17](<restrictedstockunitaward017.jpg>)

> **Source slide transcript**
>
> 17 2.3 Licenciement justifié. Si votre Date de cessation d’emploi survient pour des motifs justifiés, l’ensemble de vos droits découlant du présent Accord, acquis ou non, prennent fin immédiatement. 2.4 Soumission de la Prime au Plan. L’octroi de la Prime en vertu du présent Accord est organisé conformément au Plan et la Prime est payable uniquement conformément aux conditions de celui-ci qui sont en vigueur. Le Plan comporte certaines définitions, restrictions, limitations et d’autres conditions qui s’appliquent toutes au présent Accord. L’ENSEMBLE DES DISPOSITIONS DU PLAN SONT INTÉGRÉES AUX PRÉSENTES PAR RENVOI ET FONT PARTIE INTÉGRANTE DU PRÉSENT ACCORD COMME SI CHACUNE D’ENTRE ELLES Y FIGURAIT EXPLICITEMENT. Si le Plan devient nul ou inexécutoire en vertu d’une loi ou d’une décision judiciaire, le présent Accord devient nul et sans effet. Rien de ce qui est énoncé dans le présent Accord ne vise à restreindre ou à exclure toute définition, restriction, limitation ou autre condition du Plan susceptible d’être pertinente à l’égard du présent Accord et spécifiquement appliquée à ce dernier par le Comité, et aucune de ses dispositions ne saurait être interprétée en ce sens. En cas de conflit entre les dispositions du présent Accord et le Plan, la règle d’interprétation considère que les conditions du Plan priment et, partant, s’appliquent. 2.5 Ajustements en cas de Changement relatif aux Actions ordinaires. En cas de fractionnement des actions, de dividendes en actions, de recapitalisation, de reclassement ou de regroupement d’actions, de fusion, de vente d’actifs ou d’événements similaires, le nombre et le type d’actions qui constituent la Prime en vertu du présent Accord seront ajustés de manière appropriée et équitable pour éviter la dilution ou la majoration des droits qui vous sont octroyés ou reconnus. 2.6 Accusé de réception. La Société et vous-même convenez que les UAR sont attribuées et régies par l’Avis d’octroi, le présent Accord (y compris son éventuel Appendice) et les dispositions du Plan (intégrées aux présentes par renvoi). Vous (i) accusez réception d’un exemplaire de chacun des documents susmentionnés, (ii) déclarez les avoir lus attentivement et en comprendre les dispositions et (iii) acceptez par les présentes les UAR soumises à l’ensemble des conditions énoncées dans les présentes et à celles stipulées dans le Plan et l’Avis d’octroi. 2.7 Impôts et retenues. (a) Retenues (applicable uniquement aux individus soumis à la législation fiscale des États-Unis). La présente Prime est soumise à la retenue de l’ensemble des impôts applicables. La Société est en droit de retenir ou de vous autoriser à lui verser tous impôts de l’État fédéral, des États fédérés ou des autorités locales applicables à la prime, à sa dévolution ou à tout autre événement entraînant une obligation fiscale relativement à la présente Prime. Si vous n’avez pas versé l’intégralité du montant correspondant aux retenues d’impôt applicables à la Société à la date où cette dernière est tenue de s’en acquitter auprès des autorités fiscales concernées (ou à une date antérieure spécifiée par la Société en vue de lui permettre de respecter ses obligations à temps), la Société est en droit, unilatéralement, de retenir de la présente Prime le nombre d’Actions ordinaires qu’elle estime suffisant pour respecter les retenues fiscales imposées par la loi. Les impôts des États fédérés font l’objet d’une retenue au taux applicable fixé par l’État dans lequel vous êtes employé par la Société ou dans lequel vous avez travaillé

---

![Slide 18](<restrictedstockunitaward018.jpg>)

> **Source slide transcript**
>
> 18 pour cette dernière en dernier lieu. En aucun cas le nombre d’actions retenues ne peut être supérieur au nombre nécessaire au respect des exigences relatives aux retenues d’impôts sur le revenu et sur le travail de l’État fédéral, des États fédérés ou des autorités locales. Vous pouvez décider de céder des Actions ordinaires acquises par le passé ou de demander à la Société de retenir des Actions ordinaires relatives à la présente Prime dans un montant suffisant à respecter tout ou partie des retenues fiscales imposées par la loi. (b) Responsabilité fiscale (applicable uniquement aux individus soumis aux législations fiscales hors États-Unis) Indépendamment de toute action entreprise par la Société ou la Filiale qui vous emploie ou a recours à vos services concernant l’impôt sur le revenu, la sécurité sociale, l’impôt sur les salaires, les acomptes versés ou tout autre élément fiscal relatif à votre participation au Plan qui s’appliquent à vous en vertu de la loi (les « Éléments fiscaux »), vous acceptez qu’en définitive, les obligations se rapportant aux Éléments fiscaux sont et demeurent votre responsabilité et peuvent être supérieures au montant réellement retenu par la Société ou la Filiale qui vous emploie ou a recours à vos services. Vous reconnaissez en outre que la Société ou la Filiale qui vous emploie ou a recours à vos services (1) ne fait aucune déclaration et ne prend aucun engagement concernant le traitement de tous Éléments fiscaux relatifs à un quelconque aspect des UAR, notamment, de manière non limitative, l’octroi, la dévolution ou le règlement des UAR, la vente ultérieure d’Actions ordinaires acquises en vertu du règlement en question et la réception de tous dividendes et (2) ne s’engage pas à structurer les conditions de l’octroi ou tout aspect des UAR de manière à réduire ou à éliminer votre obligation relative aux Éléments fiscaux ou d’obtenir un quelconque résultat fiscal particulier, et n’est pas dans l’obligation de le faire. Par ailleurs, si vous êtes devenu assujetti à l’impôt dans plus d’une juridiction entre la Date de dévolution des UAR et celle de tout événement fiscal applicable, le cas échéant, vous acceptez que la Société ou la Filiale qui vous emploie ou a recours à vos services (ou le faisait par le passé, le cas échéant) soit tenue de retenir ou de justifier des Éléments fiscaux dans plus d’une juridiction. (1) Avant tout événement imposable ou donnant lieu à une retenue fiscale, le cas échéant, vous vous acquittez de toutes vos obligations ou prenez des dispositions satisfaisant la Société ou la Filiale qui vous emploie ou a recours à vos services en vue de respecter l’ensemble des Éléments fiscaux. À cet égard, vous autorisez la Société ou la Filiale qui vous emploie ou a recours à vos services (ou ses représentants, à sa discrétion) à respecter les obligations relatives à l’ensemble des Éléments fiscaux au travers d’une des démarches suivantes ou d’une combinaison de celles-ci : (A) retenue sur vos salaires ou toute autre rémunération en espèces versée par la Société ou la Filiale qui vous emploie ou a recours à vos services ; (B) retenue sur les produits de la vente d’Actions ordinaires acquises par le règlement des UAR, soit par une vente volontaire, soit par une vente obligatoire organisée par la Société (en votre nom, en vertu de la présente autorisation) ; (C) retenue sur des Actions ordinaires à émettre lors du règlement des UAR.

---

![Slide 19](<restrictedstockunitaward019.jpg>)

> **Source slide transcript**
>
> 19 (2) Pour éviter un traitement comptable négatif, la Société peut retenir ou justifier des Éléments fiscaux en prenant en considération les montants prévus par la loi ou d’autres taux de retenue applicables. Si l’obligation relative aux Éléments fiscaux est remplie à travers la retenue d’Actions ordinaires, à des fins fiscales, il est considéré que l’intégralité des Actions ordinaires soumises aux UAR dévolues ont été émises à votre intention, même si un certain nombre d’Actions ordinaires sont retenues exclusivement aux fins du paiement des Éléments fiscaux. (3) Enfin, vous vous engagez à verser à la Société ou à la Filiale qui vous emploie ou a recours à vos services tout montant des Éléments fiscaux que celle-ci peut être tenue de retenir ou de justifier en conséquence de votre participation au Plan et qui ne peut être acquitté par les moyens décrits ci-avant. La Société peut refuser d’émettre ou de remettre les Actions ordinaires ou le produit de la vente de celles-ci si vous ne respectez pas vos obligations relatives aux Éléments fiscaux. 2.8 Respect de la loi applicable. L’émission d’Actions ordinaires est soumise et conditionnée au respect, par la Société et vous-même, y compris toutes déclarations, garanties et accords écrits que l’Administrateur est susceptible d’exiger, de toutes les (i) lois et réglementations américaines, tant au niveau de l’État fédéral que des États fédérés, (ii) lois applicables de votre pays de résidence en matière d’émission ou de vente d’Actions ordinaires et (iii) réglementations applicables de toute bourse ou tout système automatisé de cotation où sont inscrites ou cotées les Actions ordinaires de la Société au moment de l’émission ou de la cession. Nonobstant les autres dispositions du présent Accord, la Société n’est tenue à aucune obligation d’émission d’Actions ordinaires en vertu du présent Accord si ladite émission enfreint toute loi, réglementation ou exigence applicable d’une entité boursière ou similaire. 2.9 Section 409A de l’Internal Revenue Code (applicable uniquement aux individus soumis à la législation fiscale fédérale des États-Unis). (a) Les UAR autres que celles qui continuent d’être dévolues en conséquence de votre Licenciement involontaire pour motifs économiques et les équivalents de dividendes payables en vertu du présent Accord ont vocation à être exemptées de la section 409A de l’Internal Revenue Code en vertu de l’exemption des reports à court terme. Par conséquent, les UAR (autres que celles qui continuent d’être dévolues en conséquence de votre Licenciement involontaire pour motifs économiques) sont réglées et les équivalents de dividendes versés au plus tard le 15e jour du troisième mois qui suit la dernière des dates ci-après : (i) la fin de votre année d’imposition durant laquelle intervient la Date de dévolution des UAR ou (ii) la fin de l’exercice de la Société durant lequel intervient la Date de dévolution des UAR. (b) Les UAR qui continuent d’être dévolues en conséquence de votre Licenciement involontaire pour motifs économiques sont soumises aux dispositions de la présente sous-section (b). Toute distribution à titre de règlement de ces UAR intervient pour autant que votre Licenciement involontaire pour motifs économiques constitue une « cessation de service » au sens du règlement du Trésor § 1.409A-1(h). Si la Société établit que vous êtes un « employé déterminé » au sens de la section 409A de l’Internal Revenue Code (c’est-à-dire un responsable dont la rémunération annuelle est supérieure à 130 000 $ [ajusté en fonction de l’inflation], un détenteur de cinq pour cent des parts de la Société ou un détenteur d’un pour cent

---

![Slide 20](<restrictedstockunitaward020.jpg>)

> **Source slide transcript**
>
> 20 des parts dont la rémunération annuelle est supérieure à 150 000 $), la distribution à titre de règlement de toutes les UAR qui seraient payables dans les six mois suivant votre cessation de service sera différée au premier jour ouvrable suivant la date marquant les six mois de votre cessation de service. Toute distribution à titre de règlement de ces UAR qui serait effectuée plus de six mois après votre cessation de service (sans application du délai de six mois) ne sera pas soumise au délai de six mois décrit dans la présente sous-section. 2.10 Confidentialité des données. (a) Réglementations concernant la confidentialité des données aux États-Unis (uniquement applicables si la Prime est soumise aux lois des États-Unis sur la confidentialité des données). À travers la conclusion du présent Accord et l’acception de la présente Prime, vous (a) consentez explicitement et sans équivoque à la collecte, à l’utilisation et au transfert, par voie électronique ou autre, de toutes vos données personnelles nécessaires pour faciliter la mise en œuvre, l’administration et la gestion de la Prime et du Plan, (b) comprenez que la Société peut, aux fins de la mise en œuvre, de l’administration et de la gestion du Plan, détenir certaines informations vous concernant, notamment, de manière non limitative, vos nom, adresse personnelle, numéro de téléphone, date de naissance, numéro de sécurité sociale ou autre numéro d’identification, salaire, nationalité, poste et les détails de l’ensemble des primes ou droits à Actions qui vous ont été octroyés dans le cadre du Plan ou d’une autre manière (les « Données personnelles »), (c) comprenez que des Données personnelles puissent être transférées à des tiers contribuant à la mise en œuvre, à l’administration et à la gestion du Plan, notamment tout courtier auquel la garde des Actions a été confiée lors de la dévolution de la Prime, que ces destinataires peuvent être établis dans votre pays ou ailleurs et que leur pays d’établissement peut disposer de lois et de protections différentes du vôtre en matière de confidentialité des données, (d) renoncez à tous les droits de confidentialité dont vous disposez relativement aux données et (e) autorisez la Société, ses Filiales et leurs représentants à stocker et transmettre lesdites informations par voie électronique. (b) Réglementations concernant la confidentialité des données hors États-Unis (uniquement applicables si la Prime est soumise à des lois sur la confidentialité des données en dehors des États-Unis). (1) À travers la conclusion du présent Accord et l’acception de la présente Prime, vous consentez explicitement et sans équivoque à la collecte, à l’utilisation et au transfert, par voie électronique ou autre, de vos données personnelles, comme décrit dans le présent Accord ainsi que dans tous autres documents relatifs à l’octroi des UAR, le cas échéant, par la Filiale qui vous emploie ou a recours à vos services ainsi que la Société et ses Filiales, aux fins exclusives de la mise en œuvre, de l’administration et de la gestion de votre participation du Plan. (2) Vous comprenez que la Société et la Filiale qui vous emploie ou a recours à vos services peut détenir certaines informations vous concernant, notamment, de manière non limitative, vos nom, adresse personnelle, numéro de téléphone, date de naissance, numéro de sécurité sociale ou autre numéro d’identification, salaire, nationalité, poste, toutes Actions ordinaires ou tous mandats d’administrateur dans la Société, les détails de l’ensemble des UAR et autres droits à Actions ordinaires octroyés, annulés, exercés, acquis, non acquis ou

---

![Slide 21](<restrictedstockunitaward021.jpg>)

> **Source slide transcript**
>
> 21 en suspens en votre faveur, aux fins exclusives de la mise en œuvre, de l’administration et de la gestion du Plan (les « Données »). (3) Vous comprenez que les Données seront transférées à un conseiller juridique, un courtier ou tout autre prestataire de services de plan d’action choisi par la Société à l’avenir pour assister cette dernière dans la mise en œuvre, l’administration et la gestion du Plan. Vous comprenez que les destinataires des Données peuvent être établis aux États-Unis ou ailleurs et que leur pays d’établissement (p. ex. les États-Unis) peut disposer de lois et de protections différentes du vôtre en matière de confidentialité des données. Vous comprenez que si vous résidez en dehors des États-Unis, vous pouvez demander une liste reprenant le nom et l’adresse de tous les destinataires potentiels des Données en contactant votre représentant local des ressources humaines ou celui de la Société. Vous autorisez la Société ainsi que tous autres destinataires éventuels chargés d’assister la Société (actuellement ou à l’avenir) dans la mise en œuvre, l’administration et la gestion du Plan à recevoir, détenir, utiliser, conserver et transférer les Données, par voie électronique ou autre, aux fins exclusives de la mise en œuvre, de l’administration et de la gestion de votre participation au Plan. Vous comprenez que les Données seront détenues aussi longtemps que le requièrent la mise en œuvre, l’administration et la gestion de votre participation au Plan. Vous comprenez que si vous résidez en dehors des États-Unis, vous pouvez, à tout moment, consulter les Données, demander des informations complémentaires sur leur stockage et leur traitement, demander toutes les modifications nécessaires aux Données, refuser votre consentement ou le retirer, dans tous les cas sans frais, en contactant par écrit votre représentant local des ressources humaines ou celui de la Société. Vous comprenez toutefois que le refus ou le retrait de votre consentement peut avoir une incidence sur votre capacité à participer au Plan. Pour de plus amples informations sur les conséquences du refus de consentement ou du retrait de celui-ci, vous comprenez que vous pouvez contacter votre représentant local des ressources humaines ou celui de la Société. 2.11 Successeurs et ayants droit. Le présent Accord lie tous les successeurs et ayants droit de la Société. 2.12 Droit applicable. Le présent Accord est régi, interprété et exécuté dans toute la mesure du possible conformément aux dispositions applicables du Code et, autrement, conformément au droit de l’État du Michigan, sans égard aux principes relatifs aux conflits de droit, étant entendu que si vous êtes un ressortissant étranger ou êtes employé en dehors des États-Unis, le présent Accord sera régi, interprété et exécuté en vertu du droit étranger applicable dans la mesure où ledit droit diffère du Code et du droit de l’État du Michigan. Toute procédure liée au présent Accord ou en découlant sera engagée, exercée ou poursuivie dans le tribunal d’arrondissement du comté de Kent, dans le Michigan, situé à Grand Rapids, dans le Michigan, ou dans l’United States District Court for the Western District of Michigan et dans la cour d’appel correspondante. 2.13 Déchéance des UAR. Si la Société, à la suite d’une faute, est tenue de préparer un retraitement comptable en raison d’un cas grave de non-respect des exigences relatives à la présentation des informations financières en vertu des lois sur les valeurs mobilières, alors (a) si votre incitation ou votre rémunération fondée sur des actions est soumise à la déchéance automatique en raison de ladite faute et du retraitement, en vertu de la section 304 du Sarbanes- Oxley Act de 2002 ou (b) si le Comité établit que vous avez sciemment pris part à la faute, que

---

![Slide 22](<restrictedstockunitaward022.jpg>)

> **Source slide transcript**
>
> 22 vous vous êtes sciemment abstenu de l’empêcher ou que vos actions ou inactions se rapportant à la faute et au retraitement constituent un cas de négligence grave, (i) vous serez tenu de rembourser à la Société le montant de tout paiement (y compris les équivalents de dividendes) relatif aux UAR acquises ou accumulées durant la période de douze mois suivant la première émission publique ou le dépôt auprès de la SEC (selon l’éventualité qui se produit en premier) du document financier exprimant ladite exigence de présentation des informations financières et (ii) toutes les UAR en suspens (y compris les équivalents de dividendes qui s’y rapportent) n’ayant pas encore été réglées seront déchues immédiatement. En outre, les Actions ordinaires acquises en vertu du présent Accord et tous gains ou bénéfices résultant de leur vente seront soumis à toutes les politiques de récupération ou de recouvrement adoptées par la Société ultérieurement. 2.14 Règles particulières pour les bénéficiaires hors États-Unis (uniquement applicables si vous résidez en dehors des États-Unis) (a) Nature de la libéralité. Par votre acceptation de la libéralité, vous reconnaissez, comprenez et acceptez que : (1) le Plan est établi par la Société de manière volontaire, il est discrétionnaire de nature et peut être modifié, suspendu ou résilié par la Société à tout moment, sauf stipulation contraire dans le Plan ; (2) l’octroi des UAR est volontaire et occasionnel et n’instaure aucun droit contractuel ou autre d’octrois d’UAR à l’avenir ni d’avantages remplaçant les UAR, même si ces dernières ont été octroyées à plusieurs reprises par le passé ; (3) toutes les décisions relatives aux octrois d’UAR à l’avenir, le cas échéant, relèvent de l’entière discrétion de la Société ; (4) vous participez au Plan sur une base volontaire ; (5) les UAR et les Actions ordinaires qui y sont soumises constituent un élément extraordinaire qui ne relève pas du champ d’application de votre contrat de travail ou de services, le cas échéant ; (6) les UAR et les Actions ordinaires qui y sont soumises n’ont pas vocation à remplacer de quelconques droits à pension ou rémunérations ; (7) les UAR et les Actions ordinaires qui y sont soumises ne font pas partie de la rémunération normale ou attendue aux fins du calcul de toute cessation d’emploi, démission, licenciement, licenciement pour motif économique, renvoi, prestations de fin de service, gratifications, primes d’ancienneté, prestations de retraire ou de sécurité sociale ou paiements similaires et ne doivent en aucun cas être considérées comme une rémunération découlant de tous services passés rendus à la Société, à la Filiale qui vous emploie ou a recours à vos services ou à toute autre Filiale ; (8) la libéralité et votre participation au Plan ne peuvent être interprétées dans le sens de l’instauration d’un contrat de travail ou de services avec la Société ou toute Filiale ;

---

![Slide 23](<restrictedstockunitaward023.jpg>)

> **Source slide transcript**
>
> 23 (9) la valeur future des Actions ordinaires sous-jacentes est inconnue et impossible à déterminer avec certitude ; (10) la déchéance des UAR résultant de votre Date de cessation d’emploi ne peut donner lieu à aucune demande ou aucun droit d’indemnisation (pour quelque raison que ce soit, qu’il s’avère ou non, par la suite, qu’elle était invalide ou en violation du droit du travail de la juridiction où vous êtes employé ou où vous fournissez vos services ou des conditions de votre contrat de travail, le cas échéant) ; par ailleurs, en contrepartie de l’octroi des UAR auxquelles vous n’auriez pas droit en d’autres circonstances, vous acceptez irrévocablement de ne jamais engager de poursuite contre la Société ou la Filiale qui vous emploie ou a recours à vos services, de renoncer à votre capacité, le cas échéant, d’engager de telles poursuites et de libérer la Société ou la Filiale qui vous emploie ou a recours à vos services de telles revendications ; nonobstant ce qui précède, si un tribunal d’une juridiction compétente autorise une poursuite de ce type, il est considéré, irrévocablement, de par votre participation au Plan, que vous acceptez de ne pas faire valoir cette poursuite et de signer tous les documents nécessaires à son rejet ou à son retrait ; (11) vous reconnaissez et acceptez que ni la Société, ni la Filiale qui vous emploi ou a recours à vos services, ni toute autre Filiale ne sont responsables de toute variation de change entre la devise du pays dans lequel vous résidez et le dollar américain susceptible d’avoir une incidence sur la valeur des UAR ou tout montant qui vous est dû en vertu du règlement des UAR ou de la vente ultérieure de toutes Actions ordinaires acquises lors du règlement. (b) Appendice. Nonobstant toutes les dispositions du présent Accord, l’octroi d’UAR est soumis à toutes les conditions particulières énoncées dans l’Appendice au présent Accord concernant votre pays. En outre, si vous emménagez dans l’un des pays repris dans l’Appendice, les conditions particulières concernant ce pays s’appliquent à vous si la Société établit que l’application de ces dispositions est nécessaire ou recommandée en vue de respecter les lois du pays où vous résidez ou de faciliter l’administration du Plan. Si vous emménagez aux États-Unis, les conditions particulières de l’Appendice s’appliquent ou cessent de s’appliquer à vous si la Société établit que l’application ou non de ces dispositions est nécessaire ou recommandée en vue de faciliter l’administration du Plan. L’Appendice fait partie intégrante du présent Accord. (c) Imposition d’autres exigences. La Société se réserve le droit, d’une part, d’imposer d’autres exigences à votre participation au Plan, aux UAR et à toutes Actions ordinaires acquises en vertu du Plan si elle établit que cela s’avère nécessaire ou recommandé en vue de respecter les lois du pays dans lequel vous résidez ou de faciliter l’administration du Plan et, d’autre part, de vous demander de signer tous les accords ou engagements complémentaires nécessaires à la mise en œuvre de ce qui précède. 2.15 Non-concurrence et non-sollicitation. a) Non-concurrence. Au cours de votre emploi au sein de la Société et de ses Filiales et pendant une période de douze (12) mois suivant votre Date de Fin de Contrat (la « Période Restreinte »), vous ne pouvez pas, (i) directement ou indirectement, sans le

---

![Slide 24](<restrictedstockunitaward024.jpg>)

> **Source slide transcript**
>
> 24 consentement écrit préalable de la Société, prendre de participation significative ou de contrôle en tant que propriétaire, partenaire, actionnaire, concédant de licence, administrateur, dirigeant, agent ou consultant pour toute Personne qui exploite une entreprise en concurrence avec une entreprise dirigée par la Société ou l'une de ses Filiales, où que ce soit dans le ou les pays dans lesquels vous travaillez régulièrement ou fournissez des services; ni (ii) accepter un emploi ou un engagement pour la fourniture de services à quelque titre que ce soit, y compris en tant qu'employé, administrateur, consultant ou conseiller, directement ou indirectement, avec toute Personne qui exploite une entreprise en concurrence avec une entreprise dirigée par le Société ou l'une de ses Filiales où que ce soit dans le ou les pays dans lesquels vous travaillez régulièrement ou fournissez des services. Aux fins des présentes, l’exploitation d'une entreprise en concurrence avec une entreprise exploitée par la Société ou l'une de ses Filiales comprend la vente, la fabrication, la distribution ou la recherche et développement de tout produit ou service similaire à un produit ou service vendu, distribué, commercialisé ou en cours de recherche ou développement (y compris par le biais d'une coentreprise ou d'un investissement dans une autre entité) par la Société ou l'une de ses Filiales, y compris les médicaments en vente libre ou les produits nutritionnels, les produits pharmaceutiques génériques d’ordonnance topique étendue, les produits nutritionnels infantiles, les produits de soins bucco-dentaires et tout autre produit, de marque de distributeur ou de valeur de marque, que la Société ou un Affilié commercialise ou prévoit activement de commercialiser au cours de votre emploi au sein de la Société et pendant une période d'un an suivant votre Date de Fin de Contrat. En cas de vente, de transfert ou de toute autre cession de l'activité Produits Pharmaceutiques d'Ordonnance Perrigo pendant la Période Restreinte, la présente Section 2.15 a) ne s'appliquera pas à l'activité Produits Pharmaceutiques d'Ordonnance Perrigo. Nonobstant ce qui précède, aucune partie de cette disposition ne vous empêche de détenir passivement deux pour cent (2 %) ou moins des titres en circulation de toute catégorie d'une société cotée sur une bourse nationale ou cotée sur un système de cotation automatisé. Vous pouvez faire une demande écrite au DPRH de la Société pour obtenir une dérogation à la présente Section 2.15 a) et cette exception ne peut être refusée sans motif raisonnable, en particulier lorsque vous cherchez un emploi auprès d’une entreprise qui n'est pas en concurrence avec le segment de la Société où vous avez travaillé ou fourni des services au cours des deux dernières années de votre emploi au sein de la Société. b) Non-sollicitation des Fournisseurs de Services. Pendant votre emploi au sein de la Société et de ses Filiales et pendant la Période Restreinte, vous ne pouvez pas, directement ou indirectement, sans le consentement écrit préalable de la Société, i) solliciter, recruter ou embaucher activement toute Personne qui est, à ce moment-là ou à tout moment au cours de la période de 12 mois précédant cette sollicitation ou ce recrutement, était employé ou consultant de la Société ou de l'une de ses Filiales, ni ii) solliciter ou encourager un employé de la Société ou de l'une de ses Filiales à quitter son emploi au sein de la Société ou de l'une de ses Filiales, ni (iii) interférer dans la relation de la Société ou de l'une de ses Filiales avec toute Personne ou entité qui est employée par, ou autrement engagée dans la prestation de services pour, la Société ou l'une de ses Filiales. c) Non-sollicitation des Clients. Pendant votre emploi au sein de la Société et de ses Filiales et au cours de la Période Restreinte, vous ne pouvez pas, directement ou indirectement, seul ou en association avec toute autre personne, sans le consentement écrit préalable de la Société, i) inciter ou tenter d’inciter tout client (ancien ou actuel), fournisseur, titulaire d’une licence, franchisé, partenaire de coentreprise ou autre relation commerciale de la

---

![Slide 25](<restrictedstockunitaward025.jpg>)

> **Source slide transcript**
>
> 25 Société ou de l'une de ses Filiales (collectivement, les «Clients»), à cesser de faire affaire avec la Société ou l’une de ses Filiales, ni ii) détourner tout ou partie des activités d'un Client avec la Société vers un concurrent de la Société ou l’une de ses Filiales, ni (iii) interférer, de quelque manière que ce soit, dans la relation entre tout Client, d'une part, et la Société ou l'une de ses Filiales, d'autre part. d) Recours et Mesure Injonctive. Vous reconnaissez qu'une violation dans votre chef de l'un des engagements prévus dans la présente Section 2.15 causerait des dommages irréparables à la Société et à ses Filiales à hauteur d'un montant qui serait significatif, mais pas aisément vérifiable, et que tout recours en justice (y compris le paiement de dommages) serait insuffisant. En conséquence, vous convenez que, nonobstant toute disposition contraire du présent Accord, outre tout autre dommage qu'elle est en mesure de démontrer, la Société et ses Filiales ont droit (sans qu'il soit nécessaire de démontrer une perte économique ou d'autres dommages réels) à une mesure injonctive (y compris des ordonnances restrictives temporaires, des injonctions préliminaires et des injonctions permanentes), sans dépôt de caution, auprès de tout tribunal compétent, pour toute violation réelle ou imminente de l'un des engagements énoncés dans la présente Section 2.15, outre tout autre recours légal ou équitable qu'elles pourraient avoir. En outre, en cas de Violation Volontaire d'une Clause Restrictive (au sens de la présente Section 2.15), i) tous vos droits au titre du présent Accord, acquis ou non, prennent fin immédiatement, et (ii) tou(te)s Actions, espèces ou autres biens qui vous sont payé(e)s ou livré(e)s conformément au présent Accord, sont confisqué(e)s et vous devez rembourser ces Actions, espèces ou autres biens à la Société, au plus tard trente (30) jours civils après que la Société vous a demandé leur remboursement. Aux fins du présent Accord, «Violation Volontaire d'une Clause Restrictive» signifie une violation significative, dans votre chef, de l'une des clauses de la présente Section 2.15, dont vous saviez ou auriez pu savoir, en vous renseignant correctement, qu’elle constituerait une violation significative. Les phrases précédentes de la présente Section 2.15 ne doivent pas être comprises comme une renonciation aux droits que la Société et ses Filiales peuvent avoir pour obtenir des dommages-intérêts en vertu du présent Accord ou autrement, et tous ces droits ne sont pas limités. La Période Restreinte est suspendue pendant (et est réputée automatiquement prolongée de) toute période durant laquelle vous violez les dispositions de la Section 2.15 a), b) ou c), selon le cas. Dans le cas où un tribunal ou une juridiction compétente statue que toute disposition de la présente Section 2.15 est nulle ou plus restrictive que ne le permet la loi applicable de cette juridiction, alors, aux fins uniquement de l'application de la présente Section 2.15 dans la juridiction de ce tribunal, cette disposition doit être interprétée et appliquée comme si elle prévoyait la restriction maximale autorisée par la loi en vigueur. e) Confirmations. 1) Vous reconnaissez que la Société et ses Filiales ont consacré et continueront de consacrer beaucoup de temps, d'argent et d'efforts pour le développement des stratégies commerciales, des relations avec les employés, les clients et autres, ainsi que du goodwill en vue de bâtir une organisation efficace. Vous reconnaissez que la Société et ses Filiales ont un intérêt commercial légitime dans, et le droit de protéger leur goodwill et leurs relations avec leurs employés, clients et autres, et que la Société et ses Filiales pourraient être gravement lésées par la perte ou la détérioration de ses relations avec ses employés, clients et

---

![Slide 26](<restrictedstockunitaward026.jpg>)

> **Source slide transcript**
>
> 26 autres. En outre, vous reconnaissez que la Société et ses Filiales ont le droit de protéger et de préserver la valeur de continuité de la Société et de ses Filiales dans la mesure permise par la loi. 2) À la lumière des confirmations qui précèdent, vous acceptez que les clauses contenues dans le présent Accord sont raisonnables et correctement requises pour la protection adéquate de l’entreprise et du goodwill de la Société et de ses Filiales. En outre, vous reconnaissez que, bien que votre respect des clauses contenues dans le présent Accord puisse vous empêcher de gagner votre vie dans une entreprise similaire à celle de la Société et de ses Filiales, votre expérience et vos capacités sont telles que vous avez d'autres opportunités de gagner votre vie et des moyens de subsistance adéquats pour vous et les personnes à votre charge. 3) À la lumière des confirmations contenues dans la présente Section 2.15, vous acceptez de ne pas contester le caractère raisonnable, la validité ou l'applicabilité des restrictions qui vous sont imposées et des obligations qui vous sont faites en vertu de la présente Section 2.15. **** Nous nous réjouissons de pouvoir continuer à bénéficier de votre contribution à la croissance de la Société. Veuillez accuser réception de votre exemplaire du Plan et de la présente Prime. Meilleures salutations, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 27](<restrictedstockunitaward027.jpg>)

> **Source slide transcript**
>
> 27 PERRIGO COMPANY PLC OVEREENKOMST OVER VOORWAARDELIJK TOEGEKENDE AANDELEN (OP BASIS VAN DIENSTEN) (Volgens het Langetermijnincentiveplan uit 2026 van de Perrigo Company plc) AAN: Participant Name BETREFT: Mededeling over voorwaardelijk toegekende aandelen (op basis van diensten) Hiermee willen we u melden dat Perrigo Company plc (het 'Bedrijf') u een award heeft toegekend volgens het Langetermijnincentiveplan uit 2026 van de Perrigo Company plc (het 'Plan'), dat van kracht wordt vanaf de Grant Date (de 'Toekenningsdatum'). Deze Award bestaat uit op basis van diensten voorwaardelijk toegekende aandelen. De algemene voorwaarden van deze incentive vindt u in de rest van deze overeenkomst (inclusief speciale algemene voorwaarden in een bijlage voor uw land ('Bijlage') (samen de 'Overeenkomst'). De termen in hoofdletters die niet anderszins in deze Overeenkomst bepaald zijn, hebben de betekenis die volgens het Plan aan die termen zijn toegeschreven. SECTIE 1 Voorwaardelijk toegekende aandelen – Toezegging op basis van diensten 1.1 Toekenning. Vanaf de toekenningsdatum en afhankelijk van de algemene voorwaarden van deze Overeenkomst en het Plan, kent het Bedrijf u Number of Awards Granted ('voorwaardelijk toegekende aandelen' of 'RSU's'). Elke RSU geeft u recht op één gewoon aandeel van het Bedrijf, met een nominale waarden van € 0,001 per aandeel ('Gewoon aandeel') op de toezeggingsdatum van de toepasselijke RSU, op voorwaarde dat aan de toezeggingsvoorwaarden in Sectie 1.2 is voldaan. 1.2 Toezegging. Behalve zoals voorzien in Sectie 1.3, worden de in Sectie 1.1 toegekende RSU's als volgt toegezegd na de Toekenningsdatum ('Toezeggingsdatum(s) van RSU') Vesting Schedule (Dates & Quantities); op voorwaarde echter dat u verder in dienst blijft van het Bedrijf vanaf de Toekenningsdatum via de toepasselijke Toezeggingsdatum van RSU. Behalve zoals voorzien in Sectie 1.3, als uw Beëindigingsdatum vóór de Toezeggingsdatum van RSU wordt bereikt, worden de onder Sectie 1.1 toegekende RSU's die niet eerder zijn toegezegd sinds zulke beëindiging, permanent verbeurd op uw Beëindigingsdatum. 1.3 Speciale toezeggingsregels. Niettegenstaande bovenstaande Sectie 1.2: (a) Als uw Beëindigingsdatum wordt bereikt door overlijden, handicap of pensioen met toestemming van het Bedrijf, dan worden alle onder Sectie 1.1 toegekende RSU's die niet vóór zulke Beëindigingsdatum zijn toegezegd, volledig toegezegd.

---

![Slide 28](<restrictedstockunitaward028.jpg>)

> **Source slide transcript**
>
> 28 (b) Als uw Beëindigingsdatum wordt bereikt wegens een Onvrijwillig ontslag om Economische redenen, worden onder Sectie 1.1 toegekende RSU's die anders voor toezegging onder Sectie 1.2 zouden worden gepland in de periode van 24 maanden volgend op zulke Beëindigingsdatum, blijven toegezegd tijdens zo’n periode van 24 maanden volgens het toezeggingsschema dat van kracht is vóór zo’n Beëindigingsdatum; op voorwaarde echter dat als uw Beëindigingsdatum wordt bereikt om een reden die zowel in deze subsectie (b) en in onderstaande subsectie (c) wordt beschreven, dan zijn de speciale toezeggingsregels beschreven in subsectie (c) van toepassing in plaats van de toezeggingsregels beschreven in deze subsectie (b). Elke RSU waarvan de toezegging niet gepland is in zo’n periode van 24 maanden, wordt permanent verbeurd op de Beëindigingsdatum. (c) Als uw Beëindigingsdatum is bereikt wegens Beëindiging zonder oorzaak of een Ontslag om goede reden bij of na een Wijziging van de zeggenschap (zoals gedefinieerd in het Plan en deze definitie kan hierna worden gewijzigd) en vóór de tweede (2) verjaardag van de Wijziging van de zeggenschap, worden alle onder Sectie 1.1 toegekende RSU's die vóór zulke Beëindigingsdatum niet zijn toegezegd of verbeurd, volledig toegezegd. (d) Zoals gebruikt in deze Sectie 1.3, hebben de volgende termen de hieronder vermelde betekenissen: (1) 'Ontslag om goede reden' verwijst naar uw vrijwillig ontslag uit het Bedrijf en het bestaan van een of meer van de volgende omstandigheden die zich zonder uw toestemming voordeden: (i) een belangrijke wijziging in de geografische locatie waarbij u vereist bent om diensten uit te voeren, zodat de afstand tussen uw huis en uw voornaamste werkplek met meer dan 48 km groter wordt, of (ii) een belangrijke daling van uw autoriteit, plichten of verantwoordelijkheden of een belangrijke daling in uw basisloon of mogelijkheden tot incentivecompensatie; op voorwaarde echter dat een vrijwillig ontslag uit het Bedrijf niet wordt beschouwd als een Ontslag om goede reden tenzij u het Bedrijf schriftelijk een kennisgeving stuurde van uw vrijwillig ontslag en van het bestaan van de voorwaarden die leiden tot het ontslag binnen de 90 dagen van hun aanvankelijke bestaan. Het Bedrijf heeft vervolgens 30 dagen om de omstandigheid op te lossen. In dat geval wordt u niet geacht een Ontslag om goede reden te hebben opgelopen. In het geval het Bedrijf de voorwaarde niet kan oplossen binnen de termijn van 30 dagen, valt uw Beëindigingsdatum op de 31e dag na de ontvangst door het Bedrijf van zulke schriftelijke kennisgeving. (2) 'Beëindiging zonder oorzaak' betekent de onvrijwillige beëindiging van uw tewerkstelling of contractuele relatie door het Bedrijf zonder Oorzaak, inclusief maar niet beperkt tot, (i) een beëindiging die van kracht wordt wanneer u een verlof hebt opgebruikt tijdens, of op het einde van een opzeggingsperiode volgens de Worker Adjustment and Retraining Notification Act (“WARN”), en (ii) een situatie waarin u op goedgekeurd verlof bent tijdens hetwelke uw positie beveiligd is volgens de toepasselijke wetgeving (bv. een verlof volgens de Family Medical Leave Act), u uit zulk verlof terugkomt en geen tewerkstelling of een andere vorm van contractuele relatie met het Bedrijf kunt krijgen. 1.4 Afrekening van RSU's. Zodra praktisch mogelijk na de Toezeggingsdatum van de RSU, draagt het Bedrijf u één Gewoon aandeel over voor elke RSU die wordt toegezegd op zo’n datum (de datum van zo’n overdracht wordt de 'afrekeningsdatum' genoemd voor de

---

![Slide 29](<restrictedstockunitaward029.jpg>)

> **Source slide transcript**
>
> 29 doeleinden van deze Overeenkomst); op voorwaarde echter dat het Bedrijf de aandelen mag inhouden die anders aan u kunnen worden overgedragen, voor zover noodzakelijk om verschuldigde belastingen in te houden wegens de toezegging van de RSU's, in overeenstemming met Sectie 2.6. U hebt als houder van aandelen geen rechten met betrekking tot RSU's die hier zijn toegekend vóór de datum van uitgifte aan u van een certificaat of certificaten voor zulke aandelen. Niettegenstaande het voorgaande, kan de Commissie naar eigen goeddunken ervoor kiezen om de RSU's contant af te rekenen op basis van de reële marktwaarde van de Gewone aandelen op de Toezeggingsdatum van de RSU. 1.5 Dividendequivalenten. De onder Sectie 1.1 toegekende RSU's komen in aanmerking voor het ontvangen van dividendequivalenten in overeenstemming met het volgende: (a) Er wordt een 'Rekening' geopend in uw naam. Zo’n rekening dient alleen voor het bijhouden van gegevens. Er worden geen activa of andere bedragen van de algemene activa van het Bedrijf opzijgezet met betrekking tot deze rekening. (b) Op elke datum waarop een contant dividend wordt betaald met betrekking tot Gewone aandelen, crediteert het Bedrijf uw Rekening met het dividendenbedrag in dollar dat u ontvangen zou hebben als elke RSU die u op de registratiedatum in bezit hebt voor zulke dividendenbetaling een Gewoon aandeel was geweest. Op deze Rekening worden geen intresten of andere inkomsten bijgezet. (c) Vanaf elke Toezeggingsdatum van de RSU ontvangt u een betaling die gelijk is aan het bedrag van dividenden die op de toezeggingsdatum van de RSU's zou betaald zijn als er Gewone aandelen zouden zijn geweest tijdens de periode die begint op de Toekenningsdatum en eindigt op de Toezeggingsdatum van de RSU, en dan wordt de Rekening passend gedebiteerd. Als u RSU's verbeurt, worden alle bedragen in de Rekening die aan zulke RSU's toe te wijzen zijn, eveneens verbeurd. (d) Als dividenden worden betaald onder de vorm van Gewone aandelen in plaats van contant geld, dan wordt u gecrediteerd met één extra RSU voor elk Gewoon aandeel dat als dividend zou zijn ontvangen, als uw uitstaande RSU's gewone aandelen waren geweest. Zulke extra RSU's zullen worden toegezegd of verbeurd op hetzelfde ogenblik als de RSU waarop ze betrekking hebben. SECTIE 2 Algemene Voorwaarden 2.1 Niet-overdraagbaarheid. De Award volgens deze Overeenkomst kan alleen worden overgedragen via een testament of via de wetgeving voor afstamming en schenkingen. 2.2 Geen rechten als houder van aandelen. U hebt als houder van aandelen geen enkel recht met betrekking tot Gewone aandelen die onder de onder deze Overeenkomst toegekende RSU vallen, en dit vóór de datum van uitgifte aan u van een certificaat of certificaten voor zulke aandelen.

---

![Slide 30](<restrictedstockunitaward030.jpg>)

> **Source slide transcript**
>
> 30 2.3 Oorzaak van de beëindiging. Als uw Beëindigingsdatum om bepaalde oorzaken wordt bereikt, dan stoppen al uw rechten volgens deze Overeenkomst, toegezegd of niet, onmiddellijk. 2.4 Award onderhevig aan het Plan. De toekenning van de Award volgens deze Overeenkomst verloopt conform het Plan en de Award kan alleen worden betaald in overeenstemming met de toepasselijke voorwaarden van het Plan. Het Plan bevat bepaalde definities, beperkingen, begrenzingen en andere algemene voorwaarden die alle van toepassing zijn op deze Overeenkomst. ALLE BEPALINGEN VAN HET PLAN ZIJN HIERIN OPGENOMEN DOOR MIDDEL VAN VERWIJZING EN WORDEN OP DEZELFDE MANIER EEN DEEL VAN DEZE OVEREENKOMST ALSOF ELK VAN DEZE BEPALINGEN VOLLEDIG IN DEZE OVEREENKOMST VERMELD STAAN. Mocht het Plan nietig of onafdwingbaar worden door een wettelijke of gerechtelijke beslissing, dan is deze Overeenkomst niet rechtsgeldig. Niets in deze Overeenkomst is bedoeld, en geen enkele van haar bepalingen mag zo worden opgevat, om een definitie, beperking, begrenzing of andere algemene voorwaarde te beperken of uit te sluiten die relevant is voor deze Overeenkomst en specifiek erop kan worden toegepast door de Commissie. In geval van een tegenstrijdigheid in de bepalingen van deze Overeenkomst en het Plan, worden de voorwaarden van het Plan in regel als superieur geacht en toegepast. 2.5 Aanpassingen in het geval van een wijziging in de Gewone aandelen. In het geval van een aandelensplitsing, stockdividend, herkapitalisatie, herclassificatie of combinatie van aandelen, fusie, verkoop van activa of soortgelijke gebeurtenis, wordt het aantal te verlenen aandelen volgens deze Overeenkomst dienovereenkomstig op een billijke manier aangepast om de verwatering of uitbreiding van de rechten te voorkomen die u zijn toegekend of u ter beschikking staan. 2.6 Bevestiging. Het Bedrijf en u komen overeen dat de RSU's worden toegekend volgens en onderworpen aan de Kennisgeving van toekenning, deze Overeenkomst (inclusief de Bijlage, indien van toepassing) en de bepalingen van het Plan (hierin opgenomen via verwijzing). U: (i) bevestigt de ontvangst van een exemplaar van elk van de voornoemde documenten, (ii) erkent dat u hun bepalingen zorgvuldig hebt gelezen en ermee vertrouwd bent, en (iii) aanvaardt hierbij de RSU's die onderhevig zijn aan alle hierin vermelde algemene voorwaarden en die in het Plan en de Kennisgeving van toekenning staan. 2.7 Belastingen en voorheffingen. (a) Voorheffingen (alleen van toepassing op personen die onderhevig zijn aan de Amerikaanse belastingswetten). Deze Award is onderworpen aan de voorheffingen van alle toepasselijke belastingen. Het Bedrijf kan belastingen inhouden of u vragen die te betalen. Het gaat dan om federale, staats- of lokale belastingen die van toepassing zijn op de toekenning, toezegging of andere gebeurtenis die aanleiding geeft tot een belastingsverplichting met betrekking tot deze Award. Als u niet het volledige bedrag van de voorheffingen aan het Bedrijf hebt betaald tegen de datum waarop het Bedrijf zulke voorheffingen aan de bevoegde belastingsinstantie moet betalen (of op een vroegere datum die het Bedrijf kan bepalen om mee te werken aan het tijdig voldoen aan zijn verplichtingen inzake voorheffingen), dan heeft het Bedrijf het eenzijdige recht om Gewone aandelen met betrekking tot deze Award in te houden en

---

![Slide 31](<restrictedstockunitaward031.jpg>)

> **Source slide transcript**
>
> 31 dit voor het bedrag dat het Bedrijf voldoende acht om de door de wet vereiste roerende voorheffing te voldoen. Belastingen van de staat worden ingehouden voor het toepasselijke percentage dat bepaald is door de staat waarin u tewerkgesteld bent of het laatst door het Bedrijf tewerkgesteld was. Het aantal ingehouden aandelen mag in geen geval het aantal overschrijden dat nodig is om de maximale federale, staat- en lokale voorheffingen op inkomsten en tewerkstelling te voldoen. U kunt ervoor kiezen om afstand te doen van eerder verworven Gewone aandelen of om het Bedrijf Gewone aandelen met betrekking tot deze Award te laten inhouden, en dit voor een bedrag dat volstaat om alle of een deel van de door de wet vereiste voorheffingen te voldoen. (b) Aansprakelijkheid voor belastingen (alleen van toepassing op personen die onderhevig zijn aan belastingswetten buiten de VS). Ongeacht een actie die het Bedrijf of het filiaal dat u tewerkstelt of u in dienst neemt onderneemt met betrekking tot een of alle inkomstenbelastingen, sociale zekerheid, loonbelasting, betaling van een voorschot of andere belastingen met betrekking tot uw deelname aan het Plan en, wettelijk van toepassing op u ('Belastingen'), erkent u dat de uiteindelijke aansprakelijkheid voor alle Belastingen die van u is en blijft en het bedrag kan overschrijden dat wordt ingehouden door het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt. U erkent verder dat het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt (1) geen verklaringen aflegt of acties onderneemt met betrekking tot de behandeling van Belastingen in verband met enig aspect van de RSU's, inclusief maar niet beperkt tot de toekenning, toezegging of afrekening van de RSU's, de daaropvolgende verkoop van Gewone aandelen die verworven zijn conform zulke afrekening, en de ontvangst van dividenden; en (2) zich niet verbindt tot en niet verplicht is om de looptijd van de toekenning of enig aspect van de RSU's te organiseren om uw aansprakelijkheid voor Belastingen te beperken of weg te werken of om een specifiek resultaat na belastingen te behalen. Als u belastingen moet betalen in meer dan één jurisdictie tussen de Toekenningsdatum van de RSU en de datum van een relevant belastbaar feit, als van toepassing, dan erkent u dat het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt (of u eerder tewerkstelde of inhuurde, als van toepassing) mogelijk in meer dan één jurisdictie Belastingen moet inhouden of aanrekenen. (1) Vóór een relevant belastbaar feit of relevante voorheffing, als van toepassing, betaalt u aan of doet u het nodige voor het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt om aan alle Belastingen te voldoen. Hiervoor machtigt u het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt, of hun respectieve agenten, volgens hun keuze, om aan de verplichtingen met betrekking tot alle Belastingen te voldoen door een of een combinatie van de volgende zaken: (A) inhouden op uw loon of andere contante compensatie die u wordt betaald door het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt; of (B) inhouden op inkomsten van de verkoop van Gewone aandelen verworven door afrekening van de RSU's, hetzij via een vrijwillige verkoop of via een verplichte verkoop die door het Bedrijf geregeld is (in uw naam volgend op deze autorisatie); of (C) inhouden op Gewone aandelen die worden uitgegeven bij afrekening van de RSU's.

---

![Slide 32](<restrictedstockunitaward032.jpg>)

> **Source slide transcript**
>
> 32 (2) Om een negatieve boekhoudkundige behandeling te vermijden, kan het Bedrijf zaken inhouden of aanrekenen voor Belastingen door toepasselijke statutaire inhoudingsbedragen of andere toepasselijke inhoudingstarieven te overwegen. Als aan de verplichting voor Belastingen voldaan is door in te houden op Gewone aandelen, dan wordt u voor belastingsdoeleinden geacht het volledige aantal Gewone aandelen te hebben uitgegeven die onderworpen zijn aan de toegezegde RSU's, ook al werd een aantal Gewone aandelen louter ingehouden om de Belastingen te betalen. (3) Ten slotte betaalt u het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt een bedrag aan belastingen dat het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt mogelijk moet inhouden of aanrekenen ten gevolge van uw deelname aan het Plan en dat niet kan worden voldaan met de eerder beschreven middelen. Het Bedrijf kan weigeren om de Gewone aandelen of de inkomsten van de verkoop van de Gewone aandelen uit te geven of te leveren, als u uw verplichtingen met betrekking tot de Belastingen niet naleeft. 2.8 Overeenstemming met de toepasselijke wetgeving. De uitgifte van Gewone aandelen is onderhevig aan en hangt af van de naleving door het Bedrijf en u, inclusief schriftelijke verklaringen, garanties en overeenkomsten die de Beheerder u kan vragen voor naleving van alle (i) toepasselijke federale wetten en voorschriften en die van een Amerikaanse staat, (ii) toepasselijke wetten van het land waar u woont die relevant zijn voor de uitgifte of verkoop van Gewone aandelen, en (iii) toepasselijke vereisten van een beurs of geautomatiseerd offertesysteem waarbij de Gewone aandelen van het Bedrijf worden vermeld of aangeboden op het ogenblik van zulke uitgifte of overdracht. Niettegenstaande een andere bepaling van deze Overeenkomst, is het Bedrijf niet verplicht om Gewone aandelen volgens deze Overeenkomst uit te geven, als zulke uitgifte een inbreuk vormt op een toepasselijke wet of voorschrift of vereiste van een effectenbeurs of soortgelijke instelling. 2.9 Wetboek Sectie 409A (alleen van toepassing op personen die onderhevig zijn aan de federale Amerikaanse belastingswetten). (a) Andere RSU's dan RSU's die toegezegd blijven wegens uw Onvrijwillig ontslag om economische redenen en dividendequivalenten die te betalen zijn volgens deze Overeenkomst, zijn bedoeld om vrijgesteld te worden van het Wetboek Sectie 409A onder de vrijstelling voor opschortingen op korte termijn. RSU's (andere dan RSU's die toegezegd blijven wegens uw Onvrijwillig ontslag om economische redenen) worden afgerekend en dividendequivalenten worden betaald niet later dan de 15e dag van de derde maand die volgt op uiterlijk (i) het einde van uw belastingjaar waarin de toezeggingsdatum van de RSU valt, of (ii) het einde van het boekjaar van het Bedrijf waarin de toezeggingsdatum van de RSU valt. (b) RSU's die toegezegd blijven wegens uw Onvrijwillig ontslag om economische redenen zijn onderhevig aan de bepalingen van deze subsectie (b). Elke verdeling in de afrekening van zulke RSU's vindt plaats op voorwaarde dat uw Onvrijwillig ontslag om economische redenen vormt een 'ontslag' zoals gedefinieerd in Schatkistverordening §1.409A- 1(h). Als het Bedrijf bepaalt dat u een 'specifieke werknemer' bent zoals gedefinieerd in het Wetboek Sectie 409A (d.w.z. een ambtenaar met een jaarlijkse compensatie van meer dan $ 130.000 (zoals aangepast voor inflatie), vijf procent bezit van het Bedrijf of één procent bezit met een jaarlijkse compensatie van meer dan $ 150.000), dan wordt de verdeling in de

---

![Slide 33](<restrictedstockunitaward033.jpg>)

> **Source slide transcript**
>
> 33 afrekening van zulke RSU's die betaalbaar zouden zijn binnen de zes maanden van uw ontslag, worden opgeschort tot de eerste werkdag na zes maanden na uw ontslag. Elke verdeling in afrekening van zulke RSU's die langer dan zes maanden na uw ontslag zou plaatsvinden (zonder toepassing van de opschorting van zes maanden), is niet onderhevig aan de opschorting van zes maanden zoals beschreven in deze subsectie. 2.10 Gegevensprivacy. (a) Amerikaanse regels voor gegevensprivacy (alleen toepasselijk als deze Award onderworpen is aan de Amerikaanse wetten voor gegevensprivacy). Door deze Overeenkomst aan te gaan en deze Award te aanvaarden, (a) gaat u uitdrukkelijk en ondubbelzinnig akkoord met de verzameling, het gebruik en de overdracht, op elektronische of andere wijze, van de persoonsgegevens die nodig zijn om de invoering, de uitvoering en het beheer van het Award en het Plan te vergemakkelijken, (b) begrijpt u dat het Bedrijf, om het Plan in te voeren, uit te voeren en te beheren, bepaalde persoonsgegevens over u kan bijhouden, inclusief maar niet beperkt tot uw naam, thuisadres en telefoonnummer, geboortedatum, socialezekerheidsnummer of ander identificatienummer, salaris, nationaliteit, functietitel en informatie over alle awards of rechten op Aandelen die u volgens het Plan of anders zijn toegewezen ('Persoonsgegevens'), (c) begrijpt u dat Persoonsgegevens kunnen worden overgedragen aan derden die helpen bij de invoering, uitvoering en het beheer van het Plan, inclusief elke makelaar bij wie de bij toezegging van de Award uitgegeven Aandelen in bewaring kunnen worden gegeven, en dat deze ontvangers zich in uw land of elders kunnen bevinden, en dat het land van de ontvanger andere wetten en beschermingsmaatregelen voor gegevensprivacy kan hebben dan uw land, (d) u afstand doet van alle rechten op gegevensbescherming die u mogelijk hebt met betrekking tot de gegevens, en (e) u het Bedrijf, zijn filialen en agenten de toestemming geeft om zulke informatie op elektronische wijze op te slaan en door te sturen. (b) Niet-Amerikaanse regels voor gegevensprivacy (alleen toepasselijk als deze Award onderworpen is aan wetten voor gegevensprivacy van buiten de VS) (1) Door deze Overeenkomst aan te gaan en deze Award te aanvaarden, gaat u uitdrukkelijk en ondubbelzinnig akkoord met de verzameling, het gebruik en de overdracht, op elektronische of andere wijze, van de persoonsgegevens zoals beschreven in deze Overeenkomst en elk ander document over de toekenning van RSU door en bij, zoals toepasselijk, het filiaal dat u tewerkstelt of in dienst neemt, het Bedrijf en zijn filialen uitsluitend voor de invoering, uitvoering en het beheer van uw deelname aan het Plan. (2) U begrijpt dat het Bedrijf en het filiaal dat u tewerkstelt of in dienst neemt bepaalde persoonsgegevens van u kan bijhouden, inclusief maar niet beperkt tot uw naam, thuisadres en telefoonnummer, geboortedatum, socialezekerheidsnummer of ander identificatienummer, salaris, nationaliteit, functietitel, Gewone aandelen of bestuursmandaten in het Bedrijf, gegevens van alle RSU's of elk ander recht op Gewone aandelen dat is toegekend, geannuleerd, uitgeoefend, toegewezen, niet toegewezen of in uw voordeel uitstaat, uitsluitend om het Plan in te voeren, uit te voeren en te beheren ('Gegevens'). (3) U begrijpt dat gegevens worden overgedragen aan een juridisch adviseur of een makelaar of een andere dienstverlener van aandelenplannen die in de toekomst

---

![Slide 34](<restrictedstockunitaward034.jpg>)

> **Source slide transcript**
>
> 34 door het Bedrijf kan worden geselecteerd, en die het Bedrijf helpt bij de invoering, uitvoering en het beheer van het Plan. U begrijpt dat de ontvangers van de Gegevens in de Verenigde Staten of elders kunnen gevestigd zijn, en dat het land van de ontvanger (bv. de Verenigde Staten) andere wetten en beschermingen voor gegevensprivacy kan hebben dan het land waar u woont. U begrijpt dat als u niet in de Verenigde Staten woont, u een lijst met namen en adressen van mogelijke ontvangers van de Gegevens kunt opvragen door contact op te nemen met uw lokale medewerker van de personeelsdienst of die van het Bedrijf. U autoriseert het Bedrijf en alle andere mogelijke ontvangers die (nu of in de toekomst) het Bedrijf kunnen helpen met de invoering, uitvoering en het beheer van het Plan om de Gegevens in elektronische of andere vorm te ontvangen, bezitten, gebruiken, bij te houden en over te dragen, uitsluitend en alleen om uw deelname aan het Plan in te voeren, uit te voeren en te beheren. U begrijpt dat Gegevens maar zo lang worden bijgehouden als nodig is om uw deelname aan het Plan in te voeren, uit te voeren en te beheren. U begrijpt dat als u niet in de Verenigde Staten woont, u op elk ogenblik gegevens kunt inzien, extra informatie over de opslag en verwerking van gegevens kunt opvragen, noodzakelijke wijzigingen aan gegevens kunt vragen of de toestemmingen erin kunt weigeren of intrekken, steeds zonder kosten, door schriftelijk contact op te nemen met uw lokale medewerker van de personeelsdienst of die van het Bedrijf. U begrijpt echter dat het weigeren of intrekken van uw toestemming een invloed kan hebben op de mogelijkheid of u aan het Plan kunt deelnemen. Meer informatie over de gevolgen van uw weigering of intrekking van uw toestemming kunt u krijgen door contact op te nemen met uw lokale medewerker van de personeelsdienst of die van het Bedrijf. 2.11 Opvolgers en gevolgmachtigden. Deze Overeenkomst is bindend voor alle opvolgers en gevolmachtigden van het Bedrijf. 2.12 Toepasselijke wetgeving. Deze Overeenkomst wordt beheerd door en wordt opgevat en afgedwongen in overeenstemming met de toepasselijke voorzieningen van de Code en dit zo veel mogelijk, en anderszins met de wetten van de staat Michigan, ongeacht de beginselen van wetsconflicten, op voorwaarde dat u een buitenlander bent of buiten de Verenigde Staten tewerkgesteld bent. Deze Overeenkomst wordt beheerd door en wordt opgevat en afgedwongen in overeenstemming met de toepasselijke buitenlandse wetgeving, in die mate dat die wetgeving verschilt van de Code en de wetten van de staat Michigan. Elk geding met betrekking tot of voortvloeiende uit deze Overeenkomst wordt gestart, vervolgd of verdergezet in het Circuit Court in Kent County, Michigan, gevestigd in Grand Rapids, Michigan of in het United States District Court voor het Western District van Michigan, en in om het even welke beroepsrechtbank daarvan. 2.13 Verbeuring van RSU's. Als het Bedrijf, ten gevolge van wangedrag, een bijstelling van gerapporteerde resultaten moet voorbereiden wegens belangrijke niet-naleving van een vereiste voor financiële verslaggeving volgens de effectenwetgeving, dan: (a) als uw compensatie op basis van een incentive of vermogen automatisch verbeurd wordt verklaard wegens zo’n wangedrag en bijstelling onder Sectie 304 van de Sarbanes-Oxley Act van 2002, of (b) de Commissie stelt dat u bewust ofwel wangedrag beging of er niet in slaagde het te voorkomen, of uw acties of gebrek aan actie met betrekking tot het wangedrag en bijstelling een teken is van grote nalatigheid, dan (i) moet u het Bedrijf het betaalde bedrag (inclusief dividendequivalenten) terugbetalen dat u verkreeg met RSU's die werden verdiend of verzameld tijdens de twaalf maanden na de eerste uitgifte of indiening bij de SEC (wat ook het eerst

---

![Slide 35](<restrictedstockunitaward035.jpg>)

> **Source slide transcript**
>
> 35 gebeurt) van het financiële document dat zulke vereiste voor financiële verslaggeving omvat, en (ii) moeten alle uitstaande RSU's (inclusief verwante dividendequivalenten) die nog niet zijn afgerekend, onmiddellijk worden verbeurdverklaard. Daarnaast zijn volgens deze Overeenkomst verworven Gewone aandelen en alle inkomsten of winsten uit de verkoop van zulke Gewone aandelen onderworpen aan een 'terugvorderingsbeleid' of terugverdienbeleid dat later door het Bedrijf is aangenomen. 2.14 Speciale regels voor niet-Amerikaanse begunstigden (alleen van toepassing als u niet in de VS woont) (a) Aard van de toekenning. Door de toekenning te aanvaarden, erkent, begrijpt en gaat u ermee akkoord dat: (1) het Plan vrijwillig door het Bedrijf is opgesteld, discreet van aard is en op elk ogenblik kan worden gewijzigd, aangepast, opgeschort of beëindigd, behalve zoals anders voorzien in het Plan; (2) de toekenning van de RSU's vrijwillig en incidenteel is en geen contractueel of ander recht creëert om toekomstige toekenningen van RSU's of voordelen in plaats van de RSU's te ontvangen, zelfs niet als de RSU's in het verleden herhaaldelijk zijn toegekend; (3) alle beslissingen met betrekking tot toekomstige toekenningen van RSU's, als er al zijn, uitsluitend worden genomen door het Bedrijf; (4) u vrijwillig deelneemt aan het Plan; (5) de RSU's en de Gewone aandelen onderhevig aan de RSU's een buitengewoon item zijn dat buiten het toepassingsgebied van uw tewerkstelling of servicecontract valt, als dat er is; (6) de RSU's en de Gewone aandelen onderhevig aan de RSU's niet bedoeld zijn om pensioenrechten of compensatie te vervangen; (7) de RSU's en de Gewone aandelen onderhevig aan de RSU's geen onderdeel vormen van de normale of verwachte compensatie voor het berekenen van een opzegging, genomen ontslag, gedwongen ontslag, einde van servicebetalingen, bonussen, awards voor lange dienst, pensioen of sociale uitkeringen of soortgelijke betalingen en in geen geval mogen worden beschouwd als compensatie voor of op welke manier ook in verband met vorige diensten aan het Bedrijf, het filiaal dat u tewerkstelt of in dienst neemt of elk ander filiaal; (8) de toekenning en uw deelname aan het plan niet geïnterpreteerd worden als een vorm van tewerkstelling of servicecontract met het Bedrijf of een filiaal; (9) de toekomstige waarde van de onderliggende Gewone aandelen onbekend en onbepaalbaar is en niet met zekerheid kan worden voorspeld;

---

![Slide 36](<restrictedstockunitaward036.jpg>)

> **Source slide transcript**
>
> 36 (10) geen vordering of recht op compensatie of schadevergoeding zal voortvloeien uit de verbeuring van de RSU's wegens uw ontslagdatum (om welke reden ook, of deze later al dan niet als ongeldig wordt geacht en of ze al dan niet een inbreuk vormt op de arbeidswetten in de jurisdictie waar u tewerkgesteld bent of diensten verleent, of de voorwaarden in uw arbeidsovereenkomst, als die er is), en als tegenprestatie voor de RSU's waar u anders geen recht op hebt, u er ontegensprekelijk mee akkoord gaat dat u nooit een vordering instelt tegen het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt, u afstand doet van de mogelijkheid, als die er is, om zulke vordering in te stellen, en u het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt van zulke vordering vrijstelt; als niettegenstaande het vorige, zulke vordering ontvankelijk wordt verklaard door een hof van de bevoegde jurisdictie, dan wordt u door uw deelname aan het Plan ontegensprekelijk geacht zulke vordering niet in te dienen en ermee akkoord te gaan dat u voor alle documenten zorgt die nodig zijn om zulke vordering te af te wijzen of in te trekken; en (11) u erkent en ermee akkoord gaat dat noch het Bedrijf, het filiaal dat u tewerkstelt of in dienst neemt of elk ander filiaal aansprakelijk is voor een schommeling van de wisselkoers tussen de valuta van het land waarin u verblijft en de Amerikaanse dollar, die van invloed kan zijn op de waarde van de RSU's of bedragen die u verschuldigd zijn conform de afrekening van de RSU's of de daaropvolgende verkoop van Gewone aandelen die bij de afrekening zijn verworven. (b) Bijlage. Niettegenstaande de voorzieningen in deze Overeenkomst, is de toekenning van de RSU onderhevig aan speciale algemene voorwaarden die in een Bijlage voor uw land bij deze Overeenkomst vermeld staan. Bovendien, als u verhuist naar een van de landen die in de Bijlage vermeld staan, zijn de speciale algemene voorwaarden voor dat land op u van toepassing, in de mate waarin het Bedrijf bepaalt dat de toepassing van zulke voorzieningen nodig of raadzaam zijn om te voldoen aan de wetten van het land waarin u verblijft of om de uitvoering van het Plan te vergemakkelijken. Als u naar de Verenigde Staten verhuist, zijn de speciale algemene voorwaarden in de Bijlage op u van toepassing, of zijn ze niet langer van toepassing, in de mate waarin het Bedrijf bepaalt dat de toepassing of anders van zulke voorzieningen nodig of raadzaam zijn om de uitvoering van het Plan te vergemakkelijken. De Bijlage vormt een onderdeel van deze Overeenkomst. (c) Impositie van overige vereisten. Het Bedrijf behoudt zich het recht voor om andere vereisten op te leggen aan uw deelname aan het Plan, op de RSU's en alle volgens het Plan verworven Gewone aandelen, in de mate waarin het Bedrijf bepaalt dat het nodig of raadzaam is om te voldoen aan de wetten van het land waarin u verblijft of om de uitvoering van het Plan te vergemakkelijken, en om u te vragen extra overeenkomsten of garanties te tekenen die nodig kunnen zijn om het voorgaande te verwezenlijken. 2.15 Niet-concurrentie- en niet-wervingsbeding. (a) Niet-concurrentiebeding. Tijdens uw tewerkstelling bij het Bedrijf en zijn filialen en gedurende een termijn van twaalf (12) maanden volgend op uw Beëindigingsdatum (de 'Beperkte termijn'), mag u niet (i) rechtstreeks of onrechtstreeks, zonder voorafgaande schriftelijke toestemming van het Bedrijf, een aanzienlijk of meerderheidsbelang hebben als eigenaar, partner, aandeelhouder, licentiehouder, directeur, kaderlid, agent of consultant voor om

---

![Slide 37](<restrictedstockunitaward037.jpg>)

> **Source slide transcript**
>
> 37 het even wie die een bedrijf heeft dat een concurrent is van een onderdeel van het Bedrijf of een van zijn filialen ergens in het land of de landen waarin u regelmatig werkzaam bent of diensten verleent; of (ii) werk of een verbintenis voor het verstrekken van diensten aanvaarden in om het even welke hoedanigheid, inclusief als werknemer, directeur, consultant of adviseur, rechtstreeks of onrechtstreeks, bij om het even wie die een bedrijf heeft dat een concurrent is van een onderdeel van het Bedrijf of een van zijn filialen ergens in het land of de landen waarin u regelmatig werkzaam bent of diensten verleent. In dit verband omvat het hebben van een bedrijf dat een concurrent is van een onderdeel van het Bedrijf of een van zijn filialen de verkoop, productie, distributie of onderzoek en ontwikkeling van een product of dienst die lijkt op een product en dienst die wordt verkocht, verdeeld, op de markt gebracht of onderzocht (inclusief via een joint venture of investering in een andere entiteit) door het Bedrijf of een van zijn filialen, inclusief een OTC-geneesmiddel of voedingsproducten van een huismerk en kwaliteitsmerk, farmaceutische producten met een uitgebreid actueel algemeen voorschrift, kindervoedingsproducten, mondverzorgingsproducten en elk ander product of alle andere producten die het Bedrijf of een filiaal op de markt brengt of actief plant om op de markt te brengen tijdens uw tewerkstelling bij het Bedrijf en tijdens de termijn van een jaar na uw Beëindigingsdatum. Als er tijdens de Beperkte termijn een voltooide verkoop, overdracht of andere voorziening is van het bedrijf Perrigo Prescription Pharmaceutical, is deze Sectie 2.15(a) niet van toepassing op het bedrijf Perrigo Prescription Pharmaceutical. Niettegenstaande het voorgaande, kan niets in deze bepaling u verhinderen om passief twee procent (2%) of minder van de uitstaande effecten van om het even welke klasse van een bedrijf op de nationale effectenbeurs of op een geautomatiseerd offertesysteem in het bezit te hebben. U kunt een schriftelijk verzoek richten aan de CHRO van het Bedrijf voor een uitzondering op deze Sectie 2.15(a) en zulke uitzondering wordt niet op onredelijke wijze geweigerd, in het bijzonder wanneer u wilt worden tewerkgesteld door een bedrijf dat geen concurrent is van het segment van het Bedrijf waar u hebt gewerkt of diensten hebt verleend tijdens de laatste twee jaar van uw tewerkstelling bij het Bedrijf. (b) Niet-werving van dienstverleners. Tijdens uw tewerkstelling bij het Bedrijf en zijn filialen en voor de duur van de Beperkte termijn, mag u niet, rechtstreeks on onrechtstreeks, zonder de voorafgaande schriftelijke toestemming van het Bedrijf, (i) actief iemand rekruteren, aanwerven of inhuren die op dat ogenblik of om het even wanneer tijdens de termijn van 12 maanden voorafgaand zulke rekrutering of aanwerving een werknemer of consultant was van het Bedrijf of een van zijn filialen, (ii) een werknemer van het Bedrijf of een van zijn filialen vragen of aanmoedigen om de tewerkstelling bij het Bedrijf of een van zijn filialen te verlaten of (iii) zich inmengen in de relatie van het Bedrijf of een van zijn filialen met een persoon of entiteit die tewerkgesteld is of zich anderszins bezighoudt om diensten te verlenen voor het Bedrijf of een van zijn filialen. (c) Niet-werving van klanten. Tijdens uw tewerkstelling bij het Bedrijf en zijn filialen en gedurende de Beperkte termijn mag u niet, rechtstreeks of onrechtstreeks, alleen of in samenwerking met iemand anders, zonder de voorafgaande schriftelijke toestemming van het Bedrijf, (i) een klant (voormalig of actueel), leverancier, licentiehouder, franchisehouder, , joint venture-partner of andere zakenrelatie van het Bedrijf of een van zijn filialen (samen 'Klanten' genoemd) te bewegen tot of proberen te bewegen tot niet langer zaken te doen met het Bedrijf of filiaal, (ii) alle of een deel van de zaken van een Klant met het Bedrijf overdragen naar een

---

![Slide 38](<restrictedstockunitaward038.jpg>)

> **Source slide transcript**
>
> 38 concurrent van het Bedrijf of filiaal, of (iii) op een of andere manier zich inmengen in de relatie tussen enerzijds een Klant en anderzijds het Bedrijf of een filiaal. (d) Rechtsmiddelen en dwangmaatregelen tot rechtsherstel. U erkent dat een door u gemaakte inbreuk op een van de clausules in deze Sectie 2.15 onherstelbare schade zou toebrengen aan het Bedrijf en zijn filialen voor een bedrag dat aanzienlijk maar niet onmiddellijk achterhaalbaar is, en dat elk rechtsmiddel (inclusief de betaling van schadevergoeding) ontoereikend zou zijn. Dienovereenkomstig gaat u ermee akkoord dat, niettegenstaande een tegenstrijdige bepaling in deze overeenkomst, het Bedrijf en zijn filialen naast elke andere schade die het kan aantonen ook recht heeft (zonder economisch verlies of andere daadwerkelijke schade te moeten aantonen) op dwangmaatregelen tot rechtsherstel (inclusief tijdelijke gerechtelijke bevelen, voorlopige voorzieningen en permanente voorzieningen), zonder borgstelling, in een hof van de bevoegde jurisdictie voor een feitelijke of mogelijke inbreuk van een van de clausules in deze Sectie 2.15 naast elke andere juridische of billijke rechtsmiddelen die het heeft. Daarnaast, in geval van uw opzettelijke inbreuk op de beperkende clausule (zoals gedefinieerd in deze Sectie 2.15), (i) vervallen al uw rechten volgens deze Overeenkomst, al dan niet toegezegd, onmiddellijk, en (ii) worden alle Aandelen, contacten of andere eigendom die u conform deze Overeenkomst zijn betaald of geleverd verbeurd verklaard en moet u die Aandelen, contanten of andere eigendommen terugbetalen aan het Bedrijf, en dit niet later dan dertig (30) kalenderdagen nadat het Bedrijf om uw terugbetaling heeft gevraagd. Voor de doeleinden van deze Overeenkomst verwijst "opzettelijke inbreuk op de beperkende clausule" op uw aanzienlijke inbreuk op een van de clausules in deze Sectie 2.15 waarvan u wist of door gepast onderzoek had moeten weten dat het om een aanzienlijke inbreuk zou gaan. De voorafgaande zinnen van deze Sectie 2.15 mogen niet worden beschouwd als een afstand van de rechten op schadevergoedingen die het Bedrijf en zijn filialen kunnen hebben conform deze Overeenkomst of anders, en al deze rechten zijn onbeperkt. De Beperkte termijn is van kracht tijdens (en wordt geacht automatisch te worden verlengd met) een termijn waarin u in overtreding bent van de bepalingen van Sectie 2.15(a), (b) of (c), als van toepassing. Als een hof van de bevoegde jurisdictie bepaalt dat een bepaling van deze Sectie 2.15 ongeldig is of meer beperkt dan toegelaten volgens de geldende wetgeving van zulke jurisdictie, dan wordt deze bepaling, uitsluitend voor de handhaving van deze Sectie 2.15 binnen de jurisdictie van het hof, geïnterpreteerd en afgedwongen alsof ze voorzag in de maximale beperking die toegelaten is volgens zulke geldende wetgeving. (e) Bevestigingen. (1) U erkent dat het Bedrijf en zijn filialen aanzienlijke hoeveelheden tijd, geld en moeite hebben besteed en zullen blijven besteden voor het ontwikkelen van bedrijfsstrategieën, relaties met werknemers, klanten en anderen, en goodwill om een doeltreffende organisatie op te bouwen. U erkent dat het Bedrijf en zijn filialen een rechtmatig commercieel belang heeft in zijn goodwill en relaties met werknemers, klanten en anderen en het recht deze te beschermen, en dat het Bedrijf en zijn filialen ernstige schade kunnen ondervinden door het verlies of de verslechtering van zijn relaties met werknemers, klanten en anderen. U erkent daarnaast dat het Bedrijf en zijn filialen het recht hebben om de bedrijfswaarde van het Bedrijf en zijn filialen te beschermen en te behouden voor zover wettelijk toegestaan.

---

![Slide 39](<restrictedstockunitaward039.jpg>)

> **Source slide transcript**
>
> 39 (2) In het licht van de voorgaande erkenningen gaat u ermee akkoord dat de clausules in deze Overeenkomst redelijk en naar behoren vereist zijn voor de gepaste bescherming van de onderdelen en goodwill van het Bedrijf en zijn filialen. U erkent daarnaast dat, hoewel uw naleving van de clausules in deze Overeenkomst kunnen verhinderen dat u de kost verdient in een bedrijf dat vergelijkbaar is met de onderdelen van het Bedrijf en zijn filialen, u met uw ervaring en bekwaamheden andere kansen hebt om de kost te verdienen en over voldoende middelen te beschikken voor u en uw gezin. (3) In het licht van de erkenningen in deze Sectie 2.15 gaat u ermee akkoord om de redelijkheid, geldigheid of afdwingbaarheid van beperkingen op en verplichtingen van u in deze Sectie 2.15 niet te betwisten of aan te vechten. **** We kijken uit naar uw aanhoudende bijdrage tot de groei van het Bedrijf. Gelieve de ontvangst van het Plan en deze Award te bevestigen. Hoogachtend, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 40](<restrictedstockunitaward040.jpg>)

> **Source slide transcript**
>
> 40 PERRIGO COMPANY PLC UMOWA PRZYDZIAŁU AKCJI WARUNKOWYCH (W OPARCIU O STOSUNEK PRACY) (W ramach długoterminowego programu motywacyjnego Perrigo Company plc 2026) DO: Participant Name ODP.: Powiadomienie o przyznaniu Akcji warunkowych (w oparciu o stosunek pracy) Informujemy, że Perrigo Company plc („Spółka”) przyznała Prawo w ramach długoterminowego programu motywacyjnego Perrigo Company plc 2026 („Program”), obowiązującego od Grant Date („Data Przyznania”). Prawo dotyczy Akcji warunkowych, opartych o stosunek pracy. Warunki niniejszego świadczenia motywacyjnego zostały określone w pozostałej części niniejszej umowy (w tym wszelkich specjalnych warunkach określonych w dowolnym załączniku dla danego kraju („Załącznik”) (łącznie „Umowa”). Terminy pisane wielką literą, które nie zostały inaczej zdefiniowane w niniejszej Umowie będą miały przypisane znaczenie w ramach Programu. § 1 Przekazanie Akcji warunkowych (w oparciu o stosunek pracy) 1.1 Przyznanie. Od Daty Przyznania i zgodnie z warunkami niniejszej Umowy i Programu, Spółka przyznaje Ci Number of Awards Granted („Akcje warunkowe” lub „RSU”). Każda RSU uprawnia Cię do nabycia prawa do akcji zwykłej Spółki, o wartości nominalnej 0,001 EUR na akcję („Akcja zwykła”) z Datą Przekazania RSU, pod warunkiem, że spełnione są warunki przekazania opisane w § 1.2. 1.2 Przekazanie. Z wyjątkiem przypadków określonych w § 1.3, RSU przyznane w § 1.1 zostają przekazane jak następuje po upływie Daty Przyznania („Data(-y) Przekazania RSU”): Vesting Schedule (Dates & Quantities) pod warunkiem kontynuowania zatrudnienia Twojej osoby przez Spółkę od Daty Przyznania do odpowiedniej Daty Przekazania. Z wyjątkiem przypadków określonych w § 1.3, jeśli Twoja Data Rozwiązania Umowy przypada przed Datą Przekazania RSU, wszelkie RSU przyznane zgodnie z § 1.1, które nie zostały wcześniej przekazane z taką Datą Rozwiązania Umowy, zostaną trwale utracone z Twoją Datą Rozwiązania Umowy. 1.3 Specjalne Zasady Przekazywania Praw. Niezależnie od treści powyższego § 1.2: (a) Jeśli Twoja Data Rozwiązania Umowy nastąpi z powodu śmierci, Niepełnosprawności lub Przejścia na emeryturę za zgodą Spółki, wszelkie RSU przyznane zgodnie z § 1.1, które nie zostały przekazane przed tą Datą Rozwiązania Umowy, zostaną w pełni przekazane. (b) Jeśli Data Rozwiązania Umowy nastąpi z powodu Niedobrowolnego Rozwiązania Umowy z przyczyn ekonomicznych, wszelkie RSU przyznane zgodnie z § 1.1,

---

![Slide 41](<restrictedstockunitaward041.jpg>)

> **Source slide transcript**
>
> 41 których przekazanie w innym przypadku zostałoby zaplanowane, zgodnie z § 1.2, w ciągu 24 miesięcy po takiej Dacie Rozwiązania Umowy, będą nadal przekazywane podczas 24- miesięcznego okresu zgodnie z harmonogramem przekazywania obowiązującym przed taką Datą Rozwiązania Umowy; jednak pod warunkiem, że jeśli Twoja Data Rozwiązania Umowy nastąpi z przyczyny opisanej zarówno w niniejszym podpunkcie (b), jak i w podpunkcie (c) poniżej, zamiast opisanych w niej zasad przekazywania opisanych w podpunkcie (b), zastosowanie mają specjalne zasady przekazywania praw opisane w podpunkcie (c). Wszelkie RSU, które nie zostaną przekazane w ciągu 24 miesięcy, zostają utracone z Datą Rozwiązania Umowy. (c) Jeżeli Data Rozwiązania Umowy przypada z powodu Rozwiązania Umowy bez przyczyny lub Odejścia na mocy porozumienia stron w związku ze Zmianą Kontroli lub po tej Zmianie (jak określono w Programie, a taka definicja może zostać zmieniona poniżej) i przed upływem dwóch (2) lat od Zmiany Kontroli wszystkie RSU, które przyznano zgodnie z § 1.1, które nie zostały przekazane lub zostały utracone przed taką Datą Rozwiązania Umowy, zostaną w pełni przekazane. (d) W rozumieniu niniejszego § 1.3, następujące terminy mają znaczenie określone poniżej: (1) „Odejście na mocy porozumienia stron” oznacza dobrowolne zwolnienie się ze Spółki i zaistnienie jednej lub większej liczby z następujących zmian, do których doszło bez Twojej zgody: (i) istotna zmiana położenia geograficznego, w którym musisz wykonywać usługi, przez co dojazdy z domu do głównego miejsca pracy wzrosną o ponad 48 kilometrów, lub (ii) istotne zmniejszenie uprawnień, ograniczenie obowiązków lub odpowiedzialności lub istotne zmniejszenie podstawy wynagrodzenia lub premii motywacyjnych; pod warunkiem jednak, że dobrowolna rezygnacja z pracy dla Spółki nie będzie uważana za Odejście na mocy porozumienia stron, chyba że przekażesz Spółce pisemne zawiadomienie o dobrowolnej rezygnacji i zaistnieniu zmian uzasadniających odejście w ciągu 90 dni od ich pierwszego zaistnienia. Spółka będzie miała wówczas 30 dni na naprawienie zaistniałej sytuacji, a w takim przypadku nie zostaniesz uznany(-a) za osobę, która podjęła decyzję o Odejściu na mocy porozumienia stron. W przypadku, gdy Spółka nie naprawi zaistniałej sytuacji w ciągu 30 dni, Twoja Data Rozwiązania Umowy przypadnie 31. dnia po otrzymaniu przez Spółkę potwierdzenia odbioru takiego pisemnego powiadomienia. (2) „Rozwiązanie Umowy bez Przyczyny” oznacza niedobrowolne rozwiązanie stosunku pracy lub stosunku umownego przez Spółkę bez powodu, w tym między innymi (i) rozwiązanie wchodzące w życie w przypadku wyczerpania przerwy w świadczeniu pracy podczas lub pod koniec okresu wypowiedzenia na mocy Ustawy o wcześniejszym powiadomieniu pracowników o zwolnieniach grupowych („WARN” - Worker Adjustment and Retraining Notification Act) oraz (ii) sytuację, w której przebywasz na zatwierdzonej przerwie w świadczeniu pracy, podczas której Twoje stanowisko jest chronione na mocy obowiązującego prawa (np. urlop na mocy Ustawy o urlopach rodzinnych i zdrowotnych [Family Medical Leave Act]), powracasz z takiego urlopu i nie możesz zostać zatrudniony ani uzyskać żadnej innej formy stosunku umownego ze Spółką. 1.4 Rozliczenie RSU. Tak szybko jak tylko jest to możliwe po upływie Daty Przekazania RSU, Spółka przekaże Ci jedną Zwykłą Akcję za każde RSU nabyte w tym dniu

---

![Slide 42](<restrictedstockunitaward042.jpg>)

> **Source slide transcript**
>
> 42 (dla celów niniejszej Umowy data takiego przekazania będzie stanowić „datę rozliczenia”); jednak pod warunkiem, że Spółka może wstrzymać akcje, które w innym wypadku zostałyby Ci przekazane, w zakresie niezbędnym do uiszczenia zaliczki na podatek z powodu przekazania RSU, zgodnie z § 2.6. Jako Akcjonariusz nie będziesz posiadać żadnych praw w stosunku do jakichkolwiek Akcji Zwykłych w ramach RSU przed datą wydania Ci certyfikatu lub certyfikatów takich akcji. Niezależnie od powyższego, Komisja, według własnego uznania, może zdecydować o rozliczeniu RSU w gotówce w oparciu o rzeczywistą wartość rynkową Akcji Zwykłych w Dniu Przekazania RSU. 1.5 Ekwiwalenty dywidendy. RSU przyznane zgodnie z § 1.1 uprawniają do otrzymania ekwiwalentów dywidendy zgodnie z następującymi warunkami: (a) „Rachunek” zostanie utworzony na Twoje imię i nazwisko. Rachunek taki służy wyłącznie do prowadzenia księgowości i żadne aktywa ani inne kwoty nie zostaną przekazane na taki Rachunek z ogólnych aktywów Spółki. (b) Każdego dnia wypłaty dywidendy pieniężnej w odniesieniu do Akcji Zwykłych, Spółka zasila Twój Rachunek kwotą dywidendy w dolarach, którą otrzymałbyś (otrzymałabyś), gdyby każda posiadana przez Ciebie RSU w dniu odnotowania wypłaty takiej dywidendy stanowiła Akcję Zwykłą. Na takim Rachunku nie będą naliczane odsetki ani inne dochody. (c) Z każdą Datą Przekazania RSU, otrzymasz płatność równą kwocie dywidendy, która zostałaby wypłacona z tytułu przekazania RSU w tym dniu, gdyby były to Akcje Zwykłe w okresie rozpoczynającym się z Datą Przyznania i kończącym się z Datą Przekazania RSU, a Rachunek zostanie odpowiednio obciążony. W przypadku utraty RSU, wszelkie kwoty na Rachunku, które można powiązać z takimi RSU, również zostają utracone. (d) Jeśli dywidendy są wypłacane w formie Akcji Zwykłych, a nie w gotówce, otrzymasz jedną dodatkową RSU na każdą Akcję Zwykłą, która zostałaby przekazana w ramach dywidendy, gdyby Twoje pozostałe RSU stanowiły Akcje Zwykłe. Takie dodatkowe RSU zostają przekazane lub utracone w tym samym czasie, co RSU, z którymi są one powiązane. § 2 Ogólne Warunki 2.1 Niezbywalność. Prawo przyznane w ramach niniejszej Umowy nie może zostać zbyte w sposób inny niż na mocy testamentu lub przez dziedziczenia i podziału. 2.2 Brak praw powiązanych z posiadaniem Akcji. Jako Akcjonariusz nie będziesz posiadać żadnych praw w stosunku do jakichkolwiek Akcji Zwykłych w ramach RSU przed datą wydania Ci certyfikatu lub certyfikatów takich akcji. 2.3 Rozwiązanie Umowy z przyczyny leżącej po stronie pracownika. Jeśli Data Rozwiązania Umowy nastąpi z przyczyny leżącej po stronie pracownika, wszystkie prawa

---

![Slide 43](<restrictedstockunitaward043.jpg>)

> **Source slide transcript**
>
> 43 wynikające z niniejszej Umowy niezwłocznie wygasają niezależnie od tego, czy prawa te zostały nabyte czy nie. 2.4 Prawa przyznane w ramach Programu. Przyznanie Prawa na mocy niniejszej Umowy odbywa się zgodnie z Programem, przy czym Prawo może zostać zrealizowane wyłącznie zgodnie z obowiązującymi warunkami Programu. Program zawiera określone definicje, restrykcje, ograniczenia i inne warunki, z których wszystkie mają zastosowanie w ramach niniejszej Umowy. WSZYSTKIE POSTANOWIENIA PROGRAMU ZOSTAJĄ WŁĄCZONE DO NINIEJSZEJ UMOWY PRZEZ ODNIESIENIE I STANOWIĄ CZĘŚĆ NINIEJSZEJ UMOWY W TEN SAM SPOSÓB, TAK JAKBY KAŻDE TAKIE POSTANOWIENIE ZOSTAŁO W PEŁNI WPISANE DO NINIEJSZEJ UMOWY. Jeżeli Program stanie się nieważny lub niewykonalny z mocy prawa lub decyzji sądowej, niniejsza Umowa traci moc wiążącą. Żadne z postanowień niniejszej Umowy nie ma na celu ani nie należy interpretować żadnego z jej postanowień jako ograniczającego lub usuwającego jakąkolwiek definicję, restrykcję, ograniczenie lub inny warunek Programu, który jest istotny dla niniejszej Umowy i który może zostać w określony sposób zastosowany w niej przez Komisję. W przypadku wystąpienia sprzeczności pomiędzy postanowieniami niniejszej Umowy i Programu, w oparciu o zasadę wykładni warunki Programu zostaną uznane za nadrzędne i obowiązujące. 2.5 Korekty w przypadku Zmiany Akcji Zwykłych. W przypadku podziału akcji, dywidendy w postaci akcji, dokapitalizowania, przeklasyfikowania lub połączenia akcji, połączenia spółek, sprzedaży aktywów lub podobnego zdarzenia, liczba i rodzaj akcji, względem których przyznawane jest Prawo w ramach niniejszej Umowy oraz ich cena wykonania zostaną odpowiednio skorygowane w sprawiedliwy sposób, aby zapobiec „rozwodnieniu” lub rozszerzeniu przyznanych lub przysługujących Ci praw. 2.6 Potwierdzenie odbioru. Spółka i Ty zgadzacie się, że RSU jest przyznawana na podstawie Zawiadomienia o Przyznaniu, niniejszej Umowy (w tym Załącznika, jeśli ma on zastosowanie) i postanowień Programu (włączonych tutaj przez odniesienie). Ty: (i) potwierdzasz otrzymanie kopii każdego z powyższych dokumentów, (ii) zapewniasz, że dokładnie przeczytałeś(-aś) i zapoznałeś(-aś) się z ich zapisami, oraz (iii) niniejszym akceptujesz RSU zgodnie z wszystkimi warunkami określonymi w niniejszym dokumencie oraz te określone w Programie i Zawiadomieniu o Przyznaniu. 2.7 Podatki i zaliczki na podatek. (a) Zaliczki na podatek (dotyczy tylko osób fizycznych podlegających amerykańskim przepisom podatkowym). Przyznane Prawo podlega potrąceniu wszystkich należnych podatków. Spółka może odmówić lub zezwolić na przekazanie jej wszelkich federalnych, stanowych lub lokalnych podatków należnych przy przyznawaniu, przekazywaniu lub innym zdarzeniu nakładającym zobowiązanie podatkowe w związku z przyznanym Prawem. Jeśli nie przekazałeś(-aś) Spółce pełnej kwoty zaliczki na podatek do dnia, w którym Spółka jest zobowiązana do zapłaty takiej zaliczki właściwemu organowi podatkowemu (lub w takim wcześniejszym terminie, który Spółka może określić w celu uzyskania pomocy w terminowym wywiązaniu się z obowiązków związanych z płatnością zaliczki na podatek), Spółka będzie miała jednostronne prawo do wstrzymania Akcji Zwykłych, względem których przyznawane jest

---

![Slide 44](<restrictedstockunitaward044.jpg>)

> **Source slide transcript**
>
> 44 Prawo w wysokości, którą uzna za wystarczającą do opłacenia zaliczki na podatek wymaganej przez prawo. Podatki stanowe będą potrącane według właściwej stawki ustalonej przez stan, w którym jesteś zatrudniony(-a) lub byłeś(-aś) ostatnio zatrudniony(-a) przez Spółkę. W żadnym wypadku liczba akcji nie może przekroczyć liczby niezbędnej do spełnienia maksymalnych federalnych, stanowych i lokalnych wymogów dotyczących potrącania podatku dochodowego i podatku odprowadzanego z tytułu zatrudnienia. Możesz zrezygnować z wcześniej nabytych Akcji Zwykłych lub nakazać Spółce wstrzymanie Akcji Zwykłych związanych z przyznanym Prawem w kwocie wystarczającej do pokrycia całości lub części zaliczki na podatek wymaganej przez prawo. (b) Zobowiązanie podatkowe (dotyczy tylko osób fizycznych podlegających przepisom podatkowym poza USA) Niezależnie od jakichkolwiek działań podejmowanych przez Spółkę lub, jeśli jest to inny podmiot, przez Podmiot Powiązany zatrudniający lub angażujący Cię, w odniesieniu do jakiejkolwiek części lub całości podatku dochodowego, ubezpieczenia społecznego, podatku od wynagrodzeń, płatności na konto lub innych elementów podatkowych związanych z uczestnictwem w Programie i zgodnie z prawem („Pozycje Podatkowe”), przyjmujesz do wiadomości, że ostateczne zobowiązanie za wszystkie Pozycje Podatkowe spoczywa na Tobie i może przekraczać kwotę faktycznie potrąconą przez Spółkę lub zatrudniający lub angażujący Podmiot Powiązany. Ponadto przyjmujesz do wiadomości, że Spółka i/lub zatrudniający lub angażujący Podmiot Powiązany (1) nie składają żadnych oświadczeń ani zobowiązań dotyczących traktowania jakichkolwiek Pozycji Podatkowych w związku z dowolnym aspektem RSU, w tym między innymi, przyznaniem, przekazaniem lub wykonaniem RSU, późniejszą sprzedażą Akcji Zwykłych nabytych w wyniku takiego wykonania oraz otrzymywaniem dywidend; oraz (2) nie zobowiązują się do modyfikacji warunków przyznania lub jakiegokolwiek aspektu RSU w celu zmniejszenia lub usunięcia zobowiązania związanego z Pozycjami Podatkowymi lub osiągnięcia określonego wyniku podatkowego. Ponadto, jeśli podlegasz opodatkowaniu w więcej niż jednej jurysdykcji między Datą Przyznania a datą jakiegokolwiek istotnego zdarzenia podlegającego opodatkowaniu, w zależności od przypadku, potwierdzasz, że Spółka i/lub Podmiot Powiązany zatrudniają lub angażują Cię (lub zatrudniali lub angażowali wcześniej, w zależności od przypadku), możesz zostać zobowiązany(-a) do zapłaty zaliczki na podatek lub rozliczenia Pozycji Podatkowych w więcej niż jednej jurysdykcji. (1) Przed każdym odpowiednim zdarzeniem podlegającym opodatkowaniu lub zdarzeniem związanym z zapłatą zaliczki na podatek, zależnie od przypadku, zapłacisz lub dokonasz odpowiednich uzgodnień zadowalających Spółkę i/lub Podmiot Powiązany, który Cię zatrudnia lub angażuje, w celu spełnienia wszystkich Pozycji Podatkowych. W związku z tym upoważniasz Spółkę i/lub zatrudniający lub angażujący Podmiot powiązany, lub ich odpowiednich przedstawicieli, według własnego uznania, do wypełnienia zobowiązań w stosunku do wszystkich Pozycji Podatkowych poprzez jedną czynność lub kombinację następujących czynności: (A) potrącenie z wynagrodzenia lub innego wynagrodzenia pieniężnego wypłacanego Tobie przez Spółkę i/lub zatrudniający lub angażujący Podmiot powiązany; lub

---

![Slide 45](<restrictedstockunitaward045.jpg>)

> **Source slide transcript**
>
> 45 (B) potrącenie z wpływów ze sprzedaży Akcji Zwykłych nabytych w wyniku wykonania RSU albo w drodze dobrowolnej sprzedaży, albo w drodze obowiązkowej sprzedaży zorganizowanej przez Spółkę (w Twoim imieniu, zgodnie z niniejszym upoważnieniem); lub (C) wstrzymanie emisji Akcji Zwykłych przy zrealizowaniu RSU. (2) Aby uniknąć negatywnej oceny prawnobilansowej, Spółka może potrącać lub rozliczać Pozycje Podatkowe, uwzględniając obowiązujące ustawowe kwoty zaliczek na podatek lub inne obowiązujące stawki podatku u źródła. Jeżeli zobowiązanie dotyczące Pozycji Podatkowych zostaje zrealizowane poprzez odprowadzanie podatku z Akcji Zwykłych, dla celów podatkowych, uznaje się, że emitowano dla Ciebie pełną liczbę Akcji Zwykłych w ramach wykonanego RSU, bez względu na to, że pewna liczba Akcji Zwykłych jest wstrzymywana wyłącznie w celu spłaty Pozycji Podatkowych. (3) Spłacisz Spółce lub zatrudniającemu lub angażującemu Podmiotowi Powiązanemu wszelkie Pozycje Podatkowe, które Spółka lub zatrudniający lub angażujący Podmiot Powiązany może być zobowiązany do zatrzymania lub rozliczenia w wyniku uczestnictwa w Programie, których nie można zaspokoić opisanymi wcześniej środkami. Spółka może odmówić emisji lub dostarczenia Akcji Zwykłych lub wpływów ze sprzedaży Akcji Zwykłych, jeżeli nie wywiążesz się ze swoich zobowiązań związanych z Pozycjami Podatkowymi. 2.8 Zgodność z obowiązującym prawem. Emisja Akcji Zwykłych będzie podlegać i będzie uzależniona od przestrzegania przez Spółkę i Ciebie, w tym wszelkich pisemnych oświadczeń, gwarancji i umów, o które Administrator może Cię poprosić w celu zachowania zgodności ze wszystkimi (i) prawami i przepisami stanowymi i federalnymi obowiązującymi w Stanach Zjednoczonych, (ii) obowiązującymi przepisami prawa kraju, który zamieszkujesz, dotyczące emisji lub sprzedaży Akcji Zwykłych, oraz (iii) obowiązującymi wymogami dowolnej giełdy papierów wartościowych lub automatycznego systemu notowań, w którym Akcje Zwykłe Spółki mogą być wymienione lub notowane w momencie takiej emisji lub zbycia. Bez względu na jakiekolwiek inne postanowienie niniejszej Umowy, Spółka nie będzie zobowiązana do emisji jakichkolwiek Akcji Zwykłych w ramach niniejszej Umowy, jeżeli taka emisja naruszyłaby obowiązujące prawo lub obowiązujące przepisy lub wymogi jakiejkolwiek giełdy papierów wartościowych lub podobnego podmiotu.

---

![Slide 46](<restrictedstockunitaward046.jpg>)

> **Source slide transcript**
>
> 46 2.9 Art. 409A Kodeksu (dotyczy tylko osób podlegających federalnym przepisom podatkowym w Stanach Zjednoczonych). (a) RSU inne niż RSU, które nadal są przekazywane z powodu Niedobrowolnego Rozwiązania Umowy z przyczyn ekonomicznych i ekwiwalenty dywidendy należne na podstawie niniejszej Umowy, mają być zwolnione z postanowień art. 409A Kodeksu w ramach zwolnienia krótkich okresów przejściowych. W związku z powyższym, RSU (inne niż RSU, które są wciąż przekazywane z powodu Twojego Niedobrowolnego Rozwiązania Umowy z przyczyn ekonomicznych) zostaną rozliczone, a ekwiwalenty dywidendy zostaną wypłacone nie później niż 15-ego dnia trzeciego miesiąca następującego po (i) zakończeniu roku podatkowego, w którym przypada Data Przekazania RSU, lub (ii) zakończeniu roku podatkowego Spółki, w którym przypada Data Przekazania RSU. (b) RSU, które są wciąż przekazywane z powodu Twojego Niedobrowolnego Rozwiązania Umowy z przyczyn ekonomicznych, podlegają postanowieniom niniejszego podpunktu (b). Dystrybucja takich RSU przy rozliczeniu nastąpi pod warunkiem, że Twoje Niedobrowolne Rozwiązanie Umowy z przyczyn ekonomicznych stanowi „odejście z pracy”, zgodnie z definicją zawartą w Regulacji Skarbowej §1.409A-1(h) (Treasury Regulation). Jeśli Spółka ustali, że jesteś „pracownikiem określonym” w definicji zawartej w art. 409A Kodeksu (tj. osobą funkcyjną z rocznym wynagrodzeniem przekraczającym 130 000 USD (po uwzględnieniu inflacji), pięcioprocentowym właścicielem Spółki lub jednoprocentowym właścicielem z rocznym wynagrodzeniem przekraczającym 150 000 USD), dystrybucja takich RSU przy rozliczeniu, które byłyby należne w ciągu sześciu miesięcy od odejścia z pracy, zostanie opóźniona do pierwszego dnia roboczego po upływie sześciu miesięcy od momentu odejścia z pracy. Jakakolwiek dystrybucja związana z rozliczeniem takich RSU, która nastąpiłaby po upływie sześciu miesięcy od momentu odejścia z pracy (bez zastosowania sześciomiesięcznego opóźnienia), nie będzie podlegać sześciomiesięcznemu opóźnieniu opisanemu w niniejszym podpunkcie. 2.10 Ochrona danych osobowych. (a) Zasady dotyczące ochrony danych osobowych w Stanach Zjednoczonych (obowiązujące tylko wtedy, gdy przyznane Prawo podlega amerykańskim przepisom o ochronie danych osobowych). Zawierając niniejszą Umowę i akceptując przyznane Prawo, (a) wyraźnie i jednoznacznie wyrażasz zgodę na gromadzenie, wykorzystywanie i przekazywanie, w formie elektronicznej lub innej, jakichkolwiek danych osobowych, które są niezbędne do ułatwienia wdrożenia, administrowania i zarządzania Prawem i Programem, (b) rozumiesz, że Spółka może, w celu wdrożenia, administrowania i zarządzania Programem, posiadać Twoje określone dane osobowe, w tym między innymi imię i nazwisko, adres zamieszkania i numer telefonu, datę urodzenia, numer ubezpieczenia społecznego lub inny numer identyfikacyjny, dane dot. wynagrodzenia, narodowości, stanowiska i szczegółowe informacje na temat wszystkich Praw lub uprawnień do Akcji przyznanych Ci w ramach Programu lub w inny sposób („Dane Osobowe”), (c) rozumiesz, że Dane Osobowe mogą zostać przekazane dowolnym stronom trzecim pomagającym we wdrażaniu Programu, administrowaniu i zarządzaniu nim, w tym dowolnemu brokerowi, u którego złożone w depozycie mogą zostać Akcje wyemitowane po przekazaniu lub wykonaniu Prawa, oraz że Ci odbiorcy mogą znajdować się w Twoim kraju lub w innym miejscu, a w kraju odbiorcy mogą obowiązywać inne przepisy i zabezpieczenia danych

---

![Slide 47](<restrictedstockunitaward047.jpg>)

> **Source slide transcript**
>
> 47 osobowych niż w Twoim kraju, (d) zrzekasz się wszelkich praw związanych z ochroną prywatności danych, które możesz posiadać w stosunku do danych, oraz (e) upoważniasz Spółkę, jej Podmioty Powiązane i pełnomocnicy do przechowywania i przekazywania takich informacji w formie elektronicznej. (b) Zasady dotyczące ochrony danych osobowych obowiązujące poza Stanami Zjednoczonymi (obowiązujące tylko wtedy, gdy Prawo podlega przepisom o ochronie danych osobowych innych państw) (1) Zawierając niniejszą Umowę i akceptując przyznane Prawo, wyraźnie i jednoznacznie wyrażasz zgodę na gromadzenie, wykorzystywanie i przekazywanie, w formie elektronicznej lub innej, swoich danych osobowych, jak opisano w niniejszej Umowie oraz wszelkich innych materiałach dot. przyznania Opcji, w stosownych przypadkach, przez zatrudniający lub angażujący Podmiot Powiązany, Spółkę i jej Podmioty Powiązane wyłącznie w celu wdrożenia, administrowania i zarządzania twoim uczestnictwem w Programie. (2) Rozumiesz, że Spółka i zatrudniający lub angażujący Podmiot Powiązany może przechowywać określone dane osobowe, w tym między innymi imię i nazwisko, adres zamieszkania i numer telefonu, datę urodzenia, numer ubezpieczenia społecznego lub inny numer identyfikacyjny, wynagrodzenie, narodowość, stanowisko, wszelkie Akcje Zwykłe lub stanowiska dyrektorskie w Spółce, szczegółowe informacje na temat Opcji lub wszelkich innych praw do przyznanych Akcji Zwykłych, anulowanych, wykonywanych, przekazanych, nieprzekazanych lub pozostałych, wyłącznie w celu realizacji, administrowania i zarządzanie Programem („Dane”). (3) Rozumiesz, że Dane zostaną przekazane radcy prawnemu lub brokerowi lub innemu dostawcy usług w zakresie Programu akcji, który może zostać wybrany przez Spółkę w przyszłości, który wspiera Spółkę we wdrażaniu, administrowaniu i zarządzaniu Programem. Rozumiesz, że odbiorcy Danych mogą znajdować się w Stanach Zjednoczonych lub w innych krajach, a w kraju odbiorcy (np. Stanach Zjednoczonych) mogą obowiązywać inne przepisy dotyczące ochrony danych osobowych i zabezpieczeń niż w Twoim kraju zamieszkania. Rozumiesz, że jeśli mieszkasz poza Stanami Zjednoczonymi, możesz poprosić o listę z imionami i nazwiskami, i adresami wszelkich potencjalnych odbiorców Danych, kontaktując się z lokalnym przedstawicielem działu kadr lub przedstawicielem działu kadr Spółki. Upoważniasz Spółkę i innych potencjalnych odbiorców, którzy mogą pomóc Spółce (obecnie lub w przyszłości) we wdrażaniu, administrowaniu i zarządzaniu Programem w celu otrzymywania, posiadania, używania, przechowywania i przekazywania Danych, w formie elektronicznej lub innej, wyłącznie w celu wdrożenia, administrowania i zarządzania Twoim uczestnictwem w Programie. Rozumiesz, że Dane będą przechowywane tylko tak długo, jak będzie to konieczne do wdrożenia, administrowania i zarządzania Twoim uczestnictwem w Programie. Rozumiesz, że jeśli mieszkasz poza Stanami Zjednoczonymi, możesz w dowolnym momencie przeglądać Dane, żądać dodatkowych informacji na temat przechowywania i przetwarzania Danych, wymagać wszelkich niezbędnych zmian Danych lub odmówić lub cofnąć zgody w niniejszym dokumencie, w każdym przypadku bez ponoszenia kosztów, kontaktując się na piśmie z lokalnym przedstawicielem działu kadr lub przedstawicielem działu kadr Spółki. Rozumiesz jednak, że odmowa lub wycofanie Twojej zgody może wpłynąć na Twoją zdolność do uczestnictwa w Programie. Aby uzyskać więcej informacji na temat konsekwencji odmowy

---

![Slide 48](<restrictedstockunitaward048.jpg>)

> **Source slide transcript**
>
> 48 wyrażenia zgody lub wycofania zgody, rozumiesz, że możesz skontaktować się z lokalnym przedstawicielem działu kadr lub przedstawicielem działu kadr Spółki. 2.11 Następcy Prawni i Cesjonariusze. Niniejsza Umowa będzie wiążąca dla jednego lub wszystkich następców prawnych i cesjonariuszy Spółki. 2.12 Obowiązujące Prawo. Niniejsza Umowa podlega, będzie interpretowana i realizowana zgodnie z obowiązującymi przepisami Kodeksu w maksymalnym możliwym zakresie, a w inny sposób przez ustawodawstwo stanu Michigan, bez względu na zasady kolizji przepisów prawnych, pod warunkiem, że jesteś cudzoziemcem lub osobą zatrudnioną poza Stanami Zjednoczonymi, niniejsza Umowa podlega, będzie interpretowana i realizowana zgodnie z obowiązującym prawem zagranicznym, w zakresie, w jakim takie prawo różni się od Kodeksu i prawa stanu Michigan. Wszelkie postępowania związane z niniejszą Umową lub wynikające z niej będą wszczynane, ścigane lub kontynuowane w Sądzie Okręgowym w hrabstwie Kent w Grand Rapids w stanie Michigan lub w amerykańskim sądzie rejonowym dla północnej części stanu Michigan, i w dowolnym amerykańskim sądzie apelacyjnym. 2.13 Utrata RSU. Jeśli Spółka, w wyniku niewłaściwego postępowania, jest zobowiązana do sporządzenia korekty rachunkowej z powodu istotnej niezgodności z jakimkolwiek wymogiem sprawozdawczości finansowej wynikającym z przepisów dotyczących papierów wartościowych, wówczas (a) jeżeli kapitałowe świadczenie pracownicze zostają automatycznie utracone z powodu takiego niewłaściwego postępowania i sporządzenia korekty, zgodnie z art. 304 ustawy Sarbanes-Oxley Act z 2002 r. lub (b) Komitet stwierdza, że świadomie angażowałeś(-aś) się lub nie zapobiegłeś(-as) niewłaściwemu działaniu, a Twoje działania lub zaniechania stanowiły rażące zaniedbanie w stosunku do niewłaściwego postępowania i korekty, (i) będziesz zobowiązany(-a) do zwrotu Spółce wszelkich zysków związanych z dowolną Opcją zrealizowaną w okresie dwunastu miesięcy od pierwszej publicznej emisji lub przedłożenia w SEC (w zależności od tego, co nastąpi wcześniej) dokumentu finansowego zawierającego taki wymóg sprawozdawczości finansowej, oraz (ii) wszelkie pozostałe Opcje zostaną niezwłocznie utracone. Ponadto Akcje Zwykłe nabyte w wyniku wykonania Opcji oraz wszelkie zyski ze sprzedaży takich Akcji Zwykłych podlegają wszelkim zasadom „wycofania” lub zwrotu nienależnych korzyści, przyjętym później przez Spółkę. 2.14 Zasady specjalne dla Beneficjentów spoza Stanów Zjednoczonych (obowiązują tylko w przypadku osób mieszkających poza Stanami Zjednoczonymi) (a) Charakter przyznania. Przyjmując przyznanie, potwierdzasz, rozumiesz i zgadzasz się, że: (1) Program jest dobrowolnie opracowywany przez Spółkę, ma charakter uznaniowy i może być modyfikowany, zmieniany, zawieszany lub zakończony przez Spółkę w dowolnym momencie, chyba że Program stanowi inaczej. (2) przyznanie RSU jest dobrowolne i okazjonalne i nie stwarza żadnego umownego ani innego prawa do przyznania RSU w przyszłości lub korzyści zamiast RSU, nawet jeśli RSU była wielokrotnie przyznawana w przeszłości;

---

![Slide 49](<restrictedstockunitaward049.jpg>)

> **Source slide transcript**
>
> 49 (3) wszelkie ewentualne decyzje dotyczące przyszłych przyznanych Opcji będą podejmowane według wyłącznego uznania Spółki; (4) dobrowolnie uczestniczysz w Programie; (5) RSU i Akcje Zwykłe będące przedmiotem RSU są pozycją nadzwyczajną i która wykracza poza zakres umowy o pracę lub umowy o świadczenie usług, jeżeli taka istnieje; (6) RSU i Akcje Zwykłe będące przedmiotem RSU nie mają na celu zastąpienia jakichkolwiek uprawnień emerytalnych lub wynagrodzeń; (7) RSU i Akcje Zwykłe będące przedmiotem RSU nie są częścią normalnego lub oczekiwanego wynagrodzenia do celów wyliczania wszelkich odpraw, zwolnień, rozwiązań, odpraw wypłacanych na zakończenie stosunku pracy, premii, nagród jubileuszowych, emerytur lub rent lub świadczeń socjalnych lub podobnych zapłat, i w żadnym wypadku nie powinny być uważane za wynagrodzenie za wcześniejsze świadczenia na rzecz Spółki, zatrudniającego lub angażującego Cię Podmiotu powiązanego lub jakiegokolwiek innego Podmiotu powiązanego; (8) przyznanie i Twoje uczestnictwo w Programie nie będą interpretowane jako umowa o pracę lub umowa o świadczenie usług zawiązana ze Spółką lub jakimkolwiek Podmiotem powiązanym; (9) przyszła wartość bazowych Akcji Zwykłych jest nieznana, nieokreślona i nie można jej z absolutną pewnością przewidzieć; (10) żadne roszczenie lub prawo do wynagrodzenia lub odszkodowania nie powstanie w wyniku utraty RSU wynikającego z Daty Rozwiązania Umowy (z jakiegokolwiek powodu, niezależnie od tego, czy okaże się ona później nieważna i czy narusza przepisy prawa pracy w jurysdykcji, w której jesteś zatrudniony(-a) lub świadczysz usługi, lub warunki umowy o pracę, jeśli takie istnieją), a biorąc pod uwagę przyznanie RSU, do której w innym przypadku nie jesteś uprawniony(-a), nieodwołalnie zgadzasz się nigdy nie wnosić żadnych roszczeń w stosunku do Spółki lub zatrudniającego lub angażującego Podmiotu Powiązanego zrezygnujesz z ewentualnej możliwości wniesienia takiego roszczenia i zwolnisz Spółkę i zatrudniający lub angażujący Podmiot powiązany od takiego roszczenia; jeżeli, niezależnie od powyższego, jakiekolwiek takie roszczenie jest dozwolone przez sąd właściwej jurysdykcji, wówczas, biorąc udział w Programie, nieodwołalnie zostanie uznane, że zgodziłeś(- aś) się nie dochodzić takiego roszczenia i zgadzasz się na wykonanie wszelkich dokumentów niezbędnych do wniesienia wniosku o oddalenie lub wycofanie takiego roszczenia; i (11) potwierdzasz i zgadzasz się, że ani Spółka, Podmiot Powiązany zatrudniający lub angażujący Cię, ani żaden inny Podmiot powiązany nie będzie odpowiedzialny za jakiekolwiek wahania kursów wymiany walut między walutą kraju, w którym mieszkasz, a dolarem amerykańskim, które mogą mieć wpływ na wartość RSU lub dowolnych kwot Tobie należnych, zgodnie z rozliczeniem RSU lub późniejszą sprzedażą Akcji Zwykłych nabytych w wyniku rozliczenia.

---

![Slide 50](<restrictedstockunitaward050.jpg>)

> **Source slide transcript**
>
> 50 (b) Załącznik. Niezależnie od jakichkolwiek postanowień niniejszej Umowy, przyznanie RSU będzie podlegać specjalnym warunkom określonym w dowolnym Załączniku do niniejszej Umowy dla Twojego kraju. Ponadto, jeśli przeprowadzisz się do jednego z krajów wymienionych w Załączniku, obowiązują Cię specjalne warunki dla takiego kraju, o ile Spółka stwierdzi, że zastosowanie takich postanowień jest konieczne lub wskazane w celu zapewnienia zgodności z przepisami prawa kraju zamieszkania lub w celu ułatwienia zarządzania Programem. Jeśli przeprowadzisz się do Stanów Zjednoczonych, obowiązują Cię specjalne warunki zawarte w Załączniku, lub przestają Cię obowiązywać w zakresie w jakim Spółka stwierdzi, że zastosowanie lub inne działanie dla takich postanowień jest konieczne lub wskazane w celu ułatwienia zarządzania Programem. Załącznik stanowi część niniejszej Umowy. (c) Nałożenie innych wymogów. Spółka zastrzega sobie prawo do nałożenia innych wymogów na uczestnictwo w Programie, na RSU i na Akcje Zwykłe nabyte w ramach Programu, w zakresie, w jakim Spółka uzna to za konieczne lub wskazane w celu zapewnienia zgodności z prawem kraju, w którym przebywasz, w celu ułatwienia administrowania Programem lub w celu ułatwienia zarządzania nim, a także do nałożenia wymogów podpisania wszelkich dodatkowych umów lub zobowiązań, które mogą być konieczne do osiągnięcia powyższego. 2.15 Zakaz konkurencji i zakaz podejmowania współpracy. (a) Zakaz konkurencji. W okresie zatrudnienia w Spółce i jej Podmiotach stowarzyszonych oraz przez okres dwunastu (12) miesięcy od Daty rozwiązania umowy („Okres ograniczony”) nie możesz (i) bezpośrednio ani pośrednio, bez uprzedniej pisemnej zgody Spółki nawiązać współpracy ani nabyć istotnego lub kontrolnego pakietu jako właściciel, partner, akcjonariusz, licencjodawca, członek zarządu, dyrektor, agent lub konsultant jakiejkolwiek Osoby, która prowadzi działalność konkurencyjną w stosunku do działalności prowadzonej przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych w dowolnym miejscu w kraju lub krajach, w których normalnie wykonujesz pracę lub świadczysz usługi; lub (ii) przyjąć oferty zatrudnienia ani zaangażować się w jakimkolwiek charakterze, w tym jako pracownik, członek zarządu, konsultant lub doradca, bezpośrednio lub pośrednio, na rzecz każdej Osoby, która prowadzi działalność konkurencyjną w stosunku do działalności prowadzonej przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych w dowolnym miejscu w kraju lub krajach, w których normalnie wykonujesz pracę lub świadczysz usługi. Dla celów niniejszej Umowy prowadzenie działalności konkurencyjnej w stosunku do działalności prowadzonej przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych obejmuje sprzedaż, produkcję, dystrybucję lub badania i rozwój jakiegokolwiek produktu lub usługi, podobnych do produktu lub usługi sprzedawanej, dystrybuowanej, wprowadzanej na rynek, badanej lub rozwijanej (w tym poprzez wspólne przedsięwzięcie lub inwestycję w inny podmiot) przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych, włączając w to sprzedawane bez recepty leki i suplementy diety marek sklepowych i ekonomicznych, generyczne produkty farmaceutyczne o przedłużonym działaniu do stosowania zewnętrznego wydawane na receptę, odżywki dla niemowląt, produkty do pielęgnacji jamy ustnej oraz każdy inny produkt lub produkty, które Spółka lub Podmiot stowarzyszony wprowadza lub planuje wprowadzić na rynek w okresie Twojego zatrudnienia w Spółce oraz w ciągu jednego roku od Daty rozwiązania umowy. W przypadku zakończenia sprzedaży, przeniesienia lub innej formy zbycia działalności Spółki Perrigo Prescription Pharmaceutical w Okresie ograniczonym niniejszy punkt 2.15(a) nie będzie miał zastosowania

---

![Slide 51](<restrictedstockunitaward051.jpg>)

> **Source slide transcript**
>
> 51 do działalności Spółki Perrigo Prescription Pharmaceutical. Niezależnie od powyższego żaden element niniejszego postanowienia nie zakazuje biernego posiadania dwóch procent (2%) lub mniej pozostających w obrocie papierów wartościowych jakiejkolwiek klasy dowolnej spółki notowanej na krajowej giełdzie papierów wartościowych lub w automatycznym systemie notowań. Możesz złożyć pisemną prośbę do dyrektora działu kadr Spółki o wyjątek od postanowień niniejszego punktu 2.15(a), a udzielenie zgody na ten wyjątek nie zostanie bezzasadnie wstrzymane, w szczególności w przypadku chęci zatrudnienia w firmie, która nie konkuruje z segmentem Spółki, w której pracowałeś lub świadczyłeś usługi w ciągu ostatnich dwóch lat zatrudnienia w Spółce. (b) Zakaz podejmowania współpracy z Usługodawcami. W okresie zatrudnienia w Spółce i jej Podmiotach stowarzyszonych oraz w czasie trwania Okresu ograniczonego nie możesz, bezpośrednio ani pośrednio, bez uprzedniej pisemnej zgody Spółki, (i) aktywnie oferować stanowiska, rekrutować ani zatrudniać jakiejkolwiek osoby, która jest w danym momencie lub która w dowolnym momencie w okresie 12 miesięcy przed takim oferowaniem stanowiska lub zatrudnieniem była pracownikiem lub konsultantem Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych, (ii) nakłaniać lub zachęcać jakiegokolwiek pracownika Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych do odejścia z pracy w Spółce lub którymkolwiek z jej Podmiotów stowarzyszonych, lub (iii) ingerować w relacje Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych z jakąkolwiek osobą lub podmiotem, który jest zatrudniony lub w inny sposób zaangażowany w świadczenie usług na rzecz Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych. (c) Zakaz podejmowania współpracy z Klientami. W okresie zatrudnienia w Spółce i jej Podmiotach stowarzyszonych oraz w czasie trwania Okresu ograniczonego nie możesz, bezpośrednio ani pośrednio, sam lub wspólnie z jakąkolwiek inną Osobą, bez uprzedniej pisemnej zgody Spółki, (i) nakłaniać lub usiłować nakłaniać jakiegokolwiek klienta, kontrahenta (byłego lub obecnego), dostawcy, licencjobiorcy, franczyzobiorcy, partnera joint venture lub osoby pozostającej w innych relacjach biznesowych ze Spółką lub którymkolwiek z jej Podmiotów stowarzyszonych (zwanych łącznie „Klientami”) do zaprzestania prowadzenia interesów ze Spółką lub którymkolwiek z jej Podmiotów stowarzyszonych, (ii) kierować całości lub części interesów Klienta prowadzonych ze Spółką do jakiegokolwiek konkurenta Spółki lub jej Podmiotów stowarzyszonych, lub (iii) w jakikolwiek sposób zakłócać relacji pomiędzy jakimkolwiek Klientem, z jednej strony, a Spółką lub którymkolwiek z jej Podmiotów stowarzyszonych z drugiej strony. (d) Środki zaradcze i zabezpieczenie roszczeń w drodze nakazu lub zakazu sądowego. Przyjmujesz do wiadomości, że naruszenie któregokolwiek z postanowień zawartych w niniejszym punkcie 2.15 spowodowałoby nieodwracalne szkody dla Spółki i jej Podmiotów stowarzyszonych w znacznej kwocie, której nie dałoby się w prosty sposób ustalić, i że wszelkie środki prawne (w tym zapłata odszkodowania) byłyby niewystarczające. W związku z tym zgadzasz się, że niezależnie od jakichkolwiek postanowień niniejszej Umowy, oprócz innych form odszkodowania, którego wysokość Spółka jest w stanie wykazać, Spółka i jej Podmioty stowarzyszone są uprawnione (bez konieczności wykazania straty ekonomicznej lub innej rzeczywistej szkody) do zabezpieczenia roszczeń w drodze nakazu lub zakazu sądowego (w tym tymczasowych środków zabezpieczających, nakazów tymczasowych i nakazów stałych), bez składania kaucji przez dowolny sąd właściwej jurysdykcji w odniesieniu do jakiegokolwiek

---

![Slide 52](<restrictedstockunitaward052.jpg>)

> **Source slide transcript**
>
> 52 naruszenia lub groźby naruszenia któregokolwiek z postanowień niniejszego punktu 2.15, oprócz wszelkich innych przysługujących Spółce środków prawnych lub zadośćuczynień na zasadzie słuszności. Ponadto w przypadku umyślnego naruszenia postanowienia ograniczającego (zgodnie z definicją zawartą w niniejszym punkcie 2.15), (i) wszystkie prawa przysługujące Ci na mocy niniejszej Umowy, niezależnie od tego, czy zostały one nabyte, czy też nie, wygasają ze skutkiem natychmiastowym, oraz (ii) wszelkie Akcje, środki pieniężne lub inne przedmioty majątkowe wypłacone lub przekazane Ci zgodnie z niniejszą Umową zostają utracone i jesteś zobowiązany do zwrotu takich Akcji, środków pieniężnych lub innych przedmiotów majątkowych Spółce, nie później niż trzydzieści (30) dni kalendarzowych po złożeniu przez Spółkę wniosku o ich zwrot. Dla celów niniejszej Umowy „Umyślne naruszenie postanowienia ograniczającego” oznacza istotne naruszenie przez Ciebie któregokolwiek z postanowień niniejszego punktu 2.15, co do którego wiedziałeś lub powinieneś był wiedzieć po należytej weryfikacji, że stanowi takie istotne naruszenie. Nie należy interpretować poprzednich zdań niniejszego punktu 2.15 jako zrzeczenia się ewentualnych praw przysługujących Spółce i jej Podmiotom stowarzyszonym z tytułu odszkodowania na mocy niniejszej Umowy lub z innego tytułu, a wszystkie takie prawa są nieograniczone. Okres ograniczony zostaje zawieszony podczas (i zostanie uznany za automatycznie przedłużony o) każdego okresu, w którym naruszasz postanowienia odpowiednio punktu 2.15(a), (b) lub (c). W przypadku gdy sąd właściwej jurysdykcji uzna, że którekolwiek z postanowień niniejszego punktu 2.15 jest nieważne lub bardziej restrykcyjne, niż zezwala na to prawo właściwe dla takiej jurysdykcji, wówczas wyłącznie w odniesieniu do wykonania postanowień niniejszego punktu 2.15 w ramach jurysdykcji tego sądu, postanowienie takie będzie interpretowane i wykonywane w myśl maksymalnego ograniczenia dozwolonego przez takie prawo właściwe. (e) Potwierdzenia. (1) Potwierdzasz, że Spółka i jej Podmioty stowarzyszone poświęciły i nadal będą poświęcać znaczną ilość czasu, pieniędzy i wysiłku na rozwój strategii biznesowych, stosunków z pracownikami, klientami i innymi podmiotami oraz dobrej woli na zbudowanie efektywnej organizacji. Potwierdzasz, że Spółka i jej Podmioty stowarzyszone mają uzasadniony interes biznesowy i prawo do ochrony swojej wartości i relacji z pracownikami, klientami i innymi osobami, a także, że Spółka i jej Podmioty stowarzyszone mogą poważnie ucierpieć na skutek utraty lub pogorszenia relacji z pracownikami, klientami i innymi osobami. Ponadto potwierdzasz, że Spółka i jej Podmioty stowarzyszone mają prawo do ochrony i zachowania wartości Spółki i Podmiotów stowarzyszonych w zakresie dozwolonym przez prawo. (2) W świetle powyższych potwierdzeń zgadzasz się, że zobowiązania zawarte w niniejszej Umowie są rozsądne i uzasadnione dla celów odpowiedniej ochrony interesów i wartości firmy Spółki i jej Podmiotów stowarzyszonych. Ponadto potwierdzasz, że chociaż przestrzeganie zobowiązań zawartych w niniejszej Umowie może uniemożliwić Ci osiąganie dochodów z pracy w przedsiębiorstwie prowadzącym działalność podobną do działalności Spółki i jej Podmiotów stowarzyszonych, to dzięki swojemu doświadczeniu i umiejętnościom masz inne możliwości osiągania dochodów oraz odpowiednie środki wsparcia dla siebie i osób pozostających na Twoim utrzymaniu.

---

![Slide 53](<restrictedstockunitaward053.jpg>)

> **Source slide transcript**
>
> 53 (3) W świetle potwierdzeń zawartych w niniejszym punkcie 2.15, zobowiązujesz się nie kwestionować ani nie podważać zasadności, ważności ani wykonalności jakichkolwiek ograniczeń i zobowiązań zawartych w niniejszym punkcie 2.15. **** Czekamy na Twój ciągły wkład w rozwój Spółki. Proszę potwierdzić otrzymanie Programu i przyznanego Prawa. Z poważaniem, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 54](<restrictedstockunitaward054.jpg>)

> **Source slide transcript**
>
> 54 APPENDIX PERRIGO COMPANY PLC Additional Terms and Provisions to Restricted Stock Unit Award Agreement (Service-Based) Terms and Conditions This Appendix (the “Appendix”) includes additional terms and conditions that govern the restricted stock units (“RSUs” or “Award”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement. The Award will not create any entitlement to receive any similar benefit in the future. Notifications This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of January 2023. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the RSUs and Ordinary Shares are issued to you or the shares issued upon vesting of the RSUs are sold. In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable. Conditions et dispositions supplémentaires à l’ Accord relatif à l’attribution d’unités d’action avec restrictions (rémunération fondée sur les services) Conditions Le présent Appendice (l’« Appendice ») comprend des conditions complémentaires régissant les unités d’action avec restrictions (« UAR » ou « Prime ») qui vous sont attribuées en vertu du Plan si vous résidez dans l’un des pays repris ci-dessous. Certains termes commençant par une lettre majuscule utilisés dans le présent Accord mais qui n’y sont pas définis ont le sens qui leur est

---

![Slide 55](<restrictedstockunitaward055.jpg>)

> **Source slide transcript**
>
> 55 attribué dans le Plan ou l’Accord. La Prime n’instaure aucun droit à recevoir des avantages similaires à l’avenir. Notifications Le présent Appendice comprend également des informations spécifiques aux pays dont vous devez avoir connaissance eu égard à votre participation au Plan. Les informations se fondent sur les lois relatives aux valeurs mobilières, au contrôle des échanges et autres en vigueur dans les pays respectifs en janvier 2023. Souvent complexes, ces lois font l’objet de modifications fréquentes. Par conséquent, la Société vous recommande vivement de ne pas considérer les renseignements repris aux présentes comme l’unique source d’information relative aux conséquences de votre participation au Plan, car ces renseignements peuvent être obsolètes au moment de la dévolution des UAR ou de l’émission des Actions ordinaires pour votre compte, ou de la vente des actions émises lors de la dévolution des UAR. Par ailleurs, ces informations sont d’ordre général et peuvent ne pas s’appliquer à votre situation particulière. De plus, la Société n’est pas en mesure de vous garantir un quelconque résultat particulier. Par conséquent, il vous est conseillé de demander des conseils professionnels appropriés quant à la manière dont les lois de votre pays en la matière peuvent s’appliquer à votre situation particulière. Enfin, veuillez noter que si vous êtes citoyen ou résident d’un pays autre que celui dans lequel vous travaillez actuellement ou si votre emploi est transféré après l’octroi, les informations figurant dans l’Appendice peuvent ne pas appliquer. Extra voorwaarden en voorzieningen bij De Overeenkomst over voorwaardelijk toegekende aandelen (op basis van diensten) Algemene voorwaarden Deze Bijlage (de 'Bijlage') omvat extra algemene voorwaarden voor de voorwaardelijk toegekende aandelen ('RSU's' of 'Award') die u volgens het Plan zijn toegekend als u in een van onderstaande landen woont. Bepaalde termen in hoofdletters die in deze Bijlage werden gebruikt maar niet gedefinieerd, hebben de betekenis die in het Plan en/of de Overeenkomst is vermeld. De Award creëert geen recht om een soortgelijk voordeel in de toekomst te krijgen. Meldingen Deze Bijlage bevat ook landenspecifieke informatie waarvan u op de hoogte moet zijn met betrekking tot uw deelname aan het Plan. De informatie is gebaseerd op de effecten-, wisselcontrole- en andere wetten die in de respectieve landen sinds januari 2023 van kracht zijn. Zulke wetten zijn vaak complex en worden regelmatig aangepast. Daarom raadt het Bedrijf u ten sterkste aan de informatie hierin niet te gebruiken als enige bron van informatie over de gevolgen van uw deelname aan het Plan, omdat de informatie verouderd kan zijn op het ogenblik dat uw toezegging in de RSU's en de Gewone aandelen u worden uitgekeerd of wanneer de bij de toezegging van de RSU's uitgegeven aandelen worden verkocht.

---

![Slide 56](<restrictedstockunitaward056.jpg>)

> **Source slide transcript**
>
> 56 Ook is de informatie algemeen van aard en mag u ze niet toepassen op uw specifieke situatie. Het Bedrijf bevindt zich evenmin in een positie om u een specifiek resultaat te verzekeren. We raden u dan ook aan om professioneel advies te vragen over hoe de relevante wetten in uw land van toepassing kunnen zijn op uw specifieke situatie. Ten slotte, merk op dat als u een burger of inwoner bent van een ander land dan het land waarin u op dit moment werkt, of uw tewerkstelling na de toekenning verhuist, de informatie in de Bijlage mogelijk niet van toepassing is. Dodatkowe warunki i postanowienia Umowa przydziału Akcji warunkowych (w oparciu o stosunek pracy) Warunki Niniejszy Załącznik („Załącznik”) zawiera dodatkowe warunki, które regulują akcje warunkowe („RSU”) przyznaną w ramach Programu, jeśli mieszkasz w jednym z wymienionych poniżej krajów. Określone terminy pisane wielką literą, które nie zostały zdefiniowane w niniejszym Załączniku, mają znaczenie określone w Programie i/lub Umowie. Prawo nie uprawnia do uzyskiwania podobnych korzyści w przyszłości. Powiadomienia Niniejszy Załącznik zawiera również informacje dotyczące poszczególnych krajów, o których powinieneś(-as) wiedzieć w związku z uczestnictwem w Programie. Informacje oparte są na papierach wartościowych, kontroli dewizowej i innych przepisach obowiązujących w odpowiednich krajach od stycznia 2023 r. Takie przepisy prawa są często skomplikowane i często się zmieniają. W związku z tym Spółka zdecydowanie zaleca, aby nie polegać na informacjach wymienionych w niniejszym dokumencie jako jedynym źródle informacji związanych z konsekwencjami uczestnictwa w Programie, gdyż informacje te mogą być nieaktualne w momencie nabycia lub wykonywania opcji na akcje, a Akcje Zwykłe są Ci wydawane lub w przypadku sprzedaży Akcji Zwykłych nabytych w ramach Programu. Ponadto informacje mają charakter ogólny i mogą nie mieć zastosowania do konkretnej sytuacji, a Spółka nie jest w stanie zapewnić Ci żadnego konkretnego rezultatu. W związku z tym zaleca się zasięgnięcie odpowiedniej profesjonalnej porady dotyczącej tego, w jaki sposób odpowiednie przepisy w Twoim kraju mogą mieć zastosowanie do konkretnej sytuacji. Wreszcie należy pamiętać, że jeśli jesteś obywatelem/obywatelką lub rezydentem/rezydentką kraju innego niż kraj, w którym obecnie pracujesz lub przenosisz się do nowego miejsca po przyznaniu, informacje zawarte w Załączniku mogą nie mieć zastosowania. Australia Important Notice No financial product advice is provided in this Appendix, this Agreement or the Plan (the “Plan Documents”) and nothing should be taken to constitute a recommendation or statement of opinion that is intended to influence a person or persons in making a decision to participate in the Plan. The Plan Documents do not take into account your objectives, financial situation and

---

![Slide 57](<restrictedstockunitaward057.jpg>)

> **Source slide transcript**
>
> 57 needs. You should consider obtaining your own financial product advice from a person who is licensed by the Australian Securities and Investments Commission to give such advice. If you intend to apply to participate in the Plan, you must make your own independent assessment and investigation in relation to your legal and taxation position including seeking professional advice. You must base any decision you may make on such independent assessment, investigation or advice. Offer made without disclosure A copy of the terms of the Plan will be provided to you with this Agreement. Notwithstanding the terms of the Plan, an offer to receive RSUs and participate in the Plan, if received in Australia, is made without disclosure to investors in reliance on the regulatory relief set out in Division 1A of Part 7.12, and for the purposes of section 1100N(b), of the Corporations Act 2001 (Cth). As set out in this Agreement, an RSU represents the right to receive one Ordinary Share subject to all the relevant vesting conditions being met, or otherwise waived, in accordance with the Plan. For the avoidance of doubt, a RSU will only be considered earned and able to vest and convert into an Ordinary Share following the assessment of whether the relevant vesting conditions have been met. The RSUs will be issued for nil consideration. You are not required to pay for an RSU or for the subsequent issue or transfer of an Ordinary Share on vesting of that RSU, however your responsibility for any taxes will be as set out in the terms of the Plan and this Agreement. Clause 1.5(d) of this Agreement provides that you will be credited one additional RSU for each Ordinary Share that you would have received had your outstanding RSUs been Ordinary Shares. Notwithstanding that clause, for the purposes of complying with any applicable laws (including the conditions of any applicable regulatory relief), the Company’s board of directors may determine, in its sole discretion, to pay any dividend equivalents to which you are entitled under clause 1.5 of this Agreement wholly in cash. The Company will not provide you with any loans or financial assistance under the Plan in connection with the offer of the RSUs. No RSUs or resulting Ordinary Shares provided to you under the Plan will be held by a trustee/nominee. The indicative daily price of the Ordinary Shares on the New York Stock Exchange (NYSE), quoted in US dollars, is available on the Company’s website at http://perrigo.investorroom.com/stock-information. The Ordinary Shares are also quoted on the NASDAQ Stock Market (NASDAQ) (refer to NASDAQ’s website at http://www.nasdaq.com/symbol/prgo).

---

![Slide 58](<restrictedstockunitaward058.jpg>)

> **Source slide transcript**
>
> 58 The Australian dollar equivalent of the Ordinary Shares can be determined using prevailing exchange rate published by Thomson Reuters (Prevailing Exchange Rate) Alternatively, the Company will advise you of the price of its Ordinary shares (in equivalent Australian dollars) as soon as possible following receipt of any request for such information. This information may be obtained by you contacting your local Human Resources representative. Before accepting an offer to be granted RSUs, you should satisfy yourself that you have a sufficient understanding of the risks set out below and should consider if the RSUs are a suitable investment for you, having regard to your own investment objectives, financial circumstances and taxation position: (a) the vesting conditions for your RSUs may not be satisfied for reasons beyond the Company or your control; (b) you are not permitted to transfer your RSUs unless permitted under this Agreement or the Plan; (c) if your RSUs vest and you subsequently receive Shares: (i) the value of those shares may rise and fall according to investor sentiment, general economic conditions and outlook, international and local stock markets, employment, inflation, interest rates, government policy, taxation and regulation; and (ii) there is no guarantee that an active trading market for the shares will exist or that the price of the shares will increase. There may be relatively few potential buyers or sellers of the shares on the NYSE, NASDAQ ,TASE or any other applicable market at any time and this may increase the volatility of the market price of the shares. It may also affect the prevailing market price at which you may be able to sell your Shares. (iii) except as otherwise provided in this Agreement, you will have no voting, dividend, or other stockholder rights in any Shares until you become the registered holder of those Shares. Until you become the registered holder of Shares, you will have only the rights of an unsecured creditor with respect to those Shares; (d) there may be taxation implications arising for you in participating under this Agreement and in the Plan. The tax consequences of participating in the Plan are based on complex tax laws, which may be subject to varying interpretations, and the application of such laws may depend, in large part, on the surrounding facts and circumstances. The tax regime applying to you may change. Please note that the above risks are only general risks of acquiring and holding RSUs under the Plan. It does not purport to list every risk that may be associated with the Plan now or in the future. There may be other risks of participating in the Plan or holding shares that are specific to your circumstances. If you acquire Ordinary Shares following exercise of your RSU and you offer those shares for sale to a person or entity resident in Australia, then the offer may be subject to disclosure requirements

---

---

![Slide 59](<restrictedstockunitaward059.jpg>)

> **Source slide transcript**
>
> 59 under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer. If at the time of vesting, the Company determines that it is not legal under Australian securities laws to issue or transfer the Ordinary Shares, the outstanding RSUs will be cancelled and no Shares will be issued or transferred to you nor will any benefits in lieu of shares be paid to you. Exchange Control Information. Exchange control reporting mandates disclosure of payments equal to or exceeding AUD10,000 made to a foreign individual or entity. This reporting is generally done automatically by the financial institution making the transfer. Austria Notifications Exchange Control Information. If you hold Ordinary Shares outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter is less than €5,000,000 (when converted to Euros if applicable). If the threshold is met or exceeded, quarterly reporting obligations exist If quarterly obligations apply, the reporting date is the end of each quarter and the deadline for filing the report is the 15th of the month following the end of the quarter. When shares are sold, there may be exchange control obligations if the cash received is held in a bank account outside Austria. If the volume of all your accounts abroad exceeds €10,000,000 (when converted to Euros if applicable), the balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month. Belgium Notifications Foreign Asset/Account Reporting Information. You are required to report any security or bank accounts (including brokerage accounts) you maintain outside of Belgium on your annual tax return. In a separate report, you are required to provide the National Bank of Belgium with certain details regarding such foreign accounts (including the account number, bank name and country in which any such account was opened). This report, as well as additional information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under Kredietcentrales / Centrales des crédits caption. Stock Exchange Tax. A stock exchange tax could apply for Belgian tax residents transacting through a non-Belgium broker once the shares are sold. It is recommended that you consult with your personal tax advisor with respect to your requirements.

![Slide 60](<restrictedstockunitaward060.jpg>)

> **Source slide transcript**
>
> 60 Notifications Communication d’informations relatives aux actifs ou comptes étrangers. Vous êtes tenu de déclarer, dans votre déclaration fiscale annuelle, tout compte-titres ou compte en banque (y compris les comptes de courtage) que vous détenez en dehors de la Belgique. Dans une déclaration distincte, vous êtes tenu de communiquer à la Banque Nationale de Belgique certains détails concernant les comptes étrangers (notamment le numéro de compte, le nom de la banque et le pays où le compte a été ouvert). Cette déclaration ainsi que toutes les informations indiquant comment la remplir sont disponibles sur le site web de la Banque Nationale de Belgique (www.nbb.be) à la section « Centrales des crédits/Kredietcentrales ». Taxe sur les opérations de bourse. Une taxe sur les opérations de bourse peut s’appliquer aux résidents fiscaux belges effectuant des transactions via un courtier non belge lors de la vente des actions. Il est recommandé de consulter votre conseiller fiscal personnel concernant vos obligations. Meldingen Informatie over buitenlands vermogen/rekeningrapportering. U moet alle garantie- of bankrekeningen (inclusief beleggingsrekeningen) die u buiten België bezit, vermelden op uw jaarlijkse belastingsbrief. In een afzonderlijk overzicht moet u de Nationale Bank van België informatie geven over zulke buitenlandse rekeningen (inclusief het rekeningnummer, de naam van de bank en het land waarin zulke rekening is geopend). Dit overzicht, evenals extra informatie over hoe u het moet opstellen, vindt u op de website van de Nationale Bank van België, www.nbb.be, onder de titel Kredietcentrales. Taks op beursverrichtingen. Een taks op beursverrichtingen kan van toepassing zijn op Belgische fiscale inwoners die transacties uitvoeren via een niet-Belgische makelaar wanneer de aandelen worden verkocht. Het wordt aanbevolen om uw persoonlijke fiscale adviseur te raadplegen met betrekking tot uw verplichtingen. Bermuda Terms and Conditions The Award Agreement is not subject to and has not received approval from the Bermuda Monetary Authority and the Registrar of Companies in Bermuda, and no statement to the contrary, explicit or implicit, is authorized to be made in this regard. The securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act 2003 of Bermuda. Brazil Terms and Conditions Labor Law Acknowledgment. You agree that, for all legal purposes, (i) the benefits provided under the Plan are the result of commercial transactions unrelated to your employment; (ii) the

![Slide 61](<restrictedstockunitaward061.jpg>)

> **Source slide transcript**
>
> 61 Plan is not a part of the terms and conditions of your employment; and (iii) the income from the RSUs, if any, is not part of your remuneration from employment. Notifications Compliance with Law. By accepting the RSUs, you agree to comply with Brazilian law when the RSUs vest and the shares are sold. You also agree to report and pay any and all taxes associated with the vesting of the RSUs, the sale of the RSUs acquired pursuant to the Plan, and the receipt of any dividends. Exchange Control Information. If you are a resident or domiciled in Brazil and hold assets and rights outside Brazil with an aggregate value exceeding US$100,000, you will be required to prepare and submit to the Central Bank of Brazil an annual declaration of such assets and rights. Assets and rights that must be reported include RSUs. Canada Notifications Payout of RSUs in Shares Only. With respect to all Employees residing in Canada, the Company will convert all vested RSUs only into an equivalent number of Shares and the Plan will not provide an option to settle the RSUs in cash. Foreign Asset/Account Reporting Notice. Canadian residents may be required to report foreign property (including Shares) on an annual basis on form T1135 (Foreign Income Verification Statement) if the total cost of the foreign property exceeds CAD 100,000 at any time in the year. The grant of RSUs must be reported if the CAD 100,000 cost threshold is exceeded because of other foreign property held. RSUs may be reported at a nil cost. The form must be filed by April 30 of the following year. It is recommended that you consult with your personal tax advisor with respect to your requirements. Tax Information. Withholding will include both federal income tax as well as provincial tax. Terms and Conditions Resale Restrictions. The Ordinary Shares received by Canadian residents pursuant to this Plan will be subject to an indefinite holding period and the resale of the Ordinary Shares will be prohibited, unless certain conditions are met in respect of the Company in accordance with applicable Canadian securities laws or another applicable Canadian prospectus exemption is available. Eligibility of Participants. Notwithstanding the terms of this Agreement or the Plan, no offers of RSUs or Ordinary Shares may be made to you if you are not an employee, executive officer, director or consultant of the Company or a related entity of the Company, in accordance with Section 2.24 of National Instrument 45-106.

![Slide 62](<restrictedstockunitaward062.jpg>)

> **Source slide transcript**
>
> 62 Employment Law Matters: Notwithstanding the terms of this Agreement or the Plan, the term “Termination Date” shall mean the earliest of: a) Any date specified in this Agreement or the Plan; b) The date on which the Company or any applicable Affiliate delivers to you notice in a form prescribed by the Company that the Company is thereby terminating the employment relationship (regardless of whether the notice or termination is lawful or unlawful or is in breach of any contract of employment); c) Except in the event of a Separation for Good Reason, the date on which you deliver notice in a form prescribed by the Company to the Company or any applicable Affiliate that you are terminating the employment relationship (regardless of whether the notice or termination is lawful or unlawful or is in breach of any contract of employment); d) The date on which you cease to provide services to the Company or any applicable Affiliate, except where you are on an authorized leave of absence; and e) The date on which you cease to be considered an “employee” of the Company or any applicable Affiliate under applicable law. Notwithstanding the terms of this Agreement or the Plan, the definition of “Cause” shall be determined in accordance with applicable laws in the jurisdiction of employment. In accordance with Section 2.13, you consent and agree to the payment of the reimbursements set out therein, including through deductions of the amounts specified in paragraph 2.13 from any wages owed by the Company to the employee. The provisions set out in Section 2.15(a) do not apply to employees in the province of Ontario other than executive employees who are exempted from XV.1 of the Ontario Employment Standards Act, 2000. Czech Republic Terms and Conditions Consent to Receive Documents in English. By accepting the Award, you confirm that you have read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly. Přijetím tohoto Oznámení potvrzujete, že jste přečetl a porozuměl jste Podmínkám plánu (“Plan”) a Smlouvě (“Agreement”), které Vám byly poskytnuty v anglickém jazyce. Zároveň prohlašujete, že souhlasíte s podmínkami uvedenými v těchto dokumentech. Applicable Law

![Slide 63](<restrictedstockunitaward063.jpg>)

> **Source slide transcript**
>
> 63 Nothing in the Agreement shall prejudice any rights you may have under mandatory provisions of Czech law. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United States District Court for the Western District of Michigan, and in any appellate court thereof or before the competent court of the Participant or the Company within the meaning of Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters, and Czech Act No. 99/1963 Coll., on the Code of Civil Procedure. Data Privacy All personal information will be processed in accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (General Data Protection Regulation) and applicable Czech legal regulations on the protection of personal data. Changes to the Agreement Sections 2.14 (a) (10), 2.15 (a), (b) and (e) (3) shall not apply. Notifications Restriction on cash payments. Under Czech Act No. 254/2004 Coll., on Cash Payments, as amended, it is prohibited to receive or provide payments in cash exceeding the amount of CZK 270.000 within one day. Payments exceeding this amount must be executed cashless. This restriction relates to payments from one contracting party to one other contracting party. Thus, it is not a restriction on the sum of all payments made by one individual or entity within one day. Nevertheless, since the restriction on cash payments may be subject to a change (especially a lower threshold might be set), we recommend consulting your personal legal advisor prior to receiving or providing a larger amount of cash payments. Denmark Tax Reporting Information. You may have to report your foreign broker accounts and shares held in a foreign bank or broker to the Danish tax administration. It is recommended that you consult with your personal tax advisor with respect to your requirements. Terms and Conditions The Agreement will under no circumstances entail that your relationship with the contracting company can be considered as an employment. Thus, any references to you as an employee or to the relationship as an employment, shall be construed as an reference to you as an independent contractor and a contractor relationship. The Danish Contract Act (in Danish: aftaleloven) and Danish case law regulate the terms of

![Slide 64](<restrictedstockunitaward064.jpg>)

> **Source slide transcript**
>
> 64 the Award Agreement. Below, it is outlined when the Danish Contract Act, Danish case law and other applicable legislation deviate from terms stated in the Award Agreement: Section 1.3, subsection d, litra 2 (i and ii) in the Award Agreement is amended to the following: “(2) “Termination without Cause” means the involuntary termination of your contractual relationship by the Company without any Cause.” Regardless of section 2.3 in the Award Agreement, vested and acquired shares do not lapse as a consequence of your Termination Date for reasons of Cause. In relation to Section 2.7 in the Award Agreement the following also applies, which supersedes section 2.7 in case of conflicting regulation: In addition to section 2.10, subsection b, all personal information will be managed in accordance with the European Data Protection Regulation (in Danish: databeskyttelsesforordningen) and the Danish Data Protection Act (in Danish: personbeskyttelsesloven). Section 2.15, subsection a – d in the Award Agreement is void and unenforceable in Denmark and instead the following is agreed: 2.15 NON-COMPETITION AND NON-SOLICITATION 2.15.1. You will be covered by this non-competition and non-solicitation clause for 6 months after the effective date of termination. 2.15.2. In this period, you are entitled to – only with the prior written consent of the affiliate employing or retaining you (the “Affiliate”) – be engaged or financially interested, directly or indirectly, in any business which develops and/or distributes products or services that compete or may compete with the Affiliate or any group companies’ products and/or services or in any other business competing with the Affiliate or any group companies in any other way. This restriction includes any interest whatsoever by way of, for example, employment, ownership in full or in part, membership of a board, consultancy services and the like in Denmark and abroad. 2.15.3. During 6 months after the effective date of termination, you are only with the prior written consent of the Affiliate entitled to be in contact with or have business relations, directly or indirectly, with customers, suppliers or cooperation partners, etc., with whom you have had business relations within the last 12 months prior to the termination. In connection with the termination, the Affiliate will prepare a list of the customers, suppliers and cooperation partners covered by the restriction in this clause. In this connection, you must loyally contribute to the drafting of a thorough list covering all customers, suppliers and/or cooperation partners with whom you have had business relations within the last 12 months prior to the termination. Your deliberate failure to contribute loyally to this list will be considered a material breach of the contract and the Award Agreement. 2.15.4. The effective date of termination is to be construed as the date on which you may be

![Slide 65](<restrictedstockunitaward065.jpg>)

> **Source slide transcript**
>
> 65 ordered or entitled to cease work after the expiry of the notice period, notwithstanding whether you actually end your work with the contracting company at an earlier date. 2.15.5. The non-competition part of this clause will cease to apply, if the Affiliate gives notice of termination to you without you having reasonably caused the termination. The non-competition part of this clause will also cease to apply, if you cease work from the Affiliate for reasonable cause due to the contracting company’s failure to fulfil its obligations, cf. section 11 (1) in the Danish Act on Employment Clauses (in Danish: ansættelsesklausulloven). In both situations, the non-solicitation part of this clause will be maintained. 2.15.6. The Affiliate may terminate the clause with one month's notice to expire at the end of a month. 2.15.7. In the event of your breach of the clause, the Affiliate will be entitled to a penalty of between three and six months' fee for any one breach of the clause and compensation for any additional loss. In the event of a persistent breach of the clause, each month or part of a month is deemed to constitute an independent breach entitling the Affiliate to a new, independently agreed penalty. Any payment of the agreed penalty shall not lead to the discontinuance of your obligation to comply with the clause. The Affiliate may also seek to restrain any breach of the clause through the issue of an injunction. 2.15.8. This clause may be invoked by the Affiliate from the date on which you have been contracted with the contracting company for six months. Estonia No country specific provisions. Finland Notifications Tax Reporting Information. If you hold Ordinary Shares acquired under the Plan, you are generally required to include those Ordinary Shares as assets in your individual tax return. France Terms and Conditions Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly. En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause.

![Slide 66](<restrictedstockunitaward066.jpg>)

> **Source slide transcript**
>
> 66 Notifications Tax Reporting Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return. Tax Information. The RSUs are not intended to qualify as a French tax qualified restricted stock units under French tax law. Foreign Asset/Account Reporting Information. If you are a French resident and hold cash or shares of Common Stock outside of France, you must declare all foreign bank and brokerage accounts (including any accounts that were opened or closed during the tax year) on an annual basis on a special form, No. 3916, together with your income tax return. Renseignements relatifs aux comptes et avoirs étrangers. Si vous êtes résident français et que vous détenez des liquidités ou des Actions ordinaires en dehors de la France, vous êtes tenu de déclarer chaque année, en même temps que votre déclaration de revenus, les références de vos comptes bancaires et comptes-titres étrangers (y compris les comptes qui ont été ouverts ou fermés pendant l’exercice fiscal) par le biais d’un formulaire spécifiquement prévu à cet effet, le formulaire No 3916. Germany Notifications Exchange Control Information. Cross-border payments related to securities transactions in excess of €50,000 must be reported by the seventh working day of the month following the respective payment to the German Central Bank (Bundesbank). If you use a German bank to transfer a cross-border payment related to securities transactions in excess of €50,000 (e.g. in connection with the sale of shares acquired under the Plan), the bank will make the report for you. In addition, you must report any cross-border shareholdings in companies if the share in the capital or the voting rights amount(s) to 10% or more and the investment object exceeds a balance sheet total of €6,000,000 (by the last working day of the sixth calendar month following December 31). Tax Reporting Information. In case of an acquisition of shares in foreign companies with an overall investment amount of more than €150,000 (or in case of an acquisition of 10% or more of the shares in a foreign company), you should consult with your tax advisor whether the investment would have to be reported to your tax office. (Direct and indirect acquisitions of shares in a company have to be added for the purpose of calculating the amounts above.) Greece Notifications Exchange Control Information. Pursuant to your Award, if you withdraw funds of €15,000 or more from a bank in Greece and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation

![Slide 67](<restrictedstockunitaward067.jpg>)

> **Source slide transcript**
>
> 67 of Greek anti-money laundering rules. Hungary No country specific provisions. India Notifications Exchange Control Notification. You understand that you must repatriate any dividends and proceeds from the sale of shares acquired under the Plan to India and convert the proceeds into local currency within 180 days of receipt assuming share holding is less than 10% of the company's share capital or as prescribed under applicable Indian exchange control laws as may be amended from time to time. You will receive a foreign inward remittance certificate ("FIRC") from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event the Reserve Bank of India or your employer requests proof of repatriation. Tax Information. The amount subject to tax on receipt of the shares will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law. Foreign Asset/Account Reporting Information. You are required to declare in the applicable schedules of your annual tax return (a) any foreign assets held by you (e.g., Ordinary Shares acquired under the Plan and, possibly, the Award), (b) any foreign bank accounts for which you have signing authority and (c) any foreign custodian accounts. Ireland Notifications Director Notification Obligation. If you are a director, shadow director or secretary of the Company's Irish Subsidiary or Affiliate, you must notify the Irish Subsidiary or Affiliate in writing within five business days of receiving or disposing of an interest exceeding 1% of the Company (e.g., RSUs, shares, etc.), or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary). Terms and Conditions Israel Type of Grant □ Capital Gain Award (“CGA”)

![Slide 68](<restrictedstockunitaward068.jpg>)

> **Source slide transcript**
>
> 68 □ Ordinary Income Award (“OIA”) □ 3(i) Award □ Unapproved 102 Award Terms and Conditions Settlement of RSUs. Notwithstanding anything to the contrary in this Agreement, if the RSUs granted hereunder are 102 Awards, the RSUs shall be settled in Ordinary Shares only. Trust. All Approved 102 Awards shall be held in trust by a trustee designated by the Company ("Trustee") or shall be supervised by the Trustee in accordance with the instructions set forth by the Israeli Tax Authority (“ITA”), for the requisite lockup period prescribed by the Ordinance and the regulations promulgated thereunder, or such other period as may be required by the ITA, during which period Awards or Ordinary Shares issued thereunder, and all rights resulting from them, including bonus shares, must be held by the Trustee. The Trustee shall not release any Approved 102 Awards, Ordinary Shares issued upon the exercise of any Approved 102 Awards, or any rights, including bonus shares, resulting from such Approved 102 Awards or Ordinary Shares, prior to the full payment of your tax liability. The Trustee or the Israeli Affiliate shall withhold any applicable taxes in accordance with Section 102 or any applicable tax ruling obtained by the Company. Without derogating from the foregoing, if your RSUs do not qualify as Approved 102 Awards the Company may still at its sole discretion, deposit your RSUs in trust to ensure that taxes are properly withheld. You hereby release the Trustee from any liability in respect of any action or decision duly taken and executed in good faith in relation to any RSUs or Ordinary Shares issued to you thereunder. Tax. Without derogating from Section 2.7(b) above, you hereby agree to indemnify the Company and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability for all such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to you. Compliance with Law. By accepting the RSUs, you agree to comply with the provisions of Section 102 and the regulations and rules promulgated thereunder or any tax ruling to be obtained by the Company in connection with your RSUs. Italy Terms and Conditions Plan Document Acknowledgment. In accepting the RSUs, you acknowledge that you have received a copy of the Plan and the Agreement and have reviewed the Plan and the Agreement, including this Appendix, in their entirety and fully understand and accept all provisions of the Plan and the Agreement, including this Appendix. Notifications

![Slide 69](<restrictedstockunitaward069.jpg>)

> **Source slide transcript**
>
> 69 Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any foreign investments or investments (including the Ordinary Shares issued at vesting of the RSUs, cash or proceeds from the sale of Ordinary Shares acquired under the Plan) held outside of Italy, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at vesting of the RSUs. You should report the market value of the shares on 31 December each year; and (b) any changes during the financial year which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You should calculate the IVAFE (Tax on Foreign Financial Products) due on the shareholding. Where the asset is held for part of the year, the tax should be pro-rated. You are exempt from these formalities if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf. Kazakhstan Notifications Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to report the acquisition of shares of a foreign company to the National Bank of Kazakhstan. Latvia No country specific provisions. Lithuania No country specific provisions. Luxembourg Notifications Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf. Mexico Terms and Conditions Modification. By accepting the RSUs, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment.

![Slide 70](<restrictedstockunitaward070.jpg>)

> **Source slide transcript**
>
> 70 Plan Document Acknowledgment. By accepting the award of the RSUs, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement. In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) Participation in the Plan does not constitute an acquired right; (ii) The Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) Participation in the Plan is voluntary; and (iv) The Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares. Labor Law Acknowledgement and Policy Statement. In accepting the RSUs, you expressly recognize the Company is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Ordinary Shares does not constitute an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and on a wholly commercial basis and your sole employer is Perrigo de Mexico S.A. De C.V. (“Perrigo Mexico”). Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your employer, Perrigo Mexico, and do not form part of the employment conditions and/or benefits provided by Perrigo Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment. You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of the Company; therefore, the Company reserves the absolute right to amend and/or discontinue your participation at any time without any liability to you. Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan. Spanish Translation Modificaciόn. Al aceptar las Unidades de Acción Restringida (RSUs, por sus siglas en inglés) usted entiende y esta de acuerdo que cualquier modificación del plan o del acuerdo o su terminación no constituirá un cambio o detrimento de los términos y condiciones de su empleo. Confirmación del Documento del Plan. Al aceptar el otorgamiento de las RSUs, usted reconoce que ha recibido copias y ha revisado dicho acuerdo en su totalidad y que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo.

![Slide 71](<restrictedstockunitaward071.jpg>)

> **Source slide transcript**
>
> 71 Adicionalmente, al firmar el acuerdo, usted reconoce que ha leído, y aprobado de manera específica y expresa los términos y condiciones en el acuerdo en el que se describe y establece claramente los siguiente: (i) La participación en el Plan no constituye un derecho adquirido; (ii) El plan y la participación en el mismo, son ofrecidos por la Compañía de manera totalmente discrecional; (iii) La participación en el Plan es voluntaria; y (iv) La Compañía, y cualquier Sociedad controladora, Subsidiaria o Filiales no son responsables por ningún decremento en el valor de las Acciones. Constancia de aceptación de la ley laboral y declaración de la política. Al aceptar las RSUs, usted reconoce expresamente que la Compañía, es la única responsable de la administración del Plan, y que su participación en el Plan y la adquisición de las acciones comunes no constituyen una relación de trabajo entre usted y la Compañía dado que usted participa en el Plan de manera completamente comercial y el único empleador que tiene es Perrigo de México, S.A. de C.V. (« Perrigo de Mexico »). Con base en lo anterior, usted reconoce expresamente que el Plan y los beneficios que usted pueda obtener de la participación en el Plan, no establecen ningún derecho entre usted y su empleador Perrigo de México y no forman parte de las condiciones de trabajo ni de las prestaciones ofrecidas por Perrigo de México y cualquier modificación del Plan o la terminación de éste, no constituyen un cambio o deterioro de los términos y condiciones de su trabajo. Además, usted comprende que su participación en el Plan es el resultado de una decisión unilateral y discrecional de la Compañía; por lo tanto, la Compañía se reserva el derecho absoluto de modificar y/o interrumpir la participación de usted en cualquier momento sin ninguna responsabilidad para usted. Finalmente, usted declara que no se reserva ninguna acción o derecho de presentar algún reclamo o demanda en contra de la Compañía por compensación, daño o perjuicio alguno como resultado de su participación en el Plan, en consecuencia, otorga el más amplio finiquito al Empleador, así como a la Compañía, a su Sociedad controladora, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan. Netherlands Notifications Insider-Trading Notification. Dutch insider-trading rules prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor. Norway Insider-Trading Notification. Norwegian insider-trading rules prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal

![Slide 72](<restrictedstockunitaward072.jpg>)

> **Source slide transcript**
>
> 72 advisor as well as the Company. Exchange Control Information. Cross-border payments in excess of NOK 100,000 must be reported to the Norwegian foreign exchange register (Valutaregisteret). If you use a Norwegian bank to transfer a cross-border payment in excess of NOK 100,00 in connection with the sale of shares acquired under the Plan, the bank will make the report on your behalf. Foreign Asset/Account Reporting Information. In your Norwegian income tax return, each year you are required to report any security, shares or bank accounts (including brokerage accounts and the Company “Account” referenced in section 1.5 of the Agreement) you maintain outside of Norway. The Company “Account” should not be treated as taxable wealth, as long as the right to receive the dividends is conditional, but you must report it. Poland Terms and Conditions Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly. Notifications Exchange Control Information. If you hold foreign securities (including shares pursuant to the Award) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland (“NBP”). Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 (or equivalent thereof in another currency) at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 26th day of the month following the end of each quarter. In case you are being in regime of a joint marital property, the above threshold shall apply to joint property of the spouses. In addition, if you hold, at the beginning or end of the year, at least 10% of votes in the decision- making body of the entity based abroad (and you are person meeting the previously mentioned criteria), an annual notification, on the official form, must be submitted by you to the NBP by May 31 of the following year. If at the end of the year you did not reach the given threshold but in the next year, at the end of a calendar quarter, you reach the threshold, you are obliged to submit the appropriate form to NBP for this quarter and each of the following quarters of this calendar year (within 26 days from the end of each calendar quarter). Such reports are filed on special forms available on the website of the NBP. The foregoing duties represents personal responsibilities of each shareholder and cannot be fulfilled by any entity on your behalf. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services.

![Slide 73](<restrictedstockunitaward073.jpg>)

> **Source slide transcript**
>
> 73 Furthermore, at the banks’ request, you may be required to inform eligible banks, within the meaning of the Foreign Exchange Act, about all foreign exchange transactions performed through them. You are also required to retain the documents connected with foreign exchange transactions for a period of five years, as measured from the end of the year in which such transaction occurred. Warunki Zgoda na otrzymywanie informacji w języku angielskim. Akceptując Opcję, potwierdzasz przeczytanie i zrozumienie Programu i Umowy, które zostały dostarczone w języku angielskim. W związku z tym akceptujesz warunki tych dokumentów. Powiadomienia Informacje o kontroli dewizowej. Jeśli jesteś w posiadaniu zagranicznych papierów wartościowych (w tym akcji) i posiadasz rachunki za granicą, możesz być zobowiązany(-a) do złożenia określonych sprawozdań w Narodowym Banku Polskim („NBP”. W szczególności, jeśli wartość papierów wartościowych i środków pieniężnych gromadzonych na takich rachunkach zagranicznych przekracza na koniec roku 7 000 000 PLN (lub ekwiwalent tej kwoty w innej walucie), należy co kwartał składać raporty z transakcji i sald rachunków do 26 dnia miesiąca następującego po zakończeniu każdego kwartału. W przypadku pozostawania we wspólności majątkowej z małżonkiem, powyższy próg dotyczy majątku wspólnego małżonków. Ponadto, jeżeli posiadasz na początek lub koniec roku co najmniej 10% głosów w organie stanowiącym podmiotu z siedzibą za granicą (i jesteś osobą spełniającą wyżej wskazane warunki) musisz złożyć w NBP do 31 maja następnego roku dodatkowy raport. Jeśli pod koniec roku nie osiągnąłeś(-aś) określonego progu, ale w następnym roku, pod koniec kwartału kalendarzowego, osiągniesz próg, musisz złożyć odpowiedni formularz do NBP za ten kwartał i każdy z kolejnych kwartałów tego roku kalendarzowego (w ciągu 26 dni od zakończenia każdego kwartału kalendarzowego). Takie raporty są składane w specjalnych formularzach dostępnych na stronie internetowej NBP. Ponadto, jeśli jesteś obywatelem Polski i przekazujesz środki za granicę w wysokości przekraczającej równowartość 15 000 EUR w PLN, przelewu należy dokonać za pośrednictwem upoważnionego banku, instytucji płatniczej lub instytucji pieniądza elektronicznego uprawnionej do świadczenia usług płatniczych. Ponadto na żądanie banków niezbędne może być poinformowanie uprawnionych banków, w rozumieniu ustawy Prawo dewizowe (Foreign Exchange Act), o wszystkich transakcjach walutowych przeprowadzanych za ich pośrednictwem. Jesteś również zobowiązany(-a) do przechowywania dokumentów związanych z transakcjami wymiany walut przez okres pięciu lat, mierzony od końca roku, w którym taka transakcja została wykonana Portugal

![Slide 74](<restrictedstockunitaward074.jpg>)

> **Source slide transcript**
>
> 74 Terms and Conditions Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Award Agreement. Conhecimento da Lingua. O Contratado, pelo presente instrumento, declara expressamente que tem pleno conhecimento da língua inglesa e que leu, compreendeu e livremente aceitou e concordou com os termos e condições estabelecidas no Plano e no Acordo de Atribuição (Award Agreement em inglês). Romania Notifications Statistical Reporting. According to art. 92 of NBR Reg. 4/2021, if you, as a resident of Romania within the meaning of NBR Reg. 4/2021, acquire more than 10% of the share capital in a foreign company, the acquisition must be reported to the National Bank of Romania (“NBR”) for statistical purposes within 30 calendar days of acquiring the ownership right over the shares of the foreign company. You should consult your personal advisor to determine whether you will be required to submit such documentation to the NBR pursuant to your participation in the Plan. Insider-Trading. Insider-trading rules prohibit you from carrying out certain transactions involving shares if you have inside information about the Company (insider dealing). If you are uncertain whether the insider-trading rules apply to you, including with regard to the fact that the Company is listed on the New York Stock Exchange (NYSE), you should consult your personal legal advisor. Depending on the applicable market abuse legislation, you might be subject to certain restrictions on the freedom to trade the shares that are settled through the RSU award, including any applicable prohibition on insider dealing, market manipulation or the unlawful disclosure of inside information. Serbia No country specific provisions. Slovakia Foreign Asset Reporting. You may have a foreign asset reporting obligation if you are considered providing independent professional services “podnikatel”. You should consult with a personal tax advisor to understand your filing obligations. Slovenia No country specific provisions. South Africa Terms and Conditions

![Slide 75](<restrictedstockunitaward075.jpg>)

> **Source slide transcript**
>
> 75 Tax Information. By accepting the RSUs, you agree that, immediately upon vesting of the RSUs, you may need to notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon vesting, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer. It is recommended that you consult with your personal tax advisor with respect to your requirements. Notifications Exchange Control Information. Because no transfer of funds from South Africa is required under the RSUs, no filing or reporting requirements should apply when the award is granted nor when Ordinary Shares are issued upon vesting of the RSUs. However, because the exchange control regulations are subject to change, you should consult your personal advisor prior to vesting and settlement of the award to ensure compliance with current regulations. Spain Terms and Conditions No Entitlement for Claims or Compensation. By accepting the award of RSUs, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of RSUs under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any RSUs will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the RSUs shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the RSUs and the underlying shares is unknown and unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the RSUs and any right to the underlying shares shall be null and void. You understand and agree that, as a condition of the grant of the RSUs, your termination of service for any reason other than death or disability (including for the reasons listed below) will automatically result in the cancellation and loss of any RSUs that may have been granted to you and that were not or did not become vested on the date of termination of service. In particular, you understand and agree that, unless otherwise expressly provided by the Company in this Agreement, the RSUs will be cancelled without entitlement to the Shares or to any amount as indemnification if you terminate service by reason of, but not limited to, the following: resignation; disciplinary dismissal adjudged to be with cause; disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to a "despido improcedente"); individual or collective layoff on objective grounds, whether adjudged to be with cause or adjudged or recognized to be without cause; material

![Slide 76](<restrictedstockunitaward076.jpg>)

> **Source slide transcript**
>
> 76 modification of the terms of employment under Article 41 of the Workers’ Statute; relocation under Article 40 of the Workers’ Statute; Article 50 of the Workers’ Statute; unilateral withdrawal by your employer; and under Article 10.3 of Royal Decree 1382/1985. Notifications Exchange Control Information. You must declare the acquisition, ownership and disposition of stock in a foreign company (including Ordinary Shares acquired under the Plan) to the Spanish Dirección General de Comercio e Inversiones (the “DGCI”), the Bureau for Commerce and Investments, which is a department of the Ministry of Economy and Competitiveness, for statistical purposes. Generally, the declaration must be made in January for Ordinary Shares acquired or sold during (or owned as of December 31 of) the prior year; however, this obligation only applies in the cases in which you hold 10% or more of the share capital of the Company or 10% or more of the voting rights of the Company. Additionally, you may be required to declare electronically to the Bank of Spain any securities accounts (including brokerage accounts held abroad), any foreign instruments (e.g., Ordinary Shares) and any transactions with non-Spanish residents (including any payments of cash or shares made to you by the Company) if the balances in such accounts together with the value of such instruments as of December 31, or the volume of transactions with non-Spanish residents during the prior or current year, exceeds €1,000,000. Generally, you will only be required to report on an annual basis (by January 20 of each year). Note that if the value is less than €1,000,000, there is only an obligation to declare this information to the Bank of Spain upon request from the Bank of Spain, in which case the deadline is two months since the request is received. When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. Should amounts exceed €12,500, you will need to provide the following information to the Spanish Registered Entity: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required. Exceptions to this rule are when you move funds through a Spanish resident bank account opened abroad, or when collections and payments are carried out in cash. These exceptions, however, are subject to their own reporting requirements. Foreign Asset Reporting Requirements. If you hold assets or rights outside of Spain (including shares acquired under the Plan), you may have to file an informational tax report, Form 720, with the tax authorities declaring such ownership by March 31st of the following year. Generally, there is no obligation to file Form 720 if the total value of the following does not exceed Euro 50,000:
>
> - the securities, shares, rights and participations held by you, on December 31 or at any time

![Slide 77](<restrictedstockunitaward077.jpg>)

> **Source slide transcript**
>
> 77 throughout the year, in any kind of entities or in investment funds located outside Spain;
>
> - any transfer of own capital to third parties located abroad; and
> - life and disability insurances in which the individual was policy holder on December 31st. Please note that if an asset is jointly owned, the value is not prorated. Please also note that the application of the rules in respect of valuation of assets and transfers during the year should be carefully analyzed. If the limit of Euro 50,000 euros is exceeded for this described group of assets, all the elements of this group must be reported. For those taxpayers who have filed Form 720 in previous years, they will only be obliged to file it again: (a) When the aggregated value of the assets included in the mentioned group (shares/insurances) had increased in an amount higher than Euro 20,000 regarding the informative return filed in a previous year. (b) When the individual’s condition (owner, co-owner, co-titleholder or co-authorized) had changed or was extinguished during the year, before 31st December, with regard to any of the assets. Please note that the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for assets and rights that you hold abroad. Other tax obligations: Tax residents in Spain may also have the obligation to file the Wealth tax return if the value corresponding to their worldwide net wealth exceeds an exempt threshold that will depends on each Autonomous Community. The deadline to file this Wealth return would be from April to June regarding the net assets held on 31 December of the previous year. In addition, since 2023, a new direct tax has been established, the Solidarity tax on Large Fortunes, which is complementary to the Wealth tax and applies to individuals whose net wealth exceeds Euro 3,000,000. In this tax, the amount effectively paid under the Wealth Tax may be credited in order to avoid double taxation. Both tax obligations should be assessed with your personal tax advisor in order to determine whether you are required to file either or both tax returns. Sweden Terms and Conditions The following shall apply in addition to what is set out under section 2.14 of the Award Agreement: Forfeiture of entitlements under the Plan in case of termination shall apply in case of termination of employment regardless of whether such termination of employment may be justified under Swedish employment protection legislation, and regardless of whether such

![Slide 78](<restrictedstockunitaward078.jpg>)

> **Source slide transcript**
>
> 78 termination may be challenged by you, and regardless of whether such termination is invalidated by verdict or a court order. Tax withholdings. You authorize the Company and/or the Employing Company to withhold or sell shares otherwise distributable to you upon vesting or settlement to satisfy the Company’s payroll tax withholding obligations. Switzerland Notifications Securities Law Information. The RSUs and the issuance of any Ordinary Shares thereunder is not intended to be publicly offered in or from Switzerland. Neither this Award Agreement nor any other materials relating to the Award (1) constitute a prospectus, (2) may be publicly distributed nor otherwise made publicly available in Switzerland, or (3) have been or will be filed with, approved or supervised by any Swiss regulatory authority (in particular, the Swiss Financial Market Supervisory Authority (FINMA)). Tax Information. If you are obliged to submit an ordinary annual tax return in Switzerland, you are required to file a salary certificate with the Swiss tax authorities together with your Swiss tax return. The Company or the Affiliate employing you is obliged to prepare a specific attachment regarding the RSUs to this salary certificate. Before Settlement, for wealth tax purposes, the number of RSUs should be declared with p.m (zero value) in the asset statement of the tax return. After Settlement the total number of Ordinary Shares received are subject to wealth tax at the end of the calendar year and must be declared in your Swiss tax return. Turkey Notifications Securities Law Informations. Under Turkish law, you are not permitted to sell Ordinary Shares acquired under the Plan in Turkey. The Ordinary Shares are currently traded on the Nasdaq Global Select Market, which is located outside of Turkey, under the ticker symbol “PRGO” and the Ordinary Shares may be sold through this exchange. Ukraine Notifications Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU). Terms and Conditions The Award will be outside the scope of your employment or service contract (if any) and as such will not constitute a part of your compensation package under the respective employment or service contract.

![Slide 79](<restrictedstockunitaward079.jpg>)

> **Source slide transcript**
>
> 79 United Kingdom Terms and Conditions Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement: If payment or withholding of the income tax due in connection with the RSUs is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of His Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit. * * * * *

---

## EX-10.6

SEC source: [performancebasedrestrict.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/performancebasedrestrict.htm)

![Slide 1](<performancebasedrestrict001.jpg>)

> **Source slide transcript**
>
> PERRIGO COMPANY PLC RESTRICTED STOCK UNIT AWARD AGREEMENT (PERFORMANCE-BASED) (Under the Perrigo Company plc 2026 Long-Term Incentive Plan) TO: Participant Name RE: Notice of Restricted Stock Unit Award (Performance-Based) This is to notify you that Perrigo Company plc (the “Company”) has granted you an Award under the Perrigo Company plc 2026 Long-Term Incentive Plan (the “Plan”), effective as of Grant Date (the “Grant Date”). This Award consists of performance-based restricted stock units. The terms and conditions of this incentive are set forth in the remainder of this agreement (including any special terms and conditions set forth in any appendix for your country (“Appendix”) (collectively, the “Agreement”). The capitalized terms that are not otherwise defined in this Agreement shall have the meanings ascribed to such terms under the Plan. SECTION 1 Restricted Stock Units – Performance-Based Vesting 1.1 Grant. As of the Grant Date, and subject to the terms and conditions of this Agreement and the Plan, the Company grants to you Number of Awards Granted performance- based restricted stock units (“PSUs”). The number of PSUs awarded in this Section 1.1 is referred to as the “Target Award.” The Target Award may be increased or decreased depending on the level of attainment of Performance Goals for designated Performance Measures as described in Section 1.2. Each PSU shall entitle you to one ordinary share of the Company, nominal value €0.001 per share (“Ordinary Share”) on the PSU Vesting Date set forth in Section 1.2, provided the applicable Performance Goals for each Performance Measure are satisfied. 1.2 Vesting. The number of PSUs awarded in Section 1.1 vesting, if any, shall be determined as of the PSU Vesting Date. That number will be determined based on the average level of attainment of annual Performance Measure(s) for each fiscal year in the Performance Period, in accordance with the schedule determined by the Committee at the time the Performance Measures and applicable Performance Goals are established by the Committee. The Committee shall establish annually one or more Performance Measures and the Performance Goals with respect to each Performance Measure that must be attained for Threshold, Target and Maximum performance for a fiscal year. The Performance Measure and Performance Goals for each fiscal year will be provided to you. Following the end of each fiscal year in the Performance Period, the Committee will determine the percentage of Target Award PSUs that would be payable for such fiscal year, based on the attainment of the Performance Goals for each Performance Measure(s) established by the Committee for that fiscal year. The percentage of the Target Award that would be payable under the schedule shall be adjusted, pro rata, to reflect the attained performance between Threshold and Target, and Target and Maximum.

---

![Slide 2](<performancebasedrestrict002.jpg>)

> **Source slide transcript**
>
> 2 At the end of the Performance Period, the percentage payout for each fiscal year in the Performance Period will be averaged to determine the actual percentage of Target Award PSUs that will vest and be payable on the PSU Vesting Date. In no event will the calculation of a positive payout percentage for any fiscal year be construed to guarantee that any PSUs will vest on the PSU Vesting Date. Payout percentages for the individual fiscal years are determined solely for purposes of determining the average annual payout percentage for the three-year Performance Period. Except as provided in Section 1.4, the PSUs will be permanently forfeited if your Termination Date occurs prior to the PSU Vesting Date. If the average annual performance payout for the Performance Period is less than the Threshold performance level established by the Committee, all PSUs that have not previously been forfeited shall be forfeited as of the PSU Vesting Date. If the average annual performance payout for the Performance Period exceeds the Maximum performance level established by the Committee, in no event will the number of PSUs vesting exceed 200% of the Target Award. 1.3 Definitions. The following terms shall have the following meanings under this Section 1. (a) “Performance Goal” means the level of performance that must be attained with respect to a Performance Measure for a fiscal year for Minimum, Target and Maximum payout. (b) “Performance Measure” for any fiscal year means one or more financial measures, as determined by the Committee. The Committee shall provide how the Performance Measure will be adjusted, if at all, as a result of extraordinary events or circumstances, as determined by the Committee, or to exclude the effects of extraordinary, unusual, or non- recurring items; changes in applicable laws, regulations, or accounting principles; currency fluctuations; discontinued operations; non-cash items, such as amortization, depreciation, or reserves; asset impairment; or any recapitalization, restructuring, reorganization, merger, acquisition, divestiture, consolidation, spin-off, split-up, combination, liquidation, dissolution, sale of assets, or other similar corporation transaction. (c) “Performance Period” means a period of three consecutive fiscal years of the Company, beginning with the first day of the fiscal year of the Company in which the Grant Date occurs and ending on the last day of the third fiscal year in the 3-year period. (d) “PSU Vesting Date” means the last day of the Performance Period. (e) “Separation for Good Reason” means your voluntary resignation from the Company and the existence of one or more of the following conditions that arose without your consent: (i) a material change in the geographic location at which you are required to perform services, such that your commute between home and your primary job site increases by more than 30 miles, or (ii) a material diminution in your authority, duties or responsibilities or a material diminution in your base compensation or incentive compensation opportunities; provided, however, that a voluntary resignation from the Company shall not be considered a Separation for Good Reason unless you provide the Company with notice, in writing, of your

---

![Slide 3](<performancebasedrestrict003.jpg>)

> **Source slide transcript**
>
> 3 voluntary resignation and the existence of the condition(s) giving rise to the separation within 90 days of its initial existence. The Company will then have 30 days to remedy the condition, in which case you will not be deemed to have incurred a Separation for Good Reason. In the event the Company fails to cure the condition within the 30 day period, your Termination Date shall occur on the 31st day following the Company’s receipt of such written notice. (f) “Termination without Cause” means the involuntary termination of your employment or contractual relationship by the Company without Cause, including, but not limited to, (i) a termination effective when you exhaust a leave of absence during, or at the end of, a notice period under the Worker Adjustment and Retraining Notification Act (“WARN”), and (ii) a situation where you are on an approved leave of absence during which your position is protected under applicable law (e.g., a leave under the Family Medical Leave Act), you return from such leave, and you cannot be placed in employment or other form of contractual relationship with the Company. 1.4 Special Vesting Rules. Notwithstanding Section 1.2 above or anything to the contrary in the Plan, if your Termination Date occurs by reason of a Termination without Cause or a Separation for Good Reason on or after a Change in Control (as defined in the Plan and as such definition may be amended hereafter) and prior to the two (2) year anniversary of the Change in Control, all of the PSUs awarded under Section 1.1 that have not previously been forfeited shall become fully vested as if the greater of Target and actual achievement of performance had been obtained for the Performance Period; provided that, for those PSUs for which the Performance Period has ended, the PSUs shall be payable based on actual performance. If your Termination Date occurs because of death, Disability, or Retirement, the PSUs shall vest or be forfeited as of the PSU Vesting Date set forth in Section 1.2, based on the attainment of the performance goals. If your Termination Date occurs in the 24-month period preceding the PSU Vesting Date because of an Involuntary Termination for Economic Reasons, all of the PSUs awarded hereunder shall vest or be forfeited as of the date set forth in Section 1.2, depending on the attainment of Performance Goals; provided, however, that if your Termination Date occurs for a reason that is both described in this sentence and in the first sentence of this Section 1.4, the special vesting rules described in the first sentence of this Section 1.4 shall apply in lieu of the vesting rules described in this sentence. 1.5 Settlement of PSUs. As soon as practicable following the date of the Committee’s first regularly scheduled meeting following the last day of the Performance Period at which the Committee certifies the average payout for each of the three years in the Performance Period (or, if earlier, the date on which the PSUs become vested pursuant to the special vesting rules described in Section 1.4), the Company shall transfer to you one Ordinary Share for each PSU, if any, that becomes vested pursuant to Section 1.2 or 1.4 of this Agreement (the date of any such transfer shall be the “settlement date” for purposes of this Agreement); provided, however, the Company in its discretion may settle PSUs in cash, based on the fair market value of the shares on the vesting date. No fractional shares shall be transferred. Any fractional share shall be rounded to the nearest whole share. The income attributable to the vesting of PSUs and the amount of any required tax withholding will be determined based on the value of the shares on the settlement date. PSUs are not eligible for dividend equivalents. SECTION 2

---

![Slide 4](<performancebasedrestrict004.jpg>)

> **Source slide transcript**
>
> 4 General Terms and Conditions 2.1 Nontransferability. The Award under this Agreement shall not be transferable other than by will or by the laws of descent and distribution. 2.2 No Rights as a Stockholder. You shall not have any rights as a stockholder with respect to any Ordinary Shares subject to the PSU awarded under this Agreement prior to the date of issuance to you of a certificate or certificates for such shares. 2.3 Cause Termination. If your Termination Date occurs for reasons of Cause, all of your rights under this Agreement, whether or not vested, shall terminate immediately. 2.4 Award Subject to Plan. The granting of the Award under this Agreement is being made pursuant to the Plan and the Award shall be payable only in accordance with the applicable terms of the Plan. The Plan contains certain definitions, restrictions, limitations and other terms and conditions all of which shall be applicable to this Agreement. ALL THE PROVISIONS OF THE PLAN ARE INCORPORATED HEREIN BY REFERENCE AND ARE MADE A PART OF THIS AGREEMENT IN THE SAME MANNER AS IF EACH AND EVERY SUCH PROVISION WERE FULLY WRITTEN INTO THIS AGREEMENT. Should the Plan become void or unenforceable by operation of law or judicial decision, this Agreement shall have no force or effect. Nothing set forth in this Agreement is intended, nor shall any of its provisions be construed, to limit or exclude any definition, restriction, limitation or other term or condition of the Plan as is relevant to this Agreement and as may be specifically applied to it by the Committee. In the event of a conflict in the provisions of this Agreement and the Plan, as a rule of construction the terms of the Plan shall be deemed superior and apply. 2.5 Adjustments in Event of Change in Ordinary Shares. In the event of a stock split, stock dividend, recapitalization, reclassification or combination of shares, merger, sale of assets or similar event, the number and kind of shares subject to Award under this Agreement will be appropriately adjusted in an equitable manner to prevent dilution or enlargement of the rights granted to or available for you. 2.6 Acknowledgment. The Company and you agree that the PSUs are granted under and governed by the Notice of Grant, this Agreement (including the Appendix, if applicable) and by the provisions of the Plan (incorporated herein by reference). You: (i) acknowledge receipt of a copy of each of the foregoing documents, (ii) represent that you have carefully read and are familiar with their provisions, and (iii) hereby accept the PSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice of Grant. 2.7 Taxes and Withholding. (a) Withholding (Only Applicable to Individuals Subject to U.S. Tax Laws). This Award is subject to the withholding of all applicable taxes. The Company may withhold, or permit you to remit to the Company, any Federal, state or local taxes applicable to the grant, vesting or other event giving rise to tax liability with respect to this Award. If you have not remitted the full amount of applicable withholding taxes to the Company by the date the Company is required to pay such withholding to the appropriate taxing authority (or such earlier date that the Company may specify to assist it in timely meeting its withholding obligations), the

---

![Slide 5](<performancebasedrestrict005.jpg>)

> **Source slide transcript**
>
> 5 Company shall have the unilateral right to withhold Ordinary Shares relating to this Award in the amount it determines is sufficient to satisfy the tax withholding required by law. State taxes will be withheld at the appropriate rate set by the state in which you are employed or were last employed by the Company. In no event may the number of shares withheld exceed the number necessary to satisfy the maximum Federal, state and local income and employment tax withholding requirements. You may elect to surrender previously acquired Ordinary Shares or to have the Company withhold Ordinary Shares relating to this Award in an amount sufficient to satisfy all or a portion of the tax withholding required by law. (b) Responsibility for Taxes (Only Applicable to Individuals Subject to Tax Laws Outside the U.S.). Regardless of any action the Company or, if different, the Affiliate employing or retaining you takes with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company or the Affiliate employing or retaining you. You further acknowledge that the Company and/or the Affiliate employing or retaining you (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PSUs, including, but not limited to, the grant, vesting or settlement of the PSUs, the subsequent sale of Ordinary Shares acquired pursuant to such settlement and the receipt of any dividends; and (2) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the PSUs to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Further, if you have become subject to tax in more than one jurisdiction between the PSU Grant Date and the date of any relevant taxable event, as applicable, you acknowledge that the Company and/or the Affiliate employing or retaining you (or formerly employing or retaining you, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction. (1) Prior to any relevant taxable or tax withholding event, as applicable, you will pay or make adequate arrangements satisfactory to the Company and/or the Affiliate employing or retaining you to satisfy all Tax-Related Items. In this regard, you authorize the Company and/or the Affiliate employing or retaining you, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: (A) withholding from your wages or other cash compensation paid to you by the Company and/or the Affiliate employing or retaining you; or (B) withholding from proceeds of the sale of Ordinary Shares acquired upon settlement of the PSUs either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (C) withholding in Ordinary Shares to be issued upon settlement of the PSUs. (2) To avoid negative accounting treatment, the Company may withhold or account for Tax-Related Items by considering applicable statutory withholding

---

![Slide 6](<performancebasedrestrict006.jpg>)

> **Source slide transcript**
>
> 6 amounts or other applicable withholding rates. If the obligation for Tax-Related Items is satisfied by withholding in Ordinary Shares, for tax purposes, you are deemed to have been issued the full number of Ordinary Shares subject to the vested PSUs, notwithstanding that a number of the Ordinary Shares are held back solely for the purpose of paying the Tax-Related Items. (3) Finally, you shall pay to the Company or the Affiliate employing or retaining you any amount of Tax-Related Items that the Company or the Affiliate employing or retaining you may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Ordinary Shares or the proceeds of the sale of Ordinary Shares, if you fail to comply with your obligations in connection with the Tax-Related Items. 2.8 Compliance with Applicable Law. The issuance of Ordinary Shares will be subject to and conditioned upon compliance by the Company and you, including any written representations, warranties and agreements as the Administrator may request of you for compliance with all (i) applicable U.S. state and federal laws and regulations, (ii) applicable laws of the country where you reside pertaining to the issuance or sale of Ordinary Shares, and (iii) applicable requirements of any stock exchange or automated quotation system on which the Company’s Ordinary Shares may be listed or quoted at the time of such issuance or transfer. Notwithstanding any other provision of this Agreement, the Company shall have no obligation to issue any Ordinary Shares under this Agreement if such issuance would violate any applicable law or any applicable regulation or requirement of any securities exchange or similar entity. 2.9 Short Term Deferral (Only Applicable to Individuals Subject to U.S. Federal Tax Laws). PSUs payable under this Agreement are intended to be exempt from Code Section 409A under the exemption for short-term deferrals. Accordingly, PSUs will be settled no later than the 15th day of the third month following the later of (i) the end of the Employee’s taxable year in which the vesting date occurs, or (ii) the end of the fiscal year of the Company in which the vesting date occurs. 2.10 Data Privacy. (a) U.S. Data Privacy Rules (Only Applicable if this Award is Subject to U.S. Data Privacy Laws). By entering into this Agreement and accepting this Award, you (a) explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of any of your personal data that is necessary to facilitate the implementation, administration and management of the Award and the Plan, (b) understand that the Company may, for the purpose of implementing, administering and managing the Plan, hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, and details of all awards or entitlements to Shares granted to you under the Plan or otherwise (“Personal Data”), (c) understand that Personal Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, including any broker with whom the Shares issued upon vesting of the Award may be deposited, and that these recipients may be located in your country or elsewhere, and that the recipient’s country may have different data privacy laws and protections than your country, (d) waive any

---

![Slide 7](<performancebasedrestrict007.jpg>)

> **Source slide transcript**
>
> 7 data privacy rights you may have with respect to the data, and (e) authorize the Company, its Affiliates and its agents, to store and transmit such information in electronic form. (b) Non-U.S. Data Privacy Rules (Only Applicable if this Award is Subject to Data Privacy Laws Outside of the U.S.) (1) By entering into this Agreement and accepting this Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other PSU grant materials by and among, as applicable, the Affiliate employing or retaining you, the Company and its Affiliates for the exclusive purpose of implementing, administering and managing your participation in the Plan. (2) You understand that the Company and the Affiliate employing or retaining you may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Ordinary Shares or directorships held in the Company, details of all PSUs or any other entitlement to Ordinary Shares awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). (3) You understand that Data will be transferred to legal counsel or a broker or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country of residence. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local or Company human resources representative. You authorize the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local or Company human resources representative. You understand, however, that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local or Company human resources representative. 2.11 Successors and Assigns. This Agreement shall be binding upon any or all successors and assigns of the Company.

---

![Slide 8](<performancebasedrestrict008.jpg>)

> **Source slide transcript**
>
> 8 2.12 Applicable Law. This Agreement shall be governed by and construed and enforced in accordance with the applicable Code provisions to the maximum extent possible and otherwise by the laws of the State of Michigan without regard to principals of conflict of laws, provided that if you are a foreign national or employed outside the United States, this Agreement shall be governed by and construed and enforced in accordance with applicable foreign law to the extent that such law differs from the Code and Michigan law. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United Stated District Court for the Western District of Michigan, and in any appellate court thereof. 2.13 Forfeiture of PSUs. (a) For Section 16 Officers. If you are or were designated as an officer of the Company in accordance with Rule 16a-1(f) of the Exchange Act (“Section 16 Officer”), any PSUs and Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to the Compensation Recovery Policy of Perrigo or any other “clawback” or recoupment policy now in effect or later adopted by the Company. (b) For All Other Employees. If you are not a Section 16 Officer, if the Company, as a result of misconduct, is required to prepare an accounting restatement due to material noncompliance with any financial reporting requirement under the securities laws, and the Committee determines you either knowingly engaged in or failed to prevent the misconduct, or your actions or inactions with respect to the misconduct and restatement constituted gross negligence, you shall (i) be required to reimburse the Company the amount of any payment relating to any PSUs earned or accrued during the twelve month period following the first public issuance or filing with the SEC (whichever first occurred) of the financial document embodying such financial reporting requirement, and (ii) all outstanding PSUs that have not yet been settled shall be immediately forfeited. In addition, Ordinary Shares acquired under this Agreement, and any gains or profits on the sale of such Ordinary Shares, shall be subject to any “clawback” or recoupment policy now in effect or later adopted by the Company. 2.14 Special Rules for Non-U.S. Grantees (Only Applicable if You Reside Outside of the U.S.) (a) Nature of Grant. In accepting the grant, you acknowledge, understand and agree that: (1) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, except as otherwise provided in the Plan. (2) the grant of the PSUs is voluntary and occasional and does not create any contractual or other right to receive future grants of PSUs, or benefits in lieu of the PSUs, even if PSUs have been granted repeatedly in the past; (3) all decisions with respect to future PSU grants, if any, will be at the sole discretion of the Company;

---

![Slide 9](<performancebasedrestrict009.jpg>)

> **Source slide transcript**
>
> 9 (4) you are voluntarily participating in the Plan; (5) the PSUs and the Ordinary Shares subject to the PSUs are an extraordinary item and which is outside the scope of your employment or service contract, if any; (6) the PSUs and the Ordinary Shares subject to the PSUs are not intended to replace any pension rights or compensation; (7) the PSUs and the Ordinary Shares subject to the PSUs are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments and in no event should be considered as compensation for, or relating in any way to, past services for the Company, the Affiliate employing or retaining you or any other Affiliate; (8) the grant and your participation in the Plan will not be interpreted to form an employment or service contract with the Company or any Affiliate; (9) the future value of the underlying Ordinary Shares is unknown, indeterminable and cannot be predicted with certainty; (10) no claim or entitlement to compensation or damages shall arise from forfeiture of the PSUs resulting from your Termination Date (for any reason whatsoever, whether or not later found to be invalid and whether or not in breach of employment laws in the jurisdiction where you are employed or rendering services, or the terms of your employment agreement, if any), and in consideration of the grant of the PSUs to which you are otherwise not entitled, you irrevocably agree never to institute any claim against the Company or the Affiliate employing or retaining you, waive your ability, if any, to bring any such claim, and release the Company and the Affiliate employing or retaining you from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request dismissal or withdrawal of such claim; and (11) you acknowledge and agree that neither the Company, the Affiliate employing or retaining you nor any other Affiliate shall be liable for any foreign exchange rate fluctuation between the currency of the country in which you reside and the United States Dollar that may affect the value of the PSUs or of any amounts due to you pursuant to the settlement of the PSUs or the subsequent sale of any Ordinary Shares acquired upon settlement. (b) Appendix. Notwithstanding any provisions in this Agreement, the PSU grant shall be subject to any special terms and conditions set forth in any Appendix to this Agreement. Moreover, if you relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan. If you relocate to the United States, the special terms and conditions in the Appendix will apply, or cease to apply, to you, to the extent the Company determines that the application or otherwise of

---

![Slide 10](<performancebasedrestrict010.jpg>)

> **Source slide transcript**
>
> 10 such provisions is necessary or advisable in order to facilitate the administration of the Plan. The Appendix constitutes part of this Agreement. (c) Imposition of Other Requirements. The Company reserves the right to impose other requirements on your participation in the Plan, on the PSUs and on any Ordinary Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with laws of the country where you reside or to facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. 2.15 Noncompetition and Nonsolicitation. (a) Noncompetition. During your employment with the Company and its Affiliates and for a twelve (12) month period following your Termination Date (the “Restricted Period”), you shall not (i) directly or indirectly, without the prior written consent of the Company, engage in or invest as an owner, partner, stockholder, licensor, director, officer, agent or consultant for any Person that conducts a business that is in competition with a business conducted by the Company or any of its Affiliates anywhere in the world; or (ii) accept employment or an engagement for the provision of services in any capacity, including as an employee, director, consultant or advisor, directly or indirectly, with any Person that conducts a business that is in competition with a business conducted by the Company or any of its Affiliates anywhere in the world except where prohibited by local law. For purposes hereof, conducting a business that is in competition with a business conducted by the Company or any of its Affiliates shall include the sale, manufacture, distribution or research and development of any product or service that is similar to a product or service sold, distributed, marketed or being researched or developed (including through a joint venture or investment in another entity) by the Company or any of its Affiliates, including store brand and value brand OTC drug or nutritional products, extended topical generic prescription pharmaceutical products, infant nutrition products, oral care products, and any other product or products that the Company or an Affiliate is marketing or actively planning to market during your employment with the Company and during the one­year period following your Termination Date. If there is a completed sale, transfer or other disposition of the Perrigo Prescription Pharmaceutical business during the Restricted Period, this Section 2.15(a) will not apply to the Perrigo Prescription Pharmaceutical business. Notwithstanding the foregoing, nothing in this provision shall prevent you from passively owning two percent (2%) or less of the outstanding securities of any class of any company listed on a national securities exchange or quoted on an automated quotation system. You may make a written request in writing to the CHRO of the Company for an exception to this Section 2.15(a) and such exception will not be unreasonably withheld. (b) Nonsolicitation of Service Providers. During your employment with the Company and its Affiliates and for the duration of the Restricted Period, you shall not, directly or indirectly, without the prior written consent of the Company, (i) actively solicit, recruit or hire any Person who is at such time, or who at any time during the 12­month period prior to such solicitation or hiring had been, an employee or consultant of the Company or any of its Affiliates, (ii) solicit or encourage any employee of the Company or any of its Affiliates to leave

---

![Slide 11](<performancebasedrestrict011.jpg>)

> **Source slide transcript**
>
> 11 the employment of the Company or any of its Affiliates or (iii) interfere with the relationship of the Company or any of its Affiliates with any Person or entity who or that is employed by or otherwise engaged to perform services for the Company or any of its Affiliates except where prohibited by local law. (c) Nonsolicitation of Clients. During your employment with the Company and its Affiliates and for the duration of the Restricted Period, you shall not, directly or indirectly, alone or in association with any other Person, without the prior written consent of the Company, (i) induce or attempt to induce any client, customer (whether former or current), supplier, licensee, franchisee, joint venture partner or other business relation of the Company or any of its Affiliates (collectively, “Clients”) to cease doing business with the Company or any such Affiliate, (ii) divert all or any portion of a Client’s business with the Company to any competitor of the Company or any such Affiliate, or (iii) in any way interfere with the relationship between any Client, on the one hand, and the Company or any such Affiliate, on the other hand except where prohibited by local law. (d) Remedies and Injunctive Relief. You acknowledge that a violation by you of any of the covenants contained in this Section 2.15 would cause irreparable damage to the Company and its Affiliates in an amount that would be material but not readily ascertainable, and that any remedy at law (including the payment of damages) would be inadequate. Accordingly, you agree that, notwithstanding any provision of this Agreement to the contrary, in addition to any other damages it is able to show, the Company and its Affiliates shall be entitled (without the necessity of showing economic loss or other actual damage) to injunctive relief (including temporary restraining orders, preliminary injunctions and permanent injunctions), without posting a bond, in any court of competent jurisdiction for any actual or threatened breach of any of the covenants set forth in this Section 2.15 in addition to any other legal or equitable remedies it may have. In addition, in the event of your Willful Restrictive Covenant Breach (as defined in this Section 2.15), (i) all of your rights under this Agreement, whether or not vested, shall terminate immediately, and (ii) any Shares, cash or other property paid or delivered to you pursuant to this Agreement shall be forfeited and you shall be required to repay such Shares, cash or other property to the Company, no later than thirty (30) calendar days after the Company makes demand to you for repayment. For purposes of this Agreement, “Willful Restrictive Covenant Breach” means your material breach of any of the covenants set forth in this Section 2.15 which you knew, or with due inquiry, should have known, would constitute such a material breach. The preceding sentences of this Section 2.15 shall not be construed as a waiver of the rights that the Company and its Affiliates may have for damages under this Agreement or otherwise, and all such rights shall be unrestricted. The Restricted Period shall be tolled during (and shall be deemed automatically extended by) any period during which you are in violation of the provisions of Section 2.15(a), (b) or (c), as applicable. In the event that a court of competent jurisdiction determines that any provision of this Section 2.15 is invalid or more restrictive than permitted under the governing law of such jurisdiction, then, only as to enforcement of this Section 2.15 within the jurisdiction of such court, such provision shall be interpreted and enforced as if it provided for the maximum restriction permitted under such governing law. (e) Acknowledgments.

---

![Slide 12](<performancebasedrestrict012.jpg>)

> **Source slide transcript**
>
> 12 (1) You acknowledge that the Company and its Affiliates have expended and will continue to expend substantial amounts of time, money and effort to develop business strategies, employee, customer and other relationships and goodwill to build an effective organization. You acknowledge that the Company and its Affiliates have a legitimate business interest in and right to protect its goodwill and employee, customer and other relationships, and that the Company and its Affiliates could be seriously damaged by the loss or deterioration of its employee, customer and other relationships. You further acknowledge that the Company and its Affiliates are entitled to protect and preserve the going concern value of the Company and its Affiliates to the extent permitted by law. (2) In light of the foregoing acknowledgments, you agree that the covenants contained in this Agreement are reasonable and properly required for the adequate protection of the businesses and goodwill of the Company and its Affiliates. You further acknowledge that, although your compliance with the covenants contained in this Agreement may prevent you from earning a livelihood in a business similar to the business of the Company and its Affiliates, your experience and capabilities are such that you have other opportunities to earn a livelihood and adequate means of support for you and your dependents. (3) In light of the acknowledgements contained in this Section 2.15, you agree not to challenge or contest the reasonableness, validity or enforceability of any limitations on, and obligations of, you contained in this Section 2.15. **** We look forward to your continuing contribution to the growth of the Company. Please acknowledge your receipt of the Plan and this Award. Very truly yours, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 13](<performancebasedrestrict013.jpg>)

> **Source slide transcript**
>
> 13 PERRIGO COMPANY PLC ACCORD RELATIF À L’ATTRIBUTION D’UNITÉS D’ACTION AVEC RESTRICTIONS (RÉMUNÉRATION FONDÉE SUR LES PERFORMANCES) (Dans le cadre du Plan d’incitation à long terme 2026 de Perrigo Company plc) À : Participant Name OBJET : Avis d’attribution d’unités d’action avec restrictions (rémunération fondée sur les performances) Les présentes visent à vous informer que Perrigo Company plc (la « Société ») vous a octroyé une Prime dans le cadre du Plan d’incitation à long terme 2026 de Perrigo Company plc (le « Plan »), avec prise d’effet à la Grant Date (la « Date d’octroi »). Cette Prime est constituée d’unités d’action avec restrictions sur la base des performances. Les conditions de cette incitation sont exposées dans le reste du présent accord, dénommé collectivement l’« Accord » (y compris toutes les conditions particulières stipulées dans les appendices applicables à votre pays [l’« Appendice »]). Les termes commençant par une lettre majuscule utilisés dans le présent Accord et qui n’y sont pas définis ont le sens qui leur est attribué en vertu du Plan. SECTION 1 Unités d’action avec restrictions — Dévolution sur la base des performances 1.1 Octroi. À compter de la Date d’octroi et sous réserve des conditions du présent Accord et du Plan, la Société vous octroie Number of Awards Granted unités d’action avec restrictions sur la base des performances (« UARP »). Le nombre d’UARP attribuées dans la présente section 1.1. est appelé la « Prime cible ». La Prime cible peut être augmentée ou réduite en fonction du niveau d’atteinte des Objectifs de performance relatifs aux Mesures de performances décrites à la section 1.2. Chaque UARP vous donne droit à une action ordinaire de la Société d’une valeur nominale de 0,001 € par action (« Action ordinaire ») à la Date de dévolution des UARP stipulée à la section 1.2, pour autant que les Objectifs de performance de chaque Mesure de performance aient été remplis. 1.2 Dévolution. Le nombre d’UARP attribuées à la section 1.1, le cas échéant, sera déterminé à compter de la Date de dévolution des UARP. Ce nombre sera déterminé sur la base du niveau d’atteinte moyen de la ou des Mesures de performance annuelles de chaque exercice de la Période de performance, conformément au programme fixé par le Comité au moment où il établit les Mesures de performance et les Objectifs de performance applicables.

---

![Slide 14](<performancebasedrestrict014.jpg>)

> **Source slide transcript**
>
> 14 Sur une base annuelle, le Comité établit une ou plusieurs Mesures de performance et, pour chacune d’entre elles, les Objectifs de performance à atteindre pour les performances Seuil, Cible et Maximum d’un exercice. La Mesure de performance et les Objectifs de performance de chaque exercice vous seront communiqués. Au terme de chaque exercice de la Période de performance, le Comité détermine le pourcentage des UARP de la Prime Cible payables pour l’exercice concerné sur la base de l’atteinte des Objectifs de performance de chaque Mesure de performance établie par le Comité. Le pourcentage de la Prime cible payable en vertu du programme est ajusté au pro rata pour correspondre aux performances atteintes entre le Seuil et la Cible ainsi qu’entre la Cible et le Maximum. Une moyenne du pourcentage de paiement relatif à chaque exercice de la Période de performance est établie au terme de cette dernière pour déterminer le pourcentage réel d’UARP de la Prime cible qui sera dévolu et versé à la Date de dévolution des UARP. En aucun cas le calcul d’un pourcentage de paiement positif, pour quelque exercice que ce soit, ne peut être interprété comme une garantie de dévolution d’UARP à la Date de dévolution. Les pourcentages de paiement relatifs aux exercices individuels sont établis uniquement aux fins de la détermination du pourcentage de paiement annuel moyen de la Période de performance d’une durée de trois ans. Sous réserve des cas prévus à la section 1.4, les UARP sont définitivement déchues si votre Date de cessation d’emploi survient avant la Date de dévolution des UARP. Si le pourcentage de paiement annuel moyen de la Période de performance est inférieur au niveau Seuil fixé par le Comité, l’ensemble des UARP qui n’ont pas été déchues jusqu’alors le deviennent à compter de la Date de dévolution des UARP. Si le pourcentage de paiement annuel moyen de la Période de performance est supérieur au niveau Maximum établi par le Comité, en aucun cas le nombre d’UARP dévolues ne peut dépasser 200 % de la Prime cible. 1.3 Définitions. Dans le cadre de la présente section 1, les termes ci-après ont la signification suivante. (a) Par « Objectif de performance », on entend le niveau de la Mesure de performance correspondante qui doit être atteint (Seuil, Cible et Maximum) pour un exercice donné. (b) Par « Mesure de performance », on entend, pour tout exercice, une ou plusieurs mesures financières déterminées par le Comité. Ce dernier communique les modalités d’ajustement de la Mesure de performance, s’il y a lieu, en cas d’événements ou de circonstances extraordinaires, qu’il lui appartient de déterminer, ou en vue d’exclure les effets d’éléments extraordinaires, inhabituels ou non récurrents résultant de modifications de la législation, des réglementations ou des principes comptables applicables, de variations de change, d’opérations abandonnées, d’éléments non monétaires tels qu’amortissements, dépréciations ou réserves, de perte de valeur des actifs ou de toute recapitalisation, restructuration, réorganisation, fusion, acquisition, cession, consolidation, essaimage, scission, regroupement, liquidation, dissolution, vente d’actifs ou autres transactions commerciales similaires.

---

![Slide 15](<performancebasedrestrict015.jpg>)

> **Source slide transcript**
>
> 15 (c) Par « Période de performance », on entend une période de trois exercices consécutifs de la Société débutant le premier jour du premier exercice au cours duquel survient la Date d’octroi et se terminant le dernier jour du troisième exercice. (d) Par « Date de dévolution des UARP », on entend le dernier jour de la Période de performance. (e) Par « Départ pour motifs justifiés », on entend votre démission volontaire de la Société et l’existence d’une ou de plusieurs des conditions suivantes, survenues sans votre consentement : (i) une modification importante de l’emplacement géographique où vous êtes tenu de fournir les services, de sorte que le trajet entre votre domicile et votre lieu de travail principal est allongé de plus de 50 km ou (ii) une réduction importante de votre autorité, de vos fonctions ou de vos responsabilités ou une baisse considérable de votre rémunération de base ou de vos possibilités de rémunération incitatives, étant toutefois entendu qu’une démission volontaire de la Société n’est pas considérée comme un Départ pour motifs justifiés tant que vous ne signifiez pas à la Société, par écrit, ladite démission et l’existence de la ou des conditions donnant lieu à la cessation d’emploi dans un délai de 90 jours après le moment où elles surviennent pour la première fois. La Société dispose ensuite de 30 jours pour remédier à la situation, auquel cas il ne sera pas considéré que vous avez subi un Départ pour motifs justifiés. Si la Société n’est pas en mesure de remédier à la situation dans ce délai de 30 jours, votre Date de cessation d’emploi intervient le 31e jour suivant la réception de votre avis écrit par la Société. (f) Par « Licenciement sans motif valable », on entend la cessation involontaire et sans motif de votre emploi ou de la relation contractuelle qui vous lie à la Société, notamment, de manière non limitative, (i) un licenciement intervenant lorsque vous épuisez un congé durant ou au terme d’une période de préavis en vertu du Worker Adjustment and Retraining Notification Act (« WARN ») et (ii) une situation dans laquelle vous bénéficiez d’un congé autorisé durant lequel votre poste est protégé en vertu de la loi applicable (par exemple le Family Medical Leave Act) et, à votre retour de congé, vous ne pouvez pas être employé ou conclure une autre forme de relation contractuelle avec la Société. 1.4 Règles de dévolution particulières. Nonobstant la Section 1.2 ci-dessus, si votre Date de cessation d’emploi survient en raison d’un Licenciement sans motif valable ou d’un Départ pour motifs justifiés au moment ou à la suite d’un Changement de contrôle (défini dans le Plan, cette définition pouvant être modifiée par la suite) et avant le deuxième (2e) anniversaire du Changement de contrôle, toutes les UARP attribuées en vertu de la Section 1.1 qui n’ont pas été déchues jusqu’alors sont intégralement dévolues, comme si la performance Cible avait été atteinte pour la Période de performance applicable lors de votre Date de cessation d’emploi. Si votre Date de cessation d’emploi survient à la suite d’un décès, d’un Handicap ou d’un Départ à la retraite, les UARP sont dévolues ou déchues à compter de la Date de dévolution des UARP établie à la section 1.2, sur la base de la réalisation des objectifs de performance. Si votre Date de cessation d’emploi survient dans les 24 mois précédant la Date de dévolution des UARP en raison d’un Licenciement involontaire pour motifs économiques, toutes les UARP attribuées en vertu des présentes sont dévolues ou déchues à la date arrêtée à la section 1.2, en fonction de l’atteinte des Objectifs de performance ; toutefois, si votre Date de cessation d’emploi survient pour un motif décrit aussi bien dans la présente phrase que dans la première phrase de la présente

---

![Slide 16](<performancebasedrestrict016.jpg>)

> **Source slide transcript**
>
> 16 section 1.4, les règles de dévolution particulières décrites à la première phrase de la présente section 1.4 s’appliquent au lieu de celles décrites dans la présente phrase. 1.5 Règlement des UARP. Le plus tôt possible après la date de la première réunion régulière du Comité, après le dernier jour de la Période de performance au cours duquel le Comité certifie le paiement moyen pour chacune des trois années de la Période de performance (ou, si cette date est antérieure, la date à laquelle les UARP sont dévolues en vertu des règles de dévolution particulières énoncées à la section 1.4), la Société vous cède une Action ordinaire pour chaque UARP, le cas échéant, qui est alors dévolue en vertu de la section 1.2. ou 1.4 du présent Accord (la date du transfert étant dénommée la « date de règlement » aux fins du présent Accord), étant toutefois entendu que la Société peut, à sa discrétion, régler les UARP en espèces sur la base de la juste valeur de marché des actions à la Date de dévolution. Aucune action fractionnaire ne peut être cédée. Toute action fractionnaire est arrondie au nombre d’actions entier le plus proche. Les recettes attribuables à la dévolution des UARP et le montant de toute retenue fiscale seront déterminés sur la base de la valeur des actions à la date du règlement. Les UARP ne sont pas admissibles au titre d’équivalents de dividendes. SECTION 2 Conditions générales 2.1 Incessibilité. La Prime qui fait l’objet du présent Accord ne peut être cédée par d’autres voies que par testament ou en vertu du droit successoral. 2.2 Absence de droits d’actionnaire. Vous ne détenez aucun droit en tant qu’actionnaire relatif aux Actions ordinaires soumises aux UARP attribuées en vertu du présent Accord avant la date d’émission, à votre bénéfice, d’un ou de plusieurs certificats concernant les actions en question. 2.3 Licenciement justifié. Si votre Date de cessation d’emploi survient pour des motifs justifiés, l’ensemble de vos droits découlant du présent Accord, acquis ou non, prennent fin immédiatement. 2.4 Soumission de la Prime au Plan. L’octroi de la Prime en vertu du présent Accord est organisé conformément au Plan et la Prime est payable uniquement conformément aux conditions de celui-ci qui sont en vigueur. Le Plan comporte certaines définitions, restrictions, limitations et d’autres conditions qui s’appliquent toutes au présent Accord. L’ENSEMBLE DES DISPOSITIONS DU PLAN SONT INTÉGRÉES AUX PRÉSENTES PAR RENVOI ET FONT PARTIE INTÉGRANTE DU PRÉSENT ACCORD COMME SI CHACUNE D’ENTRE ELLES Y FIGURAIT EXPLICITEMENT. Si le Plan devient nul ou inexécutoire en vertu d’une loi ou d’une décision judiciaire, le présent Accord devient nul et sans effet. Rien de ce qui est énoncé dans le présent Accord ne vise à restreindre ou à exclure toute définition, restriction, limitation ou autre condition du Plan susceptible d’être pertinente à l’égard du présent Accord et spécifiquement appliquée à ce dernier par le Comité, et aucune de ses dispositions ne saurait être interprétée en ce sens. En cas de conflit entre les dispositions du présent Accord et le Plan, la règle d’interprétation considère que les conditions du Plan priment et, partant, s’appliquent.

---

![Slide 17](<performancebasedrestrict017.jpg>)

> **Source slide transcript**
>
> 17 2.5 Ajustements en cas de Changement relatif aux Actions ordinaires. En cas de fractionnement des actions, de dividendes en actions, de recapitalisation, de reclassement ou de regroupement d’actions, de fusion, de vente d’actifs ou d’événements similaires, le nombre et le type d’actions qui constituent la Prime en vertu du présent Accord seront ajustés de manière appropriée et équitable pour éviter la dilution ou la majoration des droits qui vous sont octroyés ou reconnus. 2.6 Accusé de réception. La Société et vous-même convenez que les UARP sont attribuées et régies par l’Avis d’octroi, le présent Accord (y compris son éventuel Appendice) et les dispositions du Plan (intégrées aux présentes par renvoi). Vous (i) accusez réception d’un exemplaire de chacun des documents susmentionnés, (ii) déclarez les avoir lus attentivement et en comprendre les dispositions et (iii) acceptez par les présentes les UARP soumises à l’ensemble des conditions énoncées dans les présentes et à celles stipulées dans le Plan et l’Avis d’octroi. 2.7 Impôts et retenues. (a) Retenues (applicable uniquement aux individus soumis à la législation fiscale des États-Unis). La présente Prime est soumise à la retenue de l’ensemble des impôts applicables. La Société est en droit de retenir ou de vous autoriser à lui verser tous impôts de l’État fédéral, des États fédérés ou des autorités locales applicables à la prime, à sa dévolution ou à tout autre événement entraînant une obligation fiscale relativement à la présente Prime. Si vous n’avez pas versé l’intégralité du montant correspondant aux retenues d’impôt applicables à la Société à la date où cette dernière est tenue de s’en acquitter auprès des autorités fiscales concernées (ou à une date antérieure spécifiée par la Société en vue de lui permettre de respecter ses obligations à temps), la Société est en droit, unilatéralement, de retenir de la présente Prime le nombre d’Actions ordinaires qu’elle estime suffisant pour respecter les retenues fiscales imposées par la loi. Les impôts des États fédérés font l’objet d’une retenue au taux applicable fixé par l’État dans lequel vous êtes employé par la Société ou dans lequel vous avez travaillé pour cette dernière en dernier lieu. En aucun cas le nombre d’actions retenues ne peut être supérieur au nombre nécessaire au respect des exigences relatives aux retenues d’impôts sur le revenu et sur le travail de l’État fédéral, des États fédérés ou des autorités locales. Vous pouvez décider de céder des Actions ordinaires acquises par le passé ou de demander à la Société de retenir des Actions ordinaires relatives à la présente Prime dans un montant suffisant à respecter tout ou partie des retenues fiscales imposées par la loi. (b) Responsabilité fiscale (applicable uniquement aux individus soumis aux législations fiscales hors États-Unis). Indépendamment de toute action entreprise par la Société ou la Filiale qui vous emploie ou a recours à vos services concernant l’impôt sur le revenu, la sécurité sociale, l’impôt sur les salaires, les acomptes versés ou tout autre élément fiscal relatif à votre participation au Plan qui s’appliquent à vous en vertu de la loi (les « Éléments fiscaux »), vous acceptez qu’en définitive, les obligations se rapportant aux Éléments fiscaux sont et demeurent votre responsabilité et peuvent être supérieures au montant réellement retenu par la Société ou la Filiale qui vous emploie ou a recours à vos services. Vous reconnaissez en outre que la Société ou la Filiale qui vous emploie ou a recours à vos services (1) ne fait aucune déclaration et ne prend aucun engagement concernant le traitement de tous Éléments fiscaux relatifs à un quelconque aspect des UARP, notamment, de manière non limitative, l’octroi, la

---

![Slide 18](<performancebasedrestrict018.jpg>)

> **Source slide transcript**
>
> 18 dévolution ou le règlement des UARP, la vente ultérieure d’Actions ordinaires acquises en vertu du règlement en question et la réception de tous dividendes et (2) ne s’engage pas à structurer les conditions de l’octroi ou tout aspect des UARP de manière à réduire ou à éliminer votre obligation relative aux Éléments fiscaux ou d’obtenir un quelconque résultat fiscal particulier, et n’est pas dans l’obligation de le faire. Par ailleurs, si vous êtes devenu assujetti à l’impôt dans plus d’une juridiction entre la Date de dévolution des UARP et celle de tout événement fiscal applicable, le cas échéant, vous acceptez que la Société ou la Filiale qui vous emploie ou a recours à vos services (ou le faisait par le passé, le cas échéant) soit tenue de retenir ou de justifier des Éléments fiscaux dans plus d’une juridiction. (1) Avant tout événement imposable ou donnant lieu à une retenue fiscale, le cas échéant, vous vous acquittez de toutes vos obligations ou prenez des dispositions satisfaisant la Société ou la Filiale qui vous emploie ou a recours à vos services en vue de respecter l’ensemble des Éléments fiscaux. À cet égard, vous autorisez la Société ou la Filiale qui vous emploie ou a recours à vos services (ou ses représentants, à sa discrétion) à respecter les obligations relatives à l’ensemble des Éléments fiscaux au travers d’une des démarches suivantes ou d’une combinaison de celles-ci : (A) retenue sur vos salaires ou toute autre rémunération en espèces versée par la Société ou la Filiale qui vous emploie ou a recours à vos services ; (B) retenue sur les produits de la vente d’Actions ordinaires acquises par le règlement des UARP, soit par une vente volontaire, soit par une vente obligatoire organisée par la Société (en votre nom, en vertu de la présente autorisation) ; (C) retenue sur des Actions ordinaires à émettre lors du règlement des UARP. (2) Pour éviter un traitement comptable négatif, la Société peut retenir ou justifier des Éléments fiscaux en prenant en considération les montants prévus par la loi ou d’autres taux de retenue applicables. Si l’obligation relative aux Éléments fiscaux est remplie à travers la retenue d’Actions ordinaires, à des fins fiscales, il est considéré que l’intégralité des Actions ordinaires soumises aux UARP dévolues ont été émises à votre intention, même si un certain nombre d’Actions ordinaires sont retenues exclusivement aux fins du paiement des Éléments fiscaux. (3) Enfin, vous vous engagez à verser à la Société ou à la Filiale qui vous emploie ou a recours à vos services tout montant des Éléments fiscaux que celle-ci peut être tenue de retenir ou de justifier en conséquence de votre participation au Plan et qui ne peut être acquitté par les moyens décrits ci-avant. La Société peut refuser d’émettre ou de remettre les Actions ordinaires ou le produit de la vente de celles-ci si vous ne respectez pas vos obligations relatives aux Éléments fiscaux. 2.8 Respect de la loi applicable. L’émission d’Actions ordinaires est soumise et conditionnée au respect, par la Société et vous-même, y compris toutes déclarations, garanties et accords écrits que l’Administrateur est susceptible d’exiger, de toutes les (i) lois et réglementations américaines, tant au niveau de l’État fédéral que des États fédérés, (ii) lois

---

![Slide 19](<performancebasedrestrict019.jpg>)

> **Source slide transcript**
>
> 19 applicables de votre pays de résidence en matière d’émission ou de vente d’Actions ordinaires et (iii) réglementations applicables de toute bourse ou tout système automatisé de cotation où sont inscrites ou cotées les Actions ordinaires de la Société au moment de l’émission ou de la cession. Nonobstant les autres dispositions du présent Accord, la Société n’est tenue à aucune obligation d’émission d’Actions ordinaires en vertu du présent Accord si ladite émission enfreint toute loi, réglementation ou exigence applicable d’une entité boursière ou similaire. 2.9 Report à court terme (applicable uniquement aux individus soumis à la législation fiscale fédérale des États-Unis). Les UARP payables au titre du présent Accord ont vocation à être exemptées de la section 409A de l’Internal Revenue Code en vertu de l’exemption des reports à court terme. Par conséquent, le règlement des UARP a lieu au plus tard le 15e jour du troisième mois qui suit la dernière des dates ci-après : (i) la fin de l’année d’imposition de l’Employé durant laquelle intervient la Date de dévolution ou (ii) la fin de l’exercice de la Société durant lequel intervient la Date de dévolution. 2.10 Confidentialité des données. (a) Réglementations concernant la confidentialité des données aux États-Unis (uniquement applicables si la Prime est soumise aux lois des États-Unis sur la confidentialité des données). À travers la conclusion du présent Accord et l’acception de la présente Prime, vous (a) consentez explicitement et sans équivoque à la collecte, à l’utilisation et au transfert, par voie électronique ou autre, de toutes vos données personnelles nécessaires pour faciliter la mise en œuvre, l’administration et la gestion de la Prime et du Plan, (b) comprenez que la Société peut, aux fins de la mise en œuvre, de l’administration et de la gestion du Plan, détenir certaines informations vous concernant, notamment, de manière non limitative, vos nom, adresse personnelle, numéro de téléphone, date de naissance, numéro de sécurité sociale ou autre numéro d’identification, salaire, nationalité, poste et les détails de l’ensemble des primes ou droits à Actions qui vous ont été octroyés dans le cadre du Plan ou d’une autre manière (les « Données personnelles »), (c) comprenez que des Données personnelles puissent être transférées à des tiers contribuant à la mise en œuvre, à l’administration et à la gestion du Plan, notamment tout courtier auquel la garde des Actions a été confiée lors de la dévolution de la Prime, que ces destinataires peuvent être établis dans votre pays ou ailleurs et que leur pays d’établissement peut disposer de lois et de protections différentes du vôtre en matière de confidentialité des données, (d) renoncez à tous les droits de confidentialité dont vous disposez relativement aux données et (e) autorisez la Société, ses Filiales et leurs représentants à stocker et transmettre lesdites informations par voie électronique.

---

![Slide 20](<performancebasedrestrict020.jpg>)

> **Source slide transcript**
>
> 20 (b) Réglementations concernant la confidentialité des données hors États-Unis (uniquement applicables si la Prime est soumise à des lois sur la confidentialité des données en dehors des États-Unis). (1) À travers la conclusion du présent Accord et l’acception de la présente Prime, vous consentez explicitement et sans équivoque à la collecte, à l’utilisation et au transfert, par voie électronique ou autre, de vos données personnelles, comme décrit dans le présent Accord ainsi que dans tous autres documents relatifs à l’octroi des UARP, le cas échéant, par la Filiale qui vous emploie ou a recours à vos services ainsi que la Société et ses Filiales, aux fins exclusives de la mise en œuvre, de l’administration et de la gestion de votre participation du Plan. (2) Vous comprenez que la Société et la Filiale qui vous emploie ou a recours à vos services peut détenir certaines informations vous concernant, notamment, de manière non limitative, vos nom, adresse personnelle, numéro de téléphone, date de naissance, numéro de sécurité sociale ou autre numéro d’identification, salaire, nationalité, poste, toutes Actions ordinaires ou tous mandats d’administrateur dans la Société, les détails de l’ensemble des UARP et autres droits à Actions ordinaires octroyés, annulés, exercés, acquis, non acquis ou en suspens en votre faveur, aux fins exclusives de la mise en œuvre, de l’administration et de la gestion du Plan (les « Données »). (3) Vous comprenez que les Données seront transférées à un conseiller juridique, un courtier ou tout autre prestataire de services de plan d’action choisi par la Société à l’avenir pour assister cette dernière dans la mise en œuvre, l’administration et la gestion du Plan. Vous comprenez que les destinataires des Données peuvent être établis aux États-Unis ou ailleurs et que leur pays d’établissement (p. ex. les États-Unis) peut disposer de lois et de protections différentes du vôtre en matière de confidentialité des données. Vous comprenez que si vous résidez en dehors des États-Unis, vous pouvez demander une liste reprenant le nom et l’adresse de tous les destinataires potentiels des Données en contactant votre représentant local des ressources humaines ou celui de la Société. Vous autorisez la Société ainsi que tous autres destinataires éventuels chargés d’assister la Société (actuellement ou à l’avenir) dans la mise en œuvre, l’administration et la gestion du Plan à recevoir, détenir, utiliser, conserver et transférer les Données, par voie électronique ou autre, aux fins exclusives de la mise en œuvre, de l’administration et de la gestion de votre participation au Plan. Vous comprenez que les Données seront détenues aussi longtemps que le requièrent la mise en œuvre, l’administration et la gestion de votre participation au Plan. Vous comprenez que si vous résidez en dehors des États-Unis, vous pouvez, à tout moment, consulter les Données, demander des informations complémentaires sur leur stockage et leur traitement, demander toutes les modifications nécessaires aux Données, refuser votre consentement ou le retirer, dans tous les cas sans frais, en contactant par écrit votre représentant local des ressources humaines ou celui de la Société. Vous comprenez toutefois que le refus ou le retrait de votre consentement peut avoir une incidence sur votre capacité à participer au Plan. Pour de plus amples informations sur les conséquences du refus de consentement ou du retrait de celui-ci, vous comprenez que vous pouvez contacter votre représentant local des ressources humaines ou celui de la Société. 2.11 Successeurs et ayants droit. Le présent Accord lie tous les successeurs et ayants droit de la Société.

---

![Slide 21](<performancebasedrestrict021.jpg>)

> **Source slide transcript**
>
> 21 2.12 Droit applicable. Le présent Accord est régi, interprété et exécuté dans toute la mesure du possible conformément aux dispositions applicables du Code et, autrement, conformément au droit de l’État du Michigan, sans égard aux principes relatifs aux conflits de droit, étant entendu que si vous êtes un ressortissant étranger ou êtes employé en dehors des États-Unis, le présent Accord sera régi, interprété et exécuté en vertu du droit étranger applicable dans la mesure où ledit droit diffère du Code et du droit de l’État du Michigan. Toute procédure liée au présent Accord ou en découlant sera engagée, exercée ou poursuivie dans le tribunal d’arrondissement du comté de Kent, dans le Michigan, situé à Grand Rapids, dans le Michigan, ou dans l’United States District Court for the Western District of Michigan et dans la cour d’appel correspondante. 2.13 Déchéance des UARP. Si la Société, à la suite d’une faute, est tenue de préparer un retraitement comptable en raison d’un cas grave de non-respect des exigences relatives à la présentation des informations financières en vertu des lois sur les valeurs mobilières, alors (a) si votre incitation ou votre rémunération fondée sur des actions est soumise à la déchéance automatique en raison de ladite faute et du retraitement, en vertu de la section 304 du Sarbanes- Oxley Act de 2002 ou (b) si le Comité établit que vous avez sciemment pris part à la faute, que vous vous êtes sciemment abstenu de l’empêcher ou que vos actions ou inactions se rapportant à la faute et au retraitement constituent un cas de négligence grave, (i) vous serez tenu de rembourser à la Société le montant de tout paiement relatif aux UARP acquises ou accumulées durant la période de douze mois suivant la première émission publique ou le dépôt auprès de la SEC (selon l’éventualité qui se produit en premier) du document financier exprimant ladite exigence de présentation des informations financières et (ii) toutes les UARP en suspens n’ayant pas encore été réglées seront déchues immédiatement. En outre, les Actions ordinaires acquises en vertu du présent Accord et tous gains ou bénéfices résultant de leur vente seront soumis à toutes les politiques de récupération ou de recouvrement adoptées par la Société ultérieurement. 2.14 Règles particulières pour les bénéficiaires hors États-Unis (uniquement applicables si vous résidez en dehors des États-Unis) (a) Nature de la libéralité. Par votre acceptation de la libéralité, vous reconnaissez, comprenez et acceptez que : (1) le Plan est établi par la Société de manière volontaire, il est discrétionnaire de nature et peut être modifié, suspendu ou résilié par la Société à tout moment, sauf stipulation contraire dans le Plan. (2) l’octroi des UARP est volontaire et occasionnel et n’instaure aucun droit contractuel ou autre d’octrois d’UARP à l’avenir ni d’avantages remplaçant les UARP, même si ces dernières ont été octroyées à plusieurs reprises par le passé ; (3) toutes les décisions relatives aux octrois d’UARP à l’avenir, le cas échéant, relèvent de l’entière discrétion de la Société ; (4) vous participez au Plan sur une base volontaire ; (5) les UARP et les Actions ordinaires qui y sont soumises constituent un élément extraordinaire qui ne relève pas du champ d’application de votre contrat de travail ou

---

![Slide 22](<performancebasedrestrict022.jpg>)

> **Source slide transcript**
>
> 22 de services, le cas échéant ; (6) les UARP et les Actions ordinaires qui y sont soumises n’ont pas vocation à remplacer de quelconques droits à pension ou rémunérations ; (7) les UARP et les Actions ordinaires qui y sont soumises ne font pas partie de la rémunération normale ou attendue aux fins du calcul de toute cessation d’emploi, démission, licenciement, licenciement pour motif économique, renvoi, prestations de fin de service, gratifications, primes d’ancienneté, prestations de retraire ou de sécurité sociale ou paiements similaires et ne doivent en aucun cas être considérées comme une rémunération découlant de tous services passés rendus à la Société, à la Filiale qui vous emploie ou a recours à vos services ou à toute autre Filiale ; (8) la libéralité et votre participation au Plan ne peuvent être interprétées dans le sens de l’instauration d’un contrat de travail ou de services avec la Société ou toute Filiale ; (9) la valeur future des Actions ordinaires sous-jacentes est inconnue et impossible à déterminer avec certitude ; (10) la déchéance des UARP résultant de votre Date de cessation d’emploi ne peut donner lieu à aucune demande ou aucun droit d’indemnisation (pour quelque raison que ce soit, qu’il s’avère ou non, par la suite, qu’elle était invalide ou en violation du droit du travail de la juridiction où vous êtes employé ou où vous fournissez vos services ou des conditions de votre contrat de travail, le cas échéant) ; par ailleurs, en contrepartie de l’octroi des UARP auxquelles vous n’auriez pas droit en d’autres circonstances, vous acceptez irrévocablement de ne jamais engager de poursuite contre la Société ou la Filiale qui vous emploie ou a recours à vos services, de renoncer à votre capacité, le cas échéant, d’engager de telles poursuites et de libérer la Société ou la Filiale qui vous emploie ou a recours à vos services de telles revendications ; nonobstant ce qui précède, si un tribunal d’une juridiction compétente autorise une poursuite de ce type, il est considéré, irrévocablement, de par votre participation au Plan, que vous acceptez de ne pas faire valoir cette poursuite et de signer tous les documents nécessaires à son rejet ou à son retrait ; (11) vous reconnaissez et acceptez que ni la Société, ni la Filiale qui vous emploi ou a recours à vos services, ni toute autre Filiale ne sont responsables de toute variation de change entre la devise du pays dans lequel vous résidez et le dollar américain susceptible d’avoir une incidence sur la valeur des UARP ou tout montant qui vous est dû en vertu du règlement des UARP ou de la vente ultérieure de toutes Actions ordinaires acquises lors du règlement. (b) Appendice. Nonobstant toutes les dispositions du présent Accord, l’octroi d’UARP est soumis à toutes les conditions particulières énoncées dans l’Appendice au présent Accord. En outre, si vous emménagez dans l’un des pays repris dans l’Appendice, les conditions particulières concernant ce pays s’appliquent à vous si la Société établit que l’application de ces dispositions est nécessaire ou recommandée en vue de respecter les lois du pays où vous résidez ou de faciliter l’administration du Plan. Si vous emménagez aux États-Unis, les conditions

---

![Slide 23](<performancebasedrestrict023.jpg>)

> **Source slide transcript**
>
> 23 particulières de l’Appendice s’appliquent ou cessent de s’appliquer à vous si la Société établit que l’application ou non de ces dispositions est nécessaire ou recommandée en vue de faciliter l’administration du Plan. L’Appendice fait partie intégrante du présent Accord. (c) Imposition d’autres exigences. La Société se réserve le droit, d’une part, d’imposer d’autres exigences à votre participation au Plan, aux UARP et à toutes Actions ordinaires acquises en vertu du Plan si elle établit que cela s’avère nécessaire ou recommandé en vue de respecter les lois du pays dans lequel vous résidez ou de faciliter l’administration du Plan et, d’autre part, de vous demander de signer tous les accords ou engagements complémentaires nécessaires à la mise en œuvre de ce qui précède. 2.15 Non-concurrence et non-sollicitation. a) Non-concurrence. Au cours de votre emploi au sein de la Société et de ses Filiales et pendant une période de douze (12) mois suivant votre Date de Fin de Contrat (la « Période Restreinte »), vous ne pouvez pas, (i) directement ou indirectement, sans le consentement écrit préalable de la Société, prendre de participation significative ou de contrôle en tant que propriétaire, partenaire, actionnaire, concédant de licence, administrateur, dirigeant, agent ou consultant pour toute Personne qui exploite une entreprise en concurrence avec une entreprise dirigée par la Société ou l'une de ses Filiales, où que ce soit dans le ou les pays dans lesquels vous travaillez régulièrement ou fournissez des services; ni (ii) accepter un emploi ou un engagement pour la fourniture de services à quelque titre que ce soit, y compris en tant qu'employé, administrateur, consultant ou conseiller, directement ou indirectement, avec toute Personne qui exploite une entreprise en concurrence avec une entreprise dirigée par le Société ou l'une de ses Filiales où que ce soit dans le ou les pays dans lesquels vous travaillez régulièrement ou fournissez des services. Aux fins des présentes, l’exploitation d'une entreprise en concurrence avec une entreprise exploitée par la Société ou l'une de ses Filiales comprend la vente, la fabrication, la distribution ou la recherche et développement de tout produit ou service similaire à un produit ou service vendu, distribué, commercialisé ou en cours de recherche ou développement (y compris par le biais d'une coentreprise ou d'un investissement dans une autre entité) par la Société ou l'une de ses Filiales, y compris les médicaments en vente libre ou les produits nutritionnels, les produits pharmaceutiques génériques d’ordonnance topique étendue, les produits nutritionnels infantiles, les produits de soins bucco-dentaires et tout autre produit, de marque de distributeur ou de valeur de marque, que la Société ou un Affilié commercialise ou prévoit activement de commercialiser au cours de votre emploi au sein de la Société et pendant une période d'un an suivant votre Date de Fin de Contrat. En cas de vente, de transfert ou de toute autre cession de l'activité Produits Pharmaceutiques d'Ordonnance Perrigo pendant la Période Restreinte, la présente Section 2.15 a) ne s'appliquera pas à l'activité Produits Pharmaceutiques d'Ordonnance Perrigo. Nonobstant ce qui précède, aucune partie de cette disposition ne vous empêche de détenir passivement deux pour cent (2 %) ou moins des titres en circulation de toute catégorie d'une société cotée sur une bourse nationale ou cotée sur un système de cotation automatisé. Vous pouvez faire une demande écrite au DPRH de la Société pour obtenir une dérogation à la présente Section 2.15 a) et cette exception ne peut être refusée sans motif raisonnable, en particulier lorsque vous cherchez un emploi auprès d’une entreprise qui n'est pas en concurrence avec le segment de la Société où vous avez travaillé ou fourni des services au cours des deux dernières années de votre emploi au sein de la Société.

---

![Slide 24](<performancebasedrestrict024.jpg>)

> **Source slide transcript**
>
> 24 b) Non-sollicitation des Fournisseurs de Services. Pendant votre emploi au sein de la Société et de ses Filiales et pendant la Période Restreinte, vous ne pouvez pas, directement ou indirectement, sans le consentement écrit préalable de la Société, i) solliciter, recruter ou embaucher activement toute Personne qui est, à ce moment-là ou à tout moment au cours de la période de 12 mois précédant cette sollicitation ou ce recrutement, était employé ou consultant de la Société ou de l'une de ses Filiales, ni ii) solliciter ou encourager un employé de la Société ou de l'une de ses Filiales à quitter son emploi au sein de la Société ou de l'une de ses Filiales, ni (iii) interférer dans la relation de la Société ou de l'une de ses Filiales avec toute Personne ou entité qui est employée par, ou autrement engagée dans la prestation de services pour, la Société ou l'une de ses Filiales. c) Non-sollicitation des Clients. Pendant votre emploi au sein de la Société et de ses Filiales et au cours de la Période Restreinte, vous ne pouvez pas, directement ou indirectement, seul ou en association avec toute autre personne, sans le consentement écrit préalable de la Société, i) inciter ou tenter d’inciter tout client (ancien ou actuel), fournisseur, titulaire d’une licence, franchisé, partenaire de coentreprise ou autre relation commerciale de la Société ou de l'une de ses Filiales (collectivement, les «Clients»), à cesser de faire affaire avec la Société ou l’une de ses Filiales, ni ii) détourner tout ou partie des activités d'un Client avec la Société vers un concurrent de la Société ou l’une de ses Filiales, ni (iii) interférer, de quelque manière que ce soit, dans la relation entre tout Client, d'une part, et la Société ou l'une de ses Filiales, d'autre part. d) Recours et Mesure Injonctive. Vous reconnaissez qu'une violation dans votre chef de l'un des engagements prévus dans la présente Section 2.15 causerait des dommages irréparables à la Société et à ses Filiales à hauteur d'un montant qui serait significatif, mais pas aisément vérifiable, et que tout recours en justice (y compris le paiement de dommages) serait insuffisant. En conséquence, vous convenez que, nonobstant toute disposition contraire du présent Accord, outre tout autre dommage qu'elle est en mesure de démontrer, la Société et ses Filiales ont droit (sans qu'il soit nécessaire de démontrer une perte économique ou d'autres dommages réels) à une mesure injonctive (y compris des ordonnances restrictives temporaires, des injonctions préliminaires et des injonctions permanentes), sans dépôt de caution, auprès de tout tribunal compétent, pour toute violation réelle ou imminente de l'un des engagements énoncés dans la présente Section 2.15, outre tout autre recours légal ou équitable qu'elles pourraient avoir. En outre, en cas de Violation Volontaire d'une Clause Restrictive (au sens de la présente Section 2.15), i) tous vos droits au titre du présent Accord, acquis ou non, prennent fin immédiatement, et (ii) tou(te)s Actions, espèces ou autres biens qui vous sont payé(e)s ou livré(e)s conformément au présent Accord, sont confisqué(e)s et vous devez rembourser ces Actions, espèces ou autres biens à la Société, au plus tard trente (30) jours civils après que la Société vous a demandé leur remboursement. Aux fins du présent Accord, «Violation Volontaire d'une Clause Restrictive» signifie une violation significative, dans votre chef, de l'une des clauses de la présente Section 2.15, dont vous saviez ou auriez pu savoir, en vous renseignant correctement, qu’elle constituerait une violation significative. Les phrases précédentes de la présente Section 2.15 ne doivent pas être comprises comme une renonciation aux droits que la Société et ses Filiales peuvent avoir pour obtenir des dommages-intérêts en vertu du présent Accord ou autrement, et tous ces droits ne sont pas limités. La Période Restreinte est suspendue pendant (et est réputée automatiquement prolongée de) toute période durant laquelle vous violez les dispositions de la Section 2.15 a), b) ou c), selon le cas. Dans le cas où un tribunal ou une

---

![Slide 25](<performancebasedrestrict025.jpg>)

> **Source slide transcript**
>
> 25 juridiction compétente statue que toute disposition de la présente Section 2.15 est nulle ou plus restrictive que ne le permet la loi applicable de cette juridiction, alors, aux fins uniquement de l'application de la présente Section 2.15 dans la juridiction de ce tribunal, cette disposition doit être interprétée et appliquée comme si elle prévoyait la restriction maximale autorisée par la loi en vigueur. e) Confirmations. 1) Vous reconnaissez que la Société et ses Filiales ont consacré et continueront de consacrer beaucoup de temps, d'argent et d'efforts pour le développement des stratégies commerciales, des relations avec les employés, les clients et autres, ainsi que du goodwill en vue de bâtir une organisation efficace. Vous reconnaissez que la Société et ses Filiales ont un intérêt commercial légitime dans, et le droit de protéger leur goodwill et leurs relations avec leurs employés, clients et autres, et que la Société et ses Filiales pourraient être gravement lésées par la perte ou la détérioration de ses relations avec ses employés, clients et autres. En outre, vous reconnaissez que la Société et ses Filiales ont le droit de protéger et de préserver la valeur de continuité de la Société et de ses Filiales dans la mesure permise par la loi. 2) À la lumière des confirmations qui précèdent, vous acceptez que les clauses contenues dans le présent Accord sont raisonnables et correctement requises pour la protection adéquate de l’entreprise et du goodwill de la Société et de ses Filiales. En outre, vous reconnaissez que, bien que votre respect des clauses contenues dans le présent Accord puisse vous empêcher de gagner votre vie dans une entreprise similaire à celle de la Société et de ses Filiales, votre expérience et vos capacités sont telles que vous avez d'autres opportunités de gagner votre vie et des moyens de subsistance adéquats pour vous et les personnes à votre charge. 3) À la lumière des confirmations contenues dans la présente Section 2.15, vous acceptez de ne pas contester le caractère raisonnable, la validité ou l'applicabilité des restrictions qui vous sont imposées et des obligations qui vous sont faites en vertu de la présente Section 2.15. **** Nous nous réjouissons de pouvoir continuer à bénéficier de votre contribution à la croissance de la Société. Veuillez accuser réception de votre exemplaire du Plan et de la présente Prime. Meilleures salutations, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 26](<performancebasedrestrict026.jpg>)

> **Source slide transcript**
>
> 26 PERRIGO COMPANY PLC OVEREENKOMST OVER VOORWAARDELIJK TOEGEKENDE AANDELEN (OP BASIS VAN PRESTATIES) (Volgens het Langetermijnincentiveplan uit 2026 van de Perrigo Company plc) AAN: Participant Name BETREFT: Mededeling over voorwaardelijk toegekende aandelen (op basis van prestaties) Hiermee willen we u melden dat Perrigo Company plc (het 'Bedrijf') u een Award heeft toegekend volgens het Langetermijnincentiveplan uit 2026 van de Perrigo Company plc (het 'Plan'), dat van kracht wordt vanaf de Grant Date (de 'Toekenningsdatum'). Deze Award bestaat uit op basis van prestaties voorwaardelijk toegekende aandelen. De algemene voorwaarden van deze incentive vindt u in de rest van deze overeenkomst (inclusief speciale algemene voorwaarden in een bijlage voor uw land ('Bijlage') (samen de 'Overeenkomst'). De termen in hoofdletters die niet anderszins in deze Overeenkomst bepaald zijn, hebben de betekenis die volgens het Plan aan die termen zijn toegeschreven. SECTIE 1 Voorwaardelijk toegekende aandelen – Toezegging op basis van prestaties 1.1 Toekenning. Vanaf de toekenningsdatum en afhankelijk van de algemene voorwaarden van deze Overeenkomst en het Plan, kent het Bedrijf u Number of Awards Granted voorwaardelijk toegekende aandelen op basis van prestaties toe ('PSU's'). Het aantal toegekende PSU's in deze Sectie 1.1 wordt de 'Doelaward' genoemd. De Doelaward kan worden verhoogd of verlaagd afhankelijk van het niveau van de prestatiedoelstellingen voor aangewezen Prestatiemaatregelen zoals beschreven in Sectie 1.2. Elke PSU geeft u het recht op één gewoon

---

![Slide 27](<performancebasedrestrict027.jpg>)

> **Source slide transcript**
>
> 27 aandeel van het Bedrijf, met een nominale waarden van € 0,001 per aandeel ('Gewoon aandeel') op de toezeggingsdatum van de PSU die in Sectie 1.2 is vermeld, op voorwaarde dat de toepasselijke Prestatiedoeleinden voor elke Prestatiemaatregel zijn behaald. 1.2 Toezegging. Het aantal PSU's toegekend in Sectie 1.1 Toekenning, als die er zijn, wordt bepaald op de toezeggingsdatum van de PSU. Dat aantal wordt bepaald op basis van het gemiddelde niveau van de behaalde jaarlijkse Prestatiemaatregel(en) voor elk boekjaar in de Prestatieperiode, in overeenstemming met het schema dat door de Commissie is bepaald op het ogenblik dat de Prestatiemaatregelen en toepasselijke Prestatiedoelstellingen door de Commissie worden vastgelegd. De Commissie legt jaarlijks een of meer Prestatiemaatregelen en de Prestatiedoelstellingen met betrekking tot elke Prestatiemaatregel vast, die moeten worden behaald voor de Drempel, het Doel en de Maximale prestaties voor een boekjaar. U krijgt de Prestatiemaatregel en Prestatiedoelstellingen voor elk boekjaar. Na het einde van elk boekjaar in de Prestatieperiode bepaalt de Commissie het percentage van de PSU's van de Doelaward die voor zulk boekjaar te betalen zijn, op basis van de behaalde Prestatiedoeleinden voor elke Prestatiemaatregel die de Commissie voor dat boekjaar heeft vastgelegd. Het percentage van de Doelaward die volgens het schema te betalen zou zijn, wordt pro rata aangepast om de behaalde prestatie tussen Drempel en Doel, en Doel en Maximum te weerspiegelen. Op het einde van de Prestatieperiode wordt het gemiddelde berekend van het uitbetalingspercentage voor elk boekjaar in de Prestatieperiode om het werkelijke percentage van de PSU's van de Doelaward te bepalen dat wordt toegezegd en te betalen is op de toezeggingsdatum van de PSU. In geen geval zal de berekening van een positief uitbetalingspercentage voor een boekjaar als een verzekering worden geacht dat er PSU's zullen worden toegezegd op de toezeggingsdatum van de PSU. De uitbetalingspercentages voor de individuele boekjaren worden alleen bepaald om het gemiddelde jaarlijkse uitbetalingspercentage voor de Prestatieperiode van drie jaar te bepalen. Behalve zoals voorzien in Sectie 1.4, worden de PSU's onmiddellijk verbeurd als uw Beëindigingsdatum vóór de toezeggingsdatum van de PSU valt. Als de gemiddelde jaarlijkse prestatievergoeding voor de Prestatieperiode lager is dan de Drempelprestatie die door de Commissie is vastgelegd, dan worden alle PSU's die voordien nog niet verbeurd zijn, wel verbeurd vanaf de toezeggingsdatum van de PSU. Als de gemiddelde jaarlijkse prestatievergoeding voor de Prestatieperiode het door de Commissie vastgelegde maximale prestatieniveau overschrijdt, overschrijdt het aantal toegezegde PSU's in geen geval 200% van de Doelaward. 1.3 Definities. De volgende termen hebben de volgende betekenissen volgens deze Sectie 1. (a) 'Prestatiedoel' betekent het prestatieniveau dat moet worden gehaald met betrekking tot een Prestatiemaatregel voor een boekjaar voor Minimale, Doel- en Maximale vergoeding.

---

![Slide 28](<performancebasedrestrict028.jpg>)

> **Source slide transcript**
>
> 28 (b) 'Prestatiemaatregel' voor een boekjaar betekent een of meer financiële maatregelen, zoals vastgelegd door de Commissie. De Commissie bepaalt hoe de Prestatiemaatregel wordt aangepast, als dat al gebeurt, ten gevolge van buitengewone gebeurtenissen of omstandigheden, zoals vastgelegd door de Commissie, of om de gevolgen van buitengewone, ongewone of eenmalige items uit te sluiten; wijzigingen in toepasselijke wetgeving, voorschriften of boekhoudbeginselen; schommelingen in de wisselkoers; beëindigde bedrijfsactiviteiten; niet-geldelijke posten, zoals amortisatie, afschrijving of reserves; waardevermindering van activa; of elke herkapitalisering, herstructurering, reorganisatie, fusie, overname, afstoting, consolidatie, spin-off, opsplitsing, combinatie, liquidatie, ontbinding, verkoop van activa of een andere soortgelijke bedrijfstransactie. (c) 'Prestatieperiode' betekent een periode van drie opeenvolgende boekjaren van het Bedrijf, die start met de eerste dag van het boekjaar van het Bedrijf waarin de Toekenningsdatum valt en eindigt op de laatste dag van het derde boekjaar in de periode van drie jaar. (d) 'Toezeggingsdatum van PSU' betekent de laatste dag van de Prestatieperiode. (e) 'Ontslag om goede reden' verwijst naar uw vrijwillig ontslag uit het Bedrijf en het bestaan van een of meer van de volgende omstandigheden die zonder uw toestemming optraden: (i) een belangrijke wijziging in de geografische locatie waarbij u vereist bent om diensten uit te voeren, zodat de afstand tussen uw huis en uw voornaamste werkplek met meer dan 48 km groter wordt, of (ii) een belangrijke daling van uw autoriteit, plichten of verantwoordelijkheden of een belangrijke daling in uw basisloon of mogelijkheden tot incentivecompensatie; op voorwaarde echter dat een vrijwillig ontslag uit het Bedrijf niet wordt beschouwd als een Ontslag om goede reden tenzij u het Bedrijf schriftelijk een kennisgeving stuurde van uw vrijwillig ontslag en van het bestaan van de voorwaarden die leiden tot het ontslag binnen de 90 dagen van hun aanvankelijke bestaan. Het Bedrijf heeft vervolgens 30 dagen om de omstandigheid op te lossen. In dat geval wordt u niet geacht een Ontslag om goede reden te hebben opgelopen. In het geval het Bedrijf de voorwaarde niet kan oplossen binnen de termijn van 30 dagen, valt uw Beëindigingsdatum op de 31e dag na de ontvangst door het Bedrijf van zulke schriftelijke kennisgeving. (f) 'Beëindiging zonder oorzaak' betekent de onvrijwillige beëindiging van uw tewerkstelling of contractuele relatie door het Bedrijf zonder Oorzaak, inclusief maar niet beperkt tot, (i) een beëindiging die van kracht wordt wanneer u een verlof hebt opgebruikt tijdens, of op het einde van een opzeggingsperiode volgens de Worker Adjustment and Retraining Notification Act ('WARN'), en (ii) een situatie waarin u op goedgekeurd verlof bent tijdens hetwelke uw positie beveiligd is volgens de toepasselijke wetgeving (bv. een verlof volgens de Family Medical Leave Act), u uit zulk verlof terugkomt en geen tewerkstelling of een andere vorm van contractuele relatie met het Bedrijf kunt krijgen. 1.4 Speciale toezeggingsregels. Niettegenstaande Sectie 1.2 hierboven, als uw Beëindigingsdatum is bereikt wegens Beëindiging zonder oorzaak of een Ontslag om goede reden bij of na een Wijziging van de zeggenschap (zoals gedefinieerd in het Plan en deze definitie kan hierna worden gewijzigd) en vóór de tweede (2) verjaardag van de Wijziging van

---

![Slide 29](<performancebasedrestrict029.jpg>)

> **Source slide transcript**
>
> 29 de zeggenschap, worden alle onder Sectie 1.1 toegekende PSU's die eerder niet zijn verbeurd, volledig toegezegd alsof de Doelprestatie was verkregen voor de Prestatieperiode. Dit wordt van kracht vanaf uw Beëindigingsdatum. Als uw Beëindigingsdatum wordt bereikt wegens overlijden, handicap of pensioen, worden de PSU's toegezegd of verbeurd vanaf de toezeggingsdatum van de PSU die vermeld staat in Sectie 1.2, afhankelijk van het behalen van de prestatiedoelstellingen. Als uw Beëindigingsdatum wordt bereikt in de periode van 24 maanden die de toezeggingsdatum van de PSU voorafgaat, wegens een Onvrijwillig ontslag om Economische redenen, worden alle van de hieronder toegekende PSU's toegezegd of verbeurd vanaf de datum zoals vermeld in Sectie 1.2, afhankelijk van het behalen van de Prestatiedoelstellingen; op voorwaarde echter dat als uw Beëindigingsdatum wordt bereikt om een reden die zowel in deze zin als in de eerste zin van Sectie 1.4 wordt beschreven, dan zijn de speciale toezeggingsregels beschreven in de eerste zin van Sectie 1.4 van toepassing in plaats van de toezeggingsregels beschreven in deze zin. 1.5 Afrekening van PSU's. Zodra praktisch mogelijk na de datum van de eerste geplande vergadering van de Commissie na de laatste dag van de Prestatieperiode waarop de Commissie de gemiddelde vergoeding voor elk van de drie boekjaren in de Prestatieperiode bevestigt (of, indien vroeger, op de datum waarop de PSU’s worden toegezegd conform de speciale toezeggingsregels beschreven in Sectie 1.4), zal het Bedrijf u voor elke PSU, als er zijn, één Gewoon aandeel overdragen, dat toegezegd wordt conform Sectie 1.2 of 1.4 van deze Overeenkomst (de datum van zulke overdracht wordt de 'afrekeningsdatum' voor de doeleinden van deze Overeenkomst); op voorwaarde echter dat het Bedrijf naar zijn goeddunken PSU's contant mag afrekenen, gebaseerd op de reële marktwaarde van de aandelen op de toezeggingsdatum. Er worden geen onderaandelen overgedragen. Elk onderaandeel wordt afgerond tot het dichtstbijzijnde volledige aandeel. De inkomsten die te wijten zijn aan de toezegging van PSU's en de hoeveelheid van vereiste voorheffing worden bepaald op basis van de waarde van de aandelen op de afrekeningsdatum. PSU's komen niet in aanmerking voor dividendequivalenten. SECTIE 2 Algemene Voorwaarden 2.1 Niet-overdraagbaarheid. De Award volgens deze Overeenkomst kan alleen worden overgedragen via een testament of via de wetgeving voor afstamming en schenkingen. 2.2 Geen rechten als houder van aandelen. U hebt als houder van aandelen geen enkel recht met betrekking tot Gewone aandelen die onder de onder deze Overeenkomst toegekende PSU vallen, en dit vóór de datum van uitgifte aan u van een certificaat of certificaten voor zulke aandelen. 2.3 Oorzaak van de beëindiging. Als uw Beëindigingsdatum om bepaalde oorzaken wordt bereikt, dan stoppen al uw rechten volgens deze Overeenkomst, toegezegd of niet, onmiddellijk. 2.4 Award onderhevig aan het Plan. De toekenning van de Award volgens deze Overeenkomst verloopt conform het Plan en de Award kan alleen worden betaald in

---

![Slide 30](<performancebasedrestrict030.jpg>)

> **Source slide transcript**
>
> 30 overeenstemming met de toepasselijke voorwaarden van het Plan. Het Plan bevat bepaalde definities, beperkingen, begrenzingen en andere algemene voorwaarden die alle van toepassing zijn op deze Overeenkomst. ALLE BEPALINGEN VAN HET PLAN ZIJN HIERIN OPGENOMEN DOOR MIDDEL VAN VERWIJZING EN WORDEN OP DEZELFDE MANIER EEN DEEL VAN DEZE OVEREENKOMST ALSOF ELK VAN DEZE BEPALINGEN VOLLEDIG IN DEZE OVEREENKOMST VERMELD STAAN. Mocht het Plan nietig of onafdwingbaar worden door een wettelijke of gerechtelijke beslissing, dan is deze Overeenkomst niet rechtsgeldig. Niets in deze Overeenkomst is bedoeld, en geen enkele van haar bepalingen mag zo worden opgevat, om een definitie, beperking, begrenzing of andere algemene voorwaarde te beperken of uit te sluiten die relevant is voor deze Overeenkomst en specifiek erop kan worden toegepast door de Commissie. In geval van een tegenstrijdigheid in de bepalingen van deze Overeenkomst en het Plan, worden de voorwaarden van het Plan in regel als superieur geacht en toegepast. 2.5 Aanpassingen in het geval van een wijziging in de Gewone aandelen. In het geval van een aandelensplitsing, stockdividend, herkapitalisatie, herclassificatie of combinatie van aandelen, fusie, verkoop van activa of soortgelijke gebeurtenis, wordt het aantal te verlenen aandelen volgens deze Overeenkomst dienovereenkomstig op een billijke manier aangepast om de verwatering of uitbreiding van de rechten te voorkomen die u zijn toegekend of u ter beschikking staan. 2.6 Bevestiging. Het Bedrijf en u komen overeen dat de PSU's worden toegekend volgens en onderworpen aan de Kennisgeving van toekenning, deze Overeenkomst (inclusief de Bijlage, indien van toepassing) en de bepalingen van het Plan (hierin opgenomen via verwijzing). U: (i) bevestigt de ontvangst van een exemplaar van elk van de voornoemde documenten, (ii) erkent dat u hun bepalingen zorgvuldig hebt gelezen en ermee vertrouwd bent, en (iii) aanvaardt hierbij de PSU's die onderhevig zijn aan alle hierin vermelde algemene voorwaarden en die in het Plan en de Kennisgeving van toekenning staan. 2.7 Belastingen en voorheffingen. (a) Voorheffingen (alleen van toepassing op personen die onderhevig zijn aan de Amerikaanse belastingswetten). Deze Award is onderworpen aan de voorheffingen van alle toepasselijke belastingen. Het Bedrijf kan belastingen inhouden of u vragen die te betalen. Het gaat dan om federale, staats- of lokale belastingen die van toepassing zijn op de toekenning, toezegging of andere gebeurtenis die aanleiding geeft tot een belastingsverplichting met betrekking tot deze Award. Als u niet het volledige bedrag van de voorheffingen aan het Bedrijf hebt betaald tegen de datum waarop het Bedrijf zulke voorheffingen aan de bevoegde belastingsinstantie moet betalen (of op een vroegere datum die het Bedrijf kan bepalen om mee te werken aan het tijdig voldoen aan zijn verplichtingen inzake voorheffingen), dan heeft het Bedrijf het eenzijdige recht om Gewone aandelen met betrekking tot deze Award in te houden en dit voor het bedrag dat het Bedrijf voldoende acht om de door de wet vereiste roerende voorheffing te voldoen. Belastingen van de staat worden ingehouden voor het toepasselijke percentage dat bepaald is door de staat waarin u tewerkgesteld bent of het laatst door het Bedrijf tewerkgesteld was. Het aantal ingehouden aandelen mag in geen geval het aantal overschrijden dat nodig is om de maximale federale, staat- en lokale voorheffingen op inkomsten en tewerkstelling te voldoen. U kunt ervoor kiezen om afstand te doen van eerder verworven

---

![Slide 31](<performancebasedrestrict031.jpg>)

> **Source slide transcript**
>
> 31 Gewone aandelen of om het Bedrijf Gewone aandelen met betrekking tot deze Award te laten inhouden, en dit voor een bedrag dat volstaat om alle of een deel van de door de wet vereiste voorheffingen te voldoen. (b) Aansprakelijkheid voor belastingen (alleen van toepassing op personen die onderhevig zijn aan belastingswetten buiten de VS). Ongeacht een actie die het Bedrijf of het filiaal dat u tewerkstelt of u in dienst neemt onderneemt met betrekking tot een of alle inkomstenbelastingen, sociale zekerheid, loonbelasting, betaling van een voorschot of andere belastingen met betrekking tot uw deelname aan het Plan en, wettelijk van toepassing op u ('Belastingen'), erkent u dat de uiteindelijke aansprakelijkheid voor alle Belastingen die van u is en blijft en het bedrag kan overschrijden dat wordt ingehouden door het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt. U erkent verder dat het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt (1) geen verklaringen aflegt of acties onderneemt met betrekking tot de behandeling van Belastingen in verband met enig aspect van de PSU's, inclusief maar niet beperkt tot de toekenning, toezegging of afrekening van de PSU's, de daaropvolgende verkoop van Gewone aandelen die verworven zijn conform zo’n afrekening, en de ontvangst van dividenden; en (2) zich niet verbindt tot en niet verplicht is om de looptijd van de toekenning of enig aspect van de PSU's te organiseren om uw aansprakelijkheid voor Belastingen te beperken of weg te werken of om een specifiek resultaat na belastingen te behalen. Als u belastingen moet betalen in meer dan één jurisdictie tussen de Toekenningsdatum van de PSU en de datum van een relevant belastbaar feit, als van toepassing, dan erkent u dat het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt (of u eerder tewerkstelde of inhuurde, als van toepassing) mogelijk in meer dan één jurisdictie Belastingen moet inhouden of aanrekenen. (1) Vóór een relevant belastbaar feit of relevante voorheffing, als van toepassing, betaalt u aan of doet u het nodige voor het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt om aan alle Belastingen te voldoen. Hiervoor machtigt u het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt, of hun respectieve agenten, volgens hun keuze, om aan de verplichtingen met betrekking tot alle Belastingen te voldoen door een of een combinatie van de volgende zaken: (A) inhouden op uw loon of andere contante compensatie die u wordt betaald door het Bedrijf en/of het filiaal dat u tewerkstelt of u in dienst neemt; of (B) inhouden op inkomsten van de verkoop van Gewone aandelen verworven door afrekening van de PSU's, hetzij via een vrijwillige verkoop of via een verplichte verkoop die door het Bedrijf geregeld is (in uw naam volgend op deze autorisatie); of (C) inhouden op Gewone aandelen die worden uitgegeven bij afrekening van de PSU's. (2) Om een negatieve boekhoudkundige behandeling te vermijden, kan het Bedrijf zaken inhouden of aanrekenen voor Belastingen door toepasselijke statutaire inhoudingsbedragen of andere toepasselijke inhoudingstarieven te overwegen. Als aan de verplichting voor Belastingen voldaan is door in te houden op Gewone aandelen, dan wordt u voor belastingsdoeleinden geacht het volledige aantal Gewone aandelen te hebben uitgegeven

---

![Slide 32](<performancebasedrestrict032.jpg>)

> **Source slide transcript**
>
> 32 die onderworpen zijn aan de toegezegde PSU's, ook al werd een aantal Gewone aandelen louter ingehouden om de Belastingen te betalen. (3) Ten slotte betaalt u het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt een bedrag aan belastingen dat het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt mogelijk moet inhouden of aanrekenen ten gevolge van uw deelname aan het Plan en dat niet kan worden voldaan moet de eerder beschreven middelen. Het Bedrijf kan weigeren om de Gewone aandelen of de inkomsten van de verkoop van de Gewone aandelen uit te geven of te leveren, als u uw verplichtingen met betrekking tot de Belastingen niet naleeft. 2.8 Overeenstemming met de toepasselijke wetgeving. De uitgifte van Gewone aandelen is onderhevig aan en hangt af van de naleving door het Bedrijf en u, inclusief schriftelijke verklaringen, garanties en overeenkomsten die de Beheerder u kan vragen voor naleving van alle (i) toepasselijke federale wetten en voorschriften en die van een Amerikaanse staat, (ii) toepasselijke wetten van het land waar u woont die relevant zijn voor de uitgifte of verkoop van Gewone aandelen, en (iii) toepasselijke vereisten van een beurs of geautomatiseerd offertesysteem waarbij de Gewone aandelen van het Bedrijf worden vermeld of aangeboden op het ogenblik van zulke uitgifte of overdracht. Niettegenstaande een andere bepaling van deze Overeenkomst, is het Bedrijf niet verplicht om Gewone aandelen volgens deze Overeenkomst uit te geven, als zo’n uitgifte een inbreuk vormt op een toepasselijke wet of voorschrift of vereiste van een effectenbeurs of soortgelijke instelling. 2.9 Opschorting op korte termijn (alleen van toepassing op personen die onderhevig zijn aan de federale Amerikaanse belastingswetten). Volgens deze Overeenkomst te betalen PSU's zijn bedoeld om vrijgesteld te zijn van het wetboek Sectie 409A volgens de vrijstelling voor opschortingen op korte termijn. PSU's worden dan ook niet later dan de 15e dag van de derde maand verrekend die volgt op uiterlijk (i) het einde van het belastingjaar van de werknemer waarin de toezeggingsdatum valt, of (ii) het einde van het boekjaar van het Bedrijf waarin de toezeggingsdatum valt. 2.10 Gegevensprivacy. (a) Amerikaanse regels voor gegevensprivacy (alleen toepasselijk als deze Award onderworpen is aan de Amerikaanse wetten voor gegevensprivacy). Door deze Overeenkomst aan te gaan en deze Award te aanvaarden, (a) gaat u uitdrukkelijk en ondubbelzinnig akkoord met de verzameling, het gebruik en de overdracht, op elektronische of andere wijze, van de persoonsgegevens die nodig zijn om de invoering, de uitvoering en het beheer van de Award en het Plan te vergemakkelijken, (b) begrijpt u dat het Bedrijf, om het Plan in te voeren, uit te voeren en te beheren, bepaalde persoonsgegevens over u kan bijhouden, inclusief maar niet beperkt tot uw naam, thuisadres en telefoonnummer, geboortedatum, socialezekerheidsnummer of ander identificatienummer, salaris, nationaliteit, functietitel en informatie over alle awards of rechten op Aandelen die u volgens het Plan of anders zijn toegewezen ('Persoonsgegevens'), (c) begrijpt u dat Persoonsgegevens kunnen worden overgedragen aan derden die helpen bij de invoering, uitvoering en het beheer van het Plan, inclusief elke makelaar bij wie de bij toezegging van de Award uitgegeven Aandelen in bewaring kunnen worden gegeven, en dat deze ontvangers zich in uw land of elders kunnen bevinden, en dat het land van de ontvanger andere wetten en beschermingsmaatregelen voor gegevensprivacy

---

![Slide 33](<performancebasedrestrict033.jpg>)

> **Source slide transcript**
>
> 33 kan hebben dan uw land, (d) u afstand doet van alle rechten op gegevensbescherming die u mogelijk hebt met betrekking tot de gegevens, en (e) u het Bedrijf, zijn filialen en agenten de toestemming geeft om zulke informatie op elektronische wijze op te slaan en door te sturen. (b) Niet-Amerikaanse regels voor gegevensprivacy (alleen toepasselijk als deze Award onderworpen is aan wetten voor gegevensprivacy van buiten de VS). (1) Door deze Overeenkomst aan te gaan en deze Award te aanvaarden, gaat u uitdrukkelijk en ondubbelzinnig akkoord met de verzameling, het gebruik en de overdracht, op elektronische of andere wijze, van de persoonsgegevens zoals beschreven in deze Overeenkomst en elk ander document over de toekenning van PSU door en bij, zoals toepasselijk, het filiaal dat u tewerkstelt of in dienst neemt, het Bedrijf en zijn filialen uitsluitend voor de invoering, uitvoering en het beheer van uw deelname aan het Plan. (2) U begrijpt dat het Bedrijf en het filiaal dat u tewerkstelt of in dienst neemt bepaalde persoonsgegevens van u kan bijhouden, inclusief maar niet beperkt tot uw naam, thuisadres en telefoonnummer, geboortedatum, socialezekerheidsnummer of ander identificatienummer, salaris, nationaliteit, functietitel, Gewone aandelen of bestuursmandaten in het Bedrijf, gegevens van alle PSU's of elk ander recht op Gewone aandelen dat is toegekend, geannuleerd, uitgeoefend, toegewezen, niet toegewezen of in uw voordeel uitstaat, uitsluitend om het Plan in te voeren, uit te voeren en te beheren ('Gegevens'). (3) U begrijpt dat gegevens worden overgedragen aan een juridisch adviseur of een makelaar of een andere dienstverlener van aandelenplannen die in de toekomst door het Bedrijf kan worden geselecteerd, en die het Bedrijf helpt bij de invoering, uitvoering en het beheer van het Plan. U begrijpt dat de ontvangers van de Gegevens in de Verenigde Staten of elders kunnen gevestigd zijn, en dat het land van de ontvanger (bv. de Verenigde Staten) andere wetten en beschermingen voor gegevensprivacy kan hebben dan het land waar u woont. U begrijpt dat als u niet in de Verenigde Staten woont, u een lijst met namen en adressen van mogelijke ontvangers van de Gegevens kunt opvragen door contact op te nemen met uw lokale medewerker van de personeelsdienst of die van het Bedrijf. U autoriseert het Bedrijf en alle andere mogelijke ontvangers die (nu of in de toekomst) het Bedrijf kunnen helpen met de invoering, uitvoering en het beheer van het Plan om de Gegevens in elektronische of andere vorm te ontvangen, bezitten, gebruiken, bij te houden en over te dragen, uitsluitend en alleen om uw deelname aan het Plan in te voeren, uit te voeren en te beheren. U begrijpt dat Gegevens maar zo lang worden bijgehouden als nodig is om uw deelname aan het Plan in te voeren, uit te voeren en te beheren. U begrijpt dat als u niet in de Verenigde Staten woont, u op elk ogenblik gegevens kunt inzien, extra informatie over de opslag en verwerking van gegevens kunt opvragen, noodzakelijke wijzigingen aan gegevens kunt vragen of de toestemmingen erin kunt weigeren of intrekken, steeds zonder kosten, door schriftelijk contact op te nemen met uw lokale medewerker van de personeelsdienst of die van het Bedrijf. U begrijpt echter dat het weigeren of intrekken van uw toestemming een invloed kan hebben op de mogelijkheid of u aan het Plan kunt deelnemen. Meer informatie over de gevolgen van uw weigering of intrekking van uw toestemming kunt u krijgen door contact op te nemen met uw lokale medewerker van de personeelsdienst of die van het Bedrijf.

---

![Slide 34](<performancebasedrestrict034.jpg>)

> **Source slide transcript**
>
> 34 2.11 Opvolgers en gevolgmachtigden. Deze Overeenkomst is bindend voor alle opvolgers en gevolmachtigden van het Bedrijf. 2.12 Toepasselijke wetgeving. Deze Overeenkomst wordt beheerd door en wordt opgevat en afgedwongen in overeenstemming met de toepasselijke voorzieningen van de Code en dit zo veel mogelijk, en anderszins met de wetten van de staat Michigan, ongeacht de beginselen van wetsconflicten, op voorwaarde dat u een buitenlander bent of buiten de Verenigde Staten tewerkgesteld bent. Deze Overeenkomst wordt beheerd door en wordt opgevat en afgedwongen in overeenstemming met de toepasselijke buitenlandse wetgeving, in die mate dat die wetgeving verschilt van de Code en de wetten van de staat Michigan. Elk geding met betrekking tot of voortvloeiende uit deze Overeenkomst wordt gestart, vervolgd of verdergezet in het Circuit Court in Kent County, Michigan, gevestigd in Grand Rapids, Michigan of in het United States District Court voor het Western District van Michigan, en in om het even welke beroepsrechtbank daarvan. 2.13 Verbeuring van PSU's. Als het Bedrijf, ten gevolge van wangedrag, een bijstelling van gerapporteerde resultaten moet voorbereiden wegens belangrijke niet-naleving van een vereiste voor financiële verslaggeving volgens de effectenwetgeving, dan: als (a) uw compensatie op basis van een incentive of vermogen automatisch verbeurd wordt verklaard wegens zo’n wangedrag en bijstelling onder Sectie 304 van de Sarbanes-Oxley Act van 2002, of (b) de Commissie stelt dat u bewust ofwel wangedrag beging of er niet in slaagde het te voorkomen, of uw acties of gebrek aan actie met betrekking tot het wangedrag en bijstelling een teken is van grote nalatigheid, dan (i) moet u het Bedrijf het betaalde bedrag terugbetalen dat u verkreeg met PSU's die werden verdiend of verzameld tijdens de twaalf maanden na de eerste uitgifte of indiening bij de SEC (wat ook het eerst gebeurt) van het financiële document dat zulke vereiste voor financiële verslaggeving omvat, en (ii) moeten alle uitstaande PSU's die nog niet zijn afgerekend, onmiddellijk worden verbeurdverklaard. Daarnaast zijn volgens deze Overeenkomst verworven Gewone aandelen en alle inkomsten of winsten uit de verkoop van zulke Gewone aandelen onderworpen aan een 'terugvorderingsbeleid' of terugverdienbeleid dat later door het Bedrijf is aangenomen. 2.14 Speciale regels voor niet-Amerikaanse begunstigden (alleen van toepassing als u niet in de VS woont). (a) Aard van de toekenning. Door de toekenning te aanvaarden, erkent, begrijpt en gaat u ermee akkoord dat: (1) het Plan vrijwillig door het Bedrijf is opgesteld, discreet van aard is en op elk ogenblik kan worden gewijzigd, aangepast, opgeschort of beëindigd, behalve zoals anders voorzien in het Plan. (2) de toekenning van de PSU's vrijwillig en incidenteel is en geen contractueel of ander recht creëert om toekomstige toekenningen van PSU's of voordelen in plaats van de PSU's te ontvangen, zelfs niet als de PSU's in het verleden herhaaldelijk zijn toegekend; (3) alle beslissingen met betrekking tot toekomstige toekenningen van

---

![Slide 35](<performancebasedrestrict035.jpg>)

> **Source slide transcript**
>
> 35 PSU's, als er al zijn, uitsluitend worden genomen door het Bedrijf; (4) u vrijwillig deelneemt aan het Plan; (5) de PSU's en de Gewone aandelen onderhevig aan de PSU's een buitengewoon item zijn dat buiten het toepassingsgebied van uw tewerkstelling of servicecontract valt, als dat er is; (6) de PSU's en de Gewone aandelen onderhevig aan de PSU's niet bedoeld zijn om pensioenrechten of compensatie te vervangen; (7) de PSU's en de Gewone aandelen onderhevig aan de PSU's geen onderdeel vormen van de normale of verwachte compensatie voor het berekenen van een opzegging, genomen ontslag, gedwongen ontslag, einde van servicebetalingen, bonussen, awards voor lange dienst, pensioen of sociale uitkeringen of soortgelijke betalingen en in geen geval mogen worden beschouwd als compensatie voor of op welke manier ook in verband met vorige diensten aan het Bedrijf, het filiaal dat u tewerkstelt of in dienst neemt of elk ander filiaal; (8) de toekenning en uw deelname aan het plan niet geïnterpreteerd worden als een vorm van tewerkstelling of servicecontract met het Bedrijf of een filiaal; (9) de toekomstige waarde van de onderliggende Gewone aandelen onbekend en onbepaalbaar is en niet met zekerheid kan worden voorspeld; (10) geen vordering of recht op compensatie of schadevergoeding zal voortvloeien uit de verbeuring van de PSU's wegens uw ontslagdatum (om welke reden ook, of deze later al dan niet als ongeldig wordt geacht en of ze al dan niet een inbreuk vormt op de arbeidswetten in de jurisdictie waar u tewerkgesteld bent of diensten verleent, of de voorwaarden in uw arbeidsovereenkomst, als die er is), en als tegenprestatie voor de PSU's waar u anders geen recht op hebt, u er ontegensprekelijk mee akkoord gaat dat u nooit een vordering instelt tegen het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt, u afstand doet van de mogelijkheid, als die er is, om zulke vordering in te stellen, en u het Bedrijf of het filiaal dat u tewerkstelt of in dienst neemt van zulke vordering vrijstelt; als niettegenstaande het vorige, zulke vordering ontvankelijk wordt verklaard door een hof van de bevoegde jurisdictie, dan wordt u door uw deelname aan het Plan ontegensprekelijk geacht zulke vordering niet in te dienen en ermee akkoord te gaan dat u voor alle documenten zorgt die nodig zijn om zulke vordering af te wijzen of in te trekken; en (11) u erkent en ermee akkoord gaat dat noch het Bedrijf, het filiaal dat u tewerkstelt of in dienst neemt of elk ander filiaal aansprakelijk is voor een schommeling van de wisselkoers tussen de valuta van het land waarin u verblijft en de Amerikaanse dollar, die van invloed kan zijn op de waarde van de PSU's of bedragen die u verschuldigd zijn conform de afrekening van de PSU's of de daaropvolgende verkoop van Gewone aandelen die bij de afrekening zijn verworven. (b) Bijlage. Niettegenstaande de voorzieningen in deze Overeenkomst, is de toekenning van de PSU onderhevig aan speciale algemene voorwaarden die in een Bijlage bij deze Overeenkomst vermeld staan. Bovendien, als u verhuist naar een van de landen die in de

---

![Slide 36](<performancebasedrestrict036.jpg>)

> **Source slide transcript**
>
> 36 Bijlage vermeld staan, zijn de speciale algemene voorwaarden voor dat land op u van toepassing, in de mate waarin het Bedrijf bepaalt dat de toepassing van zulke voorzieningen nodig of raadzaam zijn om te voldoen aan de wetten van het land waarin u verblijft of om de uitvoering van het Plan te vergemakkelijken. Als u naar de Verenigde Staten verhuist, zijn de speciale algemene voorwaarden in de Bijlage op u van toepassing, of zijn ze niet langer van toepassing, in de mate waarin het Bedrijf bepaalt dat de toepassing of anders van zulke voorzieningen nodig of aangeraden zijn om de uitvoering van het Plan te vergemakkelijken. De Bijlage vormt een onderdeel van deze Overeenkomst. (c) Impositie van overige vereisten. Het Bedrijf behoudt zich het recht voor om andere vereisten op te leggen aan uw deelname aan het Plan, op de PSU's en alle volgens het Plan verworven Gewone aandelen, in de mate waarin het Bedrijf bepaalt dat het nodig of raadzaam is om te voldoen aan de wetten van het land waarin u verblijft of om de uitvoering van het Plan te vergemakkelijken, en om u te vragen extra overeenkomsten of garanties te tekenen die nodig kunnen zijn om het voorgaande te verwezenlijken. 2.15 Niet-concurrentie- en niet-wervingsbeding. (a) Niet-concurrentiebeding. Tijdens uw tewerkstelling bij het Bedrijf en zijn filialen en gedurende een termijn van twaalf (12) maanden volgend op uw Beëindigingsdatum (de 'Beperkte termijn'), mag u niet (i) rechtstreeks of onrechtstreeks, zonder voorafgaande schriftelijke toestemming van het Bedrijf, een aanzienlijk of meerderheidsbelang hebben als eigenaar, partner, aandeelhouder, licentiehouder, directeur, kaderlid, agent of consultant voor om het even wie die een bedrijf heeft dat een concurrent is van een onderdeel van het Bedrijf of een van zijn filialen ergens in het land of de landen waarin u regelmatig werkzaam bent of diensten verleent; of (ii) werk of een verbintenis voor het verstrekken van diensten aanvaarden in om het even welke hoedanigheid, inclusief als werknemer, directeur, consultant of adviseur, rechtstreeks of onrechtstreeks, bij om het even wie die een bedrijf heeft dat een concurrent is van een onderdeel van het Bedrijf of een van zijn filialen ergens in het land of de landen waarin u regelmatig werkzaam bent of diensten verleent. In dit verband omvat het hebben van een bedrijf dat een concurrent is van een onderdeel van het Bedrijf of een van zijn filialen de verkoop, productie, distributie of onderzoek en ontwikkeling van een product of dienst die lijkt op een product en dienst die wordt verkocht, verdeeld, op de markt gebracht of onderzocht (inclusief via een joint venture of investering in een andere entiteit) door het Bedrijf of een van zijn filialen, inclusief een OTC-geneesmiddel of voedingsproducten van een huismerk en kwaliteitsmerk, farmaceutische producten met een uitgebreid actueel algemeen voorschrift, kindervoedingsproducten, mondverzorgingsproducten en elk ander product of alle andere producten die het Bedrijf of een filiaal op de markt brengt of actief plant om op de markt te brengen tijdens uw tewerkstelling bij het Bedrijf en tijdens de termijn van een jaar na uw Beëindigingsdatum. Als er tijdens de Beperkte termijn een voltooide verkoop, overdracht of andere voorziening is van het bedrijf Perrigo Prescription Pharmaceutical, is deze Sectie 2.15(a) niet van toepassing op het bedrijf Perrigo Prescription Pharmaceutical. Niettegenstaande het voorgaande, kan niets in deze bepaling u verhinderen om passief twee procent (2%) of minder van de uitstaande effecten van om het even welke klasse van een bedrijf op de nationale effectenbeurs of op een geautomatiseerd offertesysteem in het bezit te hebben. U kunt een schriftelijk verzoek richten aan de CHRO van het Bedrijf voor een uitzondering op deze Sectie 2.15(a) en zulke uitzondering wordt niet op onredelijke wijze geweigerd, in het bijzonder

---

![Slide 37](<performancebasedrestrict037.jpg>)

> **Source slide transcript**
>
> 37 wanneer u wilt worden tewerkgesteld door een bedrijf dat geen concurrent is van het segment van het Bedrijf waar u hebt gewerkt of diensten hebt verleend tijdens de laatste twee jaar van uw tewerkstelling bij het Bedrijf. (b) Niet-werving van dienstverleners. Tijdens uw tewerkstelling bij het Bedrijf en zijn filialen en voor de duur van de Beperkte termijn, mag u niet, rechtstreeks on onrechtstreeks, zonder de voorafgaande schriftelijke toestemming van het Bedrijf, (i) actief iemand rekruteren, aanwerven of inhuren die op dat ogenblik of om het even wanneer tijdens de termijn van 12 maanden voorafgaand zulke rekrutering of aanwerving een werknemer of consultant was van het Bedrijf of een van zijn filialen, (ii) een werknemer van het Bedrijf of een van zijn filialen vragen of aanmoedigen om de tewerkstelling bij het Bedrijf of een van zijn filialen te verlaten of (iii) zich inmengen in de relatie van het Bedrijf of een van zijn filialen met een persoon of entiteit die tewerkgesteld is of zich anderszins bezighoudt om diensten te verlenen voor het Bedrijf of een van zijn filialen. (c) Niet-werving van klanten. Tijdens uw tewerkstelling bij het Bedrijf en zijn filialen en gedurende de Beperkte termijn mag u niet, rechtstreeks of onrechtstreeks, alleen of in samenwerking met iemand anders, zonder de voorafgaande schriftelijke toestemming van het Bedrijf, (i) een klant (voormalig of actueel), leverancier, licentiehouder, franchisehouder, , joint venture-partner of andere zakenrelatie van het Bedrijf of een van zijn filialen (samen 'Klanten' genoemd) te bewegen tot of proberen te bewegen tot niet langer zaken te doen met het Bedrijf of filiaal, (ii) alle of een deel van de zaken van een Klant met het Bedrijf overdragen naar een concurrent van het Bedrijf of filiaal, of (iii) op een of andere manier zich inmengen in de relatie tussen enerzijds een Klant en anderzijds het Bedrijf of een filiaal. (d) Rechtsmiddelen en dwangmaatregelen tot rechtsherstel. U erkent dat een door u gemaakte inbreuk op een van de clausules in deze Sectie 2.15 onherstelbare schade zou toebrengen aan het Bedrijf en zijn filialen voor een bedrag dat aanzienlijk maar niet onmiddellijk achterhaalbaar is, en dat elk rechtsmiddel (inclusief de betaling van schadevergoeding) ontoereikend zou zijn. Dienovereenkomstig gaat u ermee akkoord dat, niettegenstaande een tegenstrijdige bepaling in deze overeenkomst, het Bedrijf en zijn filialen naast elke andere schade die het kan aantonen ook recht heeft (zonder economisch verlies of andere daadwerkelijke schade te moeten aantonen) op dwangmaatregelen tot rechtsherstel (inclusief tijdelijke gerechtelijke bevelen, voorlopige voorzieningen en permanente voorzieningen), zonder borgstelling, in een hof van de bevoegde jurisdictie voor een feitelijke of mogelijke inbreuk van een van de clausules in deze Sectie 2.15 naast elke andere juridische of billijke rechtsmiddelen die het heeft. Daarnaast, in geval van uw opzettelijke inbreuk op de beperkende clausule (zoals gedefinieerd in deze Sectie 2.15), (i) vervallen al uw rechten volgens deze Overeenkomst, al dan niet toegezegd, onmiddellijk, en (ii) worden alle Aandelen, contacten of andere eigendom die u conform deze Overeenkomst zijn betaald of geleverd verbeurd verklaard en moet u die Aandelen, contanten of andere eigendommen terugbetalen aan het Bedrijf, en dit niet later dan dertig (30) kalenderdagen nadat het Bedrijf om uw terugbetaling heeft gevraagd. Voor de doeleinden van deze Overeenkomst verwijst "opzettelijke inbreuk op de beperkende clausule" op uw aanzienlijke inbreuk op een van de clausules in deze Sectie 2.15 waarvan u wist of door gepast onderzoek had moeten weten dat het om een aanzienlijke inbreuk zou gaan. De voorafgaande zinnen van deze Sectie 2.15 mogen niet worden beschouwd als een afstand van de rechten op schadevergoedingen die het Bedrijf en zijn filialen kunnen hebben conform deze

---

![Slide 38](<performancebasedrestrict038.jpg>)

> **Source slide transcript**
>
> 38 Overeenkomst of anders, en al deze rechten zijn onbeperkt. De Beperkte termijn is van kracht tijdens (en wordt geacht automatisch te worden verlengd met) een termijn waarin u in overtreding bent van de bepalingen van Sectie 2.15(a), (b) of (c), als van toepassing. Als een hof van de bevoegde jurisdictie bepaalt dat een bepaling van deze Sectie 2.15 ongeldig is of meer beperkt dan toegelaten volgens de geldende wetgeving van zulke jurisdictie, dan wordt deze bepaling, uitsluitend voor de handhaving van deze Sectie 2.15 binnen de jurisdictie van het hof, geïnterpreteerd en afgedwongen alsof ze voorzag in de maximale beperking die toegelaten is volgens zulke geldende wetgeving. (e) Bevestigingen. (1) U erkent dat het Bedrijf en zijn filialen aanzienlijke hoeveelheden tijd, geld en moeite hebben besteed en zullen blijven besteden voor het ontwikkelen van bedrijfsstrategieën, relaties met werknemers, klanten en anderen, en goodwill om een doeltreffende organisatie op te bouwen. U erkent dat het Bedrijf en zijn filialen een rechtmatig commercieel belang heeft in zijn goodwill en relaties met werknemers, klanten en anderen en het recht deze te beschermen, en dat het Bedrijf en zijn filialen ernstige schade kunnen ondervinden door het verlies of de verslechtering van zijn relaties met werknemers, klanten en anderen. U erkent daarnaast dat het Bedrijf en zijn filialen het recht hebben om de bedrijfswaarde van het Bedrijf en zijn filialen te beschermen en te behouden voor zover wettelijk toegestaan. (2) In het licht van de voorgaande erkenningen gaat u ermee akkoord dat de clausules in deze Overeenkomst redelijk en naar behoren vereist zijn voor de gepaste bescherming van de onderdelen en goodwill van het Bedrijf en zijn filialen. U erkent daarnaast dat, hoewel uw naleving van de clausules in deze Overeenkomst kunnen verhinderen dat u de kost verdient in een bedrijf dat vergelijkbaar is met de onderdelen van het Bedrijf en zijn filialen, u met uw ervaring en bekwaamheden andere kansen hebt om de kost te verdienen en over voldoende middelen te beschikken voor u en uw gezin. (3) In het licht van de erkenningen in deze Sectie 2.15 gaat u ermee akkoord om de redelijkheid, geldigheid of afdwingbaarheid van beperkingen op en verplichtingen van u in deze Sectie 2.15 niet te betwisten of aan te vechten. **** We kijken uit naar uw aanhoudende bijdrage tot de groei van het Bedrijf. Gelieve de ontvangst van het Plan en deze Award te bevestigen. Hoogachtend, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 39](<performancebasedrestrict039.jpg>)

> **Source slide transcript**
>
> 39 PERRIGO COMPANY PLC UMOWA PRZYDZIAŁU AKCJI WARUNKOWYCH (W OPARCIU O WYNIKI) (W ramach długoterminowego programu motywacyjnego Perrigo Company plc 2026) DO: Participant Name ODP.: Powiadomienie o przyznaniu jednostek akcyjnych o ograniczonych prawach (w oparciu o wyniki) Informujemy, że Perrigo Company plc („Spółka”) przyznała Prawo w ramach długoterminowego programu motywacyjnego Perrigo Company plc 2026 („Program”), obowiązującego od Grant Date („Data Przyznania”). Premia składa się z jednostek akcyjnych o ograniczonych prawach opartych o wyniki. Warunki niniejszego świadczenia motywacyjnego zostały określone w pozostałej części niniejszej umowy (w tym wszelkich specjalnych warunkach określonych w dowolnym załączniku dla danego kraju („Załącznik”) (łącznie „Umowa”). Terminy pisane wielką literą, które nie zostały inaczej zdefiniowane w niniejszej Umowie będą miały przypisane znaczenie w ramach Programu. § 1 Przekazanie jednostek akcyjnych o ograniczonych prawach (w oparciu o wyniki) 1.1 Przyznanie. Od Daty Przyznania i zgodnie z warunkami niniejszej Umowy i Programu, Spółka przyznaje Ci jednostki akcyjne o ograniczonych prawach oparte na wynikach („PSU”) w Number of Awards Granted. Liczba PSU przyznanych w niniejszym punkcie 1.1 jest określana jako „Premia Docelowa”. Premia Docelowa może zostać zwiększona lub zmniejszona w zależności od poziomu osiąganych Celów Wynikowych dla wyznaczonych Wskaźników wyników, jak opisano w § 1.2. Każda PSU uprawnia Cię do nabycia prawa do Akcji Zwykłej

---

![Slide 40](<performancebasedrestrict040.jpg>)

> **Source slide transcript**
>
> 40 Spółki, o wartości nominalnej 0,001 EUR na akcję („Akcja Zwykła”) z Datą Przekazania PSU określoną w § 1.2, pod warunkiem, że spełnione są odpowiednie Cele wynikowe dla każdego Wskaźnika wyników. 1.2 Przekazanie. Liczba przyznanych PSU, o których mowa w § 1.1, przekazywanie, o ile takowe ma miejsce, jest ustalane z Datą Przekazania PSU. Liczba ta zostanie ustalona na podstawie średniego poziomu osiąganych rocznych Wskaźników wyników dla każdego roku obrotowego w Okresie wynikowym, zgodnie z harmonogramem ustalonym przez Komisję w momencie, gdy Wskaźniki wyników i mające zastosowanie Cele wynikowe są ustalane przez Komisję. Komisja określa corocznie jeden lub więcej Wskaźników wyników i Celów wynikowych w stosunku do każdego Wskaźnika wyników, który należy osiągnąć dla Progu, Celu i maksymalnego wyniku w roku podatkowym. Dostarczone zostaną Wskaźnik wyników i Cele wynikowe dla każdego roku podatkowego. Po zakończeniu każdego roku podatkowego w Okresie wynikowym, Komisja określi procent Docelowych PSU Premii, które byłyby należne za taki rok podatkowy, w oparciu o osiągnięcie Celów wynikowych dla każdego(-ych) Wskaźnika(-ów) wyników określonego(-ych) przez Komisję na ten rok podatkowy. Procent Premii docelowej, który byłby należny zgodnie z harmonogramem, jest dostosowywany proporcjonalnie, aby uwzględnić osiągnięte wyniki między Progiem a Celem oraz Celem a Maksimum. Pod koniec Okresu wynikowego, wypłacany procent za każdy rok podatkowy w Okresie wynikowym zostanie uśredniony, aby ustalić faktyczny procent Docelowych PSU Premii, które zostaną przekazane i będą należne z Datą przekazania PSU. W żadnym wypadku obliczenie dodatniej stopy wypłaty dla dowolnego roku podatkowego nie będzie interpretowane jako gwarancja tego, że wszelkie PSU zostaną przekazane z Datą przekazania PSU. Stopa wypłaty dla poszczególnych lat podatkowych jest ustalana wyłącznie w celu ustalenia średniej rocznej stopy wypłat w trzyletnim Okresie Wynikowym. Z wyjątkiem przypadków określonych w § 1.4, PSU zostaną trwale utracone, jeśli Data rozwiązania Umowy przypadnie przed Datą przekazania PSU. Jeżeli średnia roczna wypłata za wyniki za Okres wynikowy jest niższa niż poziom wynikowy Progu, ustalony przez Komisję, wszelkie PSU, które nie zostały wcześniej utracone, przepadają z Datą przekazania PSU. Jeżeli średnia roczna wypłata za wyniki za Okres wynikowy przekroczy maksymalny poziom wynikowy ustalony przez Komitet, w żadnym wypadku liczba przekazanych PSU nie przekroczy 200% Premii docelowej. 1.3 Definicje. Poniższe terminy w niniejszym § 1 mają następujące znaczenie. (a) „Cel wynikowy” oznacza poziom wyniku, który należy osiągnąć w stosunku do Wskaźnika wyników w roku podatkowym w przypadku minimalnej, docelowej i maksymalnej wypłaty. (b) „Wskaźnik wyników” dla dowolnego roku podatkowego oznacza jeden lub więcej wskaźników finansowych określonych przez Komisję. Komitet określa, w jaki sposób Wskaźnik wyników zostanie skorygowany, jeśli w ogóle, w wyniku nadzwyczajnych zdarzeń

---

![Slide 41](<performancebasedrestrict041.jpg>)

> **Source slide transcript**
>
> 41 lub okoliczności, określonych przez Komisję, lub w celu wykluczenia skutków pozycji nadzwyczajnych, nietypowych lub jednorazowych; zmian w obowiązujących przepisach, regulacjach lub zasadach rachunkowości; wahań kursów walut; działalności zaniechanej; pozycji niepieniężnych, takich jak amortyzacja lub rezerwy; utraty wartości aktywów; lub jakiegokolwiek dokapitalizowania, restrukturyzacji, reorganizacji, połączenia, przejęcia, zbycia, konsolidacji, wydzielenia, podziału, likwidacji, rozwiązania spółki, sprzedaży aktywów lub innej podobnej transakcji korporacyjnej. (c) „Okres wynikowy” oznacza okres trzech kolejnych lat podatkowych Spółki, rozpoczynający się pierwszego dnia roku podatkowego Spółki, w którym przypada Data przyznania, i kończący się ostatniego dnia trzeciego roku obrotowego w 3-letnim okresie. (d) „Data Przekazania PSU” oznacza ostatni dzień Okresu wynikowego. (e) „Odejście na mocy porozumienia stron” oznacza dobrowolne zwolnienie się ze Spółki i zaistnienie jednej lub większej liczby z następujących zmian, do których doszło bez Twojej zgody: (i) istotna zmiana położenia geograficznego, w którym musisz wykonywać usługi, przez co dojazdy z domu do głównego miejsca pracy wzrosną o ponad 48 kilometrów, lub (ii) istotne zmniejszenie uprawnień, ograniczenie obowiązków lub odpowiedzialności lub istotne zmniejszenie podstawy wynagrodzenia lub premii motywacyjnych; pod warunkiem jednak, że dobrowolna rezygnacja z pracy dla Spółki nie będzie uważana za Odejście na mocy porozumienia stron, chyba że przekażesz Spółce pisemne zawiadomienie o dobrowolnej rezygnacji i zaistnieniu zmian uzasadniających odejście w ciągu 90 dni od ich pierwszego zaistnienia. Spółka będzie miała wówczas 30 dni na naprawienie zaistniałej sytuacji, a w takim przypadku nie zostaniesz uznany(-a) za osobę, która podjęła decyzję o Odejściu na mocy porozumienia stron. W przypadku, gdy Spółka nie naprawi zaistniałej sytuacji w ciągu 30 dni, Twoja Data Rozwiązania Umowy przypadnie 31. dnia po otrzymaniu przez Spółkę potwierdzenia odbioru takiego pisemnego powiadomienia. (f) „Rozwiązanie Umowy bez przyczyny” oznacza niedobrowolne rozwiązanie stosunku pracy lub stosunku umownego przez Spółkę bez powodu, w tym między innymi (i) rozwiązanie wchodzące w życie w przypadku wyczerpania przerwy w świadczeniu pracy podczas lub pod koniec okresu wypowiedzenia na mocy Ustawy o wcześniejszym powiadomieniu pracowników o zwolnieniach grupowych („WARN” - Worker Adjustment and Retraining Notification Act) oraz (ii) sytuację, w której przebywasz na zatwierdzonej przerwie w świadczeniu pracy, podczas której Twoje stanowisko jest chronione na mocy obowiązującego prawa (np. urlop na mocy Ustawy o urlopach rodzinnych i zdrowotnych [Family Medical Leave Act]), powracasz z takiego urlopu i nie możesz zostać zatrudniony ani uzyskać żadnej innej formy stosunku umownego ze Spółką. 1.4 Specjalne Zasady Przekazywania Praw. Niezależnie od treści powyższego § 1.2, jeżeli Data rozwiązania Umowy przypada z powodu Rozwiązania Umowy bez przyczyny lub Odejścia na mocy porozumienia stron w związku ze Zmianą kontroli lub po tej Zmianie (jak określono w Programie, a taka definicja może zostać zmieniona poniżej) i przed upływem dwóch (2) lat od Zmiany kontroli wszystkie PSU, które przyznano zgodnie z § 1.1, które wcześniej nie zostały utracone, zostaną w pełni przekazane, tak jakby osiągnięto Cel dla Okresu wynikowego obowiązującego z Datą rozwiązania Umowy. Jeśli Twoja Data rozwiązania Umowy przypadnie

---

![Slide 42](<performancebasedrestrict042.jpg>)

> **Source slide transcript**
>
> 42 z powodu śmierci, Niepełnosprawności lub Przejścia na emeryturę, PSU zostają przekazane lub utracone z Datą przekazania PSU, określoną w § 1.2, w zależności od osiągnięcia celów wynikowych. Jeśli Data rozwiązania Umowy przypada w ciągu 24 miesięcy poprzedzających Datę przekazania PSU z powodu Niedobrowolnego rozwiązania Umowy z przyczyn ekonomicznych, wszystkie PSU przyznane na mocy niniejszej Umowy zostają przekazane lub ulegają utracie z datą określoną w § 1.2, w zależności od osiągnięcia celów wynikowych; jednak pod warunkiem, że jeśli Twoja Data rozwiązania Umowy nastąpi z przyczyny opisanej zarówno w tym zdaniu, jak i w pierwszym zdaniu w niniejszym § 1.4, zamiast zasad przekazywania opisanych w niniejszym zdaniu obowiązywać będą specjalne zasady przekazywania praw, opisane w pierwszym zdaniu niniejszego § 1.4. 1.5 Rozliczenie PSU. Tak szybko jak tylko jest to możliwe po dniu pierwszego, regularnie odbywającego się posiedzenia Komisji, następującego po ostatnim dniu Okresu wynikowego, w którym Komisja poświadcza średnią wypłatę za każdy z trzech lat Okresu wynikowego (lub, jeśli wcześniej, termin, w którym PSU zostają przekazane zgodnie ze specjalnymi zasadami przekazywania praw, opisanymi w § 1.4), Spółka przekaże Ci jedną Akcję Zwykłą za każdą PSU, jeśli takowa istnieje, zgodnie z § 1.2 lub 1.4 niniejszej Umowy (data takiego przekazania jest „Datą rozliczenia” dla celów niniejszej Umowy); pod warunkiem jednak, że Spółka według własnego uznania może rozliczyć PSU w gotówce, w oparciu o rzeczywistą wartość rynkową akcji z datą przekazania. Nie zostaną przekazane żadne ułamkowe części akcji. Każda część ułamkowa akcji zostanie zaokrąglona do najbliższej całej akcji. Dochód związany z przekazaniem PSU oraz kwota wymaganej zaliczki na podatek zostaną ustalone na podstawie wartości akcji w dniu rozliczenia. PSU nie kwalifikują się jako ekwiwalenty dywidendy. § 2 Ogólne Warunki 2.1 Niezbywalność. Prawo przyznane w ramach niniejszej Umowy nie może zostać zbyte w sposób inny niż na mocy testamentu lub przez dziedziczenia i podziału. 2.2 Brak praw powiązanych z posiadaniem Akcji. Jako Akcjonariusz nie będziesz posiadać żadnych praw w stosunku do jakichkolwiek Akcji Zwykłych w ramach PSU przed datą wydania Ci certyfikatu lub certyfikatów takich akcji. 2.3 Rozwiązanie Umowy z przyczyny leżącej po stronie pracownika. Jeśli Data Rozwiązania Umowy nastąpi z przyczyny leżącej po stronie pracownika, wszystkie prawa wynikające z niniejszej Umowy niezwłocznie wygasają niezależnie od tego, czy prawa te zostały nabyte czy nie. 2.4 Prawa przyznane w ramach Programu. Przyznanie Prawa na mocy niniejszej Umowy odbywa się zgodnie z Programem, przy czym Prawo może zostać zrealizowane wyłącznie zgodnie z obowiązującymi warunkami Programu. Program zawiera określone definicje, restrykcje, ograniczenia i inne warunki, z których wszystkie mają zastosowanie w ramach niniejszej Umowy. WSZYSTKIE POSTANOWIENIA PROGRAMU ZOSTAJĄ WŁĄCZONE DO NINIEJSZEJ UMOWY PRZEZ ODNIESIENIE I STANOWIĄ CZĘŚĆ

---

![Slide 43](<performancebasedrestrict043.jpg>)

> **Source slide transcript**
>
> 43 NINIEJSZEJ UMOWY W TEN SAM SPOSÓB, TAK JAKBY KAŻDE TAKIE POSTANOWIENIE ZOSTAŁO W PEŁNI WPISANE DO NINIEJSZEJ UMOWY. Jeżeli Program stanie się nieważny lub niewykonalny z mocy prawa lub decyzji sądowej, niniejsza Umowa traci moc wiążącą. Żadne z postanowień niniejszej Umowy nie ma na celu ani nie należy interpretować żadnego z jej postanowień jako ograniczającego lub usuwającego jakąkolwiek definicję, restrykcję, ograniczenie lub inny warunek Programu, który jest istotny dla niniejszej Umowy i który może zostać w określony sposób zastosowany w niej przez Komisję. W przypadku wystąpienia sprzeczności pomiędzy postanowieniami niniejszej Umowy i Programu, w oparciu o zasadę wykładni warunki Programu zostaną uznane za nadrzędne i obowiązujące. 2.5 Korekty w przypadku Zmiany Akcji Zwykłych. W przypadku podziału akcji, dywidendy w postaci akcji, dokapitalizowania, przeklasyfikowania lub połączenia akcji, połączenia spółek, sprzedaży aktywów lub podobnego zdarzenia, liczba i rodzaj akcji, względem których przyznawane jest Prawo w ramach niniejszej Umowy oraz ich cena wykonania zostaną odpowiednio skorygowane w sprawiedliwy sposób, aby zapobiec „rozwodnieniu” lub rozszerzeniu przyznanych lub przysługujących Ci praw. 2.6 Potwierdzenie odbioru. Spółka i Ty zgadzacie się, że PSU są przyznawane na podstawie Zawiadomienia o Przyznaniu, niniejszej Umowy (w tym Załącznika, jeśli ma on zastosowanie) i postanowień Programu (włączonych tutaj przez odniesienie). Ty: (i) potwierdzasz otrzymanie kopii każdego z powyższych dokumentów, (ii) zapewniasz, że dokładnie przeczytałeś(-aś) i zapoznałeś(-aś) się z ich zapisami, oraz (iii) niniejszym akceptujesz PSU zgodnie z wszystkimi warunkami określonymi w niniejszym dokumencie oraz te określone w Programie i Zawiadomieniu o Przyznaniu. 2.7 Podatki i zaliczki na podatek. (a) Zaliczki na podatek (dotyczy tylko osób fizycznych podlegających amerykańskim przepisom podatkowym). Przyznane Prawo podlega potrąceniu wszystkich należnych podatków. Spółka może odmówić lub zezwolić na przekazanie jej wszelkich federalnych, stanowych lub lokalnych podatków należnych przy przyznawaniu, przekazywaniu lub innym zdarzeniu nakładającym zobowiązanie podatkowe w związku z przyznanym Prawem. Jeśli nie przekazałeś(-aś) Spółce pełnej kwoty zaliczki na podatek do dnia, w którym Spółka jest zobowiązana do zapłaty takiej zaliczki właściwemu organowi podatkowemu (lub w takim wcześniejszym terminie, który Spółka może określić w celu uzyskania pomocy w terminowym wywiązaniu się z obowiązków związanych z płatnością zaliczki na podatek), Spółka będzie miała jednostronne prawo do wstrzymania Akcji Zwykłych, względem których przyznawane jest Prawo w wysokości, którą uzna za wystarczającą do opłacenia zaliczki na podatek wymaganej przez prawo. Podatki stanowe będą potrącane według właściwej stawki ustalonej przez stan, w którym jesteś zatrudniony(-a) lub byłeś(-aś) ostatnio zatrudniony(-a) przez Spółkę. W żadnym wypadku liczba akcji nie może przekroczyć liczby niezbędnej do spełnienia maksymalnych federalnych, stanowych i lokalnych wymogów dotyczących potrącania podatku dochodowego i podatku odprowadzanego z tytułu zatrudnienia. Możesz zrezygnować z wcześniej nabytych Akcji Zwykłych lub nakazać Spółce wstrzymanie Akcji Zwykłych związanych z przyznanym Prawem w kwocie wystarczającej do pokrycia całości lub części zaliczki na podatek wymaganej przez prawo.

---

![Slide 44](<performancebasedrestrict044.jpg>)

> **Source slide transcript**
>
> 44 (b) Zobowiązanie podatkowe (dotyczy tylko osób fizycznych podlegających przepisom podatkowym poza Stanami Zjednoczonymi). Niezależnie od jakichkolwiek działań podejmowanych przez Spółkę lub, jeśli jest to inny podmiot, przez zatrudniający lub angażujący Podmiot powiązany w odniesieniu do jakiejkolwiek części lub całości podatku dochodowego, ubezpieczenia społecznego, podatku od wynagrodzeń, płatności na konto lub innych elementów podatkowych związanych z uczestnictwem w Programie i zgodnie z prawem („Pozycje podatkowe”), przyjmujesz do wiadomości, że ostateczne zobowiązanie za wszystkie Pozycje podatkowe spoczywa na Tobie i może przekraczać kwotę faktycznie potrąconą przez Spółkę lub zatrudniający lub angażujący Podmiot powiązany. Ponadto przyjmujesz do wiadomości, że Spółka i/lub zatrudniający lub angażujący Podmiot powiązany, (1) nie składają żadnych oświadczeń ani zobowiązań dotyczących traktowania jakichkolwiek Pozycji podatkowych w związku z dowolnym aspektem PSU, w tym między innymi, przyznaniem, przekazaniem lub wykonaniem PSU, późniejszą sprzedażą Akcji Zwykłych nabytych w wyniku takiego wykonania oraz otrzymywaniem dywidend; oraz (2) nie zobowiązują się do modyfikacji warunków przyznania lub jakiegokolwiek aspektu PSU w celu zmniejszenia lub usunięcia zobowiązania związanego z Pozycjami podatkowymi lub osiągnięcia określonego wyniku podatkowego. Ponadto, jeśli podlegasz opodatkowaniu w więcej niż jednej jurysdykcji między Datą przyznania PSU a datą jakiegokolwiek istotnego zdarzenia podlegającego opodatkowaniu, w zależności od przypadku, potwierdzasz, że Spółka i/lub Podmiot powiązany zatrudniają lub angażują Cię (lub zatrudniali lub angażowali wcześniej, w zależności od przypadku), możesz zostać zobowiązany(- a) do zapłaty zaliczki na podatek lub rozliczenia Pozycji Podatkowych w więcej niż jednej jurysdykcji. (1) Przed każdym odpowiednim zdarzeniem podlegającym opodatkowaniu lub zdarzeniem związanym z zapłatą zaliczki na podatek, zależnie od przypadku, zapłacisz lub dokonasz odpowiednich uzgodnień zadowalających Spółkę i/lub zatrudniający lub angażujący Podmiot powiązany w celu zaspokojenia wszystkich Pozycji podatkowych. W związku z tym upoważniasz Spółkę i/lub zatrudniający lub angażujący Podmiot powiązany, lub ich odpowiednich przedstawicieli, według własnego uznania, do wypełnienia zobowiązań w stosunku do wszystkich Pozycji Podatkowych poprzez jedną czynność lub kombinację następujących czynności: (A) potrącenie z wynagrodzenia lub innego wynagrodzenia pieniężnego wypłacanego Tobie przez Spółkę i/lub zatrudniający lub angażujący Podmiot powiązany; lub (B) potrącenie z wpływów ze sprzedaży Akcji Zwykłych nabytych w wyniku wykonania PSU albo w drodze dobrowolnej sprzedaży, albo w drodze obowiązkowej sprzedaży zorganizowanej przez Spółkę (w Twoim imieniu, zgodnie z niniejszym upoważnieniem); lub (C) wstrzymanie emisji Akcji Zwykłych przy zrealizowaniu PSU. (2) Aby uniknąć negatywnej oceny prawnobilansowej, Spółka może potrącać lub rozliczać Pozycje Podatkowe, uwzględniając obowiązujące ustawowe kwoty zaliczek na podatek lub inne obowiązujące stawki podatku u źródła. Jeżeli zobowiązanie

---

![Slide 45](<performancebasedrestrict045.jpg>)

> **Source slide transcript**
>
> 45 dotyczące Pozycji podatkowych zostaje zrealizowane poprzez odprowadzanie podatku z Akcji Zwykłych, dla celów podatkowych, uznaje się, że emitowano dla Ciebie pełną liczbę Akcji Zwykłych w ramach wykonanej PSU, bez względu na to, że pewna liczba Akcji Zwykłych jest wstrzymywana wyłącznie w celu spłaty Pozycji Podatkowych. (3) Spłacisz Spółce lub zatrudniającemu lub angażującemu Podmiotowi Powiązanemu wszelkie Pozycje Podatkowe, które Spółka lub zatrudniający lub angażujący Podmiot Powiązany może być zobowiązany do zatrzymania lub rozliczenia w wyniku uczestnictwa w Programie, których nie można zaspokoić opisanymi wcześniej środkami. Spółka może odmówić emisji lub dostarczenia Akcji Zwykłych lub wpływów ze sprzedaży Akcji Zwykłych, jeżeli nie wywiążesz się ze swoich zobowiązań związanych z Pozycjami Podatkowymi. 2.8 Zgodność z obowiązującym prawem. Emisja Akcji Zwykłych będzie podlegać i będzie uzależniona od przestrzegania przez Spółkę i Ciebie, w tym wszelkich pisemnych oświadczeń, gwarancji i umów, o które Administrator może Cię poprosić w celu zachowania zgodności ze wszystkimi (i) prawami i przepisami stanowymi i federalnymi obowiązującymi w Stanach Zjednoczonych, (ii) obowiązującymi przepisami prawa kraju, który zamieszkujesz, dotyczące emisji lub sprzedaży Akcji Zwykłych, oraz (iii) obowiązującymi wymogami dowolnej giełdy papierów wartościowych lub automatycznego systemu notowań, w którym Akcje Zwykłe Spółki mogą być wymienione lub notowane w momencie takiej emisji lub zbycia. Bez względu na jakiekolwiek inne postanowienie niniejszej Umowy, Spółka nie będzie zobowiązana do emisji jakichkolwiek Akcji Zwykłych w ramach niniejszej Umowy, jeżeli taka emisja naruszyłaby obowiązujące prawo lub obowiązujące przepisy lub wymogi jakiejkolwiek giełdy papierów wartościowych lub podobnego podmiotu. 2.9 Krótki okres przejściowy (dotyczy tylko osób podlegających federalnym przepisom podatkowym w Stanach Zjednoczonych). PSU należne na podstawie niniejszej Umowy mają zostać zwolnione z postanowień art. 409A Kodeksu na podstawie zwolnienia dotyczącego krótkich okresów przejściowych. W związku z tym PSU zostaną rozliczone nie później niż 15. dnia trzeciego miesiąca następującego po (i) zakończeniu roku podatkowego pracownika, w którym przypada data przekazania, lub (ii) zakończeniu roku podatkowego Spółki, w którym przypada data przekazania. 2.10 Ochrona danych osobowych. (a) Zasady dotyczące ochrony danych osobowych w Stanach Zjednoczonych (obowiązujące tylko wtedy, gdy przyznane Prawo podlega amerykańskim przepisom o ochronie danych osobowych). Zawierając niniejszą Umowę i akceptując przyznane Prawo, (a) wyraźnie i jednoznacznie wyrażasz zgodę na gromadzenie, wykorzystywanie i przekazywanie, w formie elektronicznej lub innej, jakichkolwiek danych osobowych, które są niezbędne do ułatwienia wdrożenia, administrowania i zarządzania przyznanym Prawem i Programem, (b) rozumiesz, że Spółka może, w celu wdrożenia, administrowania i zarządzania Programem, posiadać Twoje określone dane osobowe, w tym między innymi imię i nazwisko, adres zamieszkania i numer telefonu, datę urodzenia, numer ubezpieczenia społecznego lub inny numer identyfikacyjny, dane dot. wynagrodzenia, narodowości, stanowiska i szczegółowe informacje na temat wszystkich Praw lub uprawnień do Akcji przyznanych Ci w ramach Programu lub w inny sposób

---

![Slide 46](<performancebasedrestrict046.jpg>)

> **Source slide transcript**
>
> 46 („Dane Osobowe”), (c) rozumiesz, że Dane Osobowe mogą zostać przekazane dowolnym stronom trzecim pomagającym we wdrażaniu Planu, administrowaniu i zarządzaniu nim, w tym dowolnemu brokerowi, u którego złożone w depozycie mogą zostać Akcje wyemitowane po przekazaniu lub wykonaniu przyznanego Prawa, oraz że Ci odbiorcy mogą znajdować się w Twoim kraju lub w innym miejscu, a w kraju odbiorcy mogą obowiązywać inne przepisy i zabezpieczenia danych osobowych niż w Twoim kraju, (d) zrzekasz się wszelkich praw związanych z ochroną prywatności danych, które możesz posiadać w stosunku do danych, oraz (e) upoważniasz Spółkę, jej Podmioty Powiązane i pełnomocnicy do przechowywania i przekazywania takich informacji w formie elektronicznej. (b) Zasady dotyczące ochrony danych osobowych obowiązujące poza Stanami Zjednoczonymi (obowiązujące tylko wtedy, gdy Prawo podlega przepisom o ochronie danych osobowych innych państw) (1) Zawierając niniejszą Umowę i akceptując niniejszą Premię, wyraźnie i jednoznacznie wyrażasz zgodę na gromadzenie, wykorzystywanie i przekazywanie, w formie elektronicznej lub innej, swoich danych osobowych, jak opisano w niniejszej Umowie oraz wszelkich innych materiałach dot. przyznania PSU, w stosownych przypadkach, przez zatrudniający lub angażujący Podmiot powiązany, Spółkę i jej Podmioty powiązane wyłącznie w celu wdrożenia, administrowania i zarządzania twoim uczestnictwem w Programie. (2) Rozumiesz, że Spółka i zatrudniający lub angażujący Podmiot powiązany może przechowywać określone dane osobowe, w tym między innymi imię i nazwisko, adres zamieszkania i numer telefonu, datę urodzenia, numer ubezpieczenia społecznego lub inny numer identyfikacyjny, wynagrodzenie, narodowość, stanowisko, wszelkie Akcje Zwykłe lub stanowiska dyrektorskie w Spółce, szczegółowe informacje na temat PSU lub wszelkich innych praw do przyznanych Akcji Zwykłych, anulowanych, wykonywanych, przekazanych, nieprzekazanych lub pozostałych, wyłącznie w celu realizacji, administrowania i zarządzanie Programem („Dane”). (3) Rozumiesz, że Dane zostaną przekazane radcy prawnemu lub brokerowi lub innemu dostawcy usług w zakresie Programu akcji, który może zostać wybrany przez Spółkę w przyszłości, który wspiera Spółkę we wdrażaniu, administrowaniu i zarządzaniu Programem. Rozumiesz, że odbiorcy Danych mogą znajdować się w Stanach Zjednoczonych lub w innych krajach, a w kraju odbiorcy (np. Stanach Zjednoczonych) mogą obowiązywać inne przepisy dotyczące ochrony danych osobowych i zabezpieczeń niż w Twoim kraju zamieszkania. Rozumiesz, że jeśli mieszkasz poza Stanami Zjednoczonymi, możesz poprosić o listę z imionami i nazwiskami, i adresami wszelkich potencjalnych odbiorców Danych, kontaktując się z lokalnym przedstawicielem działu kadr lub przedstawicielem działu kadr Spółki. Upoważniasz Spółkę i innych potencjalnych odbiorców, którzy mogą pomóc Spółce (obecnie lub w przyszłości) we wdrażaniu, administrowaniu i zarządzaniu Programem w celu otrzymywania, posiadania, używania, przechowywania i przekazywania Danych, w formie elektronicznej lub innej, wyłącznie w celu wdrożenia, administrowania i zarządzania Twoim uczestnictwem w Programie. Rozumiesz, że Dane będą przechowywane tylko tak długo, jak będzie to konieczne do wdrożenia, administrowania i zarządzania Twoim uczestnictwem w Programie. Rozumiesz, że jeśli mieszkasz poza Stanami Zjednoczonymi, możesz w dowolnym momencie przeglądać Dane, żądać dodatkowych informacji na temat przechowywania i przetwarzania Danych,

---

![Slide 47](<performancebasedrestrict047.jpg>)

> **Source slide transcript**
>
> 47 wymagać wszelkich niezbędnych zmian Danych lub odmówić lub cofnąć zgody w niniejszym dokumencie, w każdym przypadku bez ponoszenia kosztów, kontaktując się na piśmie z lokalnym przedstawicielem działu kadr lub przedstawicielem działu kadr Spółki. Rozumiesz jednak, że odmowa lub wycofanie Twojej zgody może wpłynąć na Twoją zdolność do uczestnictwa w Programie. Aby uzyskać więcej informacji na temat konsekwencji odmowy wyrażenia zgody lub wycofania zgody, rozumiesz, że możesz skontaktować się z lokalnym przedstawicielem działu kadr lub przedstawicielem działu kadr Spółki. 2.11 Następcy Prawni i Cesjonariusze. Niniejsza Umowa będzie wiążąca dla jednego lub wszystkich następców prawnych i cesjonariuszy Spółki. 2.12 Obowiązujące Prawo. Niniejsza Umowa podlega, będzie interpretowana i realizowana zgodnie z obowiązującymi przepisami Kodeksu w maksymalnym możliwym zakresie, a w inny sposób przez ustawodawstwo stanu Michigan, bez względu na zasady kolizji przepisów prawnych, pod warunkiem, że jesteś cudzoziemcem lub osobą zatrudnioną poza Stanami Zjednoczonymi, niniejsza Umowa podlega, będzie interpretowana i realizowana zgodnie z obowiązującym prawem zagranicznym, w zakresie, w jakim takie prawo różni się od Kodeksu i prawa stanu Michigan. Wszelkie postępowania związane z niniejszą Umową lub wynikające z niej będą wszczynane, ścigane lub kontynuowane w Sądzie Okręgowym w hrabstwie Kent w Grand Rapids w stanie Michigan lub w amerykańskim sądzie rejonowym dla północnej części stanu Michigan, i w dowolnym amerykańskim sądzie apelacyjnym. 2.13 Przepadek PSU. Jeśli Spółka, w wyniku niewłaściwego postępowania, jest zobowiązana do sporządzenia korekty rachunkowej z powodu istotnej niezgodności z jakimkolwiek wymogiem sprawozdawczości finansowej wynikającym z przepisów dotyczących papierów wartościowych, wówczas (a) jeżeli kapitałowe świadczenie pracownicze ulega automatycznemu przepadkowi z powodu takiego niewłaściwego postępowania i sporządzenia korekty, zgodnie z art. 304 ustawy Sarbanes-Oxley Act z 2002 r. lub (b) Komitet stwierdza, że świadomie angażowałeś(-aś) się lub nie zapobiegłeś(-as) niewłaściwemu działaniu, a Twoje działania lub zaniechania stanowiły rażące zaniedbanie w stosunku do niewłaściwego postępowania i korekty, (i) będziesz zobowiązany(-a) do zwrotu Spółce wszelkich zysków związanych z dowolną PSU zrealizowaną w okresie dwunastu miesięcy od pierwszej publicznej emisji lub przedłożenia w SEC (w zależności od tego, co nastąpi wcześniej) dokumentu finansowego zawierającego taki wymóg sprawozdawczości finansowej, oraz (ii) wszelkie pozostałe Opcje zostaną niezwłocznie utracone. Ponadto Akcje Zwykłe nabyte w wyniku wykonania tej Umowy oraz wszelkie zyski ze sprzedaży takich Akcji Zwykłych podlegają wszelkim zasadom „wycofania” lub zwrotu nienależnych korzyści, przyjętym później przez Spółkę. 2.14 Zasady specjalne dla Beneficjentów spoza Stanów Zjednoczonych (obowiązują tylko w przypadku osób mieszkających poza Stanami Zjednoczonymi) (a) Charakter przyznania. Przyjmując przyznanie, potwierdzasz, rozumiesz i zgadzasz się, że: (1) Program jest dobrowolnie opracowywany przez Spółkę, ma charakter uznaniowy i może być modyfikowany, zmieniany, zawieszany lub zakończony przez

---

![Slide 48](<performancebasedrestrict048.jpg>)

> **Source slide transcript**
>
> 48 Spółkę w dowolnym momencie, chyba że Program stanowi inaczej. (2) przyznanie PSU jest dobrowolne i okazjonalne i nie stwarza żadnego umownego ani innego prawa do przyznania PSU w przyszłości lub korzyści zamiast PSU, nawet jeśli PSU była wielokrotnie przyznawana w przeszłości; (3) wszelkie decyzje dotyczące przyszłych przyznanych PSU, jeśli takowe zostaną podjęte, będą podejmowane według wyłącznego uznania Spółki; (4) dobrowolnie uczestniczysz w Programie; (5) PSU i Akcje Zwykłe będące przedmiotem PSU są pozycją nadzwyczajną i która wykracza poza zakres umowy o pracę lub umowy o świadczenie usług, jeżeli taka istnieje; (6) PSU i Akcje Zwykłe będące przedmiotem PSU nie mają na celu zastąpienia jakichkolwiek uprawnień emerytalnych lub wynagrodzeń; (7) PSU i Akcje Zwykłe będące przedmiotem PSU nie są częścią normalnego lub oczekiwanego wynagrodzenia do celów wyliczania wszelkich odpraw, zwolnień, rozwiązań, odpraw wypłacanych na zakończenie stosunku pracy, premii, nagród jubileuszowych, emerytur lub rent lub świadczeń socjalnych lub podobnych zapłat, i w żadnym wypadku nie powinny być uważane za wynagrodzenie za wcześniejsze świadczenia na rzecz Spółki, zatrudniającego lub angażującego Podmiotu powiązanego lub jakiegokolwiek innego Podmiotu powiązanego; (8) przyznanie i Twoje uczestnictwo w Programie nie będą interpretowane jako umowa o pracę lub umowa o świadczenie usług zawiązana ze Spółką lub jakimkolwiek Podmiotem powiązanym; (9) przyszła wartość bazowych Akcji Zwykłych jest nieznana, nieokreślona i nie można jej z absolutną pewnością przewidzieć; (10) żadne roszczenie lub prawo do wynagrodzenie lub odszkodowania nie powstanie w wyniku przepadku PSU wynikającego z Daty rozwiązania Umowy (z jakiegokolwiek powodu, niezależnie od tego, czy okaże się ona później nieważna i czy narusza przepisy prawa pracy w jurysdykcji, w której jesteś zatrudniony(-a) lub świadczysz usługi, lub warunki umowy o pracę, jeśli takie istnieją), a biorąc pod uwagę przyznanie PSU, do której w innym przypadku nie jesteś uprawniony(-a), nieodwołalnie zgadzasz się nigdy nie wnosić żadnych roszczeń w stosunku do Spółki lub zatrudniającego lub angażującego Podmiotu powiązanego zrezygnujesz z ewentualnej możliwości wniesienia takiego roszczenia i zwolnisz Spółkę i zatrudniający lub angażujący Podmiot powiązany od takiego roszczenia; jeżeli, niezależnie od powyższego, jakiekolwiek takie roszczenie jest dozwolone przez sąd właściwej jurysdykcji, wówczas, biorąc udział w Programie, nieodwołalnie zostanie uznane, że zgodziłeś(- aś) się nie dochodzić takiego roszczenia i zgadzasz się na wykonanie wszelkich dokumentów niezbędnych do wniesienia wniosku o oddalenie lub wycofanie takiego roszczenia; i (11) potwierdzasz i zgadzasz się, że ani Spółka, zatrudniający lub

---

![Slide 49](<performancebasedrestrict049.jpg>)

> **Source slide transcript**
>
> 49 angażujący Podmiot powiązany ani żaden inny Podmiot powiązany nie będzie odpowiedzialny za jakiekolwiek wahania kursów wymiany walut między walutą kraju, w którym mieszkasz, a dolarem amerykańskim, które mogą mieć wpływ na wartość PSU lub dowolnych kwot Tobie należnych, zgodnie z rozliczeniem PSU lub późniejszą sprzedażą Akcji Zwykłych nabytych w wyniku rozliczenia. (b) Załącznik. Niezależnie od jakichkolwiek postanowień niniejszej Umowy, przyznanie Opcji będzie podlegać specjalnym warunkom określonym w dowolnym Załączniku do niniejszej Umowy. Ponadto, jeśli przeprowadzisz się do jednego z krajów wymienionych w Załączniku, obowiązują Cię specjalne warunki dla takiego kraju, o ile Spółka stwierdzi, że zastosowanie takich postanowień jest konieczne lub wskazane w celu zapewnienia zgodności z przepisami prawa kraju zamieszkania lub w celu ułatwienia zarządzania Programem. Jeśli przeprowadzisz się do Stanów Zjednoczonych, obowiązują Cię specjalne warunki zawarte w Załączniku, lub przestają Cię obowiązywać w zakresie w jakim Spółka stwierdzi, że zastosowanie lub inne działanie dla takich postanowień jest konieczne lub wskazane w celu ułatwienia zarządzania Programem. Załącznik stanowi część niniejszej Umowy. (c) Nałożenie innych wymogów. Spółka zastrzega sobie prawo do nałożenia innych wymogów na uczestnictwo w Programie, na PSU i na Akcje Zwykłe nabyte w ramach Programu, w zakresie, w jakim Spółka uzna to za konieczne lub wskazane w celu zapewnienia zgodności z prawem kraju, w którym przebywasz, w celu ułatwienia administrowania Programem lub w celu ułatwienia zarządzania nim, a także do nałożenia wymogów podpisania wszelkich dodatkowych umów lub zobowiązań, które mogą być konieczne do osiągnięcia powyższego. 2.15 Zakaz konkurencji i zakaz podejmowania współpracy. (a) Zakaz konkurencji. W okresie zatrudnienia w Spółce i jej Podmiotach stowarzyszonych oraz przez okres dwunastu (12) miesięcy od Daty rozwiązania umowy („Okres ograniczony”) nie możesz (i) bezpośrednio ani pośrednio, bez uprzedniej pisemnej zgody Spółki nawiązać współpracy ani nabyć istotnego lub kontrolnego pakietu jako właściciel, partner, akcjonariusz, licencjodawca, członek zarządu, dyrektor, agent lub konsultant jakiejkolwiek Osoby, która prowadzi działalność konkurencyjną w stosunku do działalności prowadzonej przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych w dowolnym miejscu w kraju lub krajach, w których normalnie wykonujesz pracę lub świadczysz usługi; lub (ii) przyjąć oferty zatrudnienia ani zaangażować się w jakimkolwiek charakterze, w tym jako pracownik, członek zarządu, konsultant lub doradca, bezpośrednio lub pośrednio, na rzecz każdej Osoby, która prowadzi działalność konkurencyjną w stosunku do działalności prowadzonej przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych w dowolnym miejscu w kraju lub krajach, w których normalnie wykonujesz pracę lub świadczysz usługi. Dla celów niniejszej Umowy prowadzenie działalności konkurencyjnej w stosunku do działalności prowadzonej przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych obejmuje sprzedaż, produkcję, dystrybucję lub badania i rozwój jakiegokolwiek produktu lub usługi, podobnych do produktu lub usługi sprzedawanej, dystrybuowanej, wprowadzanej na rynek, badanej lub rozwijanej (w tym poprzez wspólne przedsięwzięcie lub inwestycję w inny podmiot) przez Spółkę lub którykolwiek z jej Podmiotów stowarzyszonych, włączając w to sprzedawane bez recepty leki i suplementy diety marek sklepowych i ekonomicznych, generyczne produkty farmaceutyczne o przedłużonym

---

![Slide 50](<performancebasedrestrict050.jpg>)

> **Source slide transcript**
>
> 50 działaniu do stosowania zewnętrznego wydawane na receptę, odżywki dla niemowląt, produkty do pielęgnacji jamy ustnej oraz każdy inny produkt lub produkty, które Spółka lub Podmiot stowarzyszony wprowadza lub planuje wprowadzić na rynek w okresie Twojego zatrudnienia w Spółce oraz w ciągu jednego roku od Daty rozwiązania umowy. W przypadku zakończenia sprzedaży, przeniesienia lub innej formy zbycia działalności Spółki Perrigo Prescription Pharmaceutical w Okresie ograniczonym niniejszy punkt 2.15(a) nie będzie miał zastosowania do działalności Spółki Perrigo Prescription Pharmaceutical. Niezależnie od powyższego żaden element niniejszego postanowienia nie zakazuje biernego posiadania dwóch procent (2%) lub mniej pozostających w obrocie papierów wartościowych jakiejkolwiek klasy dowolnej spółki notowanej na krajowej giełdzie papierów wartościowych lub w automatycznym systemie notowań. Możesz złożyć pisemną prośbę do dyrektora działu kadr Spółki o wyjątek od postanowień niniejszego punktu 2.15(a), a udzielenie zgody na ten wyjątek nie zostanie bezzasadnie wstrzymane, w szczególności w przypadku chęci zatrudnienia w firmie, która nie konkuruje z segmentem Spółki, w której pracowałeś lub świadczyłeś usługi w ciągu ostatnich dwóch lat zatrudnienia w Spółce. (b) Zakaz podejmowania współpracy z Usługodawcami. W okresie zatrudnienia w Spółce i jej Podmiotach stowarzyszonych oraz w czasie trwania Okresu ograniczonego nie możesz, bezpośrednio ani pośrednio, bez uprzedniej pisemnej zgody Spółki, (i) aktywnie oferować stanowiska, rekrutować ani zatrudniać jakiejkolwiek osoby, która jest w danym momencie lub która w dowolnym momencie w okresie 12 miesięcy przed takim oferowaniem stanowiska lub zatrudnieniem była pracownikiem lub konsultantem Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych, (ii) nakłaniać lub zachęcać jakiegokolwiek pracownika Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych do odejścia z pracy w Spółce lub którymkolwiek z jej Podmiotów stowarzyszonych, lub (iii) ingerować w relacje Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych z jakąkolwiek osobą lub podmiotem, który jest zatrudniony lub w inny sposób zaangażowany w świadczenie usług na rzecz Spółki lub któregokolwiek z jej Podmiotów stowarzyszonych. (c) Zakaz podejmowania współpracy z Klientami. W okresie zatrudnienia w Spółce i jej Podmiotach stowarzyszonych oraz w czasie trwania Okresu ograniczonego nie możesz, bezpośrednio ani pośrednio, sam lub wspólnie z jakąkolwiek inną Osobą, bez uprzedniej pisemnej zgody Spółki, (i) nakłaniać lub usiłować nakłaniać jakiegokolwiek klienta, kontrahenta (byłego lub obecnego), dostawcy, licencjobiorcy, franczyzobiorcy, partnera joint venture lub osoby pozostającej w innych relacjach biznesowych ze Spółką lub którymkolwiek z jej Podmiotów stowarzyszonych (zwanych łącznie „Klientami”) do zaprzestania prowadzenia interesów ze Spółką lub którymkolwiek z jej Podmiotów stowarzyszonych, (ii) kierować całości lub części interesów Klienta prowadzonych ze Spółką do jakiegokolwiek konkurenta Spółki lub jej Podmiotów stowarzyszonych, lub (iii) w jakikolwiek sposób zakłócać relacji pomiędzy jakimkolwiek Klientem, z jednej strony, a Spółką lub którymkolwiek z jej Podmiotów stowarzyszonych z drugiej strony. (d) Środki zaradcze i zabezpieczenie roszczeń w drodze nakazu lub zakazu sądowego. Przyjmujesz do wiadomości, że naruszenie któregokolwiek z postanowień zawartych w niniejszym punkcie 2.15 spowodowałoby nieodwracalne szkody dla Spółki i jej Podmiotów stowarzyszonych w znacznej kwocie, której nie dałoby się w prosty sposób ustalić, i że wszelkie środki prawne (w tym zapłata odszkodowania) byłyby niewystarczające. W związku z tym

---

![Slide 51](<performancebasedrestrict051.jpg>)

> **Source slide transcript**
>
> 51 zgadzasz się, że niezależnie od jakichkolwiek postanowień niniejszej Umowy, oprócz innych form odszkodowania, którego wysokość Spółka jest w stanie wykazać, Spółka i jej Podmioty stowarzyszone są uprawnione (bez konieczności wykazania straty ekonomicznej lub innej rzeczywistej szkody) do zabezpieczenia roszczeń w drodze nakazu lub zakazu sądowego (w tym tymczasowych środków zabezpieczających, nakazów tymczasowych i nakazów stałych), bez składania kaucji przez dowolny sąd właściwej jurysdykcji w odniesieniu do jakiegokolwiek naruszenia lub groźby naruszenia któregokolwiek z postanowień niniejszego punktu 2.15, oprócz wszelkich innych przysługujących Spółce środków prawnych lub zadośćuczynień na zasadzie słuszności. Ponadto w przypadku umyślnego naruszenia postanowienia ograniczającego (zgodnie z definicją zawartą w niniejszym punkcie 2.15), (i) wszystkie prawa przysługujące Ci na mocy niniejszej Umowy, niezależnie od tego, czy zostały one nabyte, czy też nie, wygasają ze skutkiem natychmiastowym, oraz (ii) wszelkie Akcje, środki pieniężne lub inne przedmioty majątkowe wypłacone lub przekazane Ci zgodnie z niniejszą Umową zostają utracone i jesteś zobowiązany do zwrotu takich Akcji, środków pieniężnych lub innych przedmiotów majątkowych Spółce, nie później niż trzydzieści (30) dni kalendarzowych po złożeniu przez Spółkę wniosku o ich zwrot. Dla celów niniejszej Umowy „Umyślne naruszenie postanowienia ograniczającego” oznacza istotne naruszenie przez Ciebie któregokolwiek z postanowień niniejszego punktu 2.15, co do którego wiedziałeś lub powinieneś był wiedzieć po należytej weryfikacji, że stanowi takie istotne naruszenie. Nie należy interpretować poprzednich zdań niniejszego punktu 2.15 jako zrzeczenia się ewentualnych praw przysługujących Spółce i jej Podmiotom stowarzyszonym z tytułu odszkodowania na mocy niniejszej Umowy lub z innego tytułu, a wszystkie takie prawa są nieograniczone. Okres ograniczony zostaje zawieszony podczas (i zostanie uznany za automatycznie przedłużony o) każdego okresu, w którym naruszasz postanowienia odpowiednio punktu 2.15(a), (b) lub (c). W przypadku gdy sąd właściwej jurysdykcji uzna, że którekolwiek z postanowień niniejszego punktu 2.15 jest nieważne lub bardziej restrykcyjne, niż zezwala na to prawo właściwe dla takiej jurysdykcji, wówczas wyłącznie w odniesieniu do wykonania postanowień niniejszego punktu 2.15 w ramach jurysdykcji tego sądu, postanowienie takie będzie interpretowane i wykonywane w myśl maksymalnego ograniczenia dozwolonego przez takie prawo właściwe. (e) Potwierdzenia. (1) Potwierdzasz, że Spółka i jej Podmioty stowarzyszone poświęciły i nadal będą poświęcać znaczną ilość czasu, pieniędzy i wysiłku na rozwój strategii biznesowych, stosunków z pracownikami, klientami i innymi podmiotami oraz dobrej woli na zbudowanie efektywnej organizacji. Potwierdzasz, że Spółka i jej Podmioty stowarzyszone mają uzasadniony interes biznesowy i prawo do ochrony swojej wartości i relacji z pracownikami, klientami i innymi osobami, a także, że Spółka i jej Podmioty stowarzyszone mogą poważnie ucierpieć na skutek utraty lub pogorszenia relacji z pracownikami, klientami i innymi osobami. Ponadto potwierdzasz, że Spółka i jej Podmioty stowarzyszone mają prawo do ochrony i zachowania wartości Spółki i Podmiotów stowarzyszonych w zakresie dozwolonym przez prawo. (2) W świetle powyższych potwierdzeń zgadzasz się, że zobowiązania zawarte w niniejszej Umowie są rozsądne i uzasadnione dla celów odpowiedniej ochrony interesów i wartości firmy Spółki i jej Podmiotów stowarzyszonych. Ponadto potwierdzasz, że chociaż przestrzeganie zobowiązań zawartych w niniejszej Umowie może uniemożliwić Ci

---

![Slide 52](<performancebasedrestrict052.jpg>)

> **Source slide transcript**
>
> 52 osiąganie dochodów z pracy w przedsiębiorstwie prowadzącym działalność podobną do działalności Spółki i jej Podmiotów stowarzyszonych, to dzięki swojemu doświadczeniu i umiejętnościom masz inne możliwości osiągania dochodów oraz odpowiednie środki wsparcia dla siebie i osób pozostających na Twoim utrzymaniu. (3) W świetle potwierdzeń zawartych w niniejszym punkcie 2.15, zobowiązujesz się nie kwestionować ani nie podważać zasadności, ważności ani wykonalności jakichkolwiek ograniczeń i zobowiązań zawartych w niniejszym punkcie 2.15. **** Czekamy na Twój ciągły wkład w rozwój Spółki. Proszę potwierdzić otrzymanie Programu i przyznanego Prawa. Z poważaniem, /s/ Patrick Lockwood-Taylor Patrick Lockwood-Taylor Chief Executive Officer and President

---

![Slide 53](<performancebasedrestrict053.jpg>)

> **Source slide transcript**
>
> 53 APPENDIX PERRIGO COMPANY PLC Additional Terms and Provisions to Restricted Stock Unit Award Agreement (Performance-Based) Terms and Conditions This Appendix (the “Appendix”) includes additional terms and conditions that govern the restricted stock units (Performance-Based) (“PSUs” or “Award”) granted to you under the Plan if you reside in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the Agreement. The Award will not create any entitlement to receive any similar benefit in the future. Notifications This Appendix also includes country-specific information of which you should be aware with respect to your participation in the Plan. The information is based on the securities, exchange control and other laws in effect in the respective countries as of January 2023. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you do not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that you vest in the PSUs and Ordinary Shares are issued to you or the shares issued upon vesting of the PSUs are sold. In addition, the information is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your particular situation. Finally, please note that if you are a citizen or resident of a country other than the country in which you are currently working, or transfers employment after grant, the information contained in the Appendix may not be applicable. Conditions et dispositions supplémentaires à l’

---

![Slide 54](<performancebasedrestrict054.jpg>)

> **Source slide transcript**
>
> 54 Accord relatif à l’attribution d’unités d’action avec restrictions (rémunération fondée sur les performances) Conditions Le présent Appendice (l’« Appendice ») comprend des conditions complémentaires régissant les Unités d’action avec restrictions (rémunération fondée sur les performances) (« UARP » ou « Prime ») qui vous sont attribuées en vertu du Plan si vous résidez dans l’un des pays repris ci- dessous. Certains termes commençant par une lettre majuscule utilisés dans le présent Accord mais qui n’y sont pas définis ont le sens qui leur est attribué dans le Plan ou l’Accord. La Prime n’instaure aucun droit à recevoir des avantages similaires à l’avenir. Notifications Le présent Appendice comprend également des informations spécifiques aux pays dont vous devez avoir connaissance eu égard à votre participation au Plan. Les informations se fondent sur les lois relatives aux valeurs mobilières, au contrôle des échanges et autres en vigueur dans les pays respectifs en janvier 2023. Souvent complexes, ces lois font l’objet de modifications fréquentes. Par conséquent, la Société vous recommande vivement de ne pas considérer les renseignements repris aux présentes comme l’unique source d’information relative aux conséquences de votre participation au Plan, car ces renseignements peuvent être obsolètes au moment de la dévolution des UARP ou de l’émission des Actions ordinaires pour votre compte, ou de la vente des actions émises lors de la dévolution des UARP. Par ailleurs, ces informations sont d’ordre général et peuvent ne pas s’appliquer à votre situation particulière. De plus, la Société n’est pas en mesure de vous garantir un quelconque résultat particulier. Par conséquent, il vous est conseillé de demander des conseils professionnels appropriés quant à la manière dont les lois de votre pays en la matière peuvent s’appliquer à votre situation particulière. Enfin, veuillez noter que si vous êtes citoyen ou résident d’un pays autre que celui dans lequel vous travaillez actuellement ou si votre emploi est transféré après l’octroi, les informations figurant dans l’Appendice peuvent ne pas appliquer. Extra voorwaarden en voorzieningen bij de Overeenkomst over voorwaardelijk toegekende aandelen (op basis van prestaties) Algemene voorwaarden Deze Bijlage (de 'Bijlage') omvat extra algemene voorwaarden voor de voorwaardelijk toegekende aandelen (op basis van prestaties) ('PSU's' of 'Award') die u volgens het Plan zijn toegekend als u in een van onderstaande landen woont. Bepaalde termen in hoofdletters die in deze Bijlage werden gebruikt maar niet gedefinieerd, hebben de betekenis die in het Plan en/of de Overeenkomst is vermeld. De Award creëert geen recht om een soortgelijk voordeel in de toekomst te krijgen. Meldingen

---

![Slide 55](<performancebasedrestrict055.jpg>)

> **Source slide transcript**
>
> 55 Deze Bijlage bevat ook landenspecifieke informatie waarvan u op de hoogte moet zijn met betrekking tot uw deelname aan het Plan. De informatie is gebaseerd op de effecten-, wisselcontrole- en andere wetten die in de respectieve landen sinds januari 2023 van kracht zijn. Zulke wetten zijn vaak complex en worden regelmatig aangepast. Daarom raadt het Bedrijf u ten sterkste aan de informatie hierin niet te gebruiken als enige bron van informatie over de gevolgen van uw deelname aan het Plan, omdat de informatie verouderd kan zijn op het ogenblik dat uw toezegging in de PSU's en de Gewone aandelen u worden uitgekeerd of wanneer de bij de toezegging van de PSU's uitgegeven aandelen worden verkocht. Ook is de informatie algemeen van aard en mag u ze niet toepassen op uw specifieke situatie. Het Bedrijf bevindt zich evenmin in een positie om u een specifiek resultaat te verzekeren. We raden u dan ook aan om professioneel advies te vragen over hoe de relevante wetten in uw land van toepassing kunnen zijn op uw specifieke situatie. Ten slotte, merk op dat als u een burger of inwoner bent van een ander land dan het land waarin u op dit moment werkt, of uw tewerkstelling na de toekenning verhuist, de informatie in de Bijlage mogelijk niet van toepassing is. Dodatkowe warunki i postanowienia Umowy przyznania jednostek akcyjnych o ograniczonych prawach (w oparciu o wyniki) Warunki Niniejszy Załącznik („Załącznik”) zawiera dodatkowe warunki, które regulują jednostki akcyjne o ograniczonych prawach („PSU” lub „Prawo”) przyznaną w ramach Programu, jeśli mieszkasz w jednym z wymienionych poniżej krajów. Określone terminy pisane wielką literą, które nie zostały zdefiniowane w niniejszym Załączniku, mają znaczenie określone w Programie i/lub Umowie. Prawo nie uprawnia do uzyskiwania podobnych korzyści w przyszłości. Powiadomienia Niniejszy Załącznik zawiera również informacje dotyczące poszczególnych krajów, o których powinieneś(-as) wiedzieć w związku z uczestnictwem w Programie. Informacje oparte są na papierach wartościowych, kontroli dewizowej i innych przepisach obowiązujących w odpowiednich krajach od stycznia 2023 r. Takie przepisy prawa są często skomplikowane i często się zmieniają. W związku z tym Spółka zdecydowanie zaleca, aby nie polegać na informacjach wymienionych w niniejszym dokumencie jako jedynym źródle informacji związanych z konsekwencjami uczestnictwa w Programie, gdyż informacje te mogą być nieaktualne w momencie nabycia lub wykonywania PSU, a Akcje Zwykłe są Ci wydawane lub w przypadku sprzedaży PSU nabytych w ramach Programu. Ponadto informacje mają charakter ogólny i mogą nie mieć zastosowania do konkretnej sytuacji, a Spółka nie jest w stanie zapewnić Ci żadnego konkretnego rezultatu. W związku z tym zaleca się zasięgnięcie odpowiedniej profesjonalnej porady dotyczącej tego, w jaki sposób odpowiednie przepisy w Twoim kraju mogą mieć zastosowanie do konkretnej sytuacji. Wreszcie należy pamiętać, że jeśli jesteś obywatelem/obywatelką lub rezydentem/rezydentką kraju innego niż kraj,

---

![Slide 56](<performancebasedrestrict056.jpg>)

> **Source slide transcript**
>
> 56 w którym obecnie pracujesz lub przenosisz się do nowego miejsca po przyznaniu, informacje zawarte w Załączniku mogą nie mieć zastosowania. Australia Important Notice Important Notice No financial product advice is provided in this Appendix, this Agreement or the Plan (the Plan Documents) and nothing should be taken to constitute a recommendation or statement of opinion that is intended to influence a person or persons in making a decision to participate in the Plan. The Plan documents do not take into account your objectives, financial situation and needs. You should consider obtaining your own financial product advice from a person who is licensed by the Australian Securities and Investments Commission to give such advice. If you intend to apply to participate in the Plan, you must make your own independent assessment and investigation in relation to your legal and taxation position including seeking professional advice. You must base any decision you may make on such independent assessment, investigation or advice. Offer made without disclosure A copy of the terms of the Plan will be provided to you with this Agreement. Notwithstanding the terms of the Plan, an offer to receive PSUs and participate in the Plan, if received in Australia, is made without disclosure to investors in reliance on the regulatory relief set out in Division 1A of Part 7.12, and for the purposes of section 1100N(b), of the Corporations Act 2001 (Cth). As set out in this Agreement, each PSU represents the right to receive one Ordinary Share subject to the relevant performance goals and performance measures being met, or otherwise waived, in accordance with the Plan and this Agreement. For the avoidance of doubt, a RSU will only be considered earned and able to vest and convert into an Ordinary Share following the assessment of whether the relevant vesting conditions have been met. The PSUs will be issued for nil consideration. You are not required to pay for a PSU or for the subsequent transfer of an Ordinary Share on vesting of that PSU, however your responsibility for any taxes is as set out in the terms of the Plan and this Agreement. Notwithstanding any discretion contained in the Plan, or any provision in this Agreement to the contrary, the number of PSUs granted to you will only be decreased depending on your level of attainment of performance goals against your designated performance measures. If you fully meet your performance goals against the designated performance measures, all of your PSUs will

---

![Slide 57](<performancebasedrestrict057.jpg>)

> **Source slide transcript**
>
> 57 vest. However, if you only partially meet your performance goals against the designated performance measures, only a partial number of your PSUs will vest. You will be entitled to one Share for each vested PSU. For the avoidance of doubt, there will be no increase to the number of PSUs granted to you on the Grant Date. The Company will not provide you with any loans or financial assistance under the Plan in connection with the offer of the PSUs. No PSUs or Ordinary Shares transferred to you under the Plan will be held on your behalf, by a trustee/nominee. The indicative daily price of the Ordinary Shares on the New York Stock Exchange (NYSE), quoted in US dollars, is available on the Company’s website at http://perrigo.investorroom.com/stock-information. The Ordinary Shares are also quoted on the NASDAQ Stock Market (NASDAQ) (refer to NASDAQ’s website at http://www.nasdaq.com/symbol/prgo). The Australian dollar equivalent of the Ordinary Shares can be determined using prevailing exchange rate published by Thomson Reuters (Prevailing Exchange Rate). Alternatively, the Company will advise you of the price of its Ordinary shares (in equivalent Australian dollars) as soon as possible following receipt of any request for such information. This information may be obtained by you contacting your local Human Resources representative. Before accepting an offer to be granted PSUs, you should satisfy yourself that you have a sufficient understanding of the risks set out below and should consider if the PSUs are a suitable investment for you, having regard to your own investment objectives, financial circumstances and taxation position: (a) the vesting conditions for your PSUs may not be satisfied for reasons beyond the Company’s or your control; (b) you are not permitted to transfer your PSUs unless permitted under this Agreement or the Plan; (c) you will have no voting, dividend, or other stockholder rights in any Shares until you become the registered holder of those Shares. Until you become the registered holder of Shares, you will have only the rights of an unsecured creditor with respect to those Shares (d) if your PSUs vest and you subsequently receive Ordinary Shares: (i) the value of those shares may rise and fall according to investor sentiment, general economic conditions and outlook, international and local stock markets, employment, inflation, interest rates, government policy, taxation and regulation; and (ii) there is no guarantee that an active trading market for the shares will exist or that the price of the shares will increase. There may be relatively few potential buyers or sellers of the shares on the NYSE, NASDAQ, TASE or any other applicable market at any time and this may

---

![Slide 58](<performancebasedrestrict058.jpg>)

> **Source slide transcript**
>
> 58 increase the volatility of the market price of the shares. It may also affect the prevailing market price at which you may be able to sell your shares; (e) there may be taxation implications arising for you in participating under this Agreement and in the Plan. The tax consequences of participating in the Plan are based on complex tax laws, which may be subject to varying interpretations, and the application of such laws may depend, in large part, on the surrounding facts and circumstances. The tax regime applying to you may change. Please note that the above risks are only general risks of acquiring and holding PSUs under the Plan. It does not purport to list every risk that may be associated with the Plan now or in the future. Finally, if at the time of vesting, the Company determines that it is not legal under Australian securities laws to issue shares, the outstanding PSUs will be cancelled, and no shares will be issued to you nor will any benefits in lieu of shares be paid to you. Exchange Control Information Exchange control reporting mandates disclosure of payments equal to or exceeding AUD10,000 made to a foreign individual or entity. This reporting is generally done automatically by the financial institution making the transfer. Austria Notifications Exchange Control Information. If you hold Ordinary Shares outside of Austria, you must submit a report to the Austrian National Bank. An exemption applies if the value of the shares as of any given quarter is less than €5,000,000 (when converted to Euros if applicable). If the threshold is met or exceeded, quarterly reporting obligations exist If quarterly obligations apply, the reporting date is the end of each quarter and the deadline for filing the report is the 15th of the month following the end of the quarter. When shares are sold, there may be exchange control obligations if the cash received is held in a bank account outside Austria. If the volume of all your accounts abroad exceeds €10,000,000 (when converted to Euros if applicable), the balances of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month. Belgium Notifications Foreign Asset/Account Reporting Information. You are required to report any security or bank accounts (including brokerage accounts) you maintain outside of Belgium on your annual tax return. In a separate report, you are required to provide the National Bank of Belgium with certain details regarding such foreign accounts (including the account number, bank name and country in

---

---

![Slide 59](<performancebasedrestrict059.jpg>)

> **Source slide transcript**
>
> 59 which any such account was opened). This report, as well as additional information on how to complete it, can be found on the website of the National Bank of Belgium, www.nbb.be, under Kredietcentrales / Centrales des crédits caption. Stock Exchange Tax. A stock exchange tax could apply for Belgian tax residents transacting through a non-Belgium broker once the shares are sold. It is recommended that you consult with your personal tax advisor with respect to your requirements. Notifications Communication d’informations relatives aux actifs ou comptes étrangers. Vous êtes tenu de déclarer, dans votre déclaration fiscale annuelle, tout compte-titres ou compte en banque (y compris les comptes de courtage) que vous détenez en dehors de la Belgique. Dans une déclaration distincte, vous êtes tenu de communiquer à la Banque Nationale de Belgique certains détails concernant les comptes étrangers (notamment le numéro de compte, le nom de la banque et le pays où le compte a été ouvert). Cette déclaration ainsi que toutes les informations indiquant comment la remplir sont disponibles sur le site web de la Banque Nationale de Belgique (www.nbb.be) à la section « Centrales des crédits/Kredietcentrales ». Taxe sur les opérations de bourse. Une taxe sur les opérations de bourse peut s’appliquer aux résidents fiscaux belges effectuant des transactions via un courtier non belge lors de la vente des actions. Il est recommandé de consulter votre conseiller fiscal personnel concernant vos obligations. Meldingen Informatie over buitenlands vermogen/rekeningrapportering. U moet alle garantie- of bankrekeningen (inclusief beleggingsrekeningen) die u buiten België bezit, vermelden op uw jaarlijkse belastingsbrief. In een afzonderlijk overzicht moet u de Nationale Bank van België informatie geven over zulke buitenlandse rekeningen (inclusief het rekeningnummer, de naam van de bank en het land waarin zulke rekening is geopend). Dit overzicht, evenals extra informatie over hoe u het moet opstellen, vindt u op de website van de Nationale Bank van België, www.nbb.be, onder de titel Kredietcentrales. Taks op beursverrichtingen. Een taks op beursverrichtingen kan van toepassing zijn op Belgische fiscale inwoners die transacties uitvoeren via een niet-Belgische makelaar wanneer de aandelen worden verkocht. Het wordt aanbevolen om uw persoonlijke fiscale adviseur te raadplegen met betrekking tot uw verplichtingen. Bermuda Terms and Conditions The Award Agreement is not subject to and has not received approval from the Bermuda Monetary Authority and the Registrar of Companies in Bermuda, and no statement to the contrary, explicit or implicit, is authorized to be made in this regard. The securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act 2003 of Bermuda.

![Slide 60](<performancebasedrestrict060.jpg>)

> **Source slide transcript**
>
> 60 Brazil Terms and Conditions Labor Law Acknowledgment. You agree that, for all legal purposes, (i) the benefits provided under the Plan are the result of commercial transactions unrelated to your employment; (ii) the Plan is not a part of the terms and conditions of your employment; and (iii) the income from the PSUs, if any, is not part of your remuneration from employment. Notifications Compliance with Law. By accepting the PSUs, you agree to comply with Brazilian law when the PSUs vest and the shares are sold. You also agree to report and pay any and all taxes associated with the vesting of the PSUs, the sale of the PSUs acquired pursuant to the Plan, and the receipt of any dividends. Exchange Control Information. If you are a resident or domiciled in Brazil and hold assets and rights outside Brazil with an aggregate value exceeding US$100,000, you will be required to prepare and submit to the Central Bank of Brazil an annual declaration of such assets and rights. Assets and rights that must be reported include PSUs. Canada Notifications Payout of PSUs in Shares Only. With respect to all Employees residing in Canada, the Company will convert all vested PSUs only into an equivalent number of Shares and the Plan will not provide an option to settle the PSUs in cash. Foreign Asset/Account Reporting Notice. Canadian residents may be required to report foreign property (including Shares) on an annual basis on form T1135 (Foreign Income Verification Statement) if the total cost of the foreign property exceeds CAD 100,000 at any time in the year. The grant of PSUs must be reported if the CAD 100,000 cost threshold is exceeded because of other foreign property held. PSUs may be reported at a nil cost. The form must be filed by April 30 of the following year. It is recommended that you consult with your personal tax advisor with respect to your requirements. Tax Information. Withholding will include both federal income tax as well as provincial tax. Terms and Conditions Resale Restrictions. The Ordinary Shares received by Canadian residents pursuant to this Plan will be subject to an indefinite holding period and the resale of the Ordinary Shares will be prohibited, unless certain conditions are met in respect of the Company in accordance with applicable Canadian securities laws or another applicable Canadian prospectus exemption is available.

![Slide 61](<performancebasedrestrict061.jpg>)

> **Source slide transcript**
>
> 61 Eligibility of Participants. Notwithstanding the terms of this Agreement or the Plan, no offers of PSUs or Ordinary Shares may be made to you if you are not an employee, executive officer, director or consultant of the Company or a related entity of the Company, in accordance with Section 2.24 of National Instrument 45-106. Employment Law Matters: Notwithstanding the terms of this Agreement or the Plan, the term “Termination Date” shall mean the earliest of: a) Any date specified in this Agreement or the Plan; b) The date on which the Company or any applicable Affiliate delivers to you notice in a form prescribed by the Company that the Company is thereby terminating the employment relationship (regardless of whether the notice or termination is lawful or unlawful or is in breach of any contract of employment); c) Except in the event of a Separation for Good Reason, the date on which you deliver notice in a form prescribed by the Company to the Company or any applicable Affiliate that you are terminating the employment relationship (regardless of whether the notice or termination is lawful or unlawful or is in breach of any contract of employment); d) The date on which you cease to provide services to the Company or any applicable Affiliate, except where you are on an authorized leave of absence; and e) The date on which you cease to be considered an “employee” of the Company or any applicable Affiliate under applicable law. Notwithstanding the terms of this Agreement or the Plan, the definition of “Cause” shall be determined in accordance with applicable laws in the jurisdiction of employment. In accordance with Section 2.13, you consent and agree to the payment of the reimbursements set out therein, including through deductions of the amounts specified in paragraph 2.13 from any wages owed by the Company to the employee. The provisions set out in Section 2.15(a) do not apply to employees in the province of Ontario other than executive employees who are exempted from XV.1 of the Ontario Employment Standards Act, 2000. Czech Republic Terms and Conditions Consent to Receive Documents in English. By accepting the Award, you confirm that you have read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.

![Slide 62](<performancebasedrestrict062.jpg>)

> **Source slide transcript**
>
> 62 Přijetím tohoto Oznámení potvrzujete, že jste přečetl a porozuměl jste Podmínkám plánu (“Plan”) a Smlouvě (“Agreement”), které Vám byly poskytnuty v anglickém jazyce. Zároveň prohlašujete, že souhlasíte s podmínkami uvedenými v těchto dokumentech. Applicable Law Nothing in the Agreement shall prejudice any rights you may have under mandatory provisions of Czech law. Any proceeding related to or arising out of this Agreement shall be commenced, prosecuted or continued in the Circuit Court in Kent County, Michigan located in Grand Rapids, Michigan or in the United States District Court for the Western District of Michigan, and in any appellate court thereof or before the competent court of the Participant or the Company within the meaning of Regulation (EU) No 1215/2012 of the European Parliament and of the Council of 12 December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and commercial matters, and Czech Act No. 99/1963 Coll., on the Code of Civil Procedure. Data Privacy All personal information will be processed in accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (General Data Protection Regulation) and applicable Czech legal regulations on the protection of personal data. Changes to the Agreement Sections 2.14 (a) (10), 2.15 (a), (b) and (e) (3) shall not apply. Notifications Restriction on cash payments. Under Czech Act No. 254/2004 Coll., on Cash Payments, as amended, it is prohibited to receive or provide payments in cash exceeding the amount of CZK 270.000 within one day. Payments exceeding this amount must be executed cashless. This restriction relates to payments from one contracting party to one other contracting party. Thus, it is not a restriction on the sum of all payments made by one individual or entity within one day. Nevertheless, since the restriction on cash payments may be subject to a change (especially a lower threshold might be set), we recommend consulting your personal legal advisor prior to receiving or providing a larger amount of cash payments. Denmark Tax Reporting Information. You may have to report your foreign broker accounts and shares held in a foreign bank or broker to the Danish tax administration. It is recommended that you consult with your personal tax advisor with respect to your requirements.

![Slide 63](<performancebasedrestrict063.jpg>)

> **Source slide transcript**
>
> 63 Terms and Conditions The Agreement will under no circumstances entail that your relationship with the contracting company can be considered as an employment. Thus, any references to you as an employee or to the relationship as an employment, shall be construed as an reference to you as an independent contractor and a contractor relationship. The Danish Contract Act (in Danish: aftaleloven) and Danish case law regulate the terms of the Award Agreement. Below, it is outlined when the Danish Contract Act, Danish case law and other applicable legislation deviate from terms stated in the Award Agreement: Section 1.3, subsection d, litra 2 (i and ii) in the Award Agreement is amended to the following: “(2) “Termination without Cause” means the involuntary termination of your contractual relationship by the Company without any Cause.” Regardless of section 2.3 in the Award Agreement, vested and acquired shares do not lapse as a consequence of your Termination Date for reasons of Cause. In addition to section 2.10, subsection b, all personal information will be managed in accordance with the European Data Protection Regulation (in Danish: databeskyttelsesforordningen) and the Danish Data Protection Act (in Danish: personbeskyttelsesloven). Section 2.15, subsection a – d in the Award Agreement is void and unenforceable in Denmark and instead the following is agreed: 2.15 NON-COMPETITION AND NON-SOLICITATION 2.15.1. You will be covered by this non-competition and non-solicitation clause for 6 months after the effective date of termination. 2.15.2. In this period, you are entitled to – only with the prior written consent of the affiliate employing or retaining you (the “Affiliate”) – be engaged or financially interested, directly or indirectly, in any business which develops and/or distributes products or services that compete or may compete with the Affiliate or any group companies’ products and/or services or in any other business competing with the Affiliate or any group companies in any other way. This restriction includes any interest whatsoever by way of, for example, employment, ownership in full or in part, membership of a board, consultancy services and the like in Denmark and abroad. 2.15.3. During 6 months after the effective date of termination, you are only with the prior written consent of the Affiliate entitled to be in contact with or have business relations, directly or indirectly, with customers, suppliers or cooperation partners, etc., with whom you have had business relations within the last 12 months prior to the termination. In connection with the termination, the Affiliate will prepare a list of the customers, suppliers and cooperation partners covered by the restriction in

![Slide 64](<performancebasedrestrict064.jpg>)

> **Source slide transcript**
>
> 64 this clause. In this connection, you must loyally contribute to the drafting of a thorough list covering all customers, suppliers and/or cooperation partners with whom you have had business relations within the last 12 months prior to the termination. Your deliberate failure to contribute loyally to this list will be considered a material breach of the contract and the Award Agreement. 2.15.4. The effective date of termination is to be construed as the date on which you may be ordered or entitled to cease work after the expiry of the notice period, notwithstanding whether you actually end your work with the contracting company at an earlier date. 2.15.5. The non-competition part of this clause will cease to apply, if the Affiliate gives notice of termination to you without you having reasonably caused the termination. The non-competition part of this clause will also cease to apply, if you cease work from the Affiliate for reasonable cause due to the contracting company’s failure to fulfil its obligations, cf. section 11 (1) in the Danish Act on Employment Clauses (in Danish: ansættelsesklausulloven). In both situations, the non-solicitation part of this clause will be maintained. 2.15.6. The Affiliate may terminate the clause with one month's notice to expire at the end of a month. 2.15.7. In the event of your breach of the clause, the Affiliate will be entitled to a penalty of between three and six months' fee for any one breach of the clause and compensation for any additional loss. In the event of a persistent breach of the clause, each month or part of a month is deemed to constitute an independent breach entitling the Affiliate to a new, independently agreed penalty. Any payment of the agreed penalty shall not lead to the discontinuance of your obligation to comply with the clause. The Affiliate may also seek to restrain any breach of the clause through the issue of an injunction. 2.15.8. This clause may be invoked by the Affiliate from the date on which you have been contracted with the contracting company for six months. Estonia No country specific provisions. Finland Notifications Tax Reporting Information. If you hold Ordinary Shares acquired under the Plan, you are generally required to include those Ordinary Shares as assets in your individual tax return. France Terms and Conditions Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly.

![Slide 65](<performancebasedrestrict065.jpg>)

> **Source slide transcript**
>
> 65 En acceptant cette attribution gratuite d'actions, vous confirmez avoir lu et comprenez le Plan et ce Contrat, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Vous acceptez les dispositions de ces documents en connaissance de cause. Notifications Tax Reporting Information. If you hold Ordinary Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when you file your annual tax return. Tax Information. The PSUs are not intended to qualify as a French tax qualified performance restricted stock units under French tax law. Foreign Asset/Account Reporting Information. If you are a French resident and hold cash or Ordinary Shares outside of France, you must declare all foreign bank and brokerage accounts (including any accounts that were opened or closed during the tax year) on an annual basis on a special form, No. 3916, together with your income tax return. Renseignements relatifs aux comptes et avoirs étrangers. Si vous êtes résident français et que vous détenez des liquidités ou des Actions ordinaires en dehors de la France, vous êtes tenu de déclarer chaque année, en même temps que votre déclaration de revenus, les références de vos comptes bancaires et comptes-titres étrangers (y compris les comptes qui ont été ouverts ou fermés pendant l’exercice fiscal) par le biais d’un formulaire spécifiquement prévu à cet effet, le formulaire No 3916. Germany Notifications Exchange Control Information. Cross-border payments related to securities transactions in excess of €50,000 must be reported by the seventh working day of the month following the respective payment to the German Central Bank (Bundesbank). If you use a German bank to transfer a cross-border payment related to securities transactions in excess of €50,000 (e.g. in connection with the sale of shares acquired under the Plan), the bank will make the report for you. In addition, you must report any cross-border shareholdings in companies if the share in the capital or the voting rights amount(s) to 10% or more and the investment object exceeds a balance sheet total of €6,000,000 (by the last working day of the sixth calendar month following December 31). Tax Reporting Information. In case of an acquisition of shares in foreign companies with an overall investment amount of more than €150,000 (or in case of an acquisition of 10% or more of the shares in a foreign company), you should consult with your tax advisor whether the investment would have to be reported to your tax office. (Direct and indirect acquisitions of shares in a company have to be added for the purpose of calculating the amounts above.) Greece

![Slide 66](<performancebasedrestrict066.jpg>)

> **Source slide transcript**
>
> 66 Notifications Exchange Control Information. Pursuant to your Award, if you withdraw funds of €15,000 or more from a bank in Greece and remit those funds out of Greece, you may be required to submit certain documentation/ information to the Greek bank to ensure that the transfer is not in violation of Greek anti-money laundering rules. Hungary No country specific provisions. India Notifications Exchange Control Notification. You understand that you must repatriate any proceeds from the sale of shares acquired under the Plan to India and convert the proceeds into local currency within 180 days of receipt assuming share holding is less than 10% of the company's share capital or as prescribed under applicable Indian exchange control laws as may be amended from time to time. You will receive a foreign inward remittance certificate ("FIRC") from the bank where you deposit the foreign currency. You should maintain the FIRC as evidence of the repatriation of funds in the event the Reserve Bank of India or your employer requests proof of repatriation. Tax Information. The amount subject to tax on receipt of the shares will partially be dependent upon a valuation that the Company or your employer will obtain from a Merchant Banker in India. Neither the Company nor your employer has any responsibility or obligation to obtain the most favorable valuation possible, nor obtain valuations more frequently than required under Indian tax law. Foreign Asset/Account Reporting Information. You are required to declare in the applicable schedules of your annual tax return (a) any foreign assets held by you (e.g., Ordinary Shares acquired under the Plan and, possibly, the Award), (b) any foreign bank accounts for which you have signing authority and (c) any foreign custodian accounts. Ireland Notifications Director Notification Obligation. If you are a director, shadow director or secretary of the Company's Irish Subsidiary or Affiliate, you must notify the Irish Subsidiary or Affiliate in writing within five business days of receiving or disposing of an interest exceeding 1% of the Company (e.g., PSUs, shares, etc.), or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director or secretary). Terms and Conditions

![Slide 67](<performancebasedrestrict067.jpg>)

> **Source slide transcript**
>
> 67 Israel Type of Grant □ Capital Gain Award (“CGA”) □ Ordinary Income Award (“OIA”) □ 3(i) Award □ Unapproved 102 Award Terms and Conditions Settlement of PSUs. Notwithstanding anything to the contrary in this Agreement, if the PSUs granted hereunder are 102 Awards, the PSUs shall be settled in Ordinary Shares only. Trust. All Approved 102 Awards shall be held in trust by a trustee designated by the Company ("Trustee") or shall be supervised by the Trustee in accordance with the instructions set forth by the Israeli Tax Authority (“ITA”), for the requisite lockup period prescribed by the Ordinance and the regulations promulgated thereunder, or such other period as may be required by the ITA, during which period Awards or Ordinary Shares issued thereunder, and all rights resulting from them, including bonus shares, must be held or supervised by the Trustee in accordance with the instructions set forth by the ITA. The Trustee shall not release any Approved 102 Awards, Ordinary Shares issued upon the exercise of any Approved 102 Awards, or any rights, including bonus shares, resulting from such Approved 102 Awards or Ordinary Shares, prior to the full payment of your tax liability. The Trustee or the Israeli Affiliate shall withhold any applicable taxes in accordance with Section 102 or any applicable tax ruling obtained by the Company. Without derogating from the foregoing, if your PSUs do not qualify as Approved 102 Awards the Company may still at its sole discretion deposit your PSUs in trust to ensure that taxes are properly withheld. You hereby release the Trustee from any liability in respect of any action or decision duly taken and executed in good faith in relation to any PSUs or Ordinary Shares issued to you thereunder. Tax. Without derogating from Section 2.7(b) above, you hereby agree to indemnify the Company and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability for all such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to you. Compliance with Law. By accepting the PSUs, you agree to comply with the provisions of Section 102 and the regulations and rules promulgated thereunder or any tax ruling to be obtained by the Company in connection with your PSUs. Italy Terms and Conditions Notifications

![Slide 68](<performancebasedrestrict068.jpg>)

> **Source slide transcript**
>
> 68 Tax/Exchange Control Information. You are required to report on your annual tax return: (a) any foreign investments or investments (including the Ordinary Shares issued at vesting of the PSUs, cash or proceeds from the sale of Ordinary Shares acquired under the Plan) held outside of Italy, if the investment may give rise to income in Italy (this will include reporting the Ordinary Shares issued at vesting of the PSUs if the fair market value of such Ordinary Shares combined with other foreign assets); and (b) any changes during the financial year which have had an impact during the calendar year on your foreign investments or investments held outside of Italy. You should calculate the IVAFE (Tax on Foreign Financial Products) due on the shareholding. Where the asset is held for part of the year, the tax should be pro-rated. You are exempt from these formalities if the investments are made through an authorized broker resident in Italy, as the broker will comply with the reporting obligation on your behalf. Kazakhstan Notifications Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to report the acquisition of shares of a foreign company to the National Bank of Kazakhstan. Latvia No country specific provisions. Lithuania No country specific provisions. Luxembourg Notifications Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the Service Central de La Statistique et des Etudes Economiques. If a Luxembourg financial institution is involved in the transaction, it generally will fulfill the reporting obligation on your behalf. Mexico Modification. By accepting the PSUs, you understand and agree that any modification of the Plan or the Agreement or its termination shall not constitute a change or impairment of the terms and conditions of employment. Plan Document Acknowledgment. By accepting the award of the PSUs, you acknowledge that you have received copies of the Plan, have reviewed the Plan and the Agreement in their entirety and fully understand and accept all provisions of the Plan and the Agreement.

![Slide 69](<performancebasedrestrict069.jpg>)

> **Source slide transcript**
>
> 69 In addition, by signing the Agreement, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the Agreement, in which the following is clearly described and established: (i) Participation in the Plan does not constitute an acquired right; (ii) The Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) Participation in the Plan is voluntary; and (iv) The Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the shares. Labor Law Acknowledgement and Policy Statement. In accepting the PSUs, you expressly recognize the Company is solely responsible for the administration of the Plan and that your participation in the Plan and acquisition of Ordinary Shares does not constitute an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and on a wholly commercial basis and your sole employer is Perrigo de Mexico S.A. De C.V. (“Perrigo Mexico”). Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan do not establish any rights between you and your employer, Perrigo Mexico, and do not form part of the employment conditions and/or benefits provided by Perrigo Mexico and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment. You further understand that your participation in the Plan is as a result of a unilateral and discretionary decision of the Company; therefore, the Company reserves the absolute right to amend and/or discontinue your participation at any time without any liability to you. Finally, you hereby declare that you do not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of your participation in the Plan and therefore grant a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan. Spanish Translation Modificaciόn. Al aceptar las Unidades de Acción Restringida de Rendimiento (PSUs, por sus siglas en inglés) usted entiende y esta de acuerdo que cualquier modificación del plan o del acuerdo o su terminación no constituirá un cambio o detrimento de los términos y condiciones de su empleo. Confirmación del Documento del Plan. Al aceptar el otorgamiento de las PSUs, usted reconoce que ha recibido copias y ha revisado dicho acuerdo en su totalidad y que ha entendido y aceptado completamente todas las disposiciones contenidas en el Plan y en el Acuerdo. Adicionalmente, al firmar el acuerdo, usted reconoce que ha leído, y aprobado de manera específica y expresa los términos y condiciones en el acuerdo en el que se describe y establece claramente los siguiente: (i) La participación en el Plan no constituye un derecho adquirido;

![Slide 70](<performancebasedrestrict070.jpg>)

> **Source slide transcript**
>
> 70 (ii) El plan y la participación en el mismo, son ofrecidos por la Compañía de manera totalmente discrecional; (iii) La participación en el Plan es voluntaria; y (iv) La Compañía, y cualquier Sociedad controladora, Subsidiaria o Filiales no son responsables por ningún decremento en el valor de las Acciones. Constancia de aceptación de la ley laboral y declaración de la política. Al aceptar las PSUs, usted reconoce expresamente que la Compañía, es la única responsable de la administración del Plan, y que su participación en el Plan y la adquisición de las acciones comunes no constituyen una relación de trabajo entre usted y la Compañía dado que usted participa en el Plan de manera completamente comercial y el único empleador que tiene es Perrigo de México, S.A. de C.V. (« Perrigo de Mexico »). Con base en lo anterior, usted reconoce expresamente que el Plan y los beneficios que usted pueda obtener de la participación en el Plan, no establecen ningún derecho entre usted y su empleador Perrigo de México y no forman parte de las condiciones de trabajo ni de las prestaciones ofrecidas por Perrigo de México y cualquier modificación del Plan o la terminación de éste, no constituyen un cambio o deterioro de los términos y condiciones de su trabajo. Además, usted comprende que su participación en el Plan es el resultado de una decisión unilateral y discrecional de la Compañía; por lo tanto, la Compañía se reserva el derecho absoluto de modificar y/o interrumpir la participación de usted en cualquier momento sin ninguna responsabilidad para usted. Finalmente, usted declara que no se reserva ninguna acción o derecho de presentar algún reclamo o demanda en contra de la Compañía por compensación, daño o perjuicio alguno como resultado de su participación en el Plan, en consecuencia, otorga el más amplio finiquito al Empleador, así como a la Compañía, a su Sociedad controladora, Subsidiaria o Filiales con respecto a cualquier demanda que pudiera originarse en virtud del Plan. Netherlands Notifications Insider-Trading Notification. Dutch insider-trading rules prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor. Norway Insider-Trading Notification. Norwegian insider-trading rules prohibit you from effectuating certain transactions involving shares if you have inside information about the Company. If you are uncertain whether the insider-trading rules apply to you, you should consult your personal legal advisor as well as the Company. Exchange Control Information. Cross-border payments in excess of NOK 100,000 must be reported to the Norwegian foreign exchange register (Valutaregisteret). If you use a Norwegian

![Slide 71](<performancebasedrestrict071.jpg>)

> **Source slide transcript**
>
> 71 bank to transfer a cross-border payment in excess of NOK 100,00 in connection with the sale of shares acquired under the Plan, the bank will make the report on your behalf. Foreign Asset/Account Reporting Information. In your Norwegian income tax return, each year you are required to report any security, shares or bank accounts (including brokerage accounts and the Company “Account” referenced in section 1.5 of the Agreement) you maintain outside of Norway. The Company “Account” should not be treated as taxable wealth, as long as the right to receive the dividends is conditional, but you must report it. Poland Terms and Conditions Consent to Receive Information in English. By accepting the Award, you confirm having read and understood the Plan and the Agreement, which were provided in the English language. You accept the terms of those documents accordingly. Notifications Exchange Control Information. If you hold foreign securities (including shares pursuant to the Award) and maintain accounts abroad, you may be required to file certain reports with the National Bank of Poland (“NBP”). Specifically, if the value of securities and cash held in such foreign accounts exceeds PLN 7,000,000 (or equivalent thereof in another currency) at the end of the year, you must file reports on the transactions and balances of the accounts on a quarterly basis by the 26th day of the month following the end of each quarter. In case you are being in regime of a joint marital property, the above threshold shall apply to joint property of the spouses. In addition, if you hold, at the beginning or end of the year, at least 10% of votes in the decision- making body of the entity based abroad (and you are person meeting the previously mentioned criteria), an annual notification, on the official form, must be submitted by you to the NBP by May 31 of the following year. If at the end of the year you did not reach the given threshold but in the next year, at the end of a calendar quarter, you reach the threshold, you are obliged to submit the appropriate form to NBP for this quarter and each of the following quarters of this calendar year (within 26 days from the end of each calendar quarter). Such reports are filed on special forms available on the website of the NBP. The foregoing duties represents personal responsibilities of each shareholder and cannot be fulfilled by any entity on your behalf. Additionally, if you are a Polish citizen and you transfer funds abroad in excess of the PLN equivalent of €15,000, the transfer must be made through an authorized bank, a payment institution or an electronic money institution authorized to render payment services. Furthermore, at the banks’ request, you may be required to inform eligible banks, within the meaning of the Foreign Exchange Act, about all foreign exchange transactions performed through them. You are also required to retain the documents connected with foreign exchange transactions for a

![Slide 72](<performancebasedrestrict072.jpg>)

> **Source slide transcript**
>
> 72 period of five years, as measured from the end of the year in which such transaction occurred. Warunki Zgoda na otrzymywanie informacji w języku angielskim. Akceptując Opcję, potwierdzasz przeczytanie i zrozumienie Programu i Umowy, które zostały dostarczone w języku angielskim. W związku z tym akceptujesz warunki tych dokumentów. Powiadomienia Informacje o kontroli dewizowej. Jeśli jesteś w posiadaniu zagranicznych papierów wartościowych (w tym akcji) i posiadasz rachunki za granicą, możesz być zobowiązany(-a) do złożenia określonych sprawozdań w Narodowym Banku Polskim („NBP”. W szczególności, jeśli wartość papierów wartościowych i środków pieniężnych gromadzonych na takich rachunkach zagranicznych przekracza na koniec roku 7 000 000 PLN (lub ekwiwalent tej kwoty w innej walucie), należy co kwartał składać raporty z transakcji i sald rachunków do 26 dnia miesiąca następującego po zakończeniu każdego kwartału. W przypadku pozostawania we wspólności majątkowej z małżonkiem, powyższy próg dotyczy majątku wspólnego małżonków. Ponadto, jeżeli posiadasz na początek lub koniec roku co najmniej 10% głosów w organie stanowiącym podmiotu z siedzibą za granicą (i jesteś osobą spełniającą wyżej wskazane warunki) musisz złożyć w NBP do 31 maja następnego roku dodatkowy raport. Jeśli pod koniec roku nie osiągnąłeś(-aś) określonego progu, ale w następnym roku, pod koniec kwartału kalendarzowego, osiągniesz próg, musisz złożyć odpowiedni formularz do NBP za ten kwartał i każdy z kolejnych kwartałów tego roku kalendarzowego (w ciągu 26 dni od zakończenia każdego kwartału kalendarzowego). Takie raporty są składane w specjalnych formularzach dostępnych na stronie internetowej NBP. Ponadto, jeśli jesteś obywatelem Polski i przekazujesz środki za granicę w wysokości przekraczającej równowartość 15 000 EUR w PLN, przelewu należy dokonać za pośrednictwem upoważnionego banku, instytucji płatniczej lub instytucji pieniądza elektronicznego uprawnionej do świadczenia usług płatniczych. Ponadto na żądanie banków niezbędne może być poinformowanie uprawnionych banków, w rozumieniu ustawy Prawo dewizowe (Foreign Exchange Act), o wszystkich transakcjach walutowych przeprowadzanych za ich pośrednictwem. Jesteś również zobowiązany(-a) do przechowywania dokumentów związanych z transakcjami wymiany walut przez okres pięciu lat, mierzony od końca roku, w którym taka transakcja została wykonana

![Slide 73](<performancebasedrestrict073.jpg>)

> **Source slide transcript**
>
> 73 Portugal Terms and Conditions Language Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and Award Agreement. Conhecimento da Lingua. O Contratado, pelo presente instrumento, declara expressamente que tem pleno conhecimento da língua inglesa e que leu, compreendeu e livremente aceitou e concordou com os termos e condições estabelecidas no Plano e no Acordo de Atribuição (Award Agreement em inglês). Romania Notifications Statistical Reporting. According to art. 92 of NBR Reg. 4/2021, if you, as a resident of Romania within the meaning of NBR Reg. 4/2021, acquire more than 10% of the share capital in a foreign company, the acquisition must be reported to the National Bank of Romania (“NBR”) for statistical purposes within 30 calendar days of acquiring the ownership right over the shares of the foreign company. You should consult your personal advisor to determine whether you will be required to submit such documentation to the NBR pursuant to your participation in the Plan. Insider-Trading. Insider-trading rules prohibit you from carrying out certain transactions involving shares if you have inside information about the Company (insider dealing). If you are uncertain whether the insider-trading rules apply to you, including with regard to the fact that the Company is listed on the New York Stock Exchange (NYSE), you should consult your personal legal advisor. Depending on the applicable market abuse legislation, you might be subject to certain restrictions on the freedom to trade the shares that are settled through the RSU award, including any applicable prohibition on insider dealing, market manipulation or the unlawful disclosure of inside information. Serbia Terms and Conditions No country specific provisions. Slovakia Foreign Asset Reporting. You may have a foreign asset reporting obligation if you are considered providing independent professional services “podnikatel”. You should consult with a personal tax advisor to understand your filing obligations.

![Slide 74](<performancebasedrestrict074.jpg>)

> **Source slide transcript**
>
> 74 No country specific provisions. Slovenia No country specific provisions. South Africa Terms and Conditions Tax Information. By accepting the PSUs, you agree that, immediately upon vesting of the PSUs, you may need to notify your employer of the amount of any gain realized. If you fail to advise your employer of the gain realized upon vesting, you may be liable for a fine. You will be solely responsible for paying any difference between the actual tax liability and the amount withheld by your employer. It is recommended that you consult with your personal tax advisor with respect to your requirements. Notifications Exchange Control Information. Because no transfer of funds from South Africa is required under the PSUs, no filing or reporting requirements should apply when the award is granted nor when Ordinary Shares are issued upon vesting of the PSUs. However, because the exchange control regulations are subject to change, you should consult your personal advisor prior to vesting and settlement of the award to ensure compliance with current regulations. Spain Terms and Conditions No Entitlement for Claims or Compensation. By accepting the award of PSUs, you consent to participation in the Plan, and acknowledge that you have received a copy of the Plan document. You understand that the Company has unilaterally, gratuitously and in its sole discretion decided to make awards of PSUs under the Plan to individuals who may be employees, consultants and directors throughout the world. The decision is limited and entered into based upon the express assumption and condition that any PSUs will not economically or otherwise bind the Company or any Parent, Subsidiary or Affiliate, including your employer, on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Award is given on the assumption and condition that the PSUs shall not become part of any employment contract (whether with the Company or any Parent, Subsidiary or Affiliate, including your employer) and shall not be considered a mandatory benefit, salary for any purpose (including severance compensation) or any other right whatsoever. Furthermore, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from the award, which is gratuitous and discretionary, since the future value of the PSUs and the underlying shares is unknown and unpredictable. You also understand that this Award would not be made but for the assumptions and conditions set forth hereinabove; thus, you understand, acknowledge and freely accept that, should any or all of the assumptions be mistaken or any of the conditions not be met for any reason, the Award, the PSUs and any right to the underlying shares shall be null and void.

![Slide 75](<performancebasedrestrict075.jpg>)

> **Source slide transcript**
>
> 75 You understand and agree that, as a condition of the grant of the PSUs, your termination of service for any reason other than death or disability (including for the reasons listed below) will automatically result in the cancellation and loss of any PSUs that may have been granted to you and that were not or did not become vested on the date of termination of service. In particular, you understand and agree that, unless otherwise expressly provided by the Company in this Agreement, the PSUs will be cancelled without entitlement to the Shares or to any amount as indemnification if you terminate service by reason of, but not limited to, the following: resignation; disciplinary dismissal adjudged to be with cause; disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to a "despido improcedente"); individual or collective layoff on objective grounds, whether adjudged to be with cause or adjudged or recognized to be without cause; material modification of the terms of employment under Article 41 of the Workers’ Statute; relocation under Article 40 of the Workers’ Statute; Article 50 of the Workers’ Statute; unilateral withdrawal by your employer; and under Article 10.3 of Royal Decree 1382/1985. Notifications Exchange Control Information. You must declare the acquisition, ownership and disposition of stock in a foreign company (including Ordinary Shares acquired under the Plan) to the Spanish Dirección General de Comercio e Inversiones (the “DGCI”), the Bureau for Commerce and Investments, which is a department of the Ministry of Economy and Competitiveness, for statistical purposes. Generally, the declaration must be made in January for Ordinary Shares acquired or sold during (or owned as of December 31 of) the prior year; however, this obligation only applies in the cases in which you hold 10% or more of the share capital of the Company or 10% or more of the voting rights of the Company. Additionally, you may be required to declare electronically to the Bank of Spain any securities accounts (including brokerage accounts held abroad), any foreign instruments (e.g., Ordinary Shares) and any transactions with non-Spanish residents (including any payments of cash or shares made to you by the Company) if the balances in such accounts together with the value of such instruments as of December 31, or the volume of transactions with non-Spanish residents during the prior or current year, exceeds €1,000,000. Generally, you will only be required to report on an annual basis (by January 20 of each year). Note that if the value is less than €1,000,000, there is only an obligation to declare this information to the Bank of Spain upon request from the Bank of Spain, in which case the deadline is two months since the request is received. When receiving foreign currency payments derived from the ownership of Ordinary Shares (i.e., dividends or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. Should amounts exceed €12,500, you will need to provide the following information to the Spanish Registered Entity: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used; (iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required. Exceptions to this rule are when you move funds through a Spanish resident bank account opened abroad, or when collections and payments are carried out in cash. These exceptions, however, are subject to their own reporting requirements.

![Slide 76](<performancebasedrestrict076.jpg>)

> **Source slide transcript**
>
> 76 Foreign Asset Reporting Requirements. If you hold assets or rights outside of Spain (including shares acquired under the Plan), you may have to file an informational tax report, Form 720, with the tax authorities declaring such ownership by March 31st of the following year. Generally, there is no obligation to file Form 720 if the total value of the following does not exceed Euro 50,000:
>
> - the securities, shares, rights and participations held by you, on December 31 or at any time throughout the year, in any kind of entities or in investment funds located outside Spain;
> - any transfer of own capital to third parties located abroad; and
> - life and disability insurances in which the individual was policy holder on December 31st. Please note that if an asset is jointly owned, the value is not prorated. Please also note that the application of the rules in respect of valuation of assets and transfers during the year should be carefully analyzed. If the limit of Euro 50,000 euros is exceeded for this described group of assets, all the elements of this group must be reported. For those taxpayers who have filed Form 720 in previous years, they will only be obliged to file it again: (a) When the aggregated value of the assets included in the mentioned group (shares/insurances) had increased in an amount higher than Euro 20,000 regarding the informative return filed in a previous year. (b) When the individual’s condition (owner, co-owner, co-titleholder or co-authorized) had changed or was extinguished during the year, before 31st December, with regard to any of the assets. Please note that the thresholds for annual filing requirements may change each year. Therefore, you should consult your personal advisor regarding whether you will be required to file an informational tax report for asset and rights that you hold abroad. Other tax obligations: Tax residents in Spain may also have the obligation to file the Wealth tax return if the value corresponding to their worldwide net wealth exceeds an exempt threshold that will depends on each Autonomous Community. The deadline to file this Wealth return would be from April to June regarding the net assets held on 31 December of the previous year. In addition, since 2023, a new direct tax has been established, the Solidarity tax on Large Fortunes, which is complementary to the Wealth tax and applies to individuals whose net wealth exceeds Euro 3,000,000. In this tax, the amount effectively paid under the Wealth Tax may be credited in order to avoid double taxation. Both tax obligations should be assessed with your personal tax advisor in order to determine whether you are required to file either or both tax returns.

![Slide 77](<performancebasedrestrict077.jpg>)

> **Source slide transcript**
>
> 77 Sweden Terms and Conditions The following shall apply in addition to what is set out under section 2.14 of the Award Agreement: Forfeiture of entitlements under the Plan in case of termination shall apply in case of termination of employment regardless of whether such termination of employment may be justified under Swedish employment protection legislation, and regardless of whether such termination may be challenged by you, and regardless of whether such termination is invalidated by verdict or a court order. Tax withholdings. You authorize the Company and/or the Employing Company to withhold or sell shares otherwise distributable to you upon vesting or settlement to satisfy the Company’s payroll tax withholding obligations. Switzerland Notifications Securities Law Information. The PSUs and the issuance of any Ordinary Shares thereunder is not intended to be publicly offered in or from Switzerland. Neither this Award Agreement nor any other materials relating to the Award (1) constitute a prospectus, (2) may be publicly distributed nor otherwise made publicly available in Switzerland, or (3) have been or will be filed with, approved or supervised by any Swiss regulatory authority (in particular, the Swiss Financial Market Supervisory Authority (FINMA)). Tax Information. If you are obliged to submit an ordinary annual tax return in Switzerland, you are required to file a salary certificate with the Swiss tax authorities together with your Swiss tax return. The Company or the Affiliate employing you is obliged to prepare a specific attachment regarding the PSUs to this salary certificate. Before Settlement, for wealth tax purposes, the number of PSUs should be declared with p.m (zero value) in the asset statement of the tax return. After Settlement the total number of Ordinary Shares received are subject to wealth tax at the end of the calendar year and must be declared in your Swiss tax return. Turkey Notifications Securities Law Information. Under Turkish law, you are not permitted to sell Ordinary Shares acquired under the Plan in Turkey. The Ordinary Shares are currently traded on the Nasdaq Global Select Market, which is located outside of Turkey, under the ticker symbol “PRGO” and the Ordinary Shares may be sold through this exchange. Ukraine Notifications

![Slide 78](<performancebasedrestrict078.jpg>)

> **Source slide transcript**
>
> 78 Exchange Control Information. Exchange control rules change frequently and you should consult your personal advisor to determine whether you are required to obtain a license for obtaining shares of a foreign company from the National Bank of Ukraine (NBU). Terms and Conditions The Award will be outside the scope of your employment or service contract (if any) and as such will not constitute a part of your compensation package under the respective employment or service contract. United Kingdom Terms and Conditions Income Tax and National Insurance Contribution Withholding. The following provision supplements the terms in the Agreement: If payment or withholding of the income tax due in connection with the PSUs is not made within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the income tax liability or such other period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003 occurred (the “Due Date”), the amount of any uncollected income tax shall constitute a loan owed by you to your employer, effective as of the Due Date. You agree that the loan will bear interest at the then-current official rate of His Majesty’s Revenue & Customs (“HMRC”), it shall be immediately due and repayable, and the Company or your employer may recover it at any time thereafter by any of the means referred to in Section 2.7 of the Agreement. Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities and Exchange Act of 1934, as amended), you will not be eligible for a loan from the Company or your employer to cover the income tax liability. In the event that you are a director or executive officer and the income tax is not collected from or paid by the Due Date, the amount of any uncollected income tax will constitute a benefit to you on which additional income tax and national insurance contributions (“NICs”) will be payable. You will be responsible for reporting any income tax for reimbursing the Company or your employer the value of any employee NICs due on this additional benefit. Notifications * * * * *

---

## EX-22

SEC source: [cy26q210qex22.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex22.htm)

Exhibit 22

Subsidiary Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant

As of June 27, 2026, the obligors under (i) the 5.300% Notes due 2043 issued by the Company (the “Company Notes”) consisted of the subsidiaries listed in the following table and (ii) the 5.150% Notes due 2030, the 5.375% Euro Notes due 2032, the 6.125% USD Notes due 2032, and the 4.900% Notes due 2044 issued by Perrigo Finance Unlimited Company (collectively, the “Perrigo Finance Notes”) consisted of the Company, as a guarantor, and its subsidiaries listed in the following table.

Name of Entity Obligor Type (Company Notes) Obligor Type (Perrigo Finance Notes)

Athena Neurosciences, LLC Guarantor Guarantor

Chefaro Ireland Designated Activity Company Guarantor Guarantor

Elan Pharmaceuticals, LLC Guarantor Guarantor

Galpharm Healthcare Limited Guarantor Guarantor

Galpharm International Limited Guarantor Guarantor

L. Perrigo Company Guarantor Guarantor

Medgenix Benelux NV Guarantor Guarantor

OCE-BIO BV Guarantor Guarantor

Perrigo Belgium NV Guarantor Guarantor

Perrigo Capital NV Guarantor Guarantor

Omega Pharma Innovation & Development NV Guarantor Guarantor

Omega Pharma International NV Guarantor Guarantor

Omega Pharma Limited Guarantor Guarantor

Omega Pharma Trading NV Guarantor Guarantor

PBM Canada Holdings, LLC Guarantor Guarantor

PBM Nutritionals, LLC Guarantor Guarantor

PBM Products, LLC Guarantor Guarantor

Perrigo Americas Holdings, Inc Guarantor Guarantor

Perrigo Company Guarantor Guarantor

Perrigo Company Plc (“Parent”) Issuer Guarantor

Perrigo Corporation Designated Activity Company Guarantor Guarantor

Perrigo Diabetes Care, LLC Guarantor Guarantor

Perrigo Direct, Inc. Guarantor Guarantor

Perrigo Europe Invest NV Guarantor Guarantor

Perrigo Finance (US) LLC Guarantor Guarantor

Perrigo Finance Unlimited Company Guarantor Issuer

Perrigo Florida, Inc. Guarantor Guarantor

Perrigo Holding NV Guarantor Guarantor

Perrigo Holdings Unlimited Company Guarantor Guarantor

Perrigo International Finance Designated Activity Company Guarantor Guarantor

Perrigo International Holdings, LLC Guarantor Guarantor

Perrigo International, LLC Guarantor Guarantor

Perrigo Investments, LLC Guarantor Guarantor

Perrigo Ireland 1 Designated Activity Company Guarantor Guarantor

Perrigo Ireland 10 Unlimited Company Guarantor Guarantor

Perrigo Supply Chain International Designated Activity Company Guarantor Guarantor

Perrigo Ireland 13 Designated Activity Company Guarantor Guarantor

Perrigo Ireland 2 Designated Activity Company Guarantor Guarantor

Perrigo Ireland 4 Unlimited Company Guarantor Guarantor

Perrigo Management Company Guarantor Guarantor

Perrigo Mexico Investment Holdings, LLC Guarantor Guarantor

Perrigo New York, Inc. Guarantor Guarantor

Perrigo Pharma International Designated Activity Company Guarantor Guarantor

Perrigo Pharma Limited Guarantor Guarantor

Perrigo Research & Development Company Guarantor Guarantor

Perrigo Sales Corporation Guarantor Guarantor

Perrigo UK Acquisition Limited Guarantor Guarantor

PMI Branded Pharmaceuticals, Inc. Guarantor Guarantor

Ranir (Holdings) Limited Guarantor Guarantor

Ranir Global Holdings, LLC Guarantor Guarantor

Ranir, LLC Guarantor Guarantor

Wrafton Laboratories Limited Guarantor Guarantor

---

## EX-31.1

SEC source: [cy26q210qex311.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex311.htm)

Exhibit 31.1

CERTIFICATION

I, Albert A. Manzone, certify that:

1.I have reviewed this report on Form 10-Q of Perrigo Company plc;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2026

/s/ Albert A. Manzone

Albert A. Manzone

Interim Chief Executive Officer and President

---

## EX-31.2

SEC source: [cy26q210qex312.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex312.htm)

Exhibit 31.2

CERTIFICATION

I, Eduardo Bezerra, certify that:

1.I have reviewed this report on Form 10-Q of Perrigo Company plc;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a.all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 5, 2026

/s/ Eduardo Bezerra

Eduardo Bezerra

Chief Financial Officer

---

## EX-32

SEC source: [cy26q210qex32.htm](https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/cy26q210qex32.htm)

Exhibit 32

The following statement is being made to the Securities and Exchange Commission solely for the purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.

Securities and Exchange Commission

100 F Street NE

Washington, D.C. 20549

Re: Perrigo Company plc

Ladies and Gentlemen:

In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), each of the undersigned hereby certifies that:

(i)this Quarterly Report on Form 10-Q for the period ended June 27, 2026 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(ii)the information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of Perrigo Company plc.

Date: August 5, 2026 /s/ Albert A. Manzone

Albert A. Manzone

Interim Chief Executive Officer and President

Date: August 5, 2026 /s/ Eduardo Bezerra

Eduardo Bezerra

Chief Financial Officer